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Abstract 
Introduction 
Lung cancer has developed from a rare condition into the leading cause of cancer-
related death in the United Kingdom. Lung cancer patients face a disease with a high 
symptom burden, increased psychosocial needs and a high mortality. Supportive care 
needs are often relevant from diagnosis. Despite this, there are no clear follow-up 
structures for lung cancer patients that address both cancer management and supportive 
care. The aims of this study were to evaluate supportive care needs, assess predictors of 
such needs and identify factors which could aid service provision within Stobhill lung 
cancer services. 
 
Methods 
Supportive care needs were measured using an adapted Palliative Outcome Scale (POS), 
incorporated within a larger questionnaire. All lung cancer patients attending the clinic 
could complete this questionnaire. Respiratory symptoms, performance status, service 
usage, preferences and satisfaction were also assessed. Data were stratified to allow 
evaluation of three clinical groupings: all patients, newly diagnosed patients and 
patients in the last three months of life. Analyses were phased: descriptive analyses, 
univariate tests of association and multivariate regression. 
 
Results 
Three hundred and fifty three lung cancer patients completed questionnaires. The high 
symptom burden in lung cancer was confirmed. Anxiety, pain and dyspnoea were 
identified as the key issues. Poor performance status was identified to be an independent 
predictor of increased POS score, increased anxiety, increased pain and increased 
dyspnoea. There was no independent relationship between POS and survival. Although 
the majority of patients were satisfied with the care received, there was uncertainty 
regarding who was in charge of care and some disparity in preferred structure for 
follow-up. 
 
Conclusions 
Despite recent advances in lung cancer management, improvements are still required to 
address unmet supportive care needs of patients. Particular attention should be given to 
those with poorer performance status to effectively identify and meet such needs. 
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1 Introduction 
Lung cancer patients face a disease with high symptom burden,1 increased psychosocial 
distress2 and poor survival.3 Lung cancer stands out from other cancers in both the 
symptom burden and distress it causes.4-6 Lung cancer patients also face difficult 
decisions throughout the course of their illness regarding treatment choices.7-9 Despite 
this, little is known about patients’ preferences and priorities for care.10 Lung cancer 
services are not meeting the needs of all patients; in particular, the psychological and 
social needs of patients often remain unmet.11-14 The management of lung cancer 
includes investigation, diagnosis, treatment, supportive care and follow-up.10 While 
there is growing evidence and options for most stages of management, there continues 
to be a lack of evidence regarding follow-up.10 It is within the follow-up phase that 
supportive care issues could most readily be addressed if they are identified.  
 
This study aims to evaluate the prevalence of supportive care needs within Stobhill 
Hospital’s lung cancer multidisciplinary clinic, assess predictors of overall supportive 
care needs as measured by the Palliative Outcome Scale, and evaluate the key issues 
reported by patients. It will consider patients’ perceptions of and preferences for follow-
up care and their satisfaction with the current service. It is hoped that increased 
understanding of these issues may allow service improvements in the future. 
 
A conceptual outline of the current study is presented below (Figure 1): 
• Understand lung cancer 
o History and epidemiology (Sections 1.1-1.3) 
o Management (Section 1.4) 
o Why is supportive care of importance in lung cancer? (Section 1.5.3) 
• Identify unmet need 
o Prevalence of symptoms in lung cancer (Section 5) 
o Descriptive evaluation of supportive care needs in patients attending the 
Stobhill lung cancer clinic (Section 6) 
o Key supportive care needs and their predictors (Sections 7 and 9-11) 
• Understand the urgency 
o Survival and prognostication (Sections 1.4.5 and 8) 
o Evaluation of survival within the lung cancer clinic (Section 8) 
o Predictors of poorer survival (Section 8) 
• Evaluate service and preferences 
o What is the evidence for current models of follow-up (Section 4) 
o Evaluation of patients’ views of the current service use (Section 6) 
o Identify patients’ views for future service provision (Section 6) 
o Integration of supportive care into lung cancer management (Section 1.4) 
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The clinical care of patients with lung cancer 
Identifying and supporting those with unmet needs 
 
What are the supportive care needs within the lung cancer population attending the 
Stobhill Hospital multidisciplinary lung clinic and are there identifiable factors which 
can aid service provision to meet these needs? 
Figure 1: A conceptual outline of the current study. 
 
 3
The introduction section outlines the history and epidemiology of lung cancer. It further 
describes management of lung cancer including prevention, diagnosis, staging, 
treatment, prognostication, supportive care and follow-up. The concept of symptom 
distress (or symptom burden) is introduced and the supportive care needs and symptoms 
of lung cancer are outlined. Finally, the background to the project is summarised and 
the aims presented. 
 
1.1 Historical Perspective of Lung Cancer 
Lung cancer is now the leading cause of cancer-related death worldwide,15 in contrast to 
one hundred years ago when lung cancer was virtually non-existent. In 1849, John 
Hughes Bennet, Professor of Pathology, University of Edinburgh, wrote ‘This is the 
only case of cancer of the lung which I have ever met with; so that I presume that the 
disease rarely attacks this organ in Scotland.’16 In 1912, Adler asked ‘Is it worthwhile to 
write a monograph on the subject of primary malignant tumours of the lung?’ At this 
time Dr. Issac Adler could verify only 374 cases within the world literature and lung 
cancer was a reportable disease.17-19 He notes in his introduction that ‘...even now the 
overwhelming majority of medical practitioners rarely, if ever, think of a diagnosis of 
tumour of the lungs.’18 
 
From these first few cases, the incidence of lung cancer increased throughout the 20th 
century. In 1878, lung cancer represented only 1% of cancers found at post-mortem in 
the Institute of Pathology of the University of Dresden, Germany. By 1918, this had 
increased to almost 10% and again to 14% in 1927.20 
 
In 1927, surgeon Alton Ochsner described the increase in lung cancer he was seeing as 
‘an epidemic’. He contrasted this to his time as a medical student witnessing a lung 
cancer patient’s post-mortem in which he was told the condition was so rare he may 
never see another case.21 
 
The most significant development in the last century in tackling this new epidemic was 
the recognition that smoking was the causal agent. This fact is now accepted but 
initially was a matter of great controversy.22 A variety of causative factors were 
investigated, including hereditary diatheses, industrial air pollution, gas works, wartime 
gas exposure, benzene, coal fires, road tars or petrol exposure and the flu pandemic of 
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1918.20, 23 The 10% of patients who develop lung cancer but have never smoked are the 
subject of ongoing debate.24 
 
Cigarette smoking was popularised in western cultures at the end of the 19th century. 
Initially, cigarettes were hand rolled and, therefore, expensive. In 1876, a prize was 
offered to build a machine to speed up production; James Albert Bonsack developed a 
machine capable of producing 70,000 cigarettes in ten hours. Despite offering the prize 
Allen and Ginter did not use the machine, fearing production would outstrip demand. 
James Buchanan Duke acquired two machines and developed his own business, 
becoming president of the American Tobacco Company in 1889. World War I helped 
spread the use and popularity of cigarettes. General John J. Black reportedly stated, 
‘You ask me what is needed to win this war. I answer tobacco as much as bullets.’19, 20 
 
The link between smoking and lung cancer began to be suspected in the 1930’s by 
clinicians noting that this new disease often occurred in smokers. In 1950, Wynder and 
Graham published Tobacco as a possible aetiological factor in bronchogenic 
carcinoma,25 and Sir Richard Doll and Austin Hill published a preliminary study in the 
British Medical Journal confirming that lung cancer was associated with smoking.26 
Doll and Hill went on to study 40,000 British doctors and found that the death rate 
amongst smokers from lung cancer was 20 times greater than the rate in non-smokers.27 
 
These articles were published in a climate in which doctors were avid smokers and 
advocates of cigarettes through advertising. Claims that smoking was safe were 
accepted. However, in 1964 the US Surgeon General stated that smoking was ‘harmful 
to health’ and advised stopping or avoiding cigarette smoking.20 Until this report, 
cigarette use had been increasing but, after publication, it appeared that there was 
acceptance that smoking was hazardous. In the developed world, smoking rates have 
since declined with the associated decrease in lung cancer rates lagging approximately 
20 years behind.19 Cigarette smoking continues to rise in the developing world 
(countries with low or middle incomes). By 1995, 82% of the world’s 1.1 billion 
smokers lived in developing countries.28 
 
Over the last one hundred years, lung cancer has developed from a rare condition to a 
major illness worldwide. The condition about which Adler posed the question ‘Is it 
worthwhile to write a monograph?’ is now the most common cancer in terms of 
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incidence (12.3% of world cancers) and mortality (17.8% of world cancer-related 
deaths). The condition John Hughes Bennet asserted rarely attacks in Scotland is now 
the lead cause of cancer-related death in Scotland. 
 
1.2 Epidemiology of Lung Cancer 
Estimates of the burden of lung cancer are in terms of incidence, prevalence and 
mortality. Incidence (or rate of new cases) is defined as ‘the number of new cases 
occurring expressed as an absolute number of cases per year or as a rate per 100,000 
people per year.’15 Prevalence is the number of people alive with the cancer at any given 
time, including those newly diagnosed and those surviving with the cancer.15 Mortality 
rates are the product of the incidence and the fatality of any cancer and, therefore, 
measure the average risk to the population of dying from that cancer.15  
 
The changing landscape of lung cancer across geographical areas, gender, age and 
socioeconomic divisions over the last 100 years is complex. Around 80-95% of lung 
cancer is attributable to smoking cigarettes, and the dynamic interplay between smoking 
prevalence, population growth and altering age demographics accounts for most of the 
changing patterns of incidence and mortality worldwide. There may be a modest 
contribution from other factors such as exposure to asbestos or radon, as well as air 
pollution or diet.29  
 
1.2.1 Lung Cancer Worldwide 
Lung cancer has been the commonest cancer worldwide since 1985.30 It is estimated 
that in the year 2000 there were 10.1 million new cases of cancer, 6.2 million cancer-
related deaths and 22 million people living with cancer in the year 2000. Of the 
worldwide cancer burden, lung cancer is the most common in terms of incidence (1.2 
million or 12.3% new cases) and cancer-related deaths (1.1 million or 17.8% of cancer 
deaths) but lower prevalence (7.9%) than other major cancers15 (Figure 2). 
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Figure 2: Worldwide incidence (a), mortality (b) and prevalence (c) for major cancers.  
Reprinted from The Lancet Oncology, Copyright 2001, with permission from Elsevier. 
 
This global burden has increased steadily, and these figures compare with 1985 when it 
was estimated that lung cancer deaths totalled 921,000 worldwide.19 Currently the 
highest incidences of lung cancer are seen in Europe and North America.29 with around 
52% of cases occurring within the developed world.15 However, there are likely to be 
underestimates of lung cancer in countries where health care is not readily available, as 
many people are undiagnosed or unreported.  
 
Worldwide, lung cancer is more common in males, with an incidence of 34.9 per 
100,000 men compared to 11.1 per 100,000 women.15 There has been an overall upward 
trend (by 51%) in number of cases in both genders since 1985; however, the increase 
has been smaller in men (44%) compared to women (76%). The increase within the 
male population is accounted for by population growth and aging; age standardised 
incidence rates in males have decreased slightly over this time period 
(-3.3%).30 In women, age standardised incidence rates have increased by 22%. 
However, lung cancer continues to remain greater in men, in terms of incidence and 
mortality, throughout the world (Table 1). 
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  Men Women Total 
Worldwide30 
(2003) 
Incidence 
 
35.5 (965,241) 12.1 (386,891) 
 
20 (1.35 million) 
 
 
Mortality 27.1 (848,132) 10.7 (330,786) 19.5 (1.17 million) 
USA31 
(2004) 
Incidence 89.9 (114,690) 55.2 (100,330) 68.1 (215,020) 
 
 
Mortality 73.4 (90,810) 41.1 (71,030) 53.8 (161,840) 
Europe29, 32 
(2000) 
Incidence 82.5 (303,000) 23.9 (72,000) 52.5 (375,000) 
 
 
Mortality 77 (280,000) 22.3 (67,000) 48.7 (347,000) 
UK33 
(2004) 
Incidence 76.9 (22,495) 51.8(15,818) 64.1 (38,313) 
 
 
Mortality 66.2 (19,457) 45.7 (14,008) 55.8 (33,465) 
Scotland33 
(2004) 
Incidence 102.8 (2,506) 82.2 (2,160) 92.1 (4,666) 
 
 
Mortality 89.9 (2,195) 69 (1,814) 79.1 (4,009) 
(Incidence and mortality recorded as crude rates per 100,000 persons (number of cases)) 
Table 1: Incidence and mortality rates of lung cancer collated from sources. 
 
1.2.2 Lung Cancer in Europe 
Within the European Union, the incidence of lung cancer is estimated as 52.5 persons 
per 100,000 per year with mortality being 48 deaths per 100,000 per year.32 The 
incidence of lung cancer in Europe follows the previous patterns of smoking prevalence 
in each area of Europe.34 In European men the highest incidence and mortality rates for 
lung cancer are observed in Eastern Europe with lower rates in Northern Europe. In 
females there is high incidence and mortality in Northern Europe.29 Survival from lung 
cancer is highest in France, Germany, the Netherlands and Switzerland; survival is 
lowest in Denmark, Poland, United Kingdom (UK) and Scotland.29 
 
1.2.3 Lung Cancer in the United Kingdom 
In the UK in the 1990’s, lung cancer accounted for one in six diagnoses of cancer, one 
quarter of deaths from cancer and 5% of all deaths.35 Greater Glasgow has the highest 
incidence rates of lung cancer in both males and females within the UK.36 The 
prognosis for lung cancer patients remains poor, with little improvement in survival 
over the last 25 years.19 In the UK, survival at one year for men and women diagnosed 
with lung cancer is around 25.4% and 27.5%, respectively, and five year survival is 7% 
and 8%, respectively.36   
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Within the United Kingdom and Ireland: 
• 5% of all deaths result from lung cancer;35 
• lung cancer accounts for one in four of all cancer-related deaths;33 
• in the 1990’s, 37,700 people died from lung cancer each year.35 
In patients diagnosed with lung cancer: 
• 50% die within the first four to six months;37 
• around 70% die within one year;37 
• more than 90% will have died within five years.37 
 
1.2.4 Lung Cancer in Scotland and Glasgow 
Scotland has the highest prevalence of smoking in the UK (28%).35 Out of a Scottish 
population of 5,144,200,38 over 4500 people are diagnosed each year with lung cancer.36 
In Scotland, lung cancer is the leading cause of cancer death in both males and 
females,39 and Scotland has the highest incidence of lung cancer within the UK (34% 
higher in men and 48% higher in females than the UK average);35 see Figure 3. In 
Scotland, the incidence of lung cancer in men has fallen over the last 30 years, but the 
incidence in females has been rising.40 Although squamous cell carcinoma remains the 
predominate histological type of lung cancer, rates of adenocarcinoma have been 
increasing over the same time period.40 Median survival from lung cancer in Scotland 
has been reported as 3.6 months,41, 42 5.2 months,43 6 months,44 and 9.1 months45 
dependent on area of Scotland and patient selection.  
 
Figure 3: UK lung cancer incidence by gender , country and region.35 Reproduced from Cancer 
Atlas 1991-2000 with permission of the Controller Office of Public Sector Information. 
 
Scotland has a higher mortality rate than the UK average in both males and females35 
(Figure 3). 
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Figure 4: UK lung cancer mortality by gender, country and region.35 Reproduced from Cancer 
Atlas 1991-2000 with permission of the Controller Office of Public Sector Information. 
 
Greater Glasgow Health Board has the highest incidence of and mortality from (57% 
higher than the Scottish average) lung cancer in Scotland.35 
 
 Population Male deaths 
from lung 
cancer 
Female 
deaths from 
lung cancer 
Total all 
cause 
deaths 
Total deaths 
from lung 
cancer 
Scotland 5,144,200 2239 1876 55,986 4115 
Greater 
Glasgow & 
Clyde Health 
Board 
621,466 613 559 13,704 1132 
Glasgow City 581,940 356 320 7002 676 
Table 2: Population, all cause deaths and lung cancer deaths in Scotland. Data collated from the 
General Register Office for Scotland.46 
 
Stobhill Hospital is within the Glasgow City area and within Greater Glasgow and 
Clyde Health Board. Out of the Glasgow City population of 581,94038 (11% of Scottish 
population) in 2007, 676 people died from lung cancer (16.4% of lung cancer deaths in 
Scotland). In the Greater Glasgow and Clyde Health Board catchment area, deaths from 
lung cancer numbered 1132 in 2007 (27.5% of Scottish lung cancer deaths). Greater 
Glasgow and Clyde Health Board cares for over a quarter of patients who die from lung 
cancer each year in Scotland.46 More than half of these patients live in the Glasgow City 
area.46  As such, this evaluation was conducted within an area where the population has 
a high risk of developing lung cancer and an extremely poor prognosis if diagnosed 
with lung cancer. 
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1.2.5 Deprivation and Lung Cancer 
Deprivation is a concept closely related to but not the same as poverty. Measures of 
deprivation consider material, social or multi-factorial deprivation (income, housing, 
benefits, employment and material factors). The Carstairs and Morris deprivation index 
considers material deprivation based on four indicators derived from the 198147 Scottish 
population census and updated in 1991.48, 49 
• Overcrowding: the proportion of all persons living in private households with a 
density of more than one person per room. 
• Male unemployment: the proportion of economically active males who are 
seeking work. 
• Social Class 4 or 5: the proportion of all persons in private households with 
head of household in social class 4 or 5 
• Car ownership: the proportion of all persons in private households with no car  
 
Increased incidence of lung cancer has been associated with deprivation.50 There may 
also be a predominance of non-adenocarcinoma lung cancers in deprived populations.50 
In addition, there is a small but significant difference in survival between affluent 
patients with lung cancer and those who are more deprived.51, 52 Lower socioeconomic 
status may also have an influence on quality of life in lung cancer patients.53 
 
1.3 Types of Lung Cancer 
The term ‘lung cancer’ refers to a number of different pathological entities rather than a 
single pathology. Marchesani was one of the first people to propose a histological based 
classification system for lung cancer.54 The World Health Organisation (WHO) 
classification is still based on the four histological subtypes he described: squamous cell 
carcinoma, small cell carcinoma, large cell carcinoma and adenocarcinoma.54 These are 
now considered in two main broader categories of lung cancer: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for around 75-80% 
of all lung cancer diagnosed.55 Optimal management differs for NSCLC and SCLC.56 
 
1.3.1 Non-Small Cell Lung Cancer 
NSCLC can be subdivided into adenocarcinoma (including bronchoalveolar) which 
account for around 30% of all lung cancers, squamous cell (around 30% of lung 
cancers) and large cell carcinoma.54 Currently the treatment approach for patients with 
NSCLC is directed by the extent of disease staged57 and the patient’s fitness rather than 
histological subtype.56 As treatments develop, with recognition of increased activity in 
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particular histological subtypes, the importance of histological subtype may increase.58, 
59  In Scotland, the age standardised incidence of adenocarcinoma has risen in both men 
and women since the 1970’s.34 In females the age standardised incidence of squamous 
cell lung cancer is also increasing but there has been a decrease in males.34 
Adenocarcinoma tends to present in the periphery of the lung (around 70%), arise from 
the surface epithelium or bronchial mucosal glands and have a well circumscribed 
appearance.56 In contrast, squamous cell carcinoma of the lung tends to present centrally 
as an obstructing lesion within the large airways of the lung (60%).56 Large cell 
carcinoma may account for around 9% of lung cancers,54 but the reported incidence in 
surgically resected disease is only 2-3%.60 They are often poorly differentiated but do 
not possess the typical appearance of a SCLC. Typically, they present as large 
peripheral masses, grow rapidly and metastasise early to the mediastinum and brain. 
Survival from large cell carcinoma is lower than from other NSCLC, even when 
comparing surgically resected early stage large cell disease to resected squamous or 
adenocarcimona.61 
 
1.3.2 Small Cell Lung Cancer 
SCLC tends to be an aggressive cancer that is clinically distinct from NSCLC. It is also 
known as ‘oat-cell carcinoma’.56, 62, 63 Small cell carcinomas occur predominantly in 
smokers and account for around 20% of all lung cancers. In Scotland the incidence of 
SCLC rose in males and females between the 1970’s and the late 1990’s.34 The overall 
incidence is now beginning to decrease.64 Untreated, SCLC has an extremely poor 
prognosis but in the 1970’s new chemotherapy treatments were developed that raised 
the hope of it becoming a curable disease.65 However, the good response to the initial 
chemotherapy does not often lead to persistent remission, and the disease often recurs 
rapidly. SCLC usually presents after a short period of symptoms and is generally 
associated with appreciable disease on the chest radiograph at presentation.65 The 
lesions tend to be central, affecting large airways or the mediastinum and can be 
associated with superior vena caval obstruction (SVCO) and paraneoplastic 
syndromes.66 As SCLC is rapidly progressive, the average survival of untreated limited 
stage disease (confined to the thorax) is less than three months. Untreated extensive 
stage SCLC has a life-expectancy of only six weeks.56 
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1.4 Management of Lung Cancer 
Current guidance suggests, modern cancer care should be provided by a 
multidisciplinary team (MDT).10, 55, 67-69 MDT working has not been evidenced through 
a randomised controlled trial but there has been widespread uptake of this method of 
working in cancer care.70 The MDT has been defined as ‘a group of health and social 
care professionals from a range of disciplines who meet regularly to discuss and agree 
plans of treatment and care for people with a particular type of cancer or problem, or in 
a particular location’.10 The MDT, for lung cancer, should include a respiratory 
consultant (usually the lead clinician), an oncologist, a thoracic surgeon, a diagnostic 
radiologist, a pathologist, a specialist in palliative medicine and a specialist lung cancer 
nurse.68 
 
Management includes prevention, diagnosis and communication of diagnosis, staging, 
prognostication, treatment, palliation and follow-up. There are national guidelines 
within the United Kingdom to set standards for speed of referral, investigation and time 
to treatment.10, 67 The majority of lung cancer is diagnosed at an advanced stage.55 Of 
100 new presentations of lung cancer, only 20 (20%) would proceed to curative intent 
surgery and only five to ten of these patients will survive more than five years. The 
other 80 (80%) present with inoperable disease.66 Thus, the issues relating to palliation, 
supportive care and dying often become relevant at the time of diagnosis. 
 
1.4.1 Prevention  
Primary prevention of lung cancer centres on discouraging commencement of smoking 
and, subsequently, cessation strategies for existent smokers.71-73 Other approaches 
include chemoprevention, i.e. utilising natural or synthetic chemical agents to prevent, 
reverse or suppress development of cancer and harm reduction (limiting number of 
cigarettes or cigars smoked).71, 72 The link between the incidence of lung cancer and 
smoking prevalence in populations can be seen across geographical, gender, socio-
economical and ethnic divides.29 There is a lag period of around 20 years in peak 
incidence of lung cancer after peak prevalence of smoking in each of these groups.74 
The risk of passive smoking (exposure to environmental tobacco smoke) has been 
investigated over the last 25 years. Current evidence suggests a potential moderate 
increased risk from passive smoking but larger studies are likely to be required to 
confirm this difference.24 
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The epidemiological evidence is based on assessing consistency, strength of 
relationship, specificity, temporal relationship and correlation of lung cancer to 
smoking. There is now increasing direct evidence of the carcinogenic effects of 
smoking in the lung. Elucidation of one of the pathways by which this occurs has 
identified that the chemicals contained in cigarette smoke directly damage three specific 
loci on the p53 tumour-suppressor gene known to be abnormal in around 60% of lung 
cancer cases.62 In Scotland, public policy has been used to reduce smoking. On Sunday 
26th of March, 2006 a smoking ban in public places came into force.75, 76 Other countries 
now have similar policies, including Ireland,77 England78 and Wales.79  
 
1.4.2 Diagnosis 
Pathways to diagnosis vary from patient to patient.80 Recognition of lung cancer usually 
results from an initial presentation of clinical symptoms (>90% of cases are 
symptomatic at presentation).81 The majority of patients are diagnosed through out-
patient clinics (61%), others by being admitted to in-patient care as an emergency case 
(23%).80 A smaller proportion (around 10%) have no index symptom and are diagnosed 
by incidental findings through routine investigations, occupational screening chest 
radiographs or as part of a ‘life-scan’ undertaken in a private health check.80 Symptoms 
at presentation can be considered as directly related to the tumour, related to distant 
spread of the tumour or systemic effects of the cancer (weight loss, anorexia, fatigue).66 
The reported wide range of frequencies of presenting symptoms has been collated by 
Beckles, Spiro and Rudd (Table 3).66 
 
Symptoms and Signs at Presentation Range of Frequency % 
Cough 8-75 
Weight Loss 0-68 
Dyspnoea 3-60 
Chest Pain 20-49 
Haemoptysis 6-35 
Bone Pain 6-25 
Clubbing of Fingers 0-20 
Fever 0-20 
Weakness 0-20 
Superior Vena Cava Obstruction 0-4 
Dysphagia 0-2 
Wheezing or Stridor 0-2 
Table 3: Range of frequencies of presenting signs and symptoms in lung cancer.66 
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Hamilton et al82 studied 247 primary lung cancers presenting to general practices in 
England and compared these to 1235 control cases. This approach allowed the authors 
to evaluate symptoms associated with a diagnosis of lung cancer and calculate positive 
predictive values for single symptoms and combinations of symptoms compared to the 
controls. The most frequent presenting symptoms were cough (65%), dyspnoea (56%), 
chest pain (42%), fatigue (35%), weight loss (27%), haemoptysis (20%) and anorexia 
(19%). Only haemoptysis had a positive predictive value (PPV) greater than 2% (2.4%). 
If a second presentation occurred with haemoptysis, this PPV increased to 17%. The 
authors note that the recommendation of a chest radiograph for those with 
haemoptysis10 is supported by these findings. It was also noted that there is a high 
background prevalence of respiratory symptoms in the primary care population which 
can make diagnosis difficult.82, 83 
 
Once the suspicion of lung cancer has been raised, the diagnosis is usually confirmed by 
further radiological investigations and tissue sampling.10 For all cancer management, 
there are three factors to be considered before appropriate treatment can be advised: the 
site of origin of the cancer, the type of cancer (histology) and the extent (stage) of the 
cancer. Determination of cell type in lung cancer can be achieved by obtaining tissue or 
cell samples utilising a range of invasive procedures: bronchoscopy84 (washings, 
brushings, direct biopsy85, transbronchial nodal aspiration (TBNA)85 or biopsy directed 
through endoscopic bronchial ultrasound (EBUS))86, percutaneous biopsy of lung 
lesion87 or distant metastasis, aspiration of pleural fluid, oesophageal endoscopic 
ultrasound guided biopsy, mediastinoscopy biopsy, video assisted thoracoscopy 
(VATS), open lung biopsy or surgical resection.10, 85 The most appropriate method of 
tissue sampling is considered the one most likely to produce a positive result with the 
least associated risks. This is likely to vary according to each individual’s fitness, co-
morbidities and the radiographic location of the suspected lung cancer.67 In some cases, 
factors such as the patient’s wishes, technical sampling issues or procedural risks, poor 
performance status, poor lung function or prohibitive co-morbidities prevent invasive 
tissue sampling procedures. In such cases, and in the absence of positive sputum 
cytology, the diagnosis is made on the basis of the clinical and radiological evidence. 
This may be referred to as a clinico-radiological diagnosis. 
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1.4.3 Staging of Lung Cancer 
Staging is the ‘assessment of the extent of disease and is performed for prognostic and 
therapeutic purposes.’10 Most cancers can be staged according to the ‘tumour, node and 
metastases’ (TNM) system. The International Union Against Cancer (UICC) publishes a 
classification of cancers based on this system to allow international standardisation of 
assessment.57 Lung cancer is staged using a combination of clinical, laboratory, 
radiological, and pathological investigations.54 The extent of disease is evaluated by 
radiological investigations such as computer tomography (CT) scans,88 magnetic 
resonance imaging (MRI)85, positron emission tomography (PET),89 radionucleotide 
bone scans, endobronchial ultrasound,86, 90 transeosophageal ultrasound91 and 
occasionally bone marrow aspiration.10 As techniques develop, greater detail can be 
obtained to feed into multidisciplinary decision-making. This needs to be tempered with 
an efficient, efficacious and individualised approach to investigation.  
 
1.4.3.1 Non-Small Cell Lung Cancer   
The tumour, node and metastases (TNM) classification is the internationally accepted 
method of staging in NSCLC which was introduced in 1972. It was modified in 1997, 
and further revision occurred 2009.88, 92, 93 TNM classification considers the size of the 
primary tumour and the extent of invasion, nodal involvement and presence of distant 
spread. Tumour status (T) is graded from zero to four (from absence (0) to increasing 
size and invasion), nodes (N) graded from zero to four (from absent to local to distant 
nodes) and metastases (M) are graded zero or one (absent or present). If any of these 
indices is unknown, it can be recorded with an ‘x’, i.e. Tx, Nx or Mx. Pathological 
staging (either after surgery or post-mortem) is indicated with the prefix ‘p’, i.e. pT, pN 
or pM. Clinical staging can be indicated with the prefix ‘c’, i.e. cT, cN or cM. Mountain 
classification can be used to further categorise TNM classification into stages 1 to 4 
with ‘A’ and ‘B’ subtypes on the basis of similarities in ideal treatment and expected 
prognoses.10, 56, 94 In this classification, stage 1 disease is the least advanced with 
localised disease only, ranging to stage 4 disease with distant metastases10, 56 (Figure 4). 
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When no metastases present (M0) 
N3 3B 3B 3B 3B 
N2 3A 3A 3A 3B 
N1 2A 2B 3A 3B 
N0 1A 1B 2B 3B 
 T1 T2 T3 T4 
 
Stage 4, any T or N with metastases (M1) 
 
Figure 5: Mountain classification of stages of lung cancer utilising the TNM system to assign stages 
1A, 1B, 2A, 2B, 3A, or 3B (when no metastases present) or Stage 4 (when any metastases present). 
 
‘Early stage’ lung cancer is considered to include stages 1A, 1B, 2A and 2B, and 
‘locally advanced’ lung cancer refers to stages 3A and B. Potentially curable disease is 
considered as stages 1 to 3A.88 In general, stage 1 and 2 disease is amenable to surgical 
resection if the patient wishes and has adequate fitness and pulmonary function to 
tolerate an operation. Selected patients with stage 3A disease may also be offered 
surgery (often in combination with another treatment modality). Those with stage 3B 
and stage 4 disease are considered to have incurable disease.92, 94 Overall prognosis 
worsens as the stage of disease increases.  
 
1.4.3.2 Small Cell Lung Carcinoma 
The TNM system can also be applied to SCLC. However, a further staging system is 
currently more commonly used within the clinical setting. The Veterans Administration 
Lung Group system stages SCLC as either: ‘limited’ or ‘extensive’ disease.65 This 
staging determines both treatment options and prognosis.62, 65 Limited disease is defined 
as ‘disease confined to one hemithorax and regional lymph nodes that can be 
encompassed by a reasonable radiation field’ and extensive disease is defined as 
‘disease which has spread beyond the definition of limited stage’.10 The majority of 
patients with SCLC present with extensive disease.10 
 
1.4.4 Treatment of Lung Cancer 
1.4.4.1 Treatment of Non-Small Cell Carcinoma 
NSCLC has a slower doubling time than SCLC. This, combined with a relatively lesser 
tendency to disseminate, makes surgery the best curative option whenever possible.56 It 
should be considered for those with stage 1-3A of NSCLC depending on the patient’s 
wishes, performance status95 (PS), co-morbidity and lung function. At diagnosis, less 
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than 20% of patients are suitable to undergo resection, limited by either disease extent 
or fitness for surgery.55 Despite the curative intent, less than 50% of those who do 
undergo surgery survive five years,92, 94, 96 with the majority dying of metastatic 
disease.96 Radical radiotherapy (with curative intent) may also be offered to those with 
stage 1 or 2 disease when they are unable to tolerate (or do not wish) surgical resection. 
For individuals with good PS (0 or 1) and less than 10% weight loss, radical 
radiotherapy can also be considered in stages 3A and 3B.68 At diagnosis, the majority of 
patients do not have curable disease and, as such, treatments have palliative intent. 
Treatment goals focus on lengthening survival, improving quality of life (QOL) or 
obtaining symptom control. Options in this situation include systemic chemotherapy, 
palliative radiotherapy and palliative and supportive care.55, 97 
 
1.4.4.2 Treatment of Small Cell Carcinoma 
Due to the systemic nature and rapid doubling time of SCLC, surgery is rarely an 
option.88 Patients are considered for chemotherapy and/or radiotherapy and these are 
delivered within the limits of patients’ wishes and fitness for therapy. These treatments 
prolong survival but recurrence is frequent.55 Within Scotland, the median survival for 
SCLC was around 3.5 months when studied in 1995.41 This is lower than the median 
survival seen in other countries for reasons that are likely to be multi-factorial, 
including treatment uptake and co-morbidity.98 Patients who are fit enough and have 
extensive stage disease (that responds to first line chemotherapy) or limited stage 
disease with observed response to chemotherapy can be considered for Prophylactic 
Cranial Irradiation (PCI) to prevent occurrence of brain metastases, reduce symptoms, 
increase disease free interval and extend survival.99 
 
1.4.5 Prognostication in Lung Cancer 
The art of medicine has been described as containing three core elements: diagnosis, 
prognosis and therapeutics. Prognostication is increasingly becoming part of good 
cancer care and facilitating clinical decision-making.100, 101 Prognosis is determined by 
the interplay between the tumour, the host and environmental factors. Environmental 
factors refer to treatments undertaken, the system in which the patient is cared for and 
wider societal factors such as socioeconomic status. All these factors can be further 
subdivided as either ‘essential’ (those fundamental to decision-making) or ‘additional’ 
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(factors that allow finer prognostication beyond those needed for treatment 
decisions).101  
 
There has been a great deal of study in the area of prognosis for many cancers, 
including lung cancer, and at the different stages of the cancer journey. A recent 
systematic review of the literature identified over 150 different prognostic factors in 
NSCLC.100 For overall survival, the TNM system has consistently been shown to be the 
most powerful prognostic tool.92, 94 The review stratified patients into those with 
advanced disease, locally advanced disease (cancer that has spread to nearby tissue or 
lymph nodes) and potentially resectable disease. 
 
Within the advanced disease category for NSCLC, the essential factors include: extent 
of disease, performance status102, 103 and weight loss.104-106 Additional factors include: 
refinement of anatomical cancer distribution, age, haemoglobin, lactate dehydrogenase 
(LDH), albumin, C-Reactive Protein (CRP)104-110 and gender. Further work has also 
evaluated other prognostic factors such as coagulation, proteinuria, marital status, 
quality of life (QOL), mood and symptom burden.104, 111-120 It is of note that research 
focusing on QOL has led to the development of renewed interest in symptoms and 
symptom burden as a prognostic indicators.121 
 
The majority of patients presenting with locally advanced disease have systemic 
symptoms such as reduced PS and weight loss. In this situation most studies consider 
prognostic factors to be the same as for metastatic disease.100 For patients without 
systemic signs or symptoms, there is evidence of higher survival rates, and these 
patients may represent a different prognostic group.122 
 
The category of operable NSCLC has received less attention in terms of prognostic 
investigation. The focus has been on accurate staging and determining fitness for 
surgery. There has been a great deal of study of those who have already undergone 
surgery, even though this represents the minority of patients. Again, tumour related 
factors are the main determinant of prognosis, particularly completeness of resection 
and pathological staging.94, 100 There is some evidence that markers of systemic 
inflammation (e.g. CRP) could be used to aid prognostication in patients undergoing 
surgery.123, 124 
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In SCLC the distinction between limited and extensive stage disease remains the main 
determinant of prognosis. In limited disease, prognosis is predicted by PS, gender, age 
and LDH.101, 125, 126 Prognostic scores have been developed to aid assessment for 
treatment. One such score is the Manchester Score which utilises lactate dehydrogenase, 
tumour stage, performance status, alkaline phosphatase and serum bicarbonate to 
distinguish three pre-treatment prognostic groups (the best group contained all long-
term survivors and in the worst group no patient survived more than one year).126 This 
score and the importance of these variables have been validated in subsequent 
studies.127, 128 Concurrent chemo-radiotherapy has been shown to improve median 
survival.98 In extensive stage disease, the best predictors of survival are normal LDH, 
response to combination chemotherapy and having a single metastatic lesion only.62, 101 
Patients in the terminal phase of their disease (defined as those with predicted survival 
of less than three months) are considered differently than those with localised or 
advanced cancer. At this point in the illness trajectory129 many prognostic factors have 
reduced importance.101 It has been reported that type of cancer and tumour-related 
factors are less relevant for prognostication than functional status and particular 
symptoms, especially anorexia, weight loss, dyspnoea, xerostomia and delirium.130-136 
Within advanced cancer (not specifically lung cancer) there may still be a role for the 
use of blood markers representing systemic inflammation, such as CRP.137 
 
1.4.6 Follow-Up in Lung Cancer 
After the diagnosis is made and treatments discussed and administered, follow-up is 
often arranged for patients. Follow-up may aim to serve several purposes but currently 
lacks a strong evidence base for effectiveness.138 Within cancer care across different 
settings and for different tumour types, a variety of follow-up structures and methods 
exist. The main purposes served by follow-up include: 
• assessing response to treatments provided; 
• monitoring for complications of treatments; 
• surveillance for recurrence of treated cancer; 
• surveillance for second or new cancers in higher risk groups; 
• provision of supportive care; 
• prevention of complications or recurrence. 
A review of the current evidence for follow-up and different follow-up structures has 
been undertaken (see Section 4).  
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1.4.7 Supportive and Palliative Care in Lung Cancer 
Management 
The terms ‘supportive care’ and ‘palliative care’ are used widely within the literature. 
They can be defined as separate entities with differentiation based on the prognosis 
(which is more limited in palliative care), the presence of active treatments (often 
considered supportive care) or treatments to control symptoms only (palliative care). 
There is a great deal of cross-over between these terms and some authors would make 
no major distinction between them. 
 
1.4.7.1 Supportive Care 
‘Supportive care’ is considered to be part of good management of lung cancer.139 ‘Best 
supportive care’ is a term now often utilised to describe the default or standard arm of 
many clinical trials within the oncology setting.140 Supportive care can be defined as:  
Care that helps the patient and their family to cope with cancer and the 
treatment of it – from pre-diagnosis, through the process of diagnosis and 
treatment, to cure, continuing illness or death and into bereavement. It 
helps maximise the benefits of treatment and to live as well as possible with 
the effects of the disease. It is given equal priority alongside diagnosis and 
treatment.141 
 
This broad definition emphasises that care encompasses both the patients and their 
families. It affirms that supportive care integrates into the full cancer journey from pre-
diagnosis to cure and survivorship or to end of life and bereavement care. It makes clear 
that this is not in opposition to, or less important than, other treatments for cancer but 
fits alongside and can help ‘maximise’ their benefits. This builds on a previous 
definition of supportive care provided by the European Organisation for Research and 
Treatment of Cancer (EORTC) Pain and Symptom Control Task Force: 
Supportive care for cancer patients is the multi professional attention to the 
individual’s overall physical, psychosocial, spiritual and cultural needs, and 
should be made available at all stages of the illness, for patients of all ages, 
and regardless of the current intention of any anti-cancer treatment.142 
 
The EORTC definition makes the domains of need clearer: physical, psychosocial, 
spiritual and cultural. However, there is no clear method for best identifying 
individuals’ supportive care needs, and there is little standardisation in care provision. 
This lack of clarity has been recently critiqued in the context of lung cancer clinical 
trials where ‘Best Supportive Care’ has been compared as a control to new active 
anticancer treatments.140 The authors of this paper argue that without a clear and 
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standardised definition of best supportive care, assessment of new treatment benefits is 
significantly affected and wider comparisons across different trials are hindered. 
 
1.4.7.2 Palliative Care 
Palliative care can be defined as:  
The active holistic care of patients with advanced, progressive illness. 
Management of pain and other symptoms and the provision of 
psychological, social and spiritual support is paramount. The goal of 
palliative care is achievement of the best quality of life for patients and their 
families. Many aspects of palliative care are also applicable earlier in the 
course of illness in conjunction with other treatments.141 
 
Specialist palliative care is defined as:  
The active total care of patients with progressive, far advanced disease and 
limited prognosis and their families, by a multiprofessional team who have 
undergone recognised specialist palliative care training. It provides 
physical, psychological, social and spiritual support, and will involve 
practitioners with a broad mix of skills.10 
 
In these definitions palliative care has been distinguished from supportive care. 
However, there is overlap between the areas of general palliative care, specialist 
palliative care and supportive care. Patients should have access to specialist palliative 
care services throughout their cancer journey.10, 129, 143 It is likely that the palliative care 
services will become more involved in care as the cancer becomes advanced. However, 
they can play a significant role at any point within the disease journey.12, 13, 129, 143, 144 
Within the care guidelines there is a clear emphasis on good communication and smooth 
transitions of care between specialities. This could be developed further into models of 
integrated working. However, this area has not been well studied although there are 
some examples of coordinated care from diagnosis.144, 145 A recent position paper from 
the European School of Oncology has gone further in defining the right to good 
supportive care of each cancer patient, stating that ‘When a patient has difficult 
symptoms which cannot be controlled by his/her current healthcare team, he/she has a 
right to be referred, and the current healthcare provider has an obligation to refer, to the 
local specialised palliative care team’143 (emphasis added). 
 
1.4.7.3 Assessment of Supportive Care Needs 
Supportive care needs in cancer patients are diverse and may fall into several domains: 
psychological, information and communication, physical (symptoms and function), 
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practical and spiritual. ‘Needs’ have been defined as having ‘the requirement of some 
action or resource that is necessary, desirable or useful to attain optimal well-being.’146 
Symptom assessment may identify the presence of symptoms (and now also the 
associated distress). Quality of life assessment can identify domains of reduced quality 
and satisfaction assessment can identify areas of low satisfaction. These do not usually 
assess which issues patients want help or support with. Needs assessment differs by 
identifying issues that patients do want help with and may allow the patient to indicate 
the magnitude of importance of each issue or identify areas which cause the most 
disturbance to the patients’ lives. Patient’s choice, prognosis, quality of life and 
symptom burden are central in the clinical care of lung cancer. These issues drive 
decision-making and transitions of care.143 
 
It is of note, however, that not all patients do want help from health care services for all 
care needs. In a qualitative study, Steele and Fitch evaluated the underlying reasons that 
some lung cancer patients did not want help for unmet supportive care needs.14 In their 
questionnaire (n=59) and semi-structured interview-based study (n=34), several key 
themes were identified underlying patients not seeking help for certain needs. These 
included: an ability to manage by themselves, assumption that certain symptoms or 
needs were ‘to be expected’ in lung cancer, existence of strong support networks to deal 
with issues and retain privacy, recognition of the high workloads of professionals and 
self-prioritising of needs to reduce added burden to health care teams, lack of awareness 
that resources were available to draw upon and trust in health care teams that they 
would identify and broach issues of importance. The quality of supportive care can be 
considered to be the extent to which needs are addressed. To allow patients who do 
wish help with unmet needs to access appropriate resources, it is important to be able to 
assess supportive and palliative care needs and to measure the success in meeting those 
needs.147, 148 
 
The recent National Institute for Health and Clinical Excellence (NICE) guidance on 
providing supportive and palliative care to cancer patients stressed the importance of 
standardised and systematic assessment of such needs at regular intervals in its second 
recommendation: 
Assessment and discussion of patients’ needs for physical, psychological, 
social, spiritual and financial support should be undertaken at key points 
(such as at diagnosis; at commencement, during, and at the end of 
treatment; at relapse; and when death is approaching). Cancer Networks 
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should ensure that a unified approach to assessing and recording patients’ 
needs is adopted.143  
 
Richardson et al149, 150, completed a time-limited, systematic review of ‘needs 
assessment tools’, identified between 1984-2004 to aid the process of meeting this 
recommendation in England and Wales. They defined ‘assessment’ as ‘collecting 
information on a person’s needs and circumstances and making sense of that 
information to identify needs and decide on what support or treatment to offer.’ This 
definition was further refined to specify the process should: be from or with the patient; 
have a consistent framework; be systematic in timing; be based on patients’ accounts of 
their needs, wishes and expectations; and inform the multidisciplinary team involved in 
care.  
 
Fifteen different tools were identified and reviewed. Of these 15, only three were 
specifically developed to identify needs which patients wanted help with: the Cancer 
Care Monitor (CCM),151, 152 the Sheffield Profile for Assessment and Referral to Care 
(SPARC)153 and the Initial Health Assessment (IHA).154 CCM, a computer-based tool, 
was developed to screen for cancer-related symptoms, treatment toxicities and patient 
concerns. SPARC was specifically developed to identify palliative care needs to direct 
appropriate and timely referrals to specialist palliative care services.153 IHA was 
designed to act as a clinical tool to identify supportive care needs during a patient’s first 
visit to a cancer care centre. The other tools within the review were developed to 
identify the experience of a problem, or presence of dissatisfaction, without identifying 
a wish for the need to be met.  
 
The authors of this review identified the Palliative Outcome Scale (POS) as an outcome 
measure tool designed to assess the effectiveness of palliative care interventions. As 
such, it was excluded from the systematic review. However, it is not clear why the 
baseline evaluation of supportive care needs requiring intervention would not qualify as 
an assessment tool. Wen and Gustafson155 have conducted a similar systematic review 
but widened the criteria to include tools that assessed supportive care needs of patients 
and their families. In this review, seven further tools were identified which evaluated 
the supportive care needs of the family.  
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1.4.7.4 Supportive Care Needs in Cancer and Lung Cancer 
A broad systematic review by Harrison et al156 outlines a wide range of prevalence of 
unmet supportive care needs in cancer patients. Ninety-four articles were reviewed, 
including one randomised control trial, one cohort study, 41 surveys and 52 other 
qualitative studies (interview- and focus group-based). A variety of tools have been 
used, preventing a standardised view over the cancer journey. Tools which identified 
need or inferred need were included.  
 
The majority of studies evaluated patients undergoing treatment (n=25). In this phase of 
the cancer journey, variable prevalence of unmet needs were identified in specific 
domains: activities of daily living needs (4-89%), communication issues (2-57%), 
economic needs (13-54%), information needs (11-97%), physical (21-70%), supportive 
care (13-86%) and sexuality (49-63%). The authors note that the upper range of 
prevalence of each domain was greatest in these studies compared to other phases of the 
cancer journey. They also note this may be an effect of more studies evaluating this 
phase.156 
 
At diagnosis, a narrower range of prevalence was found in each observed domain: 
activities of daily living needs (5-10%), economic needs (11%), information needs (10-
24%), physical (44%), psychosocial (6-69%) and psychological (12-17%). The authors 
note that a small number of studies address this phase of the cancer journey (n=3). Nine 
studies evaluated the advanced or palliative phase of the cancer journey and a further 14 
studies focused on post-treatment, follow-up and survivors. Lung cancer has been 
identified as having greater associated supportive care needs in comparison to other 
cancer types.146 Harrison et al156 also note that on secondary analysis of reported unmet 
supportive care needs of patients with cancer by Sanson-Fisher et al,146 lung cancer 
patients have an overall higher burden of supportive care needs compared to all other 
patients and to those being treated for breast cancer, prostate cancer, colorectal cancer 
or malignant melanoma. 
 
Supportive care needs in lung cancer have been studied previously. Krishnasamy et al13 
utilised a postal survey to identify health care needs in this population. One hundred and 
fifty-nine patients (of 466 invited participants) responded to the survey. Forty two 
percent of the respondents had undergone surgery for lung cancer (skewing this sample 
towards early stage, resectable disease). They found only 40% of patients reporting they 
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had ‘as much help as they needed’ from community services. Personal anxiety was a 
key problem in 66% of respondents but only recognised as such by 23% of hospital 
consultants. Other symptom issues identified were: pain (89%), unusual tiredness 
(85%), dyspnoea on walking (80%), cough (70%), insomnia (59%), anorexia (49%) and 
depression (49%). Social issues were identified as a problem in 58% of respondents. 
When asked to identify sources of support, most patients (76%) identified hospital 
consultants as the lead source of support. Other sources of support were identified as 
husband/wife/partner (65%), son/daughter (55%) and hospital nurse (48%). In this 
group of patients, only 6% identified specialist nurses as providing support. 
Communication issues were also identified; in particular, the giving of clear information 
to significant others was lacking. However, 71% of patients had been told their 
diagnosis by a hospital consultant and, overall, 69% felt their diagnosis had been given 
either sensitively or very sensitively.  
 
In a secondary analysis of a larger survey (888 respondents to 1492 invitations) of 
Australian cancer patients, Li and Girgis157 evaluated supportive care needs in lung 
cancer patients (n=112). This survey used the supportive care needs survey (SCNS)158 
and found lung cancer patients reported higher mean numbers of unmet psychological, 
physical and activities of daily living needs than all other patients (patients with breast, 
bowel, prostate, melanoma and other malignancies). There were similar levels of unmet 
needs in domains of health information and sexuality.  
 
The three most prevalent psychological needs reported by lung cancer patients were: 
‘concerns about the worries of those closest to you’ (53.4%), ‘fears about the cancer 
spreading’ (52%) and ‘fears about physical disability or deterioration’ (49.5%). Of note, 
in all other patients, these three issues were also the most prevalent but at lower levels 
(33%, 36.1% and 36.6% respectively) and in reverse order.  
 
The three most prevalent physical needs reported in lung cancer patients were: ‘not 
being able to do the things you used to do’ (53.3%), ‘lack of energy/tiredness’ (48%) 
and ‘pain’ (38.8%). Other patients also reported these as the most prevalent three issues 
but again at lower levels and ranking them as lack of energy, then not being as able to 
do the things you used to do, then pain.  
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Logistic regression was used to assess predictors of unmet physical and psychological 
needs. Having a diagnosis of lung cancer was an independent predictor of high levels of 
psychological (relative risk ratio=2.00, 95% CI 1.13-3.56) and physical needs (relative 
risk ratio=2.81, 95% CI 1.60-4.95). The authors conclude that the results clearly show 
there is a significantly higher burden of unmet supportive care needs reported by lung 
cancer patients compared to other malignancies. The study recruited patients from out-
patient clinics but has not specifically reported or controlled for the performance status 
of patients.  
 
Hill et al11 used a modified version of The Concerns Checklist159 alongside an interview 
completed within 28 days from diagnosis (n=80). All patients in the study rated at least 
two items as worrying to them (median 9 concerns, range 2-17). The highest rated 
concerns included: worries about the illness, worries about family and worries about 
future events related to the illness (defined as major worries ranging from very worried 
to extremely worried). Moderate worries included: feeling a burden to others, low 
energy, emotional issues, treatment concerns, dyspnoea, pain and mobility. Minor 
worries included cough, appetite, bowel issues and nausea and vomiting. It was noted 
that patients felt only 43% of their reported concerns had been considered by the 
healthcare team. Of the issues addressed, the majority related to symptoms and not 
psychosocial issues. Exploring this further, the authors rated concerns as ‘adequately 
discussed’ if more than 50% of patients reported having discussed the issue. Using this 
scale they found 70% of symptoms had been ‘dealt with’ but none of the emotional, 
psychological or social concerns had been adequately discussed.  
 
The findings of Hill et al11 in 2003 are in keeping with the study of Houts et al6 in 
Pennsylvanian cancer patients from 1986. Houts et al6 study of psychological, social 
and economic unmet needs reported a high level of need in cancer patients. Unmet 
emotional needs were most frequently reported (25%), followed by financial (13%), 
social (12%), issues related to medical staff (10%), family (8%), spiritual (7%) and 
information (6%). On regression analysis, it was found that having a diagnosis of lung 
cancer was independently associated with having higher overall unmet needs and higher 
unmet needs in each of four domains: emotional/social, economic, relations with 
medical staff and community. A diagnosis of colon, breast, uterine or prostate cancer 
was not independently associated with higher overall needs. Other characteristics 
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predicting higher unmet needs included: higher stage of disease at diagnosis, being 
younger, lower income and emotional problems pre-dating the diagnosis of cancer.  
 
Unmet supportive care needs in Pennsylvania between 1986 and 2005 have been re-
evaluated by Barg et al5 (Houts is also one of the authors of this paper). Although a 
comparison was not directly possible (altered survey method and patients included 
could be further from diagnosis), the authors were able to make some assessment of 
changes in unmet needs. They report that overall there had been very little improvement 
in needs being met and, indeed, there may have been an increase in unmet needs since 
1986. In this study, they did not look at specific cancer types. Steinberg et al160 have 
reported in 2009 that ‘distress’ is evident in 51% of newly diagnosed lung cancer 
patients. In this model, physical symptoms did not contribute to prediction of global 
distress, but 42% of the variability in distress is predicted by the psychosocial variables 
‘depression’ and ‘nervousness’. 
 
1.5 Symptom Control 
Symptom control is a major component of supportive care.161 The following section 
outlines some of the concepts regarding symptoms and symptom burden. It gives a 
further overview of symptoms in lung cancer and the psychosocial context in which 
they are experienced. A review of the literature regarding specific symptoms in lung 
cancer is presented in Section 5. 
 
1.5.1 Symptoms and Symptom Experience 
‘Symptom’ is a term that can be interpreted in many ways and used for different 
purposes. The origin of the word comes from the Latin symptoma (meaning ‘from’) and 
the Greek sumptoma (meaning ‘chance’). These derive from syn and piptein meaning 
‘that which has befallen one.’121 The biomedical approach to symptoms understands the 
term to represent perceived changes in the body, or its functions, that indicate disease or 
different phases of disease.162 The Collins dictionary defines symptom in a biomedical 
way as ‘any sensation or change in bodily function experienced by a patient that is 
associated with a particular disease’121, 163 (emphasis added). A medical anthropological 
perspective looks at symptoms as representations of the meanings that illness has for the 
person experiencing them.162 In this perspective, there is a distinction made between the 
‘disease process’ (i.e. physical, structural or pathophysiological changes), the human 
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experience of ‘illness’ and the behavioural and psychological expressions of these 
within each person’s social and societal structure.162 Supportive and palliative care 
utilise the multidisciplinary team to approach care with a wider view of symptoms and 
symptom experience, encompassing both biomedical and medical anthropological 
approaches.142 
 
Symptom experience, or symptom burden, has been described as a summation of 
symptom occurrence (frequency and intensity) and the distress felt related to that 
occurrence.121, 164, 165 Frequency, duration, severity, meaning and memory of symptoms 
will influence the impact on each individual. In this meaning-centred approach, distress 
is the impact experienced from the presence of the symptom burden.164, 166 Symptom 
experience has also been described as a dynamic process that involves the perception, 
evaluation, meaning of and response to a symptom.166 This response takes place within 
the patient’s individual psychosocial context.166 
 
Symptom burden can be defined as a summative indicator of ‘the severity of symptoms 
that are most associated with a disease or treatment’ and ‘a summary of the patient’s 
perception of the impact of these symptoms on daily living, including activity, mood, 
ability to work, and ability to relate to others.’121 Within these definitions, there is an 
emphasis on symptoms being subjective and, thus, the resulting burden and distress are 
individual. 
 
This dynamic process of symptom experience is further complicated by subtle 
disparities between recognition of distress by carers and professionals and distress felt 
by patients. Although there is a general agreement between patients and significant 
others in the assessment of general well-being and function, for concrete observable 
symptoms the significant other often reports higher symptom levels and more problems 
than the patient. This disparity is particularly true for assessments of psycho-emotional 
function.167 Throughout the lung cancer trajectory, there is evidence of these subtle 
discrepancies. Lobchuk et al168 described some congruence between patient-reported 
symptoms and carer-reported symptoms. There was, however, a difference when the 
symptoms were ranked according to reported intensity. Of particular note, it was found 
that for most symptoms caregivers rated the intensity higher than the patient. 
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This has been explored further by Broberger et al169 and subsequently by Wennman-
Larsen et al.167 In the first of these studies, both symptom distress and ratings of 
symptom occurrence were compared between lung cancer patients and caregivers. The 
authors found that there was general agreement about which symptoms might cause 
distress but a lack of congruence in rating of symptom occurrence. Again caregivers 
rated more frequent symptoms than patients.  
 
In the second of these studies, the factors influencing agreement in symptom ratings 
were investigated, again finding a higher rating by caregivers. For many symptoms it 
was noted that although in grouped studies moderate overall agreement suggested this 
may allow proxy assessment of symptom distress, this might not hold true on an 
individual basis. Factors of importance in congruence included: gender (female 
caregivers tended to match patient’s ratings better), rating of fatigue and rating of 
emotional functioning.  
 
Lack of congruence has also been observed in the last week of life in the cancer setting. 
Oi-Ling et al170 showed disparity between patient-rated, professional-rated and 
caregiver-rated symptom distress. It was found that health care professionals underrated 
many symptoms. This observation was also made in a study looking at symptom 
distress rated by patients with advanced cancer and their caregivers in the hospice 
setting.171 Given these disparities, when it is possible to assess symptom experience by 
patient-reported measures, then this should be used in preference to proxy reports. 
 
1.5.2 Symptoms in Lung Cancer 
Symptoms in lung cancer often act to prompt investigations leading to investigation and 
diagnosis,80, 82 contribute to changes in global quality of life172 and may aid 
prognostication at different phases of the cancer trajectory.116, 173 A review of the 
literature regarding symptoms in lung cancer is presented in Section 5. 
 
Several studies have shown that patients with lung cancer experience more symptom 
distress than other cancers and many chronic conditions.1, 12, 104, 114, 119, 174-177 There is a 
decline in function and an increase in symptom burden as the cancer advances.12, 178, 179 
A recent study of patients with advanced cancer by Johnsen et al175 found lung cancer 
was a significant independent predictor of dyspnoea and reduced social function. It has 
been estimated that 25% of lung cancer patients have depression or other psychosocial 
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needs which are unmet but are amenable to intervention.2 Those who are not offered 
anti-cancer treatments, and patients with SCLC, are at higher risk of psychosocial 
morbidity.2 It has also been found that there is an early peak in distress around the time 
of diagnosis.1, 174 Furthermore, there is a complex interplay between the cancer journey 
and physical and psychosocial disease trajectories.129, 180 
 
Figure 6: Lung cancer: physical, social, psychological and spiritual well-being in the last year of 
life.180 Reprinted from The Journal of Pain and Symptom Management, Copyright 2007, with  
permission from Elsevier. 
 
1.5.3 Why is Supportive Care of Importance in Lung Cancer? 
Lung cancer stands out from other cancers and conditions as a disease of high symptom 
burden and increased psychosocial morbidity. Having lung cancer has been reported to 
be an independent predictor of distress in comparison to other cancers4-6, 146, 157 and non-
malignant conditions.181, 182 The majority of patients have incurable disease at 
presentation and, of the few who could be offered curative treatments on the basis of 
staging, many are not fit for such treatments due to comorbidity. As such, these burdens 
of lung cancer are faced in the context of a poor survival and a high mortality. Despite 
this, current models of lung cancer care often do not address supportive care issues 
adequately12, 13 or at all.11 Considering these factors, the importance of providing timely, 
efficient and effective supportive care is very clear.  
 
The aims of this study have been established to assess the current need within the 
Stobhill lung cancer service, to identify factors that may help improve services and to 
establish patients’ views on models of care (Section 2). 
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1.6 Summary of Introduction 
Over the last one hundred years, lung cancer has developed from a rare condition to 
become a worldwide epidemic. Lung cancer is now the leading cause of cancer-related 
death within Scotland, the United Kingdom and worldwide. In Scotland, lung cancer is 
diagnosed in over 4000 people each year and accounts for over 25% of cancer related 
deaths. Compared to many other cancers, lung cancer is associated with higher 
symptom burden, increased psychosocial distress, reduced physical function and worse 
survival. These issues may be further compounded by co-morbidities and high levels of 
deprivation within the lung cancer population.  
 
The term ‘lung cancer’ describes a number of different pathologies. The different types 
can be broadly classified into two divisions based on cell types: non-small cell lung 
cancer and small-cell lung cancer. Further distinction can be considered using sub-types 
of cell and the extent of the disease in any individual. The management options may 
vary according to type of cell (and increasingly sub-type), the stage of disease and the 
patients’ fitness to tolerate any given intervention. Individual prognosis also varies 
according to cell type, stage and physical function at diagnosis. In the UK, 
multidisciplinary care is now considered the gold standard for lung cancer management 
in order to achieve a holistic approach to lung cancer. Although patient-centred care is 
being promoted through UK government policy, there remains a deficit in the 
recognition of the needs of many lung cancer patients.  
 
This lack of recognition is mirrored by the large proportion of supportive care needs 
remaining unmet within this population. However, palliative and supportive care is 
increasingly being recognised as a vital part in cancer management. Such care is now 
being integrated into routine clinical care from diagnosis and into end points within 
clinical trials. These end points may include symptom burden (or distress) or quality of 
life and are increasingly assessed by patient-reported outcome measures. The 
relationship between symptom burden and quality of life is an area of current study.  
 
Within lung cancer there is a wide variation of reported symptom prevalence throughout 
the disease trajectory. Recently, the concepts of symptom burden and symptom distress 
have been developed to aid assessment of the occurrence, severity, frequency and 
associated impact of such symptoms. A wide variety of measurement tools have been 
used to allow some insight into physical and psycho-emotional symptoms. The role of 
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symptoms within the detection and management of lung cancer is pivotal and may also 
provide further prognostic information. The role of symptoms in follow-up is well 
described, but there remains discussion regarding the use of symptom driven follow-up 
instead of routine clinico-radiological follow-up. 
 
Patient reported outcome measures are now being used within clinical and research 
settings to aid individual management, identify items of unmet need, facilitate clinical 
audit and direct service development. The Palliative Outcome Scale is one such measure 
which has been developed and validated to assess supportive care need domains in 
advanced cancer. There may prognostic value in assessing symptom burden and quality 
of life. As such, POS may serve the dual purpose of identifying supportive and 
palliative care needs of lung cancer patients in the hospital setting and aiding 
prognostication.  
 
The aims of this study are outlined below (Section 2) and the process of development 
and methodology is described in Section 3. 
 
 33
2 Aims 
This aims below set out how this study hopes to answer the question:  
What are the supportive care needs within the lung cancer population attending the 
Stobhill Hospital multidisciplinary lung clinic and are there identifiable factors which 
can aid service provision to meet these needs? 
Primary Aim  
1. To evaluate the prevalence of supportive care needs within Stobhill Hospital’s lung 
cancer multidisciplinary clinic, to assess overall supportive care needs as measured 
by the Palliative Outcome Scale and to identify the key issues reported by patients 
in three groupings (Sections 6.1-6.2): 
a. all lung cancer patient attending the clinic, 
b. newly diagnoses lung cancer patients (within six weeks of diagnosis) and 
c. patients within the last three months of life. 
Secondary Aims 
2. To review the literature regarding symptoms related to lung cancer (Section 5). 
3. To review the literature regarding the current guidance and evidence for follow-up 
in lung cancer (Section 4). 
4. To evaluate clinical indices used within the Stobhill service to help identify patients 
with: 
a. increased supportive care needs overall as measured by POS (Section 7), 
b. a reduced survival (Section 8) and 
c. increased risk of key supportive care needs: 
i. increased anxiety and worry (Section 9), 
ii. pain (Section 10) and 
iii. dyspnoea (Section 11). 
5. To evaluate the Stobhill lung cancer service regarding (Section 6.2): 
d. service usage, 
e. patients’ satisfaction with the service, 
f. patients’ understanding of the follow-up provision and 
g. patients’ preferences for follow-up. 
6. To make recommendations regarding (Section 12): 
h. areas for development of the Stobhill lung cancer service to meet supportive 
care needs and 
i. future study and research. 
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3 Methods 
This section describes the methods employed and the design of this study. It outlines the 
population within the Stobhill lung cancer service that was evaluated and the setting in 
which this study took place. It describes the methodology used to allow evaluation of 
the three groupings of interest: all patients attending the clinic, newly diagnosed patients 
and those within the last three months of life. It details the approach to meeting the aims 
of the project and the process of development of this project. It also outlines the ethical 
framework within which the project operated.  
 
Two main literature reviews were undertaken to understand the symptoms lung cancer 
patients face and the current evidence regarding follow-up (Aims 2-3). These reviews 
provide a platform from which to consider active symptoms within the Stobhill lung 
cancer population and an understanding of the follow-up process that could inform 
possible integration of future supportive care provision. 
 
Within this study a questionnaire and case note review were used. The questionnaire 
was introduced into the Stobhill clinic to aid supportive care needs assessment, 
surveillance for active respiratory symptoms and to understand patients’ views of the 
service. The processes of project development (Section 3.3) and questionnaire 
development are outlined below (Section 3.7.2). The questionnaire contained an adapted 
Palliative Outcome Scale (POS) but also included the addition of questions regarding 
respiratory symptoms and service views. The modification of the tool may have reduced 
the validity of the questionnaire, and that has given rise to methodological issues that 
limit the scope of the conclusions. However, the use of non-validated instruments has 
been described as providing ‘important information about symptom prevalence and 
severity’, and the process of validation of cancer symptom assessment tools has varied 
considerably.183 The limitations of using a non-validated tool are discussed in Sections 3 
and 12.  
 
Defining the difference between service evaluation, audit and research can often be 
difficult.184, 185 Therefore, the ethical status of this study was determined through 
discussion, guidance from the University of Dundee,186 due process outlined by the 
National Research Ethics Committee,184 advice from the relevant Local Research Ethics 
Committee (LREC) Chairperson and subsequently full consideration by the LREC. It 
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was determined full ethics approval was not required and the study should proceed 
under service evaluation status (Appendix 1).  
 
The questionnaire provided quantitative outcomes that were analysed by descriptive 
statistics, univariate tests of association and multivariate regression. The approach to the 
analysis is outlined in Section 3. 
 
3.1 Literature Reviews 
In Section 1, the history and epidemiology of lung cancer has been described. The 
management of lung cancer has also been outlined. Lung cancer patients face a journey 
full of difficult decision-making regarding their own management. These decisions are 
made in the context of a high symptom burden. A review of the literature regarding 
symptoms in lung cancer has been completed (Section 5 and Aim 2). 
 
Within the management of lung cancer, follow-up is uniquely positioned to allow 
provision of supportive care. A review of the literature regarding lung cancer follow-up 
has been undertaken to understand the current evidence and practice from which models 
of care can be developed (Section 4 and Aim 3). 
 
3.2 Description of Study Setting 
Stobhill Hospital is located in the North of Glasgow, Scotland and has approximately 
440 in-patient beds. Its catchment area covers a population of more than 200,000 people 
within the North of Glasgow and part of East Dumbartonshire.187 This population 
includes many of the most deprived people in Scotland, with Glasgow City containing 
almost half (48%) of the 15% most deprived local populations in Scotland.188 As 
outlined previously, Glasgow has the highest incidence of lung cancer and the highest 
lung cancer-related death rate in Scotland. This places Glasgow as a lead in lung cancer 
experience within the United Kingdom. In global terms, Scotland has one of the highest 
incidences of lung cancer worldwide. 
 
In addition, it is likely that lung cancer patients in Glasgow have higher levels of co-
morbidity than other areas within the United Kingdom. This may, in part, explain the 
lower rates of active anti-cancer treatment and the higher death rates in Glasgow than in 
other areas within Scotland.41 Given the high incidence and poor prognosis of lung 
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cancer patients attending the Stobhill clinic and their associated high levels of co-
morbidity and deprivation,189, 190 lessons learned from understanding this service may 
inform other services.  
 
The Stobhill multidisciplinary lung cancer clinic, established in 1991, was the first lung 
MDT clinic in Scotland. It is available weekly and follows an MDT meeting attended 
by the respiratory team (consultant, trainee doctors and a lung cancer specialist nurse), 
radiology consultants, an oncologist, a thoracic surgeon, a palliative care consultant, a 
pathologist, clinic nurses and a cancer journey auditor. This meeting serves as a 
platform to discuss cases and make clinical team decisions. It also provides a forum for 
cross-specialty education and discussion.  
 
The majority of patients attending the clinic already have a definite diagnosis. This 
includes patients with both lung cancer and mesothelioma. A minority of patients 
attending the clinic are awaiting final investigations, repeat tests or serial CT scans to 
fully determine the diagnosis. The clinic follows on immediately after the MDT meeting 
and operates to allow assessment of the patients by the respiratory team, oncology team 
or the lung cancer specialist nurse. Surgical reviews are by arrangement and palliative 
care reviews by referral to an external clinic, home review or in-patient ward review. 
Patients may be newly diagnosed, receiving active anti-cancer treatment, being 
reviewed post-treatment, under routine follow-up or receiving supportive care. As such, 
there is a diverse range of lung cancer journey stages and supportive care needs 
represented within this clinic population. 
 
3.3 Development of this Study 
The primary aim of this study is to evaluate the prevalence of supportive care needs 
within Stobhill Hospital’s lung cancer multidisciplinary clinic, to assess overall 
supportive care needs as measured by the Palliative Outcome Scale and to identify the 
key issues reported by patients in three groupings:  
a. lung cancer patients attending the clinic, 
b. newly diagnosed lung cancer patients (within six weeks of diagnosis), and 
c. patients within the last three months of life. 
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The purpose of this study was to establish a knowledge base regarding the needs within 
the service in order to allow future service improvement and to answer the following 
question: 
What are the supportive care needs within the lung cancer population 
attending the Stobhill Hospital multidisciplinary lung clinic, and are there 
identifiable factors which can aid service provision to meet these needs? 
 
It was recognised that from this study valuable lessons could be learned which might 
also be applicable to other settings. The author of this thesis worked within the Stobhill 
service and was instrumental in establishing the project. At the initial development 
stages, the project was intended to be a service evaluation/audit rather than formal 
research, and it was not to be submitted towards a higher degree. Subsequently, the 
possibility of completing an evaluation of supportive care needs towards a formal 
higher degree was raised and considered. At that time, the author was no longer 
employed in Stobhill but worked in Tayside.  
 
This development process has raised issues regarding methodology and ethical status, 
which are addressed in Sections 3 and 12. Limitations regarding the use of instruments 
and clinical indices from the current practice rather than introducing new validated tools 
are evident; discussion follows in Section 12.  
 
3.4 Ethics 
The current study evaluated needs within the lung cancer service at one site and utilised 
tools and clinical indices in use within the Stobhill lung cancer clinic. The purpose of 
the study was to describe the prevalence of supportive care needs within this service, 
identify key issues to be addressed by future service developments, understand the 
potential role of clinical indices to target resources and evaluate current service 
provision. 
 
There is no universally agreed definition of research. It can be defined as ‘the attempt to 
derive generalisable new knowledge by addressing clearly defined questions with 
systematic and rigorous methods.’185, 191 Audit can consider current practice against 
known standards of care or can describe issues within a service. Although the definition 
of audit continues to develop, the Department of Health defines clinical audit as: 
 38
the systematic critical analysis of the quality of clinical care, 
including the procedures used for diagnosis and treatment, the use of 
resources and the resulting outcome and quality of life for the 
patient.192  
 
The National Institute for Clinical Excellence defines clinical audit as:  
a quality improvement process that seeks to improve patient care 
and outcomes through systematic review of care against explicit 
standards and the implementation of change.192 
 
A service evaluation assesses current care without judging against a set of standards.185 
Service evaluation can involve the use of an intervention such as interviews or a 
questionnaire to perform this evaluation.184  
 
It is acknowledged within the NRES guidance that there can be challenges in clearly 
defining all projects as research, audit or service evaluation.184 Furthermore, it is 
acknowledged that projects can fall within more than one category. Key discriminators 
of work being deemed research include the primary aim to derive new knowledge which 
is generalisable, hypothesis testing, involving the introduction of a new intervention and 
involving a process of systematic allocation or randomisation of patient groups.185  
 
The author of the current study was instrumental in the design, introduction and 
implementation of the questionnaire into the clinic while working within the Stobhill 
lung cancer service (August 2005 – July 2006). There was no intent to undertake 
formalised research towards a higher degree at this time. Prior to the introduction of the 
questionnaire, advice was sought from the Local Research Ethics Committee (LREC) 
Chairperson regarding the appropriate ethical framework. It was advised that the 
questionnaire could be used to evaluate service and, because this was not formal 
research, there was no requirement for further ethical approval.  
 
In 2007, the possibility of completing a study of supportive care needs using the 
questionnaire towards a formal higher degree was considered. The author of the current 
thesis was no longer employed in Stobhill but worked in Tayside. As such, the project 
was undertaken as an external worker through an honorary contract and the author did 
not contribute to clinical care during the period of the project. However, given the above 
facts, it was not clear at that time whether the project could proceed as audit/service 
evaluation or should be considered formal research. The National Research Ethics 
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Service (NRES) guidance states that researchers themselves can decide what type of 
study is being undertaken, but if there is doubt as to whether the work is research, audit 
or service evaluation, an opinion from the Chairperson of the local ethics committee 
should be sought.184, 191  
 
The University of Dundee ethics committee advises that clinical projects should be 
reviewed under the National Research Ethics Service (NRES) framework and for single 
sites through the local NRES research ethics committee.186 NRES guidance outlines 
where applications for project review should be submitted according to the nature of the 
study and population considerations: single site projects not involving prisoners, those 
who are incapacitated, medical devices or human tissue should be reviewed through the 
appropriate LREC.184  
 
Therefore, in accordance with guidance from the University of Dundee186 and NRES,184 
as detailed above, advice was sought from the Chairperson of the LREC. It was advised 
that the classification of the current study as service evaluation versus research was 
difficult and, as such, a full ethics submission was required.  
 
A full ethics submission was undertaken to allow scrutiny of the project and to classify 
the study as formal research or audit and service evaluation. The LREC had a lengthy 
discussion regarding this question, considering issues including the generation of new 
knowledge, potential for change in practice and the potential submission of work 
towards a higher degree. As a result, the LREC decided that the project was considered 
to be audit and service evaluation (see Appendix 1). As such it was not required to have 
documented, fully informed consent. However, it was important to inform patients that 
their responses were to be used towards this study. 
 
In keeping with the LREC decision, the current study proceeded as audit and service 
evaluation. Given the University of Dundee ethics committee advice186 and the NRES 
guidance184 detailed above, further formal ethical advice was not sought after receiving 
this considered decision from the LREC. Proceeding under this status has led to some 
constraints which have influenced the scope and design of this study.  
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3.5 Design 
As outlined previously, there were several stages to the development of this study. This 
staged development was driven by the altered purposes of undertaking the study, 
including formalising the work within the current thesis. However, the main driver 
throughout was to evaluate supportive care issues within the Stobhill service to aid 
future service development. 
 
Five main steps have been suggested for evaluating health needs.94 Step one includes: 
identifying the aims of the project, defining the population of interest, establishing the 
resources available and understanding the risks. Step 2 includes: profiling the 
population, gathering data and identifying needs. Step 3 includes: delineating the key 
issues, understanding the determinants of the key issues and considering the actions 
required to meet those needs. Step 4 includes: instituting action and monitoring the 
effects. Finally step 5 includes: learning from the project and measuring the impact of 
the evaluation. 
 
Methods of evaluation include questionnaires (or surveys), interviews, focus groups and 
formal research utilising purposeful sampling and randomisation. The choice of method 
will be determined by the aims of the project, the population of interest, the size of 
available sample, time available and resource constraints.193 In considering the above 
issues it was decided that a questionnaire-based study best suited the aims of the project. 
This decision was influenced by the aims of this study and the needs of the clinical 
service. Integrating assessment tools within clinical practice has been previously 
described in mixed populations194 and in lung cancer patients.195 However, these dual 
concerns have placed limitations on the project and influenced the methodology used.  
 
Questionnaires are well suited to gaining factual information from a large sample, thus 
allowing fuller representation of views from within a large population. The most 
common objective of survey research is ‘to describe’.193 Questionnaires are also cost-
effective and compare well to the resource dependent methods of interviews and focus 
groups.196, 197 In many cases a validated, previously published tool can be utilised to 
meet the project aims. This is not always the case, however, and questionnaires may 
need to be developed, or amended, to suit the specific purposes of the service in 
question.193  
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3.6 Sample Considerations 
To obtain a range of views and ensure that the sample was representative of all patients 
attending the Stobhill lung cancer clinic, it was decided that all lung cancer patients 
attending the clinic could complete the questionnaire. Therefore, a consecutive sample 
of convenience was used. As this was primarily a descriptive study, no a priori power 
study was necessary. 
 
Patients without a diagnosis of lung cancer were excluded from the study; all other 
patients were included. It was, therefore, expected that there would be a representation 
of the whole clinic population and patients at different phases within their lung cancer 
journey. 
 
The primary aim of this work was a descriptive study that considered three main 
groupings of lung cancer patients (Section 6 and Aim 1): 
1. any patient attending the multidisciplinary clinic, irrespective of phase of lung 
cancer journey; 
2. newly diagnosed patients (those within six weeks of diagnosis); 
3. patients within the last three months of life. 
 
Responses from the first two groups were obtained by evaluating the first questionnaire 
completed. The final questionnaire completed within three months of death was used to 
evaluate needs in the third group. There was no a priori stratification because timing of 
questionnaire completion prior to death could not be predicted. However, purposeful, 
post hoc coding was applied to separate the three groups of interest for detailed analysis.  
New referrals to the Stobhill lung cancer service number from around 200 to 250 per 
year. Around 130 people are confirmed to have lung cancer each year. Therefore, in 30 
months, around 325 new diagnoses could be made. Consensus discussion was 
undertaken to identify a reasonable time-frame for this project. Based on the referral 
audit data, a collection period of 30 months was thought long enough to allow adequate 
representation of all patients (new patients, those undergoing treatment, survivors in 
follow-up and those receiving supportive care), newly diagnosed patients and those 
within three months of death. 
 
There was no randomisation of patients as there was no specific intervention to assign. 
No pilot study was undertaken prior to this study; however, previous questionnaires had 
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been used within the multidisciplinary clinic for clinical care in the past. From this, it 
was clear that the use of a questionnaire was feasible. 
 
3.6.1 Expected Characteristics of the Sample Population  
The expected characteristics of the population within the study were derived from 
published UK national lung cancer audit data (Table 4). It was expected that there 
would be a predominance of males within the sample given the higher prevalence of 
lung cancer in males.3 The proportions of NSCLC and SCLC were expected to be in 
keeping with national figures: around 70% NSCLC and 15% SCLC.3, 56 The majority of 
patients were expected to have advanced or metastatic disease and therefore surgery 
would not be appropriate.3 In addition to this, it was expected that the population would 
be deprived, in keeping with the known economic landscape of the catchment area 
(Sections 1.2 and 3). 
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Chracteristic Data sourced from national lung cancer audit
Gender
Male 53% *
Female 47% *
Age
50 years and less 6.15%
51-69 35.31%
70 years and more 58.54%
Histology
NSCLC 60.90% *
SCLC 15% *
No/Negative histology 19.80% *
Other 2.80% *
Stage
1a 3.31%
1b 3.94%
2a 0.55%
2b 2.29%
3a 4.42%
3b 8.18%
4 22.99%
Unknown 45.42%
Uncertain 8.87%
Treatment
Surgery 9.88%
Chemotherapy 25.24%
Radiotherapy 22.04%
Palliative Care 17.61%
Active monitoring 12.86%
Performance status
0 13.19%
1 21.24%
2 13.66%
3 11.17%
4 3.72%
5 16.76%
Missing 20.27%  
Table 4: Expected characteristics of lung cancer patients attending Stobhill multidisciplinary lung 
cancer clinic. UK data and Scottish data (denoted by *) presented. 
 
3.7 The Lung Cancer Clinic Questionnaire 
The Lung Cancer Clinic Questionnaires (LCQ, Appendix 3) contain version 1 of POS 
(see Appendix 4) with some adaptations to suit the clinic environment. To meet the 
primary aim and secondary aims (see Section 2), further questions have also been added 
to record information related to service use, performance status, satisfaction, 
preferences regarding follow-up and understanding of current clinical structure.  
 
There are several different tools available to allow evaluation of symptoms183 and 
supportive care needs149 in cancer patients. Commonly used tools include: The 
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European Organization for Research and Treatment of Cancer Core 30-Item Quality-of-
Life Questionnaire (EORTCQLQ-C30),198 Functional Assessment of Cancer Therapy-
General (FACT-G)199 questionnaire, the Edmonton Symptom Assessment Scale 
(ESAS)200 and Symptom Distress Scale (SDS).201 Some instruments have been 
particularly focused on lung cancer patients.195 These include theLung Cancer Symptom 
Scale (LCSS)202 and the lung cancer-specific subscales of the FACT questionnaire and 
EORTC Lung Cancer 13-item (EORTC-QLQ-LC13203) questionnaires.  
 
A systematic review of cancer symptom assessment tools has recently been published 
by Kirkova et al.183 They reviewed 21 instruments used in cancer symptom assessment 
and found a great deal of variety in the tools available. The number and type of 
symptoms evaluated varied but usually included pain, fatigue and anorexia. Across all 
of the tools evaluating five or more symptoms, 56 different symptoms or issues were 
part of the assessment. The tools may assess occurrence, severity or duration. They may 
also assess ‘global distress’ or individual ‘symptom distress’. Time frames also vary 
between tools from ‘symptoms now’ to ‘symptoms over weeks’. Other dimensions such 
as practicality, validity and reliability were assessed for selected tools. No single tool 
was felt to be ideal, but the authors noted that a balance must be struck between 
comprehensiveness and patient compliance.  
 
This balance becomes more difficult as the patient’s performance status worsens and 
fatigue increases. It is noted that when reporting symptom prevalence, it is important to 
remember the filter effect that a list of symptoms will have, and that if a proxy is 
required to help complete the questionnaire, the assessment may be affected. The 
authors noted that although validated instruments provide reliability (when applied to a 
sample that is homogenous with the validation population), comprehensive non-
validated tools also contribute to knowledge regarding prevalence of symptoms and 
symptom distress. The choice of instrument relates to consideration of the purpose of 
research, targeted symptoms and the suitability to the clinical setting it is deployed 
within.183 
 
3.7.1 Patient-Reported Outcome Measures 
Outcomes can be described in terms of ‘achievement or failure to achieve desired 
goals’.204 Patient-reported outcomes (PROs) can be defined as ‘a measurement of any 
aspect of a patient’s health status that comes directly from the patient (i.e. without the 
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interpretation of the patient’s responses by a physician or anyone else)’.205 This 
definition can include information gained through measurement, but some extend it to 
include the development of the tool (i.e. contents, style and goals) being used to gain 
information.206  
 
PROs are now being integrated into clinical trials as primary and secondary end points 
and into routine clinical practice. PROs can be measured using one of the many and 
varied ‘patient reported outcome measures’ (PROMs). In 2006, the Food and Drug 
Administration (FDA) in the USA issued draft guidance on the use of PROMs in drug 
development and trials.205 Within the UK it has been said that ‘patient choice over 
treatment and care is a central feature of the NHS’. As part of delivering ‘patient-
centred care’,207 the UK government is developing the use of PROMs to promote this 
feature.208  
 
PROMs may be generic or disease-specific and utilise a variety of response 
mechanisms. They may assess global outcomes or specific domains and include tools 
for symptom assessment, quality of life assessment, satisfaction scores, health 
assessment and adherence to treatment assessment (Table 5). 
Outcome Domains  Types of outcomes measured 
Communication  Patient-provider communication  
Decision Satisfaction  
Patient involvement in decision-making  
Patient-provider concordance  
Patient decisional conflict  
Patient Attitudes and Behaviours  
Patient self-efficacy  
Patient adherence  
Patient behaviour change  
Provider Attitude and Behaviours  Provider recognition of patient problems  Provider management of patient conditions  
Satisfaction  Patient satisfaction  
Health Status  Patient health status  Patient quality of life  
Resource Use  Patient resource use  Visit length  
Table 5: Types of patient-reported outcome measures in seven domains. Modified from ‘Patient 
involvement and collaboration in shared decision-making’.209 
 
It is proposed that PROMs can be used in routine clinical practice to help prioritise 
problems, facilitate communication, identify hidden problems, elicit preferences, 
monitor changes in disease, monitor responses (or lack thereof) to treatment and to train 
new staff.210 PROMs have also been developed to aid the appropriate and timely referral 
of patients from one service to another (e.g. SPARC153). Greenhalgh et al206, 211 
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critiqued the use of PROMs and questioned the methods by which they are being 
evaluated. Noting systematic reviews, Greenhalgh et al206, 211 questioned the real impact 
of PROMs in changing practice or on decision-making; they propose studies not only 
assess if a tool can be used to promote change but also how the process occurs. (i.e. the 
factors behind the change including if the study affected these) 
 
Detmar et al212 studied the preferences of patients undergoing palliative chemotherapy 
(n=273) with regard to discussing quality of life issues with their doctor. They found 
that most patients wished to discuss physical symptoms (90.2%) and physical 
functioning (81.7%), but less wished to discuss emotional (67.4%), social functioning 
(44.3%) and family issues (52.7%). In contrast, 6.2% specifically did not wish to 
discuss emotional issues, 18.1% did not wish to discuss social functioning and 18.7% 
did not wish to discuss issues related to family. Many patients would only discuss issues 
if the discussion was initiated by the doctor (emotional (26.4%), social (36.6%) and 
family (28.6%)).  
 
Higginson and Carr,210 however, assert that PROMs do not replace all other clinical 
assessment but can operate alongside. In lung cancer, assessment of physical symptoms 
is routine but psychosocial burden is poorly assessed.11 Given that many patients would 
discuss such issues if they were raised by the health care team, PROMs may facilitate 
recognition of problems and promote discussion or action if the patient desires further 
support. 
 
The Palliative Outcome Scale (POS) was developed by Higginson and Hearn in 
response to a lack of tools which were suitable to identify supportive care needs in 
patients referred to palliative care and to be usable within the clinical environment.147 
Within the Stobhill lung cancer service, palliative care plays an active part of supportive 
care provision. Although POS has not been specifically validated in lung cancer 
patients, it has been validated in various settings including hospital, hospice and out-
patients.147, 213-215  
 
The clinical utility of this tool across settings, its low time and energy burden within the 
clinical setting and its ability to assess a variety of domains within supportive care led to 
its selection. The characteristics of the above tools have been tabulated in Table 6. 
 
 47
Instrument Item number Validated Lung cancer specific Physical Psychological Social
EORTC QLQ-C30, LC13 43 in total Yes Lung module Yes Yes Yes
FACT-L 36 in total Yes Lung module Yes Yes Yes
LCSS 9 Yes Yes Yes Yes Yes
ESAS 10 Yes No Yes Yes No
SDS 13 Yes No Yes No No
POS 12 Yes No Yes Yes Yes
Domains evaluated
 
Table 6: Summary of assessment tools including the Palliative Outcome Scale. 
 
3.7.2 Development of the Lung Multidisciplinary Clinic 
Questionnaire 
The questionnaire used was developed to identify supportive care needs and determine 
patients’ views of the service. The basis of the questionnaire was the Palliative Outcome 
Scale, version 1 (Appendix 4). The POS was chosen as it evaluates all domains of 
interest, physical symptoms, psychological needs, social concerns and service use. 
Furthermore, POS readily identifies unmet psychosocial and practical needs. This was 
of importance as needs in these domains are poorly identified and managed in lung 
cancer clinics.11-13 
 
This tool is short and readily integrated within a busy clinic environment. As such, it is 
ideal for the dual purpose of identifying individual need in real time and providing 
population information for service development. This wish to keep questionnaire burden 
low and enable clinical practice to utilise individual information in real time was the 
main driver behind the choice of POS and the decision to adapt this tool rather than use 
a battery of validated tools. The Palliative Outcome Scale is described in Section 3.7. 
 
It could be argued that a battery of detailed tools would give greater information and 
increased validity to the scope of this study. However, it is of note that in one such 
study of supportive care needs in lung cancer patients, Sanders et al216 conclude that 
they identified no useful tools for the clinical setting. This conclusion was based on the 
fact that the battery of questionnaires to assess supportive care needs, quality of life, 
function, psychological symptoms and coping mechanisms would not be suitable for the 
clinical setting given the time and resources required to use them. 
 
3.7.2.1 The Palliative Outcome Scale 
Outcomes have been described in terms of achievement or failure to achieve desired 
goals.204 Hearn and Higginson204 reviewed clinical tools available for measuring 
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supportive care outcomes suitable for a palliative population.213 They evaluated the 
specific areas of: Quality of life (QOL), symptom control (both physical and 
psychological) and family support. Twelve tools were identified as being designed for 
those with advanced cancer, providing a multidimensional assessment and not specific 
to only one cancer type. Although each tool reviewed fulfilled palliative objectives in 
part, none fully met all the criteria set.204 
 
From this background, the Palliative Outcome Scale (POS) was developed and 
validated in patients with advanced cancer in a variety of settings including outpatients, 
the community setting and in-patient hospice units.147 Further experience with POS has 
been obtained in a variety of settings and POS has been found to be adaptable and 
acceptable to patients.213, 217, 218 It has been translated into several different languages 
(German,219 Italian, Spanish,220 Portuguese, Urdu, Punjabi, Swahili and Chinese).213 
The majority of these studies have utilised version 1 of the POS. Using both the German 
and Spanish translations, anxiety perceived in the support network remained the most 
prevalent ‘severe’ issue.219, 220  
 
POS has also been adapted to assess supportive care needs in patients with motor 
neurone disease (MND).217 In contrast to the cancer studies, information needs rated 
much higher than personal or family anxieties in this small study of patients with MND. 
There has also been some recent work in developing a non-validated symptom 
assessment ‘bolt-on’ for POS, which has been used to assess symptom burden in 
patients with chronic kidney disease.221 Although POS is copyrighted, it can be used 
freely and use can be registered with Professor Irene Higginson and the POS 
Development Team, King’s College London, UK222, 223 (Appendix 2). 
 
POS allows individual item information to be gained about physical symptoms, 
psychological issues, spiritual considerations, practical concerns, emotional concerns 
(the patient’s and the patient’s perception of their family’s) and psychosocial needs 
(personal and familial).213 It defines the presence of each of these through a series of 
questions and asks the patient to rate the impact of the issue on their lives. In total, there 
are 12 questions within POS. Ten questions ask about how the individual perceives the 
effects of physical, psychosocial and practical issues over the previous three days.  
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The patient can rate the effect of the item on daily life on a five point Likert scale 
ranging from ‘none’ (0) to ‘overwhelming’ (4) (i.e. the higher the score, the greater the 
supportive care need burden). A further question asks for free text of what are the ‘main 
problems’. POS has been designed to allow self-completion, assisted completion or 
proxy completion to occur, dependent on any individual’s ability to fill out the form. 
The final question records how the questionnaire was completed (i.e. self-completed, 
help from family or help from staff).  
 
There is no suggested way to categorise POS responses, and different approaches have 
previously been taken. The tool developers have utilised analysis of severe symptoms 
(classified as either ‘severe’ or ‘overwhelming’),147 and other authors have utilised 
categories of ‘moderate to severe’ (including moderate, severe and overwhelming).218 
There is wide variation on reporting of symptoms in the literature with both means and 
medians being utilised. In addition to single item analysis, a summary score from the 
initial ten questions can be calculated ranging from to 0-40.  
 
A ‘staff’ version of POS has also been developed with an additional question assessing 
Eastern Cooperative Oncology Group (ECOG) PS. The two questionnaires can be used 
together to add mapping of supportive care needs over time and allow ‘proxy’ 
assessment to continue on from a known baseline if the patient becomes unable to 
complete the forms. Development of this patient reported outcome measure has 
involved patients’ views. Initial questions were constructed based on the previously 
available tools, utilising the most reliable and valid forms of questioning to cover the 
desired assessment domains. After a consensus panel (including a patient 
representative) development phase, the initial tool was piloted with 25 individuals. 
Further revisions were made in accordance with the findings of this study. Version 1 of 
POS was then evaluated in a multi-centre, prospective study of 450 patients with 
advanced cancer.147 This study demonstrated that the tool was appropriate for in-patient 
and out-patient clinical settings with a maximum of ten minutes being required to 
complete the form. Content was found to be valid, yielding information relevant to 
palliative and supportive care needs and not exploring irrelevant issues. Some staff 
noted that the tool could promote discussion of certain topics or aid raising a subject 
that may have otherwise remained hidden. In one centre there was concern the question 
relating to ‘Is life-worthwhile?’ may have caused distress in two patients and could be 
difficult to ask. Other centres found this question helpful.  
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Patient interviews assessed face validity (an evaluation by experts or selected patients 
whether the tool makes sense) and found a general acceptance that questions were 
appropriate and there were no missing issues. Most of the patients interviewed (9/12) 
felt it would be useful for staff to know the information yielded from POS. Two of the 
twelve felt care was at a good level and that additional information was not required. 
Comparison of staff rated responses and patient-rated responses revealed good levels of 
agreement (Cohen’s К) and correlation (Spearman correlation) for the majority of items. 
Furthermore, the proportion of items scored within one point of each other between 
patient and staff completed questionnaires was high (in 7/10 items, ≥80% of responses 
were within one point). Test/re-test reliability was high with 9/10 items having more 
than 80% of patients within one score of matching. The α reliability co-efficient for 
patient-rated scores was 0.65. POS was able to respond over time to improvements for 
all but the item relating to ‘have you been able to share how you are feeling with family 
or friends?’ These improvements were only statistically significant for patient-reported 
pain and patient perception of family anxiety. It was noted some items were rarely rated 
severe (e.g. time wasted and ‘are your personal affairs up-to-date’). The authors 
commented that a ‘floor’ effect may have been observed with such items (i.e. no further 
improvement was possible). The main issues raised in the free text section were: 
dyspnoea, weakness, tiredness, nausea and poor appetite.  
 
POS was further evaluated by Stevens et al218 in a specialist cancer centre, assessing 
patients’ needs at referral to a palliative care service and one week after. They were able 
to demonstrate the clinical usefulness of the tool, improved outcomes at one week and 
the acceptability of POS to patients. Again, in this study, the level of perceived family 
anxiety was rated higher than any other item. Adaptation of POS has occurred in a 
variety of clinical settings to reflect local environment and needs. The development 
team note that in non-specialist palliative care settings the title has been changed to 
Patient Outcome Scale to avoid any patient anxiety or distress related to the word 
‘palliative’.  
 
A second version of POS has been developed, with two further alterations:222 
• Question 7 has been changed from ‘have you felt life was worthwhile’ to ‘have 
you been feeling depressed’. 
• A trigger advising patients to visit their GP was added if their response indicated 
‘severe’ or ‘overwhelming’ depression. 
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If it is felt that the ‘worthwhile’ question could cause patients distress, then the second 
version can be used. The trigger prompts patients with severe depression to seek help. 
The developers of the Palliative Outcome Scale note that that version 2 is particularly 
suited to those people with supportive care needs who have a chronic or progressive 
disorder.222  
 
As lower QOL and higher symptom burden may be associated with poorer survival,119, 
224 POS may serve the dual purpose of identifying supportive and palliative care needs 
of lung cancer patients in the hospital setting and aiding prognostication. 
 
3.7.2.2 The Palliative Outcome Scale and Lung Cancer 
Eighty-six patients (19.6%, n=450) taking part in the development study for POS had a 
diagnosis of ‘respiratory tract’ cancer.147 In a subsequent study comparing POS with 
two other outcome measures, 22 (18.5%) further lung cancer patients participated in that 
evaluation.215 In another small study (n=30), three more lung cancer patients were 
studied using POS.218 However, this tool has not been studied in detail in ambulatory 
lung cancer patients within a hospital outpatient setting.  
 
3.7.2.3 Modifications to the Palliative Outcome Scale and Choice of 
Version One 
The developers of POS recognised that different services may need to adapt the tool to 
suit the local need.213 It is of note that such adaptations of POS have been reported in its 
use in patients with motor neurone disease214 and in patients with renal disease.221 In 
these studies the tool was not validated further but the adaptations were made to suit the 
aim of understanding need prevalence in specific conditions. It has been noted by the 
authors themselves147 that POS does not allow the detailed assessment of a full range of 
symptoms. Versions 1 and 2 specifically ask only about the effects of ‘pain’ and then 
one further question for ‘other’ symptoms. No other physical symptoms are addressed. 
 
Version 1 of POS has been used in this study since the population under evaluation did 
not suffer from chronic progressive disorders. In addition, no ‘trigger to seek advice’ 
was necessary relating to depression questions. Each patient was being reviewed at 
clinic at time of questionnaire completion, and any symptom or concern that was severe 
could be addressed at that time. 
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Rather than focusing on ‘depression’ specifically, the question of ‘do you feel life is 
worthwhile’ covers aspects of depression but also adds a wider insight into patients’ 
own views of the value or worth of life. Patients may not feel depressed but may 
consider life of little worth. Furthermore, anxiety has been noted to be a key issue in all 
previous studies utilising POS. Low self-esteem has been postulated as having a key 
role in development of maladaptive anxiety. Therefore, inclusion of the question 
regarding self-esteem was thought to be important, allowing some evaluation of this 
specific component of psychological distress.  
 
The Palliative Outcome Scale asks each patient to consider items ‘over the past three 
days’. Lung cancer is a dynamic condition with an often rapidly progressing clinical 
picture.56 However, it was intended to evaluate supportive care needs within the 
outpatient population rather than identify acute issues. Furthermore, in the out-patient 
setting review intervals are often in weeks or months. Through consensus discussion it 
was decided that the ‘three days’ period should be adapted to consideration of a longer 
period. Thus, each question was adapted to consider ‘over the past four weeks ….’ 
 
In keeping with other users of POS,213 it was considered using the word ‘palliative’ in 
the questionnaire title was inappropriate for a population of patients containing a wide 
range of cancer journey stages. As some patients attending the clinic had mesothelioma 
and some had not been diagnosed with lung cancer, the word ‘cancer’ was not used in 
the title. The title ‘Lung Multidisciplinary Clinic Questionnaire’ was therefore used 
instead of POS.  
 
3.7.3 Additional Questions and Domains within the Lung 
Cancer Clinic Questionnaire 
As outlined above, additional questions were incorporated within the Lung Cancer 
Clinic Questionnaire to allow a single instrument to be used. The additional questions 
are outlined below. 
 
3.7.3.1 Physical Symptoms and Function 
In keeping with the approach by Murphy et al,221 specific questions relating to lung 
cancer were added to allow identification of these symptoms. This was limited to three 
physical symptoms of key clinical relevance: dyspnoea, cough and haemoptysis.  
 
 53
Three new questions were framed in the POS style to address these three major 
respiratory symptoms: 
• Over the past 4 weeks, have you been affected by shortness of breath? 
• Over the past 4 weeks, have you been affected by cough? 
• Over the past 4 weeks, have you been affected by coughing up blood? 
 
These could be responded to individually in the same way as POS assesses pain and 
‘other’ symptoms: 
• Not at all, no effect  
• Slightly – but not bothered to be rid of it 
• Moderately – ‘symptom’ limits some activity 
• Severely – activities or concentration markedly affected 
• Overwhelmingly – unable to think of anything else 
 
It could be argued that further symptoms of relevance could have been added, including 
fatigue, anorexia and others. Again, the questionnaire performing a useful clinical role 
for individuals was balanced against the aim of understanding the needs of the 
population. Furthermore, it was recognised that POS allows patients to identify any 
other main symptom of relevance under the ‘other symptoms’ item. 
 
The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) is used 
within the Stobhill cancer service to aid decision making. This is a widely used scale in 
lung cancer management and its use is advised and integrated within the major British 
guidelines.10, 67 This scale has been critiqued regarding its ability to assess function in 
the elderly and may overestimate fitness for therapy.225, 226 This is of particular 
relevance when considering palliative treatments for conditions in patients who may die 
with their cancer rather than of their cancer. In lung cancer the median survival is such 
that the vast majority of patients will die of their cancer.227 Furthermore, under-
treatment of elderly patients with lung cancer is well documented.227, 228 Indeed, the 
ECOG PS has been well validated as one of the main determinants of fitness for therapy 
and prognosis100 in lung cancer10, a disease predominately affecting elderly patients.3 
Patient-rated ECOG PS has been shown to be a better prognostic guide in lung cancer 
patients than the Karnofsky Performance Status (KPS) Scale.103 ECOG PS is readily 
used within a busy clinical environment and this consideration often takes precedence 
over utilising longer study methods that may provide more subtle information relating 
to function. 
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In the patient version of POS, there is no self-assessment of PS; within the staff version 
of POS, PS can be assessed by proxy. It is known that assessment of PS can vary 
between patient self-rated, nurse-rated and doctor-rated PS.229 The ECOG scores 
functional status from normal ‘0’ to dead ‘5’. Clearly patients could not be asked to 
report a score of 5 to this question. In keeping with the staff version of POS, a question 
asking patients to report PS was included. The 0-4 Likert scale component of ECOG PS 
is similar to the POS style of question. In keeping with the intention to assess needs 
over time rather than acute events, patients were asked to assess their own PS ‘over the 
past four weeks’.  
 
3.7.3.2 Service Usage and Preferences 
To meet Aim 5, data regarding patients’ service usage was included in the LCQ. The 
occurrence of ‘new or changing’ symptoms since the last clinic review was evaluated 
with an additional question (Have you experienced any new or worsening symptoms 
since last being at clinic?) asking for a yes or no answer. 
 
The length of time since the previous attendance was estimated by the patient 
themselves as: first appointment, less than four weeks, four to eight weeks, two to four 
months or greater than four months. Actual interval times could be calculated from date 
of completion of the questionnaire.  
 
Attendance at the general practitioner within the clinic interval could be rated as ‘yes’ or 
‘no’, and free text allowed patients to indicate the reasons for attendance.  
 
The British Thoracic Society (BTS) guidelines of lung cancer management state that ‘it 
should be clear to patients who their supervising consultant is’.69 This was audited, 
allowing patients to pick one main person from general practitioner, respiratory 
consultant, oncologist, surgeon, palliative care consultant, specialist nurse, uncertain 
and other in response to the question: 
• Who do you think is the main person in overall charge of your care? 
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There is a paucity of evidence regarding patients’ preferences for follow-up care. In 
keeping with Aim 5 to gain information regarding the follow-up preference of patients, 
the following question was posed: 
• How would you prefer your on-going follow-up to be organised? 
The choice of responses reflected the different models of care that have been described 
in the literature: 
• Regular, routine appointments at this clinic even if you have no new or changing 
symptoms. 
• If new or changing symptoms develop then an arranged, rapid return to this 
clinic through your own GP. 
• By a hospital-based specialist nurse-led service with return to this clinic only if 
there are new issues to be assessed. 
 
One question assesses the patient’s perception of the number of health care 
professionals involved in their care:  
• Do you feel you are seeing too many different health care professionals? (‘Yes’ 
or ‘No’).  
 
3.7.3.3 Satisfaction with Service 
In keeping with the Scottish Government’s plan for ‘Better Health, Better Care 
2007’,230 there was a desire to determine patient satisfaction with the Stobhill lung 
cancer service. This was discussed as an additional outcome at the end of year 1 of the 
study. To achieve a survey of patient satisfaction without further instrumental burden on 
patients, the Lung Cancer Clinic Questionnaire was further modified to enable 
evaluation of this. Three satisfaction questions were added in years 2 and3. These 
questions were sourced from work previously carried out at Stobhill Hospital to develop 
a patient satisfaction questionnaire (PSQ).231 Although this has conferred further 
methodological issues, it did enable a single tool to be used, thus maintaining ease and 
speed of use. 
 
The measurement of satisfaction with services is in keeping with the desire to provide 
high quality, patient-centred care. However, there are issues surrounding this area of 
evaluation well described in the literature.232-238 Fundamental to these issues is the lack 
of an accepted definition of ‘satisfaction’236 and how it relates to patients’ real views of 
the quality of care provision.239 One definition that has been offered states satisfaction is 
‘a recipient's reaction to salient aspects of the context, process and result of the service 
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experience’. The reaction can be considered in cognitive, emotional and affective 
terms.236 
 
The need to understand the concept of satisfaction and to ground that concept within a 
strong theoretical framework before it can be applied to understanding what factors 
relate to it has been outlined by Linder-Pelz.240 Starting from this basis may reduce the 
heterogeneity in approaches taken to measure this patient-rated outcome. Turris239 
further critiques the concept and suggests that satisfaction can be seen as a symptom of 
patients’ interaction with quality rather than the underlying array of interactions. It is 
also not clear how often patients themselves would choose to assess a service in terms 
of satisfaction.236 When asked to do this, patients often rate satisfaction high. This may 
represent a bias towards trying to please healthcare professionals, wishing not to 
complain or worrying that any service rated with low satisfaction may be withdrawn.240, 
241 
 
One model of satisfaction evaluation attempts to address some of these issues by 
placing value on responses that indicate dissatisfaction. This ‘discrepancy’ model242 has 
some advantages within the healthcare environment where biases such as ‘gratitude’ 
strongly skew responses towards the positive.241 The results from this study will be 
reviewed in the context of these issues. 
 
The questions incorporated within the LCQ were sourced from work previously carried 
out at Stobhill Hospital developing a validated patient satisfaction questionnaire 
(PSQ).231 The PSQ demonstrated good internal consistency (Cronbach’s α=0.93) and 
test/re-test reliability. Overall, in this group of newly diagnosed lung cancer patients, 
high satisfaction was found. There was a strong correlation between satisfaction scores 
and symptom scores from a concurrent symptom assessment score.231 
• How satisfied were you with the way tests were carried out (taking into account 
time taken, discomfort and side effects)? 
• How satisfied were you with the way in which you were told what was wrong? 
• How satisfied are you with the way in which you are being followed up at the 
hospital clinic? 
 
Patients were asked to respond in a POS style: 
• Very satisfied 
• Satisfied 
• Unsatisfied 
• Very unsatisfied   Main reason:_________________________ 
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Responses were scored from ‘very satisfied’ (0) to ‘very unsatisfied’ (4), and a 
summary satisfaction score (0-12) was calculated, with higher scores representing lower 
satisfaction.  
 
This further adaptation to the LCQ may have influenced responses; therefore, 
comparisons of responses from year 1 and years 2/3 were completed to evaluate for 
differences. 
 
3.7.4 Timing of Questionnaires 
The timing of questionnaires was determined by their use in clinical practice. Patients 
could complete a questionnaire on any visit to the lung cancer clinic; therefore, no 
specific interval or timing was enforced in this study. To include evaluating the needs of 
lung cancer patients within the last three months of life, retrospective coding was 
required. Clearly this could only be determined after death had occurred. Therefore, 
patients could complete as many questionnaires as attendances in the clinic up until 
death. Retrospective coding was then applied to allow identification of the final 
questionnaire completed within three months of death. The detailed timing of the 
questionnaire response is outlined in Section 6.1.2. 
 
3.7.5 Distribution and Collection of Questionnaires 
The questionnaire was integrated into the routine clinical practice being offered to each 
patient when they were weighed on arrival. Demographics and weight were also 
recorded on the form. Patients could then complete the LCQ while waiting for review.  
Patients were informed that completion of the questionnaire would contribute to service 
evaluation but they were not required to complete the LCQ. Furthermore, their care 
would not be influenced if they chose not to complete the questionnaire. The LCQ was 
headed with a statement informing the patient that their responses would be used to 
improve their care and would be further analysed to develop service and help in the care 
of others (Appendix 3). The content of this header was reviewed by the LREC during 
the ethics submission. No further patient information leaflets were deemed necessary 
and signed consent was not required. Translators were available through the normal 
clinic mechanisms and forms could be completed by the patient alone, with help from 
family/friends or with help from clinic staff.  
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Completed questionnaires were returned to the nurse when they called each patient 
through for their appointment. The LCQ then accompanied the patient’s notes into the 
clinic review. As such, the clinician was able to use the tool and identify any 
individual’s needs that had been recorded. If any action was required from the 
responses, this could be initiated. The lung cancer specialist nurse was in attendance at 
the clinic and could also respond to identified needs. After the clinic, forms were stored 
over a period of four to six weeks and then collected by the author who had no input 
into the clinical setting. 
 
3.8 Data Retrieval and Collation of Questionnaires 
Patient responses to each of the LCQ questions were entered into a purpose designed 
spreadsheet using Microsoft® Office Excel 2003. Medical case notes were obtained 
with at least one month interval from date of questionnaire completion (to allow 
processing of clinic visit and treatment decisions to occur). Information obtained from 
review of the medical case notes was entered into the spreadsheet to record: patient 
number, LCQ number, gender, age, postcode, histology, stage, date of diagnosis, 
treatment recommended, treatment given, summary POS score, item POS scores, 
respiratory symptom summary score, respiratory symptom item scores, satisfaction 
summary score, satisfaction item scores, all other of LCQ item scores, PS at diagnosis 
(assessed by doctor), current PS (rated by patient), weight at diagnosis, current weight, 
date of clinic and documented involvement of palliative care services. Number of days 
from diagnosis to date of LCQ completion was calculated by subtracting diagnosis date 
from LCQ completion date. Postcodes were used to obtain Carstairs deprivation 
category and decile for each patient as established at the last Scottish census in 2001.48 
The spreadsheet was anonymised and password protected.  
 
3.9 Mortality Data 
Mortality data was obtained at six monthly intervals throughout the 30 month collection 
period. The initial search was performed by Stobhill Information Services (SIS). The 
SIS search utilises postcode, date of birth and hospital number to identify any deaths 
within the North Glasgow area. The register confirms vital status as ‘dead’ but does not 
give cause of death. Most deaths occurring would have been notified to North Glasgow 
Hospital Trust and included within this register. However, some deaths may not have 
been recorded on this register. A second, confirmatory search was performed utilising 
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the general register office for Scotland’s ‘Statutory Death Search’. All registered deaths 
within Scotland can be identified via this database and the death certificate can be 
reviewed to establish cause of death.243 The following search strategy was used to cross 
check vital status, dates of death and establish cause of death: 
• Surname 
• Surname with ‘Soundex*’ function. 
• Year range of death: 2005-2009 
• Birth year +/- 3 years 
 
*Soundex is a widely used indexing phonetic algorithm. It allows archiving of names by 
sound, as pronounced in English. Names with the same pronunciation can be encoded 
to the same representation allowing them to be matched despite minor differences in 
spelling.244 
 
Date of death and cause of death was recorded in the spreadsheet, allowing calculation 
of survival to death (or censor) from diagnosis and survival to death (or censor) from 
date of LCQ completion or diagnosis. 
 
3.10 Further Ethical Considerations 
Researching and completing service evaluations with patients who have advanced 
cancer or are near to the end of life demands consideration of several ethical issues.184, 
193, 245, 246 Despite the challenges, it has been argued that research and service evaluation 
are part of  good holistic care and that vulnerable patient groups should not be denied 
the benefits from research participation.247 Furthermore, many patients, including those 
with cancer and short prognosis, are keen to be involved in research.248, 249 Patients may 
participate through altruism, for personal gain or to gain an increased sense of 
meaning.249 
 
Informed and valid consent is necessary when engaging in research.245 This study was a 
service evaluation/clinical audit and, as such, did not require documented, informed 
consent. Guidance regarding this issue and an overall assessment was sought from and 
provided by the LREC and its Chairperson. However, it was important to ensure that 
patients understood that the questionnaire was part of a project, that responses would be 
analysed and that they were not required to complete the form. This was achieved as 
outlined above (Section 3.7.5). 
 
Although many patients do wish to take part in research, some may not. One difficulty 
in conducting evaluations within a clinical service is that patients can feel obliged or 
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coerced to take part.193 This could have implications both for the provision of service 
for patients and for the reliability of information provided. It needs to be clear that 
clinical care is not dependent on participation. In any project that engages with patients 
over the course of time, the understanding that participation remains the individual 
patient’s choice should be continually recognised.245  
 
It is also important to maintain the confidentiality of participants in any project. This 
can be achieved though anonymising data and ensuring password protection of data 
(Section 3.8).  
 
Although benefits can be gained through participation in research, it is also important to 
minimise any potential harm or distress. This includes considered wording of questions 
within surveys and interviews, providing support structures are in place to deal with 
issues raised and being mindful of this throughout any work. In this study, the nurses 
within the lung cancer clinic played a pivotal role in providing support to patients, the 
questionnaires were viewed within the clinic setting (and issues raised could be 
addressed) and the lung cancer nurse specialist was available for additional support 
provision.  
 
In dealing with the ethical issues surrounding working with vulnerable populations, it is 
wise to gain adequate supervision, follow the available guidance and seek advice from 
an experienced ethics committee during any project, as was done in this study (Section 
3.4 and Appendix 1).193 
 
3.11 Statistical Analysis 
Statistical analysis was carried out using SPSSTM Version 17.0. Data analysis was 
conducted in four phases: 
• coding, 
• descriptive analysis of prevalences and percentage responses to Lung Cancer 
Clinic Questionnaire items, 
• univariate analysis to identify associations with key issues and 
• multivariate analyses to identify independent predictors of key issues. 
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3.11.1 Coding 
To enable analysis of the three groups of interest, coding was applied to the data. The 
Microsoft® Office Excel 2003 spreadsheet data was imported into SPSSTM Version 
17.0. Coding identified patient number, first completed questionnaire (Q1), subsequent 
questionnaires (QX, where X=number of questionnaire) and ‘final’ questionnaire (QF). 
The final questionnaires were also separately coded to allow identification of when a 
patient had only completed a single questionnaire (i.e. when Q1=QF). Further coding 
facilitated separation of groups from within the data including: histology, stage of 
disease, presence or absence of metastases, age groups, POS scores, respiratory scores, 
satisfaction score, performance status, time from diagnosis to LCQ completion 
(allowing newly diagnosed patients to be identified), time from LCQ to death (allowing 
QF completed in last three months of life to be identified), percentage weight change 
from diagnosis to LCQ completion and certain/uncertain of who is in charge of care. 
 
3.11.2 Descriptive Analysis 
There is no suggested way to categorise POS responses, and different approaches have 
previously been taken. The tool developers have utilised analysis of severe symptoms 
(classified as either ‘severe’ or ‘overwhelming’),147 and other authors have utilised 
categories of ‘moderate to severe’ (including moderate, severe and overwhelming).218 
There is wide variation on reporting of symptoms in the literature with both means and 
medians being utilised. In addition to single item analysis, a summary score from the 
initial ten questions can be calculated ranging from to 0-40. Therefore, mean (SD) and 
median (range) were both reported in this study. Proportions were reported with 
confidence intervals. 
 
3.11.2.1 Population Characteristics 
Demographic and patient characteristic data is reported using proportions, means (SD) 
and medians (range). Overall median survival from diagnosis was calculated using 
Kaplan-Meier survival curves. This is compared to expected population characteristics 
as identified from the national lung cancer audit.3 
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3.11.2.2 Description of Supportive Care Needs and Lung Cancer 
Clinic Questionnaire Responses 
Supportive care need prevalences as measured by POS are reported using proportions, 
means (SD) and medians (range) in keeping with the variable methods of reporting 
within the literature. Descriptive data were tabulated and graphed. Tabulated data 
includes missing data and graphs exclude missing data. Stacked bar charts are used to 
present Palliative Outcome Scale data and PS. Individual bar charts present non-POS 
responses from the LCQ. Although the validity of the Palliative Outcome Scale was 
reduced by adaptation and incorporation within the LCQ, the responses are compared to 
previous POS studies. 
 
3.11.3 Evaluation of Predictors of Increased Supportive Care 
Needs as Measured by POS 
Comparisons across higher and lower supportive care needs (POS<10 and POS≥10) 
were completed. The point of dichotomy was determined by distribution analysis of 
mean POS scores.  
 
Categorical comparisons were made using Χ2 testing for greater than 2x2 comparisons 
and Fisher’s exact testing when considering a 2x2 contingency table. For continuous 
variables, unpaired Student’s t tests (when normal distribution) or Mann-Whitney U 
tests (when non-parametric) were used. Correlations were assessed using Pearson or 
Spearman correlation tests depending on distribution (Appendix 8). 
 
Multivariate analyses were performed using backwards logistic regression. Backwards 
logistical regression was chosen as this made no assumptions about the distribution of 
the data, allowed calculation of odds ratios, was suitable for exploratory analysis of 
outcomes and allowed independent effects to be identified. Backwards logistical 
regression is less likely to produce suppressor effects than a forwards stepwise model 
(Appendix 8).  
 
Factors were included if p<0.05 and removed if p≥0.05. As such, only statistically 
significant factors were included in the final model. This final model was assessed for 
goodness of fit utilising Hosmer-Lemeshow testing; non-significant values indicate the 
model is a good fit and the null hypothesis is accepted (i.e. there is no significant 
difference between observed and model-predicted values). The predictive success of the 
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model was compared to the null model and the effect size was evaluated using 
Nagelkerke’s R2 value. The ten individual POS items were then explored for direction 
and strength of possible correlation with the identified independent associations with 
higher supportive care.  
 
Utilising the coding described above (Section 3.11), this was repeated for each of the 
three groupings: all patients attending the lung cancer clinic, newly diagnosed patients 
and patients who died within three months of LCQ completion. 
 
3.11.4 Evaluation of Predictors of Reduced Survival from LCQ 
Survival analyses were carried out using Kaplan-Meier survival curves, log rank 
comparisons and Cox regression techniques. 
 
Kaplan-Meier survival curves were calculated for survival in days from date of LCQ 
completion to death or censor. Survival was evaluated as time from completion of LCQ 
until date of death or censor. A median survival from LCQ completion was calculated 
with 95% confidence intervals.  
 
Comparisons of factors affecting survival were completed by comparing differences in 
survival across variables of interest including a dichotomised POS score. Comparison of 
survival curves was carried out using log rank testing in SPSS. Factors were considered 
statistically significant for p<0.05. Those of clinical relevance and those identified in 
previous studies as of potential importance were then analysed by multivariate, 
backwards Cox regression. Factors were included if p <0.05 and removed if p≥0.05. 
Only statistically significant factors were included in the final model.  
 
Utilising the coding described above (Section 3.11), this was repeated for each of the 
three groupings: all patients attending the lung cancer clinic, newly diagnosed patients 
and patients who died within three months of LCQ completion. 
 
3.11.5 Evaluation of Predictors of Increased Anxiety 
Three main questions regarding anxiety and sharing of feelings are asked within POS: 
Question 1: Over the past four weeks, have you been feeling anxious or worried 
about your illness or treatment? 
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Question 2: Over the past four weeks, have any of your family or friends been 
anxious or worried about you? 
Question 3: Over the past four weeks, have you been able to share how you are 
feeling with your family or friends? 
 
Each of these questions can be answered from 0-4 (‘0’ indicating no anxiety or feeling 
able to share and ‘4’ indicating preoccupation with worry or not being able to share with 
anyone).  
 
POS responses were compared between patients who felt lower anxiety (0-1) and those 
who felt higher anxiety (2-4), and patients who perceived higher anxiety (2-4) within 
their carers and those who perceived lower anxiety (0-1). (Pearson chi squared testing 
was used for categorical data if larger than 2x2 tables, two-tailed Fisher’s exact test for 
2x2 tables and Mann-Whitney U test for non-parametric, continuous variables.) 
 
Statistically significant factors (p<0.05), those of clinical relevance and those identified 
in previous studies as of potential importance were then analysed by multivariate, 
backwards logistic regression. Factors were included if p<0.05 and removed if p≥0.05. 
Only statistically significant factors were included in the final model. This final model 
was assessed for goodness of fit utilising Hosmer-Lemeshow testing in which non-
significant values indicate the model is a good fit (i.e. the null hypothesis that there is 
no difference between observed and model-predicted values is accepted). The predictive 
success of the model was compared to the null model and the effect size was evaluated 
using Nagelkerke’s R2 value.  
 
Utilising the coding described above (Section 3.11), this was repeated for each of the 
three groupings: all patients attending the lung cancer clinic, newly diagnosed patients 
and patients who died within three months of LCQ completion. 
 
3.11.6 Evaluation of Predictors of Increased Pain 
One main question regarding pain is asked within POS: Over the past four weeks, have 
you been affected by pain? 
• Not at all, no effect  
• Slightly – but not bothered to be rid of it  
• Moderately – pain limits some activity  
• Severely – activities or concentration markedly affected  
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• Overwhelmingly – unable to think of anything else 
 
The question can be answered from 0-4 (‘0’ being no pain and ‘4’ being overwhelmed 
by pain).  
 
LCQ responses and other factors were compared between patients who scored lower 
pain (0-1) and those who felt higher pain (2-4). (Pearson chi squared testing was used 
for categorical data if larger than 2x2 tables and two-tailed Fisher’s exact test for 2x2 
tables).  
 
Statistically significant factors (p<0.05), those of clinical relevance and those identified 
in previous studies as of potential importance were then analysed by multivariate 
backwards logistic regression. Factors were included if p<0.05 and removed if p≥0.05. 
Only statistically significant factors were included in the final model. This final model 
was assessed for goodness of fit utilising Hosmer-Lemeshow testing; non-significant 
values indicate the model is a good fit and the null hypothesis is accepted (i.e. there is 
no significant difference between observed and model-predicted values). The predictive 
success of the model was compared to the null model and the effect size was evaluated 
using Nagelkerke’s R2 value.  
 
Utilising the coding described above (Section 3.11), this was repeated for each of the 
three groupings: all patients attending the lung cancer clinic, newly diagnosed patients 
and patients who died within three months of LCQ completion. 
 
3.11.7 Evaluation of Predictors of Increased Dyspnoea 
One main question regarding dyspnoea is asked within POS: Over the past 4 weeks, 
have you been affected by shortness of breath? 
• Not at all, no effect  
• Slightly – but not bothered to be rid of it  
• Moderately – breathlessness limits some activity  
• Severely – activities or concentration markedly affected  
• Overwhelmingly – unable to think of anything else’ 
 
The question can be answered from 0-4 (‘0’ being no dyspnoea and ‘4’ being 
overwhelmed by dyspnoea).  
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LCQ responses and other factors were compared between patients who felt lower 
dyspnoea (0-1) and those who felt higher dyspnoea (2-4). (Pearson chi squared testing 
was used for categorical data if larger than 2x2 tables and two-tailed Fisher’s exact test 
was used for 2x2 tables). Statistically significant factors (p<0.05), those of clinical 
relevance and those identified in previous studies as of potential importance were then 
analysed by multivariate backwards logistic regression. Factors were included if p<0.05 
and removed if p≥0.05. Only statistically significant factors were included in the final 
model. This final model was assessed for goodness of fit utilising Hosmer-Lemeshow 
testing; non-significant values indicate the model is a good fit and the null hypothesis is 
accepted (i.e. there is no significant difference between observed and model-predicted 
values). The predictive success of the model was compared to the null model and the 
effect size was evaluated using Nagelkerke’s R2 value.  
 
Utilising the coding described above (Section 3.11), this was repeated for each of the 
three groupings: all patients attending the lung cancer clinic, newly diagnosed patients 
and patients who died within three months of LCQ completion. 
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4 A Literature Review of Follow-Up of Patients 
with Lung Cancer 
4.1 Methods 
Computer searches were performed using MEDLINE, British Nursing Index (BNI) and 
EMBASE (Ovid SP, Ovid Technologies Inc., New York, NY), CINAHL (EBSCO 
Industries Inc., Birmingham, AL) and Cochrane Review. The search was limited from 
1981 to 2009, articles published in English and referring to adults with lung cancer. The 
keywords used were: ‘lung cancer follow-up’ or ‘lung cancer follow up, ‘lung cancer 
care’ and ‘lung cancer surveillance’. From these articles, further references were 
identified and searched for manually. Included were articles and guidelines with specific 
reference to follow-up of lung cancer patients or lung cancer care within the title. All 
studies were reviewed and consensus guidelines included. All other articles were 
excluded. 
 
4.2 Results 
Eleven articles were found utilising CINAHL and a further 12 articles using MEDLINE, 
BNI and EMBASE and three from article references. No additional articles were 
identified from Cochrane Reviews. Within the identified articles and from additional 
hand searches, 26 articles were found in total. These have been tabulated and considered 
under three headings: (1) guidelines and reviews, (2) follow-up after curative intent and 
anti-cancer treatments and (3) different models of lung cancer care to conventional 
follow-up and patients’ preferences. 
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Guidelines or reviews regarding follow-up in lung cancer 
Organisation/ 
Investigators 
Date Population within 
guidance remit 
Selected Guidance and statements 
ESMO32 2008 NSCLC Optimal approach to follow-up noted to be controversial. 
For those with potential curative ‘retreatment’: 
• Follow-up 3-6 monthly for 2 years then 6-12 months thereafter. 
• Radiological investigation can be considered at these reviews. 
ESMO64 2008 SCLC Radiological follow-up of asymptomatic patients not clearly defined in literature. 
Follow-up should be considered. 
For patients who achieve long term survival, monitoring for a second primary should be considered. 
ACCP250 2007 Follow-up of lung 
cancer patients after 
curative intent 
treatment 
• Initial follow-up (3-6 months) by treating specialist to monitor for complications of 
treatment. 
• MDT decision to provide follow-up beyond initial phase for surveillance. 
• All patients should be counselled on symptom recognition. 
• Routine follow-up with CXR for CT 6 monthly for 2 years then annually. 
• Blood tests, PET, fluorescence bronchoscopy not routinely recommended. 
SIGN 8010 2005 Patients with lung 
 cancer 
Paucity of research noted. 
Follow-up by clinical nurse specialists should complement conventional arrangements. 
Hospital follow-up recommended to continue if: 
• Reasonable prospect of hospital treatment or specialist advice being needed. 
• Where it is perceived to sustain a patient’s morale. 
• After surgery, initial follow-up by the surgeon. 
• After chemotherapy or radical radiotherapy initial follow-up by treating specialist. 
After palliative radiotherapy either oncologist or respiratory physician 
Follow-up arrangements should be communicated to GP. 
NICE C02467 
 
 
 
 
 
 
2005 Patients with lung 
cancer 
When patients finish treatment they should have a personal follow-up plan discussed and 
communicated to their GP. 
If Curative intent: 
• Member of MDT should routinely follow-up for 9 months with thoracic imaging as part of 
review. 
• Routine follow-up should not continue beyond 5 years. 
After chemotherapy or radiotherapy: 
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(continued) • Review should occur one month after treatment cessation and CXR if indicated. 
After treatments patients with life expectancy of >3 months should have open access to a protocol-
based nurse specialist service. 
ACR251 2005 NSCLC Follow-up with examination every 2-4 months for 2 years, 6 biannually to 5 years and annually for 
life. 
If curative intent: 
• CXR every 2-4 months (2 years), 6 monthly (to 5 years) then annually. 
• Routine CT at 3 months and then yearly. 
Different levels of CT surveillance are suggested for different initial stages and treatment 
combinations. It is noted that frequency of CT surveillance remains controversial in asymptomatic 
patients. 
ASCO252 2003 NSCLC If curative intent treatment: 
• Follow-up 3monthly with examination for 2 years then 6 monthly to 5 years, then annually 
thereafter. 
• Routine CXR not recommended, consider annual CXR if further curative intent treatment 
possible. 
• Routine CT or other radiological and blood tests not recommended. 
• Symptoms should drive appropriate investigations. 
BTS69 1998 Lung cancer Explicit, locally appropriate policies for follow-up should be agreed. 
Hospital follow-up recommended to continue if: 
• Reasonable prospect of hospital treatment or specialist advice being needed. 
• Where it is perceived to sustain a patient’s morale. 
• After surgery, initial follow-up the surgeon. 
• After chemotherapy or radical radiotherapy initial follow-up by treating specialist. 
• After palliative radiotherapy either oncologist or respiratory physician. 
Saunders et al253 
 
 
 
 
 
 
2003 Consensus statement 
for follow-up of 
treated lung cancer 
Lack of evidence base in follow-up. 
Initial follow-up should be by treating specialist and thereafter by member of MDT 
In curative intent: 
• 3 monthly review for 2 years then 6 monthly to 5 years. 
• Rapid interval access should be available to all patients. 
• CXR at each review. 
• No routine use of CT recommended. 
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(continued) In Palliative Intent: 
• Initial follow-up dependent of anticipated treatment toxicity. 
• Thereafter frequency dependent on adequacy of symptom control, usually 1-2 monthly for 1st 
6 months. 
• CXR at each review, routine CT not recommended. 
Colice et al254 2003 Follow-up of lung 
cancer patients after 
curative intent 
treatment 
• Treatment complications should be managed by treating specialist in first 3-6 months. 
• Thereafter follow-up by member of MDT. 
• Initially review and radiographic investigation 6 monthly for 2 years and then annually. 
• Patients should be counselled on symptom recognition. 
• MDT should oversee surveillance programme. 
• Other investigations not routinely recommended. 
Alberts255 2007 Follow-up after 
surgery 
• Lack of evidence base. 
• Increased frequency in first 2 years then reduced. 
• Life-long surveillance recommended in most guidelines reviewed. 
• Symptom recognition and monitoring is key to follow-up. 
• Use of CXR and CT more controversial. 
• MDT, GP or nurse-led follow-up models all advocated within literature. 
Table 7: Guidelines or reviews regarding follow-up in lung cancer. 
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Lung cancer follow-up after curative intent and active anti-cancer treatments 
Investigators Design Sample Histology Selected Findings Conclusions 
Gilbert et al256  Retrospective 
Longitudinal 
245 post-
resection 
patients with 
early stage 
disease (≤II) 
NSCLC 45.3% of patients had recurrence. 
Despite clinic follow-up, 70.3% of detected recurrences 
were identified by family doctor. 
67.5% of recurrences had associated symptom or clinical 
changes. 
Of the asymptomatic recurrences, 78.2% had an abnormal 
CXR. 24.2% were identified by CXR alone and 69.7% 
using multiple modalities. 
Symptoms at time of recurrence associated with reduced 
survival. 
No significant difference in survival between recurrences 
detected by family doctor or through clinic (For 
asymptomatic and symptomatic groups). 
64.9% of recurrences were extra-thoracic. 
Only 2.3% of recurrences detected by examination alone. 
Most recurrence is extra thoracic. 
Despite routine review more 
recurrence detected by family 
doctor than clinics. 
Most recurrences associated with 
symptoms. 
93.7% overall identified by history, 
examination ±CXR. 
Could nurse-led or telephone 
review identify recurrences? 
Walsh et al257 Retrospective 
Longitudinal 
358 patients 
after complete 
resection of 
lung cancer 
NSCLC Overall 5 year survival 54%. 37.7% had recurrence, 67% of 
which were extra-thoracic. Recurrence by initial 
pathological stage: I – 24.2%. II – 48.9%. 3a and 3b – 
54.5%. 24 % of recurrences were asymptomatic, 79% of 
which had abnormal CXRs. Physical examination alone 
detected recurrence in only 2 patients.  
Of the 102 symptomatic recurrences only 29% were 
retreated with curative intent. Of the 33 patients with 
asymptomatic recurrence only 10(30%) were retreated with 
curative intent. 3 of the 10 died within study period. 
Symptoms at recurrence predicted lower survival.  
9.8% of patients developed other malignancies during 
study. (50% within aerodigestive tract). 
Around 50% of patients who developed symptoms returned 
for assessment before a scheduled clinic. 
Routine follow-up by physician 
altered treatment strategy in <3% of 
patients. 
Routine follow-up (6 monthly) with 
CXR recommended for first year 
postoperatively then yearly CXR’s 
and symptom driven review. 
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Younes et al96 Retrospective 
Longitudinal 
130 patients 
after complete 
resection of 
lung cancer 
2 Groups: 
67 patients 
routine 
follow-up 
63 patients 
symptom 
driven follow-
up 
 
Groups 
occurred due 
to follow-up 
policy change 
NSCLC No difference in disease free survival between the two 
groups (p=0.219). 
Local recurrence detected in 1.4% of strict follow-up 
compared to 3.1% in symptom group. 
Significantly higher rate of consultations in strict routine 
group (5.9 visits/year compared to 3.25 visits/year). 
Twice as many CXR’s performed in routine group and 6 
times as many CT scans. 
Cost of follow-up was higher in routine group. 
Routine follow-up did help detect other health issues and 
there were less emergency attendances and hospital in-
patient days in this group. 91.4% of patients with 
recurrence died within 2 years. 
Routine follow-up did identify other 
health problems beyond lung 
cancer. 
These costs were mainly due to 
investigations and consultation cost. 
Routine imaging was not shown to 
be of absolute benefit but authors 
recommend use of CXR 6 monthly. 
As early detection of pre-
symptomatic recurrence does not 
translate into improved survival, 
intense follow-up not 
recommended. 
Virgo et a258 Retrospective 
Longitudinal 
182 early 
stage (<3A) 
resected lung 
cancer.  
62 non-
intensively 
followed and 
120 intensive 
 
Groups 
defined 
retrospectivel
y through 
service use  
 
NSCLC Significant variance in follow-up strategies within this 
single centre study. 
Test and visit frequency did not influence outcome. 
Time to detection of recurrence did not differ. 
Survival did not differ significantly between the two 
groups. 
 
Wide variation in follow-up 
practice. 
No difference between intensive 
follow-up and non-intensive for 
patient outcomes. 
QOL not evaluated. 
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Westeel et a259 Prospective  
Longitudinal 
192 post 
surgical lung 
cancer 
patients 
NSCLC Study to test feasibility of intensive follow-up with review 
and CXR 3 monthly, bronchoscopy and CT scan 6 
monthly. 
Recurrence detected by scheduled procedure in 63% and 
non-scheduled symptom driven procedures in  
37%. 
In recurrences detected by scheduled procedures 35 (26%) 
were asymptomatic. 10 detected by CT and 10 by 
bronchoscopy. 
Extra-thoracic recurrence in 48%. 
Curative intent treatment undertaken by 10 (5% overall) 
asymptomatic patients. 7 of these patients survived to 3 
years from recurrence. 
Symptomatic recurrence was associated with reduced 
survival. 
11% developed secondary new malignancies, mostly 
aerodigestive tract. 
Intense follow-up was more expensive and estimated 
around 13,000 dollars per year of life gained. 
Intensive follow-up is feasible and 
accepted by patients. 
Asymptomatic patients at 
recurrence had a slightly longer 
survival than symptomatic patients. 
Increased risk of second 
malignancies. 
80% of asymptomatic recurrences 
were intra-thoracic. 
Intensive follow-up may be cost-
efficient in terms of life years 
gained. 
 
Lamont et al260 Retrospective  
Longitudinal 
124 patients 
with stage 
resected lung 
cancer 
NSCLC CT follow up of lung nodules identified within first year 
post-operatively. 
Probability of developing a second primary lung cancer 
(SPLC) was 2.1% per patient per year. 
All SPLC detected were asymptomatic. Of the 19 (15%) 
patients with SPLC, 18 (14.5% overall) were potentially 
resectable Only 14 underwent resection and 9 (7.2% 
overall) had no evidence of disease at 20 months.  
Median disease free survival for SPLC was 35 months and 
28 months for local recurrence. 
Staging of second primary lung 
cancer is poorly defined. 
Those with SPLC at stage 1A have 
improved survival compared to 
those with more advanced disease 
receiving similar treatment. 
Local recurrence has a poor 
prognosis. 
Annual CT surveillance may 
improve detection of asymptomatic 
or pre-symptomatic lesions. 
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Benamore et al 
261 
Retrospective 
Longitudinal 
75 patients 
with advanced 
post treatment 
lung cancer 
(IIb to IIIb) 
40 patients in 
trials and 35 
non-trial 
patients (Less 
frequent 
follow-up and 
no routine 
CT) 
NSCLC 60% recurrence or new primary. 
64% of recurrences detected after patient sought review 
between scheduled appointments (equal numbers between 
groups). 
In the 44 patients with confirmed relapse biochemistry was 
normal in 88.6%. 
No patients had altered bloods as sole presenting feature of 
relapse. 
No difference in time to relapse between groups. 
No overall difference in survival between groups. 
Symptomatic recurrence associated with reduced survival. 
Isolated thoracic recurrence only detected in 6 (14%). 2 
underwent curative intent retreatment, 1 survived >4 
months. 
Detection of recurrence or new 
primary should only be sought if 
treatment possible. 
No difference in overall survival 
between groups found. 
Most recurrences had extra-thoracic 
disease evident. 
Routine blood tests did not 
contribute to survival outcomes. 
Routine CT did not contribute to 
survival outcomes. 
Perez et al262 Retrospective 
Longitudinal 
115 patients 
with complete 
response to 
initial 
treatment but 
subsequent 
progression 
58 patients 
with limited 
disease 
57 extensive 
stage 
SCLC 49% recurrences occurred within one year. 
44% in the second year. 
Time to progression longer in limited stage. 
Recurrence signalled by history in 71% and examination in 
further 10%. 
Symptoms of recurrence were not subtle. 
In asymptomatic recurrences were detected by CXR (12%), 
blood tests (6%) and CT (1%). 
59% of recurrences were detected between scheduled 
appointments. 
Symptomatic recurrence was associated with reduced 
survival. 
At recurrence, 33% were given supportive care, 41% 
chemotherapy, 20% radiotherapy and 5% combined 
modalities. 
All 115 patients died within follow-up period.  
Median survival 115 days (range 1-793 days). 
 
Follow-up in SCLC does not allow 
identification of potentially curable 
patients. 
RCT’s are not needed for follow-up 
strategies but utilise retrospective 
data to develop appropriate, cost 
effective follow-up. 
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Sugiyama et al263 Prospective 
Longitudinal 
94 SCLC 
patients who 
had shown 
partial or 
complete 
response to 
first line 
chemotherapy 
Grouped into 
intense (n=62) 
or non-intense 
(n=32) 
follow-up 
 
SCLC Intense included routine CT of chest and upper 
abdomen/CT or MRI brain and bone scan every 2 months 
(for 6 months) then quarterly for 1.5 years. 
Non-intense investigations by request. 
Disease recurred in 88.7% in intense group and 90.6% of 
non-intense. 
Asymptomatic recurrence in 65.5% (intense) and 41.4%% 
(non-intense) (p=0.03). 
No difference in groups in time to recurrence. 
Salvage chemotherapy delivered more often in intense 
group. 
Overall survival greater in intense group (Median survival 
of 20 months compared to 13 months). 
Intense follow-up may identify 
recurrence within asymptomatic 
patients and allow salvage 
chemotherapy before decline in PS. 
Survival was longer in intense 
follow-up group. 
20% of recurrences were detected 
with brain scanning. 
>90% of recurrences occur within 2 
years. 
Cost effectiveness not assessed. 
34% of recurrences in intense group 
were detected due to signal 
symptoms. 
Table 8: Lung cancer follow-up after curative intent and active anti-cancer treatments. 
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Different models of care for lung cancer follow-up and patients’ preferences 
Investigators Design Sample Histology Selected Findings Conclusion 
Moore et al264 RCT 203 lung cancer 
patients who had 
completed initial 
treatment and life 
expectancy >3 
months 
Mixed NSCLC, 
SCLC and 
Mesothelioma 
Randomised to 
nurse-led 
follow up (100) 
or conventional 
follow-up (103) 
Nurse-led follow up was acceptable to patients 
(75%). 
Reduced dyspnoea, better emotional functioning 
and less peripheral neuropathy in nurse-led 
group. 
No differences seen in overall survival or rates 
of progression. 
Nurses recorded progression of symptoms 
sooner than doctors. 
Patients in nurse-led group were more likely to 
die at home, had fewer CXRs and had more 
palliative radiotherapy. 
No cost differences found. 
No other differences found between groups. 
Follow-up by nurse specialists is 
safe, acceptable and cost equivalent. 
No patients in nurse-led group 
wanted to revert to conventional 
treatment at end of study. 
43% of patients in nurse-led group 
died at home compared to 23% in 
medical follow up. 
No differences in survival seen and 
symptoms detected sooner. 
Williamson et 
a265 
Audit 
Cross 
sectional 
 
40 lung cancer 
patients attending 
a new nurse-led 
clinic 
(100% response) 
Not stated Initially 57% would have preferred to see a 
doctor. 
100% were satisfied with information given. 
Future review 30% wanted nurse-led, 40% had 
no preference and 30% alternate doctor and 
nurse. 
100% were satisfied with nurse review. 
Satisfaction with nurse-led clinic 
was high. 
However majority of patients would 
have preferred medical review. 
 
Adlard et al223 
 
 
 
 
 
 
 
Service 
Description 
160 patients from 
lung MDT post 
palliative intent 
treatment 
Majority 
NSCLC but 
also SCLC, 
clinical and 
Mesothelioma 
No routine appointments made, open access if 
requested by patient or professional. 
43 % had one open access visit, 15% 2 visits, 
9% 3 visits and 33% did not visit. 
90% of visits related to symptoms. 
All visits were considered appropriate by MDT. 
50% of patients seen within 4 days of request. 
Most clinic visits arranged through macmillan 
Fewer clinic visits overall compared 
to predicted routine schedules. 
Access was rapid. 
Macmillan nurses had pivotal role. 
Symptoms were main reason to 
return. 
Some patients would have preferred 
routine return (22%). 
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(continued) nurses. 
22% of patients would have preferred routine 
review.s 
Increased telephone contact out of 
hours. 
21 patients did not use service at all. 
Temel et al266 Prospective 
Longitudinal 
Feasibility 
Phase 2 trial 
51 Newly 
Diagnosed 
ambulatory 
advanced lung 
cancer patients 
NSCLC (IIIb 
or IV) 
Feasibility study of integrating palliative care 
into follow-up and supportive care of newly 
diagnosed advanced lung cancer patients 
90% complied with at least 50% palliative care 
visits. 
Number of visits ranged from 0-17 (median 6) 
All participants surviving >6months chose to 
continue to meet with palliative care after study 
completion. 
High symptom burden confirmed through QOL 
and symptom questionnaire. 
 
Early palliative care input was 
feasible. 
Patients surviving >6months chose 
to continue with palliative care 
input. 
Symptom burden was high. 
Palliative care could be integrated 
into follow-up of advanced NSCLC 
patients from diagnosis. 
Pitorak et al144 Service 
Description 
Advanced (IIIb 
and IV) lung 
cancer 
NSCLC Outline of ‘Project Safe Conduct’, integration of 
palliative care into comprehensive cancer care 
Joint working and cross education between 
palliative care team and oncologists. 
Presence in clinics for breaking of bad news and 
symptom control. 
Patient focused care with appropriate 
interventions discussion individually within 
disease trajectories. 
Extended care for the family. 
Secondary care integrated with community 
visits. 
Culture change. 
Successful integration of palliative 
care service with oncology lung 
cancer care. 
Cross specialty training and joint 
clinics. 
Bridge between secondary and 
primary care. 
Bridge across transitions of care – 
active treatment to symptom control 
to end of life. 
Cox et al267 
 
 
(continued) 
Cross 
sectional 
34 lung cancer 
patients, post 
treatment eligible 
to attend a nurse-
NSCLC or 
SCLC 
20% of MDT patients considered suitable for 
nurse-led follow-up. 
Main symptoms were fatigue, dyspnoea and 
pain. 
Doctor follow-up more acceptable 
to patients and relatives. 
Nurse-led follow-up may be more 
acceptable if rapid access to doctor 
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led clinic Mean global QOL was at mid point on EORTC 
QLC C30 score. 
Majority had seen a doctor in MDT clinic. 
Majority wanted a check up and reassurance, 
less had specific problems they wanted to raise 
Reassurance was rated as the most useful 
component of review. 
67% felt no component of the review was ‘not 
useful’. 
Patients were significantly happier with future 
medical follow-up compared to nurse-led or 
telephone follow-up. Nurse-led follow-up was 
more acceptable than GP follow-up. 
also available. 
Symptom burden high in NSCLC. 
20% patients considered suitable for 
nurse-led follow-up at outset. 
Table 9: Different models of care for lung cancer follow-up and patients’ preferences. 
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Most of the NSCLC studies regarding follow-up after curative intent treatments were 
retrospective, longitudinal studies (n=5)256-258, 260, 261 comparing intensive with less 
intensive follow-up, trial-based follow-up against standard care or observational studies 
of the effect of intensive follow-up. Retrospective grouping was possible due to changes 
in protocols, participation in trials and data on service usage. One study was prospective 
in design.259 There were only two studies looking at follow-up methods in SCLC, one 
retrospective and one prospective.262, 263 The only randomised controlled trial (RCT) 
evaluated nurse-led follow-up against conventional medical follow-up in stable patients 
who had completed palliative treatments.264 Other than this RCT, the other studies 
relating to alternative models of follow-up or patient preference were: feasibility 
studies, audit, a prospective survey, qualitative or service descriptions. 
 
Intensive follow-up was variably defined within the studies. Definitions included: 
patients within trial protocols (compared to routine review),261, 262 standard care 
(compared to open appointments), frequent scheduled review with chest x-ray ((CXR) 
compared to less than three scheduled reviews per year but open return),96 routine 
review and CXR three monthly with CT scan and fibreoptic bronchoscopy six 
monthly,259 four or more appointments per year or four or more multichannel blood 
tests per year or four or more CXR per year or bronchoscopy or sputum screen 
(compared to none of above),258 and three monthly CT surveillance of any nodules 
detected on post-operative scan.260 The most intensive follow-up protocol included 
regular review, blood tests, CXR, two monthly CT of thorax, abdomen and brain and 
bone scan for six months then quarterly for one and a half years. This was within a 
prospective study of SCLC patients with complete or partial response to first line 
chemotherapy.263 Four studies contain information regarding symptom status at time of 
recurrence after curative intent surgery (Table 10). 
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 Gilbert et 
al256 
Walsh et 
al257 
Younes et 
al96 
Westeel et 
al259 
Total 
Sample Size 245 358 130 192 925 
Recurrence 111 
(45.3%) 
135 
(37.7% 
33 
(25.3%) 
136 
(70.8%) 
459 
(49.6%) 
Symptomatic Recurrence 55 
(22.4%) 
102 
(28.5%) 
16 
(12.3%) 
100 
(52.1%) 
303 
(32.7%) 
Asymptomatic Recurrence 31 
(12.7%) 
33 
(9.3%) 
17 
(13.1%) 
36 
(18.8%) 
131 
(14.1%) 
Detected by Physical Exam 
Alone 
2 
(0.8%) 
2 
(0.6%) 
3 
(2.3%) 
Not 
reported 
7/733 
(0.9%) 
Asymptomatic and Detected by 
CXR 
8 
(3.3%) 
26 
(7.3%) 
5 
(3.8%) 
12 
(6.3%) 
56 
(6%) 
Asymptomatic & detected by CT 0 
(0%) 
4 
(1.1%) 
7 
(5.4%) 
13 
(6.8%) 
33 
(3.6%) 
Asymptomatic & detected by 
Bronchoscopy 
0 
(0%) 
0 
(0%) 
Not 
reported 
10 
(5.2%) 
10/795 
(1.3%) 
Detected at scheduled 
appointment 
26 
(10.6%) 
Not 
reported 
Not 
reported 
85 
(44.2%) 
111/437 
(25.4%) 
Symptoms at recurrence adverse 
prognostic factor 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
 
Yes 
Table 10: Summary of number, mode and symptom status of recurrence detection in patients who 
have undergone curative intent surgery for NSCLC. Percentages of total number of patients in 
each study in brackets. 
 
4.3 Discussion 
Lung cancer follow-up has a very low evidence base. Studies have tended to focus on 
follow-up strategies in patients with NSCLC who have undergone curative intent 
surgical resection. The main focus has been on trying to establish optimal frequency and 
intensity of investigations in follow-up. There have been fewer studies into follow-up 
after treatment for SCLC and even less into follow-up after palliative treatments or 
during supportive care provision. The important outcomes have generally been 
considered to include: overall survival, disease-free survival and cost-effectiveness. 
There has been little attempt to evaluate the best structures to address quality of life 
issues and to meet supportive care needs of patients within these studies. There have 
also been few studies addressing patient and carer satisfaction with follow-up structures.  
 
4.3.1 Guidelines Relating to Follow-Up 
Within Europe, guidelines that describe appropriate follow-up include Scottish 
Intercollegiate Guideline Network (SIGN) guideline 80,10 National Institute for Health 
and Clinical Excellence (NICE) guideline 24,67 European Society for Medical Oncology 
(ESMO)32, 64 and the British Thoracic Society (BTS) guidelines.69 Another recent 
guideline regarding lung cancer management has been issued from the American 
College of Chest Physicians (ACCP).250 Further American guidelines are available from 
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the American Society of Clinical Oncology (ASCO)252 and the American College of 
Radiology.251 There are dramatically conflicting views regarding follow-up structures 
and methods, and this is recognised in many of these guidelines. ESMO note that ‘the 
optimal approach to post-treatment management of patients with thoracic malignancies, 
including the role of radiological evaluation, is controversial.’32 SIGN guideline 80 
comments that in regard to follow-up of lung cancer patients ‘there is a paucity of good 
quality research in this area’.79 As such, the recommendations remain flexible and open 
to local interpretation, although the local policy is also expected to be explicit and 
clear.69 The majority of guidance is related to follow-up of post-curative intent 
treatments in NSCLC, although ESMO gives specific guidance related to SCLC64 and 
the UK guidelines are general for all histology subtypes. The ACCP has also issued 
guidance related to the palliative care of lung cancer patients. Guidance from the USA 
is more likely to suggest defined frequencies of follow-up and utilisation of radiological 
investigations. The European and British guidance is more general and allows for local 
flexibility.  
 
All the guidelines tend to suggest initial follow-up should be carried out by the treating 
specialist, either thoracic surgeon post-operatively or oncologist after radical 
radiotherapy or chemotherapy. However, the BTS guidelines state that ‘it should be 
clear to patients who their supervising consultant is.’69 Once the initial phase is 
complete (ranging from three to twelve months), the patient’s needs and goals should be 
reviewed by the MDT and structured follow-up arranged to meet those needs. After 
palliative treatments, the guidance is less clear as to who should lead follow-up and may 
leave this to local agreement. In the curative intent setting, the majority of American 
guidelines advocate frequent initial follow-up (two to four monthly), reducing to bi-
annually at two years and then annually at five years. European and UK guidelines also 
recommend more frequent follow-up in the first two years. In the USA, follow-up is 
generally recommended to be life-long. In contrast to this, NICE guidelines state 
follow-up should cease at five years.67 The reviews and consensus statements tabulated 
above outlined similar strategies for duration of follow-up.253-255 
 
Regarding alternative models of care, SIGN and NICE guidance recognise the role of a 
nurse specialist and recommend access should be available to such a service for all 
patients in follow-up with life expectancy of greater than three months. They 
acknowledge the only randomised controlled evidence for follow-up supports the case 
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of nurse-led care in selected patients. Many of the guidelines emphasise the importance 
of symptoms within lung cancer care. They advocate counselling to make patients 
aware of this and which symptoms to be alert to. ASCO guidance recommends a 
symptom-driven approach to use of radiological investigations. 
 
Each of the guidelines promotes the role of multidisciplinary team working and good 
communication. BTS, SIGN and NICE guidance all state that communication regarding 
follow-up with the patient, and also with the primary care physician with responsibility 
for community care of that patient, is vital.  
 
4.3.2 Follow-Up After Curative Intent Treatments 
When curative intent treatment has been provided, the follow-up is firstly structured to 
assess response and attend to treatment complications. Current guidelines suggest the 
treating specialist should provide follow-up for this purpose for a period of at least three 
to six months.250 Secondly, follow-up provides surveillance for recurrence or second 
primary lung cancer (SPLC). There is no solid evidence available to guide best practice; 
however, for patients with the potential for curative re-treatment, current guidance 
suggests a history and physical examination should be performed every three to six 
months for the first two years and every six to twelve months thereafter. Radiological 
examinations are to be considered at these intervals within ESMO guidance32, 64 but are 
suggested every six months within the ACCP guidance.96, 250, 253, 254, 257 
 
Detection of SPLC in post-operative patients with NSCLC was specifically addressed 
by Lamont et al.260 Evaluating follow-up with intensive post-operative CT scan 
surveillance, this retrospective study analysed 102 patients who had pulmonary nodules 
identified on a post-operative scan. Nineteen of these patients were diagnosed with a 
SPLC (overall probability of developing a SPLC was 2.1% per patient per year) and 16 
were staged as 1A. Only 11 of the 19 identified second primary lung cancers were 
identified by CT scanning. Fourteen patients with SPLC underwent further surgery and 
nine remained without identifiable disease for a median of 20 months (Range 4-56 
months). The authors concluded there is a role for CT surveillance to detect early stage 
second primaries to allow curative intent surgery to be delivered.  
 
It is recognised that co-morbidity and co-malignancy are common in patients with lung 
cancer. Walsh et al257 reported that within their study of 385 patients with resected 
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NSCLC, 66 (17%) had one additional malignancy, either prior to study entry (42) or 
during follow-up. The identification of new non-lung cancer primary malignancies 
during studies have been reported in up to 11% of patients undergoing follow-up after 
curative intent surgery for NSCLC.257-259 However, Virgo et al258 found that 
identification of second primaries did not significantly differ (p=0.57) between the non-
intense follow-up group (n=5/46, 10.9%) and the intense follow-up group (n=16/112, 
14.3%).  
 
Non-malignant health issues are also common in the lung cancer population.190, 268 
Janssen-Heijnen et al268 report from a study of 3864 lung cancer patients a high 
prevalence for diseases related to smoking: cardiovascular disease (23%) and chronic 
obstructive pulmonary diseases (22%). In this study, they also found a co-malignancy 
prevalence of 15%.  
 
Younes et al96 found an additional purpose of frequent review was the identification of 
non-malignant health issues in a timely fashion. They reported that the patients 
frequently seen by a specialist had less emergency room attendances and less in-patient 
bed days, translating into a lower cost for care of non-lung cancer related issues. This 
cost benefit was not sustained when off-set by costs of intensive surveillance and 
radiological investigations. 
 
At time of diagnosis of NSCLC, less than 20% are suitable for curative intent surgery.55 
From the studies detailed in Table 10, only 14.1% (9.3-18.8%) of the populations 
studied who did proceed to surgery had no symptoms at the time recurrence was 
detected; 6% (3.3-7.3%) had the recurrence detected by chest radiographs; 3.6% (0-
6.8%) by CT scan of chest, abdomen or brain and less than 2% by bronchoscopy. In the 
two studies reporting detection of recurrence at a scheduled appointment (review or 
surveillance investigation), 25.4% (10.6-44.2%) of recurrences were detected at one of 
these appointments. Walsh et al257 note that nearly half of the patients in whom 
symptoms developed returned at an unscheduled time for review. It is of note that in 
each study the presence of symptoms at diagnosis was an adverse prognostic factor; this 
was often true when comparing median survival from diagnosis, operation or 
recurrence. 
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A fourth purpose to follow-up could be to provide a platform for assessment of ongoing 
symptoms or supportive care needs related to either the disease or the treatments 
provided.139 This and quality of life issues were not addressed in any of these studies 
evaluating follow-up methods. In the curative intent setting, supportive care needs and 
symptoms have not traditionally been given high importance. Sarna et al269 have 
reported high prevalence of symptom and psychosocial distress within 94 patients one, 
two and four months post-thoracotomy. Prevalence of the severe symptoms included: 
fatigue (57%), dyspnoea (49%), cough (29%) and pain (20%). Mean symptom distress 
reduced over time for most symptoms, but only anorexia, pain and dyspnoea had 
significantly improved by four months. It was also noted that 77% of patients in this 
group had a co-morbid condition. It may be that integration of symptom-focused care 
into follow-up would add additional purpose. In addition to this, the systematic 
assessment of symptoms may also identify patients with changing symptoms sooner 
than conventional follow-up. It may be that some of the patients described as 
‘asymptomatic’ from retrospective case note review had unidentified or low level, but 
changing, symptoms present. It is of note that in the study of Moore et al264 of nurse-led 
follow-up, median time to detected symptom progression was significantly (p=0.01) 
lower in the nurse-led clinic (six months) compared to conventional medical follow-up 
(10.2 months), despite objective progression rates being the same (8.3 months in nurse-
led follow-up compared to 10.2 months, p=0.47). The nurse-led clinic utilised the 
European Organisation for Research and Treatment of Cancer Quality of Life Score 
(EORTC QLQ-C30) with lung cancer module 13 (LC13) to systematically assess 
quality of life and symptoms. In the above studies, the small percentage of detected 
‘asymptomatic recurrence’ may also have included a percentage of undetected 
symptoms. 
 
4.3.3 Follow-Up in Small Cell Lung Cancer  
Only two studies were identified that looked specifically at follow-up in SCLC. The 
first paper considered those who had achieved a complete response following first line 
chemotherapy within the context of three clinical trials.262 Of the 115 patients 
considered (58 with limited disease and 57 with extensive disease), recurrences 
occurred in 49% in the first year, 44% in the second year and 7% after two years. 
Within the follow-up period, 100% of patients died, with the median survival after 
recurrence being 115 days (range 1-793 days). It was noted that 59% of recurrences 
were identified between scheduled visits due to symptom development. The authors 
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noted that the symptoms occurring were not trivial or subtle but made it evident that 
disease status had changed. In all, recurrences were detected by history in 71% of cases 
and by additional examination in a further 10%. Of the 19% not detected by clinical 
history or examination, a further 12% were diagnosed through CXR abnormalities, 6% 
by altered biochemistry and only 1% by CT scan. Signalling of disease progression by 
clinical factors was significantly more common in those with extensive disease. The 
authors concluded that clinical history and examination was the mainstay for recurrence 
or progression in SCLC. CXR added some additional value but blood tests were of little 
benefit.  
 
In contrast, Sugiyama et al263 suggested that intensive clinical and radiological follow-
up did improve detection of recurrent or progressive disease and translates into 
improved survival. They evaluated 94 patients with complete or partial response to first 
line chemotherapy for SCLC. Fifty-five patients underwent very intensive follow-up, 
consisting of frequent review and CXR, two monthly non-enhanced CT (of chest, upper 
abdomen and brain) and bone scan for the first six months and then quarterly for a 
further 18 months. For the remaining 39 patients (non-intensive follow-up), 
investigations were at the discretion of the clinician. All patients received regular 
review (monthly for two years, then bimonthly for an additional three years). Patient 
characteristics and treatment received was similar in both groups. The authors also 
noted that no patient in either arm received prophylactic cranial radiation. On 
identification of recurrence or progression, either salvage chemotherapy was delivered 
(within limits of PS ≤ 3) or whole-brain irradiation for brain disease. Those with PS of 4 
were provided supportive care. Eighty-four (89%) patients had a recurrence detected 
overall with no significant differences in sites of recurrence between the two groups. 
Forty-two percent of recurrences were symptomatic; 58% asymptomatic. Fourteen 
percent of recurrences were detected on CXR (25% of asymptomatic recurrence), 
34.5% through CT of chest or abdomen, 15.4% brain scan and 4.7% through bone scan. 
At time of detection of recurrence, the number of patients with PS of 4 was less in the 
intensive follow-up group than the non-intensive group (9.1% compared to 27.6%, 
p=0.03). In keeping with this, more patients in the intensive group received salvage 
treatment. Overall median survival was longer in the intensive group (20 months, 95% 
CI 14-27 months) compared to the non-intensive group (13 months, 95% CI 9-15 
months, p=0.04). The authors do not address cost-effectiveness or quality of life issues. 
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4.3.4 Follow-Up in Non-Curative Non-Small Cell Lung Cancer  
After palliative treatment, follow-up assesses response, monitors and responds to side 
effects and provides supportive treatment.55, 253 There is no clear guidance as to the best 
frequency or structure for this follow-up. There is also no clear evidence as to who is 
best placed to provide follow-up and who patients wish to provide such follow-up. 
Hospital-based follow-up is currently recommended to continue where there is ‘a 
reasonable prospect of hospital treatment or specialist advice being needed, … where 
this is perceived to be important to sustain a patient’s morale,’ and after treatments 
given to monitor response and side effects.69 NICE guideline 24 recommends that a 
personal follow-up plan should be agreed and patients’ views obtained for service 
development.67 SIGN guideline 80 impresses the need for ‘a patient centred approach 
[and] effective communication throughout the cancer journey.’10 
 
Benamore et al261 addressed the use of intensive follow-up in patients with stage 3 
NSCLC receiving palliative treatments. They compared 40 patients within trial 
protocols and 35 patients who had received standard treatments. Patients within the trial 
protocol had significantly more CT scans of thorax, abdomen and brain but had the 
same frequency of review. They concluded that despite the trial group having a higher 
number of asymptomatic recurrences diagnosed, there was no overall benefit in 
survival.  
 
Three studies addressed the use of nurse-led follow-up in selected lung cancer patients 
who had completed initial treatment.265, 267, 270 Moore et al270 found acceptability of 
nurse-led clinics to be 75% and noted earlier symptom progression detection without 
any significant differences in objective progression or overall survival. Of note, patients 
undergoing review by the nurse were much more likely to die at home, had fewer chest 
x-rays and were treated with more palliative radiotherapy than those within 
conventional follow-up. An audit by Williamson et al265 found high levels of 
satisfaction with the service provided by the nurse-led clinic but the majority would 
have preferred to see a doctor instead (57%). This finding was in keeping with Cox et 
al.267  
 
Two publications addressed the integration of supportive and palliative care services 
within lung cancer clinics. Temel et al266 demonstrated the feasibility of such integration 
and Pitorak et al144 described a service in operation. Both papers suggested early 
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integration is acceptable to patients, and the benefits of cross-education, bridging illness 
journey transitions and symptom control were noted. Adlard et al223 described another 
model of care based on rapid return to open access appointments. No routine 
appointments were made for patients who had completed palliative intent treatments. 
The authors described 90% of return visits related to symptoms and the majority were 
arranged through the community palliative care nurse. Only 43% of patients requested 
review and most were seen within a week. The authors noted that, from the responders 
to a questionnaire, 22% of patients would have preferred a routine review.  
 
4.3.5 Patients’ Views Regarding Follow-Up 
Traditional follow-up has usually been provided on a routine basis with fixed 
appointments for on-going review. These reviews are carried out by medical staff and 
often are accompanied by routine imaging or blood tests. Alternative models of care 
include: 
• hospital based, specialist nurse-led clinics; 
• open access clinics with patient-led, symptom driven assessment; 
• discharge to community with community services follow-up; 
• discharge to care of palliative services. 
 
There is some evidence that specialist nurse-led clinics can be as effective as medical-
based follow-up in terms of clinical care and cost efficiency.264, 270, 271 However, it may 
be that patients would prefer routine medical follow-up compared to nurse-led follow-
up or general practitioner (GP) follow-up.267 Additionally, very little is known about the 
effects of routine follow-up and what value patients place upon it.267, 272 It has been 
reported that patients with advanced lung cancer can feel apprehensive about out-patient 
appointments but do wish on-going review and prefer review chest x-rays despite 
knowing their cancer is incurable.273 It has also been reported that patients can feel a 
sense of abandonment when discharged from the hospital-based service which has 
undertaken investigation and initial treatments. This is associated with increased 
psycho-spiritual distress (see Figure 6).180 
 
4.3.6 The Role of Symptoms in Follow-Up 
Even in the context of curative intent treatment there is little evidence to support routine 
follow-up or routine imaging compared to symptom driven follow-up.96, 254, 257, 274 In 
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most of the guidelines which address follow-up within lung cancer, symptoms are 
pivotal to recognition of recurrence or progression. It has also been noted that, given the 
poor prognosis and high symptom burden in lung cancer, symptom control and quality 
of life management should be integrated into lung cancer care.139, 250, 275 Symptoms may 
also give additional prognostic information at the time of recurrence, alongside disease-
free survival time and performance status. Such prognostic information could be used to 
trigger appropriately paced referrals for symptom control or palliative oncological 
interventions. It has been suggested symptom driven follow-up may be appropriate for 
the patients in whom goals are symptom control and improved quality of life (this may 
include those with incurable disease at diagnosis, those who are unfit for curative 
treatment and those in whom curative treatment has been provided but would be unfit 
for second line treatments). It is important to utilise systematic symptom assessment in 
the cancer setting, as many distressing symptoms may not be spontaneously reported by 
patients.276 Furthermore, it should be recognised that the distress associated with any 
given symptom may not be determined solely by its severity.224 
 
4.4 Conclusions 
There are 37 million follow-up appointments within the National Health Service (NHS) 
each year. Of all outpatient ‘Did Not Attends,’ 75% are for follow-up appointments.277 
Follow-up for cancer patients has been identified for particular attention to ‘ensure that 
follow-up procedures for cancer patients are clinically appropriate, make the best use of 
resources and enhance the experience for patients.’277 Appropriate follow-up will differ 
for individual situations. Follow-up arrangements should consider patients’ wishes and 
goals, stage of disease, treatment delivered, local resources, survival outcome and 
supportive care needs. In lung cancer, there are three main follow-up pathways: after 
curative intent treatment, after palliative intent anti-cancer treatment and those for who 
best supportive care alone is being provided. These different ‘streams’ of care may be 
underpinned by different strategies overviewed by the multidisciplinary team. One such 
model has been outlined by NHS cancer improvement services, based on the British 
Thoracic Society guidelines (Figure 7).69, 277  
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Figure 7: BTS guidelines for follow-up summarised.277 Reproduced from The How To Guide: 
Achieving Cancer Waiting Times with the permission of the Cancer Services Collaborative 
Improvement Partnership, NHS. 
 
It is clear that there are many health care professionals positioned to be able to provide 
follow-up for lung cancer patients, but it is not clear who, or which mix, produces the 
best provision at each stage of the illness trajectory. In those for whom curative intent 
treatment has been delivered, there remains debate whether intensive follow-up is 
efficient and effective and to what level radiological investigation should be integrated 
within such follow-up. In particular, it is not clear if asymptomatic (or pre-
symptomatic) disease can be identified to produce improved survival without disrupting 
quality of life and within cost-effective limits. Furthermore, most of the studies within 
the literature are retrospective and defined ‘asymptomatic’ from case note entries rather 
than utilising systematic symptom assessment tools to identify any low level symptoms. 
It is possible that systematic symptom surveillance would reduce the low number of 
‘asymptomatic recurrences’ detected within these studies.  
 
In the majority of patients who received palliative intent treatments, a variety of models 
of care appear to be feasible but require further evaluation to determine the model which 
best meets patients’ needs and delivers on outcomes. In those receiving supportive care, 
there may be an additional tension for patients who wish local, community-based care 
but continue to seek reassurance from hospital-based services.  
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An ‘enhanced experience’277 for patients is likely to be gained from providing a holistic 
service. There is a challenge to structure follow-up to provide four dimensional care: 
physical, social, psychological and spiritual. Such a concept has been described for end 
of life care by Chochinov et al;278-280 ‘dignity-preserving end of life care’ encourages 
consideration of symptom control, social support, and existential comfort as an 
integrated package. This, or similar approaches, may be integrated at earlier points 
within the lung cancer disease trajectory in the future. 
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5 A Literature Review of Symptoms in Lung 
Cancer 
Cooley et al1published a systematic review of symptoms in adults with lung cancer in 
2000, limiting their search to articles published between January 1982 and August 1998, 
identified using MEDLINE and Cumulative Index of Nursing and Allied Health 
Literature (CINAHL). Their review has been extended to include more recent articles 
and it referenced articles from before 1982 from a wider range of literature indices. 
 
5.1 Methods 
Computer searches were performed using MEDLINE, British Nursing Index (BNI) and 
EMBASE (Ovid SP, Ovid Technologies Inc., New York, NY), CINAHL (EBSCO 
Industries Inc., Birmingham, AL) and Cochrane Review. The search was time limited to 
between August 1998 and February 2009, articles published in English and referring to 
adults with lung cancer. The keywords utilised by Cooley et al1 were repeated: 
‘symptoms and lung cancer’ and ‘symptom distress and lung cancer’. In addition, a 
further search term was added: ‘symptom burden and lung cancer’. From these articles, 
further references were identified and searched manually. 
 
Inclusion criteria were specific reference to symptoms of lung cancer within the title or 
clearly stated symptom prevalence results within the abstract. All other articles were 
excluded. 
 
5.2 Results 
Thirty-six articles were found utilising CINAHL and a further 356 articles using 
MEDLINE, BNI and EMBASE. No additional articles were identified from Cochrane 
Reviews. Within the identified articles and from additional hand searches, a total of 21 
new articles were found. The previous review identified 18 articles in total over the 
period of January 1982 to August 1998, making a total of 39 articles identified over the 
period from 1982 to 2009. These have been tabulated and considered in reference to the 
stage of the lung cancer journey on which each study focused: initial presentation, new 
or recent diagnosis, diagnosis established and treatment or follow-up ongoing, patients 
receiving palliative or supportive care without active anti-cancer treatments and long 
term survivors. There is some overlap within these phases, but each article has been 
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positioned according to its main focus. A summary of design, sample type and size, 
symptom measures, symptom prevalence and main findings has been tabulated (Table 
11 to Table 15). 
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Symptoms at presentation 
Investigators Design Sample Instruments Utilised Selected Findings 
Hamilton et al82 Retrospective 
Case-control 
247 lung cancer patients at 
initial presentation to primary 
care 
Compared to 1235 age, sex and 
practice matched controls 
 
Case note review Most common symptoms: cough (65%) dyspnoea (56%), chest 
pain (42%), fatigue (35%) weight loss (27%), haemoptysis (20%) 
& anorexia (19%). Many of these symptoms prevalent in control 
population. 
Haemoptysis as presenting single symptom had greatest Positive 
predictive power (2.4%). 
Combination of symptoms increased PPP e.g. Haemoptysis and 
anorexia PPV >10%. 
Dyspnoea was usually accompanied by another symptom which 
helped target investigation (dyspnoea in controls 16%).  
Beckles et al66 Review of initial 
evaluation of 
presenting 
patients 
Prevalence of presenting 
symptoms tabulated from 8 pre-
1997 studies 
Various Range of presenting frequencies of symptoms: 
Cough (80-75%), weight loss (0-68%), dyspnoea (3-60%), chest 
pain (20-49%), haemoptysis (6-35%), bone pain (6-25%), 
weakness (0-10%), dysphagia (0-2%), wheeze/stridor (0-2%). 
Podnos et al281 Retrospective 
Cross sectional 
100 consecutive lung cancer 
patients from tumour registry in 
USA 
Case note review Only 18% asymptomatic at presentation. 
Mean number of symptoms was 1.9. 
Most common symptoms at presentation: pain(46%), cough 
(44%), dyspnoea (37%), fatigue (20%), gastrointestinal symptoms 
(16.5%) and neurological symptoms (13%). 
Lövgren et al282 Retrospective 
review 
Longitudinal 
314 patients with lung cancer 
First reported symptoms 
identified then symptoms 
triggering attendance at doctor 
identified 
Case note review Most common first reported symptoms: cough (41.8%), fatigue 
(35.7%), dyspnoea (32.5%), weight loss (32.1%), chest pain 
(17.7%), anorexia (12.9%), neurological symptoms (10.9%), 
3.5 % were asymptomatic. 
Most common symptoms leading to first attendance at doctor: 
Cough (27%), dyspnoea (23.8%), chest pain (13.8%) and other 
pain (8%). 
More symptoms were reported to be present prior to seeking help 
than symptoms triggering attendance of the doctor 
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Kwang et al173 Cross sectional 8788 Korean lung cancer 
patients 
Case note review Prevalence of symptoms at diagnosis: cough(38.1%),dyspnea 
(24.0%), chest pain (12.1%), haemoptysis (9.2%), 5% or more 
weight loss during the past several months (9.0%), general 
weakness(5.7%), and hoarseness (2.2%); 6.5% asymptomatic. 
Asymptomatic patients received surgery in 60% of cases. 
Absence of symptoms reduced risk of death from NSCLC when 
controlled for age, gender, treatment, stage and smoking.  
No difference found for SCLC. 
Table 11: Summary of studies evaluating symptoms at presentation in adults with lung cancer. 
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New or recent diagnosis 
Investigators Design Sample Instruments Utilised Selected Findings 
Mccorkle & 
Benoliel182 
Short term 
Longitudinal 
 
 
Crisis Theory 
56 newly diagnosed lung cancer 
patients 
65 patients with recent 
myocardial infarction 
Tested 1 and 2 months post 
diagnosis 
Symptom Distress 
Score (SDS) 
Lung cancer patients experienced more symptoms than those with 
Myocardial infarction. 
Most patients had little or moderate symptom distress. 
Most troublesome symptoms were: 
Fatigue, pain, cough, lack of appetite and insomnia. 
No difference between 2 times tested. 
Kukull et al181 Longitudinal 53 newly diagnosed lung cancer 
patients 
SDS 
McGill Pain 
Questionnaire 
Symptom magnitude may influence survival. 
Tishelman et 
al164 
Longitudinal 400 newly diagnosed patients 
with inoperable lung cancer 
Mean 31 days from diagnosis 
Adapted SDS 
Thurstone Scale of 
symptom distress-Lung 
cancer 
Most distressing symptoms: dyspnoea, pain & fatigue at baseline, 
3 and 6 months. 
No difference by age, gender or histology. 
Differences between reported symptom occurrence and symptom 
distress. 
Wennman-
Larsen et al167 
Cross sectional  Dyadic assessment of symptom 
experience by patients and carer 
52 newly diagnosed patients 
(within 1 month) 
EORTC QLQ-C30 and 
LC13 
Carer questionnaire 
Significant others rated higher symptom distress than patient. 
Most distressing symptoms reported by patients: fatigue, cough, 
pain, dyspnoea and poor appetite. 
Carers reported: Fatigue, cough, sleep, pain, dyspnoea as most 
distressing areas. 
Female carers show greater agreement with patient rated distress. 
Cooley et al174, 
283 
 
 
 
 
 
 
Longitudinal 
Repeated 
measures 
Secondary 
analysis 
117 lung cancer patients within 
100 days of diagnosis who had 
received anti-cancer treatment 
SDS Overall most prevalent distressing baseline symptoms were: 
fatigue (64%), frequency of pain (56%), insomnia (49%), appetite 
(43%), pain severity (37%). 
Overall there was a dynamic profile for most prevalent symptom 
over time. With fatigue and pain being most stable and dyspnoea 
increasing over time. 
The 3 most distressing baseline symptoms post surgical patients 
were: pain, fatigue & insomnia. Majority of symptoms decreased 
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(continued) 
over time except pain and fatigue. 
For radiotherapy group 3 most prevalent baseline symptoms were: 
fatigue, appetite & nausea. Most symptoms decreased by 3 month 
assessment and then increased again. Dyspnoea and cough 
increased overtime. 
In chemotherapy group, 3 most prevalent baseline symptoms were 
fatigue, insomnia and appetite. 
Combine treatment group: fatigue, frequency of pain and insomnia 
were most prevalent. 
Complex dynamic changes over time were observed for individual 
symptoms. 
No consistent patient related predictors of symptom distress over 
time (age, gender, income). 
Best predictor of 3 and 6 month symptom distress was baseline 
symptom distress. 
Sarna et al284 Longitudinal,  
Descriptive,  
Correlational  
Subsample of 26 adults with 
newly diagnosed progressive 
lung cancer 
SDS Average weight change varied little over time. 
Symptom distress subtle fluctuation. 
Degner and 
Sloan119 
Cross-sectional 434 newly diagnosed cancer 
patients 
Subset of 82 newly diagnosed 
lung cancer patients  
SDS Patients with lung cancer had greater symptom distress than other 
cancers. 
Symptom distress at baseline was predictive of survival. 
Most common symptoms: fatigue, pain, loss of appetite, cough, 
insomnia. 
Females reported more distress than males. 
Increased distress associated with advanced disease. 
Gift et al285 
 
 
 
 
 
 
Cross sectional 
Cluster analysis 
 
 
Theory of 
unpleasant 
symptoms 
220 newly diagnosed lung 
cancer patients 
Structured interview 
Standardised 
questionnaire 
Self designed 
Mean of 11 symptoms reported (range 1-27). 
Common occurring symptoms: fatigue (79%), nocturia (68%), 
pain (60%) and dyspnoea (58%). Mean symptom severity scores 
ranged from 1.31 – 2.33 (scale 0-3). 
No correlation between occurrence and severity of symptoms. 
Means of most severe symptoms reported: lack of sexual interest 
(2.07), vomiting (2.00), trouble sleeping (1.89), fatigue (1.84), 
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(continued) 
pain (1.84) & dyspnoea (1.82). 
No consistent clustering of symptoms found. 
Increased symptom occurrence and severity in those with  
co-morbid conditions. 
Khalid et al104 Cross sectional 29 Lung cancer patients 
presenting at secondary care 
setting 
Compared to new diagnosis 
gastrointestinal cancer patients 
Specific focus on symptoms 
that may reduce calorie intake 
Patient-generated 
subjective global 
assessment tool 
Self designed 
Case note review 
66% of lung cancer patients reported at least one symptom. 
Significantly more reported anorexia in lung cancer patients. 
No other major differences in reported symptoms. 
Increased prevalence of symptoms in advanced disease. 
Lövgren et al286 Longitudinal 159 Inoperable lung cancer 
patients from diagnosis, 
through treatment at 1 and 3 
months 
EORTC QLQ-
C30+Lung cancer 
module 13 (LC13) 
Prevalence of main symptoms at diagnosis were: tiredness (88%), 
depression (86%), worry (83%), dyspnoea (79%), cough (74%), 
insomnia (63%), anorexia (56%), pain (56%). 
Most distressing symptoms were: fatigue, dyspnoea, cough, pain 
and insomnia. There were some differences between men and 
women. 
Prevalence of main symptoms at 3 months were: 
Tiredness (93%), weakness (84%), reduced PS (81%), dyspnoea 
(74%), depressed (66%), pain (55%), anorexia (53%). 
Table 12: Summary of studies evaluating symptoms in new or recently diagnosed adults with lung cancer. 
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Established diagnosis of lung cancer and/or have received anti-cancer treatments 
Investigators Design Sample Instruments Utilised Selected Findings 
De Maria and 
Cohen287 
Cross sectional 
subanalysis 
1395 established diagnosis lung 
cancer patients 
Standard Assessment 
tool 
Self designed registry 
data 
Symptom prevalence overall: cough (54%), weight los (50%). 
Dyspnoea (36%), chest pain (32%), hoarseness (8%) and 
Dysphagia (3%). 
Analysis of age groups (40-50, 51-69 & >70 years). 
Elderly group reported more presenting dyspnoea but less pain.  
Only 10% asymptomatic in any age group. 
No differences in weight loss. 
Co morbidity present in 44% of elderly population and only 25% 
of <70 year olds. 
Kaasa et al288 RCT 
Longitudinal 
95 patients with NSCLC 
undergoing treatments 
(51 radiotherapy, 44 
chemotherapy) 
Toxicity Questionnaire 
Self-designed 
(10 Questions) 
Main symptoms insomnia, pain, tiredness and anorexia in both 
groups. 
Nausea, vomiting and hairloss common in chemotherapy group. 
Dysphagia and sore throat common in radiotherapy group. 
Muers & 
Round289 
Longitudinal 289 patients with NSCLC 
64 post surgery 
122 post radiotherapy 
103 supportive care 
Standard Assessment 
Tool 
Self designed 
Most common symptoms at presentation were: Cough (79%), 
dyspnoea 75%), chest pain (37%), anorexia(45%) and 
fatigue(45%). Most symptoms worsened with time (pain, 
dyspnoea, malaise & anorexia). 
Sarna284 Cross sectional 69 Females with lung cancer 
43% receiving treatment 
SDS Most patients experienced more than one symptom (61%). 
Most common symptoms: fatigue, pain and insomnia. 
Higher symptom distress associated with comorbidity, low 
income, previous chemotherapy and no surgery. 
Sarna et al290 Longitudinal 
 
Subsample of 60 adults with 
advanced lung cancer.  
50% receiving chemotherapy 
SDS Pre-illness weight loss moderately correlated with decrease in PS. 
Furuta et al291 Retrospective 
Longitudinal 
240 NSCLC before receiving 
radiotherapy 
Not specified 
Chart review 
Only 15% asymptomatic before treatment. Symptoms not an 
independent predictor of survival. 
Symptoms closely correlated with stage and PS. 
Common symptoms: cough (68%), haemoptysis (35%), chest pain 
(20%), dyspnoea (17%), fatigue (5%). 
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Hopwood & 
Stephens292 
Cross sectional 655 patients with lung cancer 
232 SCLC receiving 
chemotherapy 
423 NSCLC receiving 
chemotherapy 
Adapted Rotterdam 
Symptom 
Checklist 
Most common symptoms at presentation: Tiredness, lack of 
energy, worry, anxiety, cough, dyspnoea, anorexia & insomnia 
SCLC reported more symptoms (mean 17) than NSCLC (mean 
13) and also more severe symptoms. 
Most symptoms persisted beyond treatment end. 
Females reported more psychological symptoms than males. 
Lutz et al293 Retrospective 
Case notes 
review 
54 patients with NSCLC who 
had received palliative 
radiotherapy 
Observer component of 
the LCSS 
96% patients presented with at least 1 symptom. (Median 2.3 
symptoms). 
Common moderate to severe symptoms: dyspnoea (55%), 
anorexia (28%), cough (21%), pain (14%) and fatigue (12%) 
65% of patients had post radiotherapy improvement in some 
symptoms. 
Main symptoms palliated were cough, haemoptysis and dyspnoea 
Fatigue worsened post radiotherapy Only 2 % gained complete 
palliation. 
 
Sarna & 
Brecht294 
Cross sectional 60 Females with advanced lung 
cancer receiving palliative 
treatments 
SDS Mean number of symptoms 3.2 (Range 0-12). 
Most common serious symptoms: fatigue (56.7%), outlook 
(38.3%), pain frequency (367%), insomnia (28.3%) and cough 
(21.7%). 
Some symptoms could be grouped but complex reasons for 
groupings probable. 
Stephens et 
al295 
Longitudinal 810 patients with advanced 
lung cancer within 
chemotherapy and radiotherapy 
clinical trials 
Adapted Rotterdam 
Symptom Checklist 
Clinical reports 
78% agreement in symptom occurrence assessment between 
doctors and patients. 
Doctors underestimated symptom severity. 
Increasing disparities as severity increased. 
In chemotherapy group commonest symptoms: cough (67%), 
alopecia (60%), anorexia (56%), hoarse voice (46%), chest pain 
(43%) & numbness (43%). 
In radiotherapy group: cough (84%), chest pain (56%), anorexia 
(49%), hoarse voice (33%), numbness (27%) & nausea (25%). 
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Erridge et al296 RCT of 2 
palliative 
radiotherapy 
regimens 
149 patients with lung cancer 
who presented with cough, 
haemoptysis, dyspnoea, chest 
pain or dysphagia 
(Total eligible population for 
study not known) 
Standard assessment 
score 
Self designed 
Spitzer’s QOL index 
HADS 
Improvement in total symptom score in 77% with single fraction 
and 92% in 10 fraction group. 
Complete resolution in 5% in single fraction group and 23% in 10 
fraction group. 
41and 49% patients experienced fatigue in single and 10 fration 
groups respectively. 
30 and 34% patients experienced nausea or vomiting respectively 
Anxiety and depression in around 50% of patients. 
Kurtz et al111 Longitudinal 
 
129 lung cancer patients older 
than 65 years 
Treatments noted 
Subanalysis of wider study of 
all cancer types 
Symptom experience 
scale 
No significant differences in severity of symptoms between 
treatment, gender and stage groups. 
Symptom severity was predictor of loss of function. 
Most common symptoms: fatigue (82.2%), cough (67.4%), 
nocturia (65.9%), dyspnoea (61.2%), pain (58.9%) and weakness 
(55%). 
 
Lutz et al297 Longitudinal 69 lung cancer patients with 
locally advanced disease at 
radiotherapy centre 
The lung cancer 
symptom scale 
All patients had at least one symptom at referral, 79% 3 or more 
symptoms. 
Most common symptoms at referral were: Fatigue (80%), cough 
(77%), dyspnoea (73%), appetite (65%) and chest pain (57%) 
All symptoms increased in prevalence in 0-3months prior to death 
compared to 4-6 month prior to death. 
Symptom severity and distress was higher in those surviving 
shortest. 
Oh114 Cross sectional 106 lung cancer patients from 
in-patient respiratory and 
oncology units in Korea 
Korean translation of 
SDS 
Mean symptom severity of 32.74. 
Means of most severe symptoms: anorexia (3.13), fatigue (2.97), 
outlook (2.76) and cough (2.74). 
Symptom distress was not related to age, gender or histology  
Significantly more distress in those with advanced stage compared 
to early stage lung cancer. No difference between surgery, 
chemotherapy and radiotherapy for mean symptom distress.  
More symptom distress in group not receiving anti-cancer 
treatments. Trend less symptoms in older age group. 
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Gift et al298 Longitudinal 
Cluster analysis 
 
Secondary 
analysis 
 
Theory of 
unpleasant 
symptoms 
112 lung cancer patients who 
had survived at least 6months 
from diagnosis 
 
Looked at symptom cluster of: 
fatigue, weakness, nausea, 
vomiting, anorexia, weight loss 
and dysguesia 
 
Physical Symptom 
assessment tool 
Cluster of symptoms at baseline remained at 3 & 6 months. 
Mean number and severity of symptoms declined over time. 
Baseline severity of individual symptoms did not usually correlate 
with severity later. 
No association between treatments, gender, age or co morbidity 
with number of reported symptoms. 
Advanced staging at diagnosis did predict increased symptoms 
Symptom distress was predictive of prognosis. 
For each additional unit of severity score, the odds of dying 
increased by 33%. 
Wang et al299 Cross sectional 
 
Cluster analysis 
108 lung cancer patients from 
oncology out-patients in 
Taiwan 
MD Anderson 
Symptom Inventory 
translated into 
Taiwanese 
Most common symptoms were: fatigue, insomnia, poor appetite, 
dyspnoea and ‘distress’. 
2 major symptom clusters identified of gastrointestinal symptoms 
and general symptoms. 
Table 13: Summary of studies evaluating symptoms in adults with established lung cancer and/or receiving anti-cancer treatment. 
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Palliative or supportive care settings
Investigators Design Sample Instruments Utilised Selected Findings 
Krech et al300 Cross sectional 100 lung cancer patients 
referred to palliative care 
service 
Standard Assessment 
Tool 
Self designed 
(Used within service) 
Median number of symptoms was 9 (Range 1-23). 
Most common symptoms were: pain (86%), dyspnoea 
(70%), anorexia (68%), constipation (52%), fatigue (52%). 
Depression in 34% and Anxiety in 27%. 
No gender differences in symptoms. Some age differences. 
62% of reported symptoms were moderate-severe. 
Trend that number of symptoms increased in patients with 
lower performance status. 
Vainio & 
Auvinen301 
Cross sectional 1640 patients with advanced 
cancer referred to palliative 
care service 
387 lung cancer patients 
Standardised 
Assessment Tool 
Self designed 
Most common symptom in lung cancer patients: weakness 
(60%), pain (52%), weight loss (49%), dyspnoea (46%) 
anorexia (35%). 
 
Lobchuk et 
al168 
Cross sectional 37 adults with lung cancer 
and caregivers from 
palliative care service or out-
patient oncology service 
 
SDS Patients rated top 6 most distressing symptoms as: fatigue, 
cough, pain (frequency), outlook and insomnia. 
Carers rated top 6 most distressing symptoms as: fatigue, 
outlook, insomnia, cough, pain (frequency), dyspnoea. 
Carers rated distress higher than patients (global distress and 
most individual symptoms). 
Agreement was greater for symptoms rated most distressing 
by patients. 
Lobchuk & 
Kristjanson176 
Cross sectional 37 adults with lung cancer 
and caregivers from 
palliative care service or out-
patient oncology service 
Extended qualitative analysis 
SDS 
Behavioural cues 
assessment 
Caregivers use behavioural and verbal cues to assess 
symptom distress. 
Behavioural observation did not reduce assessment 
discrepancies. 
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Edmonds et 
al178 
Retrospective 
structures 
interviews with 
bereaved carers 
449 lung cancer patients’ 
post-bereavement carers  
Compared to 87 chronic lung 
disease post-bereavement 
carers 
Structured interviews Mean number of symptoms in last year of life 6.9. 
Last year life most distressing symptoms in lung cancer: 
Pain(85%), dyspnoea (78%), anorexia (76%), mood (68%), 
cough (56%), insomnia (60%), constipation (59%), low 
sickness(46%), Mean number of symptoms in last week of 
life 5.6. In last week of life most distressing symptoms: 
anorexia (70%), dyspnoea (69%), pain (64%), low mood 
(49%), mouth problems (46%), cough (40%), insomnia 
(40%). Chronic lung disease patients post-bereavement 
carers reported comparable levels of symptom distress to 
lung cancer. 
Henoch et 
al302 
Longitudinal 106 patients with incurable 
lung cancer not under-taking 
life prolonging treatments 
Assessment of quality 
of life at the end of 
life tool 
Cancer dyspnoea 
scale 
HADS 
Mean dyspnoea scores increased over time. 
HADS depression and anxiety scores increased over time 
(only depression saw significant increase). 
QOL scores reduced over time. 
QOL score correlated strongly with anxiety and depression 
and moderately with PS, pain and dyspnoea. 
No significant correlation between QOL and gender, 
histology or occurrence of metastases. 
Skaug et al303 Retrospective 
Cross sectional 
247 of 253 lung cancer 
deaths examined 
Last 8 weeks of life 
examined 
Standardised scale  
Self designed 
Case note review 
Prevalence of main symptoms in last 8 weeks of life: pain 
(85%), dyspnoea (54%), cough (28%), nausea (27%), 
haemoptysis (9%), psychological symptoms (71%) and 
neurological symptoms (28%). 99% of patients had at least 
one symptom. Gender and initial PS did not predict any 
specific symptom occurrence. No significant difference in 
physical symptoms across age groups. 
Table 14: Summary of studies evaluating symptoms in adults with lung cancer in palliative or supportive care settings. 
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Longer Term Survivors 
Investigators Design Sample Instruments Utilised Selected Findings 
Fox & 
Lyon304 
Cross sectional 
Correlational 
 
Cluster 
analysis 
51 Norwegian lung cancer 
patients subset from previous 
QOL study 
Recruited from an internet 
based support group 
Full range of self-reported 
stages 
Shortform 36 health 
status survey (SF-36) 
Fox simple QOL 
Sclae 
Participants on average diagnosed 32 months prior to study 
50% had undergone surgery (Atpyical for lung cancer) 
93% patients reported at least ‘a little bit’ depression, fatigue 
& pain. 
Most severe symptom was fatigue. 
Depression correlated with fatigue. 
Fatigue correlated with pain. 
Depression and fatigue, but not pain, negatively correlated 
with QOL. 
Table 15: Summary of studies evaluating symptoms in survivors with lung cancer. 
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5.2.1 Design of Studies 
Nineteen (48.7%) studies used a longitudinal design; 17 (43.5%) used a cross-sectional 
design. Of the other three (7.8%) studies, one was a review of eight studies prior to 
1997 evaluating symptoms at time of presentation,66 one was a retrospective case-
control study of symptoms at initial presentation to primary care82 and the final study 
was a qualitative exploration of symptoms in the last year of life of lung cancer patients 
and chronic obstructive pulmonary disease (COPD) patients. This study used structured 
interviews with bereaved relatives to construct a picture of symptoms in the last year of 
life of the deceased patient.178 Of those focused on new or recent diagnosis, eight were 
longitudinal and five cross-sectional. Those focusing on treatment phase included nine 
longitudinal designs and seven cross-sectional. As noted in the previous review, there 
was a wide range of follow-up time in the longitudinal studies, ranging from a few 
weeks303 to five years.291 
 
5.2.2 Samples and Phase of Lung Cancer Journey Evaluated 
Five studies considered symptoms at point of presentation or prior to presentation,66, 82, 
173, 281, 282 ten studies evaluated the newly diagnosed phase of the journey,164, 167, 181, 182 
16 reported on the treatment phase,111, 114, 115, 120, 284, 287, 289-299 seven on patients 
receiving supportive care, palliative care or end of life care168, 176, 178, 300-303 and one on 
survivors of lung cancer.304 These articles did overlap and there was not always a clear 
distinction between phases. In particular, several studies evaluated from diagnosis 
through treatment. Sample sizes varied from 26305 to 8788 patients.173 
 
5.2.3 Tools for Symptom Measurement 
Within this review of lung cancer symptom assessment, several different tools have 
been utilised. Four studies used a case note review to determine presence and severity of 
symptoms, two studies used qualitative interviews, one study used a self-designed 
toxicity questionnaire and seven utilised standardised questionnaires or scales designed 
by the authors or already being used within the clinical setting. The other studies used 
recognised, or adapted, symptom assessment tools including: Symptom Distress 
Scale201 ((SDS) n=10), McGill Pain Questionnaire306 ((MPQ) n=1), European 
Organisation for Research and Treatment of Cancer Quality of Life Score198 (EORTC 
QLQ-C30) with lung cancer module 13203 ((LC13) n=2), Rotterdam Symptom 
Checklist307 ((RSCL) n=2), Lung Cancer Symptom Scale202 ((LCSS) n=2), Symptom 
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Experience Scale308241 ((SES) n=1), MD Anderson Symptom Inventory309 ((MDASI) 
n=1), Hospital Anxiety and Depression Score310 ((HADS) n=1), Assessment of Quality 
of Life at the End of Life311 ((AQEL) n=1) and Shortform 36 Health Status Survey312 
((SF-36) n=1). The SDS was the most common instrument. This 13 item self-report tool 
provides a measure of symptom distress defined as ‘the degree of discomfort being 
experienced as reported by the patient’. Eleven of the items are assessed on a five point 
Likert-type scale, ranging from 1 (indicating normal) to 5 (representing extreme distress 
such as nausea, insomnia, appetite, pain, fatigue, bowel pattern, concentration, 
appearance, outlook, breathing and cough). The final two items assess frequency of 
nausea and pain. A summated score ranging from 13 to 65 evaluates ‘global symptom 
distress’. It is of note that this tool was adapted by Tishelman et al,164 arguing that it 
actually assessed symptom occurrence rather than distress because patients are asked to 
primarily rate intensity and frequency. The adaptations explicitly rated intensity, 
frequency and distress as separate considerations.  
 
5.3 Discussion 
Weisman and Worden first reported the high symptom burden in lung cancer in 1976 in 
their study evaluating symptom distress in 163 adults newly diagnosed with a variety of 
cancers. The peak levels of emotional distress occurred within the first 100 days after 
diagnosis and were highly correlated to the number of physical symptoms.4 
 
Degner and Sloan119 utilised the Symptom Distress Scale182, 201 (SDS) to evaluate 
symptoms in a consecutive sample of 434 newly diagnosed cancer patients over six 
months from diagnosis. The 83 lung cancer patients in this study experienced 
significantly more symptom distress than the other cancer types included. Furthermore, 
symptom distress at diagnosis correlated with reduced overall survival from 
diagnosis.119 McCorkle and Benoliel182 compared symptoms in newly diagnosed lung 
cancer patients to those with a recent myocardial infarction. At one and two months 
after diagnosis, lung cancer patients reported significantly higher levels of symptom 
distress.  
 
In one study comparing palliative care needs of patients dying with chronic respiratory 
disease and lung cancer, Edmonds et al178 found no overall difference in mean number 
of symptoms between the two groups. There were differences in specific symptoms 
with significantly more dyspnoea in those with chronic respiratory disease but more 
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anorexia and constipation in the lung cancer patients. It is of note that up to 22% of lung 
cancer patients in a population-based study in the Netherlands had co-existent chronic 
obstructive pulmonary disease (COPD). In a recent unpublished prospective audit 
quantifying co-morbidity in lung cancer patients in Scotland, COPD was found to be 
co-existent in around 45% of lung cancer patients and around 50% of patients from the 
site of this study (Stobhill Hospital, Glasgow).189 It is not surprising that there may be 
site-specific symptoms which are more prevalent in specific cancers than others, such as 
dyspnoea in lung cancer.301 However, there may also be a high generalised burden of 
systemic symptoms, such as loss of appetite and fatigue, in lung cancer that is greater 
than in other cancer types.104 
 
At presentation, 90% of lung cancer patients report at least one symptom.81 There have 
been a variety of studies examining the prevalence of symptoms within the lung cancer 
population but relatively few of these studies evaluated symptoms at initial presentation. 
Table 3 outlines the wide range of potential presenting symptoms previously reported. 
Khalid et al104 surveyed newly diagnosed lung cancer patients to assess symptoms that 
may reduce nutritional intake and found that 66% of lung cancer patients presented with 
symptoms with an increased prevalence between locally advanced and metastatic 
disease. The most prevalent symptoms were: loss of appetite (58%), nausea (30%), 
early satiety (21%), xerostomia (17%) and pain of any site (12%).  
 
The more recently published large, cross-sectional study by Kwang et al173details the 
symptoms at presentation of 8788 Korean patients diagnosed with lung cancer. Only 
6.5% of cases had no symptoms on presentation 
Table 16: Comparison of symptom prevalence previously recorded66 and by Kwang et al.173 
Symptoms and Signs at 
Presentation 
Range of Frequency 
Previously Reported66 (%) 
Frequency of Symptoms 
Reported (%) Kwang et al173 
Cough 8-75 38.1 
Weight Loss 0-68 9 
Dyspnoea 3-60 24 
Chest Pain 20-49 12.1 
Haemoptysis 6-35 9.2 
Bone Pain 6-25 - 
Clubbing of fingers 0-20 - 
Fever 0-20 - 
Weakness 0-20 5.7 
SVCO 0-4 - 
Dysphagia 0-2 - 
Wheezing or Stridor 0-2 - 
Hoarseness - 2.2% 
Asymptomatic - 6.5% 
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The assessment of symptoms will be influenced by the method used. The large study by 
Kwang et al173 found there was a wide range of symptom prevalence reported. The most 
common symptoms tended to include fatigue, pain, cough, dyspnoea, insomnia and loss 
of appetite. It should be noted that pain, fatigue and anorexia were also commonly 
reported symptoms.183 In Cooley’s systematic review1 of symptoms in lung cancer 
patients in 2000, three studies evaluating newly diagnosed patients were noted. The 
most commonly reported symptoms in these studies were fatigue, pain, cough, lack of 
appetite and insomnia.119, 181, 182 Cooley1 noted that two separate studies using the SDS 
in newly diagnosed lung cancer patients, conducted in different countries and at 
different times, have reported the symptoms as the most common. More strikingly, the 
mean score on the SDS was similar in both the described studies.119, 182 Furthermore, 
Cooley went on to use the SDS to assess newly diagnosed lung cancer patients (within 
100 days) and found the most prevalent distressing symptoms again included: fatigue 
(64%), frequency of pain (56%), insomnia (49%), anorexia (43%) and severity of pain 
(37%). Few tools ask specifically about sexual dysfunction,183 but in the study by Gift et 
al285 mean score of ‘lack of sexual interest’ was reported as the highest rated severe 
symptom. 
 
In patients undergoing treatment, the additional element of treatment-related symptoms 
is introduced. The majority of studies evaluating patients in the treatment phase 
consider those actively receiving treatment or those at treatment completion. Further 
complexity is introduced by recognising that many of the treatments being delivered are 
targeted against specific symptoms, such as radiotherapy313 to palliate pain, cough or 
haemoptysis or chemotherapy314 to palliate pain and other symptoms. Thus, there is a 
dynamic interplay between host, disease and treatment relating to the global symptom 
burden. Again, design of the instrument influences the reported symptoms, and some 
studies target the questions against known toxicities of the treatment being received.288 
 
5.3.1 Quality of Life and Symptoms in Lung Cancer 
When a treatment does not improve survival, then it is recommended that the primary 
goal becomes quality of life (QOL) improvement.315, 316 Despite this goal, no precise 
definition of QOL has been agreed upon and working definitions vary widely within the 
literature.317 Broadly, QOL can be considered as a global ‘well-being’ concept defined 
as a ‘subjective evaluation of life as a whole’,121 or it can be considered ‘well-being’ 
when related to health or illness.318 The latter definition is referred to as ‘health-related 
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quality of life’(HRQOL).319 HRQOL may also be considered as a component of global 
QOL.318 Some authors classify definitions of QOL as based on ‘functional status’, 
‘subjective well-being’ or a combination of both.317 QOL can be globally rated or 
broken into domains and sub-domains. There is disagreement within the literature 
whether domains can subsequently be summated to provide a valid global score.317 
 
Concepts closely related to QOL include: functional status, life satisfaction, well-being, 
health status and needs. Within the literature there is overlap in the use of definitions of 
these concepts with QOL. Increased ambiguity can occur as some authors interchange 
the term QOL with some of these other concepts.320 As QOL research progresses, there 
are some points of consensus developing: QOL cannot be equated to patients’ objective 
circumstances; QOL is multidimensional and QOL should be assessed from the 
perspective of the patient.321 Assessment of objective factors does not consistently 
equate to predictable QOL; each individual’s QOL relates to their particular situational 
factors (i.e. the psychosocial context they live within) and internal factors (i.e. their own 
psycho-emotional state, experiences, expectations and beliefs). Although there is 
agreement that QOL is multidimensional, the nature of those dimensions is debated. 
Most authors would agree that there are four main dimensions to HRQOL: physical, 
functional, emotional and social. Other dimensions of importance may include: 
spirituality, sexuality, cognitive function311 and economic factors.53, 320 
 
Assessment of QOL relates to patient rating of either a global QOL or of domains or 
sub-domains. There are many tools available for assessing QOL in cancer and in lung 
cancer, and although many of these contain physical symptom components,322 they 
differ from symptom (or symptom distress) assessment and needs assessment. Symptom 
burden may predict overall QOL,121, 323 but it is not clear if this is an independent effect 
or if it relates to the functional effects of symptoms.172 In some chemotherapy trials, 
global QOL has not changed, but symptom burden measures do show a response to 
treatment (recognising the possible interplay between treatment-related symptoms, 
improved disease-related symptoms or worsening disease-related symptoms).324 It may 
be that symptom burden is an adequate outcome measure to allow service providers, 
patients and clinicians to make decisions about specific treatments in the future.324 
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5.3.2 Symptoms, QOL and Prognosis in Lung Cancer 
Symptoms may be predictive of mortality in cancer.1, 183, 309 In the advanced cancer 
setting, it is clear that the symptoms of anorexia, dyspnoea, xerostomia, weight loss and 
delirium are adverse prognostic factors for lung cancer and for other advanced 
cancers.132-136 
 
In lung cancer there is specific evidence of a relationship between increased symptom 
distress and worse survival. Degner and Sloan’s119 analysis of 82 lung cancer patients in 
a wider cohort of 434 ambulatory, newly diagnosed cancer patients showed a significant 
negative correlation between symptom distress (measured by the symptom distress 
scale) and survival. This relationship held true when symptom distress was measured 
any time in the six months following diagnosis. However, the authors reported three 
patients with high symptom distress but greater than five years’ survival. On further 
review, these patients had undergone thoracotomies and had significant post-surgical 
pain at time of testing. This was noted as a limitation of symptom assessment for aiding 
prognostication. Kasaa et al120 had previously found inoperable lung cancer patients 
with low symptom distress survived longer than those with higher levels of distress, 
irrespective of treatment. Kukull et al181 also found a negative correlation with higher 
symptom distress (measured by the symptom distress scale) and survival when 
controlled for age, personality factors and functional status. These studies using the 
same assessment tool found the most frequently distressing symptoms to be fatigue, 
pain, loss of appetite and insomnia. 
 
It has recently been reported that Korean patients with lung cancer who were 
asymptomatic at presentation survived longer than those who were symptomatic at 
presentation.173 In this large national survey of 8788 patients diagnosed with lung 
cancer in 2005, only 6.5% presented with no symptoms. Sixty percent of asymptomatic 
patients underwent curative intent surgery. Furthermore, those asymptomatic patients 
with NSCLC had reduced risk of death from lung cancer regardless of age, gender, 
stage at diagnosis, smoking history and whether treatment was performed. Interestingly, 
this was not the case for the asymptomatic patients with SCLC in this cohort.173 Global 
QOL or domains from within QOL assessment may also be an independent predictor of 
mortality in lung cancer at different stages of disease.115, 117, 120, 325-331  
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5.4 Conclusions 
Lung cancer patients face a high symptom burden throughout their cancer journey. 
Symptoms can be caused by the disease, treatments or comorbidities. Most patients 
experience a high number of different symptoms, commonly including dyspnoea, pain, 
fatigue, anorexia, weight loss and psychological distress. These individual symptoms 
and their combination can lead to severe symptom distress in many lung cancer patients. 
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6 Results 
6.1 Evaluation of Lung Cancer Population Attending 
the Stobhill Lung Cancer Clinic 
The multidisciplinary lung clinic provides care for patients at different times within 
their cancer journey. The characteristics of patients who completed a questionnaire were 
evaluated and compared to national audit data.332 Methods have been described in 
Section 3. 
 
6.1.1 Number of Patients Participating 
A total of 391 patients attending the multidisciplinary lung clinic completed at least one 
questionnaire (frequencies of Q1 in complete sample). Of these patients, 353 had a 
known diagnosis of lung cancer (either histological or clinico-radiological). Of the 
remaining 38 patients, 13 had a confirmed diagnosis of mesothelioma and 25 had either 
an alternative diagnosis or no confirmed diagnosis. In this group of 25 patients, the 
alternative diagnoses included: metastatic breast, colon and renal cancer, resolving 
pneumonias, tuberculosis, and pleural plaques only.  
 
6.1.2 Questionnaire Response and Timing 
Each patient could complete the questionnaire several times over the duration of their 
clinic attendances. Over the 30 month study period 862 questionnaires were returned by 
353 lung cancer patients, 219 patients completed greater than one questionnaire, 353 
questionnaires (41.1%) were initial questionnaires (Q1) and (219) 25.3% of 
questionnaires were the second returned (Q2). The time between each serial 
questionnaire is tabulated below for between Q2 and Q1, Q3 and Q2, Q4 and Q3, and 
Q1 and QF (when more than one questionnaire was completed; see Table 17). On 
average, each patient completed two questionnaires ( x =2.29, SD=1.57; median 2, 
range=1-11; see Table 18).  
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Figure 8: Bar chart of numbers of Q1 to Q12 returned (with 95% confidence intervals). 
 
 
Mean (SD) in days 100.13 (91.78) 114.77 (100.778) 113.74 (89.786) 237.34 (198.35)
Median (Range) in days 77 (0-644) 91 (0-546) 91 (7-392) 182 (7-826)
Number Percentage Number Perentage Number Percentage Number Percentage
Total 216 98.6% 132 96.4% 76 97.4% 213 97.3%
< 4 weeks 41 18.7% 19 13.9% 12 15.4% 13 5.9%
4-8 weeks 45 20.5% 18 13.1% 13 16.7% 28 12.8%
2-4 months 73 33.3% 55 40.1% 23 29.5% 46 21.0%
>4 months 57 26.0% 40 29.2% 28 35.9% 126 57.5%
Missing 3 1.4% 5 3.6% 2 2.6% 6 2.7%
Time between Q2 and Q1 Time between Q3 and Q2 Time between Q4 and Q3 Time between QF and Q1
 
Table 17: Time between serial questionnaires and between first (Q1) and final (QF) questionnaires. 
 
One questionnaire only was completed by 134 patients; the first questionnaire was, 
therefore, their final questionnaire (QF). For these patients, their final questionnaire was 
coded as ‘QF=Q1’ (see Table 18). 
Number of 
questionnaire 
Frequency of 
each 
questionnaire 
Percentage of 
total number of 
questionnaires 
Number of 
patients when  
Qx = QF 
Percentage of 
total number of 
questionnaires 
First 353 41 134 15.5 
Second 219 25.4 82 9.5 
Third 137 15.9 59 6.8 
Fourth 78 9 37 4.3 
Fifth 41 4.8 25 2.9 
Sixth 8 1.9 8 0.9 
>6 18 2 8 0.9 
Table 18: Number and percentages of questionnaires returned within study period. 
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6.1.3 Questionnaire Response and Timing 
An overall analysis of the characteristics of the population attending the lung cancer 
clinic was carried out utilising Q1 as the index questionnaire. Overall staging and 
presence of metastatic disease was tabulated (Table 19). Overall survival and median 
survival have been calculated and plotted using Kaplan-Meier survival curves (Figure 9 
and Table 20). The characteristics of patients with lung cancer were tabulated by gender 
(Table 21). 
Number % Number % Number %
NSCLC or clinical lung cancer
Stage
1A 24 6.8% 3 1.8% 1 0.8%
1B 48 13.6% 17 10.0% 7 5.8%
2A 21 5.9% 11 6.5% 6 5.0%
2B 20 5.7% 5 2.9% 2 1.7%
3A 28 7.9% 18 10.6% 6 5.0%
3B 71 20.1% 34 20.0% 31 25.6%
4 87 24.6% 54 31.8% 46 38.0%
Unknown 8 2.3% 4 2.4% 1 0.8%
SCLC
Stage
Limited 17 4.8% 9 5.3% 6 5.0%
Extensive 27 7.6% 15 8.8% 15 12.4%
Unknown 2 0.6% 0 0.0% 0 0.0%
Metastatic or not
No known metastases 239 67.7% 101 59.4% 60 49.6%
Metastatic disease 114 32.3% 69 40.6% 61 50.4%
All patients (n=353) Recent diagnosis (Q1within 6 weeks) (n=170)
Died within 3 months 
of QF completion      
(n=121)
 
Table 19: Overall numbers and percentages of stage and metastatic status of all patients, newly 
diagnosed patients and those who died within three months of completing QF. 
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Figure 9: Kaplan-Meier survival curves for all patients attending the lung cancer clinic (new and 
return patients) and all newly diagnosed patients. 
 
Median Survival (Days) Median survival (Months) Standard error Lower Upper
All patients 344 11.47 27.10 290.89 397.11
Newly diagnosed 274 9.13 34.09 207.19 340.81
95% Confidence interval
 
Table 20: Median overall survival (95% confidence intervals) for all patients and newly diagnosed 
patients. 
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Females
Number % Number % Number %
All Patients 174 49.3% 179 50.7% 353 100.0%
Year one 88 24.9% 89 25.2% 177 50.1%
Year two 53 15.0% 56 15.9% 109 30.9%
Year three 33 9.3% 34 9.6% 67 19.0%
Age
50 years and less 7 2.0% 3 0.8% 10 2.8%
51-69 years 83 23.5% 82 22.9% 165 46.5%
70 years and more 84 23.8% 95 26.9% 179 50.7%
Unknown 0 0.0% 0 0.0% 0 0.0%
Vital Status 174 49.3% 179 50.7% 353 100.0%
Alive 58 16.4% 79 22.4% 137 38.8%
Dead: cause lung cancer 104 29.5% 81 22.9% 185 52.4%
Dead: cause not lung cancer 3 0.8% 9 2.5% 12 3.4%
Dead: cause unknown 9 2.5% 10 2.8% 19 5.4%
Histology 174 49.3% 179 50.7% 353 100.0%
NSCLC 126 35.7% 114 32.3% 240 68.0%
Stage 1A 6 1.7% 16 4.5% 22 6.2%
Stage 1B 24 6.8% 15 4.2% 39 11.0%
Stage 2A 5 1.4% 8 2.3% 13 3.7%
Stage 2B 13 3.7% 4 1.1% 17 4.8%
Stage 3A 9 2.5% 9 2.5% 18 5.1%
Stage 3B 34 9.6% 23 6.5% 57 16.1%
Stage 4 33 9.3% 35 9.9% 68 19.3%
Unknown Stage 2 0.6% 4 1.1% 6 1.7%
SCLC 20 5.7% 26 7.4% 46 13.0%
Limited 9 2.5% 8 2.3% 17 4.8%
Extensive 10 2.8% 17 4.8% 27 7.6%
Unknown Stage 1 0.3% 1 0.3% 2 0.6%
CLC 28 7.9% 39 11.1% 67 19.0%
Stage 1A 0 0.0% 2 0.6% 2 0.6%
Stage 1B 4 1.1% 5 1.4% 9 2.5%
Stage 2A 2 0.6% 6 1.7% 8 2.3%
Stage 2B 1 0.3% 2 0.6% 3 0.8%
Stage 3A 3 0.8% 7 2.0% 10 2.8%
Stage 3B 6 1.7% 8 2.3% 14 4.0%
Stage 4 10 2.8% 9 2.5% 19 5.4%
Unknown Stage 2 0.6% 0 0.0% 2 0.6%
PS at diagnosis assessed by doctor 152 43.2% 156 44.1% 308 87.3%
0 18 5.1% 12 3.4% 30 8.5%
1 87 24.6% 100 28.4% 187 53.0%
2 38 10.8% 43 12.2% 81 22.9%
3 9 2.5% 1 0.3% 10 2.8%
4 0 0.0% 0 0.0% 0 0.0%
Unknown 22 6.2% 23 6.5% 45 12.7%
Current PS, rated by patient 163 46.1% 170 48.2% 333 94.3%
0 25 7.1% 26 7.4% 51 14.4%
1 64 18.1% 57 16.1% 121 34.3%
2 33 9.3% 35 9.9% 68 19.3%
3 35 9.9% 46 13.0% 81 22.9%
4 6 1.7% 6 1.7% 12 3.4%
Unknown 11 3.1% 9 2.5% 20 5.7%
Deprivation Category 171 48.4% 176 49.9% 347 98.3%
1      most affluent 0 0.0% 1 0.3% 1 0.3%
2 15 4.2% 21 5.9% 36 10.2%
3 15 4.2% 13 3.7% 28 7.9%
4 25 7.1% 9 2.5% 34 9.6%
5 29 8.2% 34 9.6% 63 17.8%
6 11 3.1% 11 3.1% 22 6.2%
7     least affluent 76 21.5% 87 24.6% 163 46.2%
Could not determine 3 0.8% 3 0.8% 6 1.7%
Deprivation Decile 171 48.4% 176 49.9% 347 98.3%
1      most affluent 5 1.4% 3 0.8% 8 2.3%
2 10 2.8% 19 5.4% 29 8.2%
3 9 2.5% 4 1.1% 13 3.7%
4 6 1.7% 8 2.3% 14 4.0%
5 2 0.6% 1 0.3% 3 0.8%
6 12 3.4% 4 1.1% 16 4.5%
7 17 4.8% 14 4.0% 31 8.8%
8 23 6.5% 25 7.1% 48 13.6%
9 5 1.4% 6 1.7% 11 3.1%
10   least affluent 82 23.2% 92 26.1% 174 49.3%
Could not determine 3 0.8% 3 0.8% 6 1.7%
Time of Q1 from diagnosis 174 49.3% 179 50.7% 353 100.0%
< 3 weeks 53 15.0% 64 18.1% 117 33.1%
3-6 weeks 31 8.8% 22 6.2% 53 15.0%
6 weeks to 3 months 19 5.4% 15 4.2% 34 9.6%
3-6 months 22 6.2% 21 5.9% 43 12.2%
6-12 months 21 5.9% 19 5.4% 40 11.3%
>12 months 25 7.1% 37 10.5% 62 17.6%
Q1 preceded diagnosis 2 0.6% 0 0.0% 2 0.6%
Not known 1 0.3% 1 0.3% 2 0.6%
Total Males
Charcteristics of lung cancer patients by Gender
 
Table 21: Characteristics of lung cancer patients by gender. 
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Within this population, there were slightly more females (50.7%) than males (49.3%). 
The mean age of patients was 69.3 years (SD 9.12 years). There was no significant 
difference in mean age between genders (p=0.192, Student’s t test). The majority of 
patients had NSCLC (68%), 13% were diagnosed with SCLC and 19% with clinico-
radiological lung cancer. There were no significant overall differences between genders 
(Χ2=3.118, df=2, p=0.21). No patient had a doctor assessed PS of 4 at diagnosis. PS=4 
was self-rated by 12 (3.4%) patients. There was no significant difference between 
gender for self-rated PS (Χ2 =1.831, df=4, p=0.767). 
 
There was a high level of deprivation within this lung cancer population. The majority 
(52.4%) of patients were in the two most deprived Carstairs deprivation categories (‘1’ 
least deprived, ‘7’ most deprived; see Figure 10). 
 
             
Figure 10: Carstairs deprivation categories compared by gender with 95% confidence intervals. 
 
Overall, 247 (69.9%) patients completed Q1 within six months of their diagnosis. Of 
these, 170 (48.1%) completed Q1 within six weeks of diagnosis. (This does not include 
the two Q1’s which were completed prior to a diagnosis being confirmed.) There was 
no overall significant difference in time of Q1 from diagnosis between gender 
(Χ2=5.341, df=5, p=0.376).  
 
6.1.4 Treatments and Time from Diagnosis 
Patients attending the lung clinic included newly diagnosed patients and routine return 
patients. This range of treatment stages represented also included those pre-treatment, 
those undertaking curative intent treatments (surgery and radical radiotherapy), those 
undertaking palliative treatments and those receiving supportive care. These have been 
tabulated (Table 22). To account for the effect of ‘routine returns’ increasing any 
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particular form of treatment, groupings of ‘time of POS from diagnosis’ was used to 
further evaluate treatments delivered (Table 23). 
All years combined, n=353 Number % Number % Number %
Treatment Given 163 50.6% 159 49.4% 322 100.0%
Surgery 32 9.9% 30 9.3% 62 19.3%
Radical Radiotherapy 13 4.0% 13 4.0% 26 8.1%
Palliative Radiotherapy 51 15.8% 44 13.7% 95 29.5%
Chemotherapy 34 10.6% 47 14.6% 81 25.2%
Supportive Care 25 7.8% 24 7.5% 49 15.2%
Combined 8 2.5% 1 0.3% 9 2.8%
Missing 11 20 31
Year 1, n=177 Number % Number % Number %
Treatment Given 81 85 166 100.0%
Surgery 22 13.3% 18 10.8% 40 24.1%
Radical Radiotherapy 4 2.4% 7 4.2% 11 6.6%
Palliative Radiotherapy 25 15.1% 18 10.8% 43 25.9%
Chemotherapy 16 9.6% 28 16.9% 44 26.5%
Supportive Care 11 6.6% 13 7.8% 24 14.5%
Combined 3 1.8% 1 0.6% 4 2.4%
Missing 7 4 11
Years 2 & 3, n=176 Number % Number % Number %
Treatment Given 82 74 156 100.0%
Surgery 10 6.4% 12 7.7% 22 14.1%
Radical Radiotherapy 9 5.8% 6 3.8% 15 9.6%
Palliative Radiotherapy 26 16.7% 26 16.7% 52 33.3%
Chemotherapy 18 11.5% 19 12.2% 37 23.7%
Supportive Care 14 9.0% 11 7.1% 25 16.0%
Combined 5 3.2% 0 0.0% 5 3.2%
Missing 4 16 20
Treatments delivered tabulated by year groups and gender
Male Female Total
 
Table 22: Table of treatments by gender: number and percentage of known treatments within all 
years and the in year 1 and years 2/3. 
 
There was a significant difference across the year groups of time from diagnosis to Q1 
(Χ2=48.55, df=5, p<0.01).  
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Q1 within 6 weeks of diagnosis
All years combined, n=170 Number % Number % Number %
Treatment Given 77 52.0% 71 48.0% 148 100.0%
Surgery 5 3.4% 5 3.4% 10 6.8%
Radical Radiotherapy 5 3.4% 5 3.4% 10 6.8%
Palliative Radiotherapy 28 18.9% 30 20.3% 58 39.2%
Chemotherapy 20 13.5% 20 13.5% 40 27.0%
Supportive Care 16 10.8% 11 7.4% 27 18.2%
Combined 3 2.0% 0 0.0% 3 2.0%
Missing 7 4.7% 15 10.1% 22 14.9%
Year 1
Treatment Given 31 54.4% 26 45.6% 57 100.0%
Surgery 1 1.8% 3 5.3% 4 7.0%
Radical Radiotherapy 0 0.0% 1 1.8% 1 1.8%
Palliative Radiotherapy 16 28.1% 11 19.3% 27 47.4%
Chemotherapy 8 14.0% 8 14.0% 16 28.1%
Supportive Care 6 10.5% 3 5.3% 9 15.8%
Combined 0 0.0% 0 0.0% 0 0.0%
Missing 5 8.8% 2 3.5% 7 12.3%
Years 2 & 3
Treatment Given 45 43.7% 58 56.3% 103 100.0%
Missing 2 1.9% 13 12.6% 15 14.6%
Surgery 4 3.9% 2 1.9% 6 5.8%
Radical Radiotherapy 5 4.9% 4 3.9% 9 8.7%
Palliative Radiotherapy 12 11.7% 19 18.4% 31 30.1%
Chemotherapy 12 11.7% 12 11.7% 24 23.3%
Supportive Care 10 9.7% 8 7.8% 18 17.5%
Combined 3 2.9% 0 0.0% 3 2.9%
Q1 within 3 months of diagnosis
All years combined, n=204 Number % Number % Number %
Treatment Given 95 52.8% 85 47.2% 180 100.0%
Surgery 7 3.9% 7 3.9% 14 7.8%
Radical Radiotherapy 7 3.9% 6 3.3% 13 7.2%
Palliative Radiotherapy 37 20.6% 35 19.4% 72 40.0%
Chemotherapy 21 11.7% 24 13.3% 45 25.0%
Supportive Care 19 10.6% 13 7.2% 32 17.8%
Combined 4 2.2% 0 0.0% 4 2.2%
Missing 8 4.4% 16 8.9% 24 13.3%
Year 1
Treatment Given 35 52.2% 32 47.8% 67 100.0%
Surgery 1 1.5% 3 4.5% 4 6.0%
Radical Radiotherapy 0 0.0% 1 1.5% 1 1.5%
Palliative Radiotherapy 19 28.4% 14 20.9% 33 49.3%
Chemotherapy 8 11.9% 10 14.9% 18 26.9%
Supportive Care 6 9.0% 4 6.0% 10 14.9%
Combined 1 1.5% 0 0.0% 1 1.5%
Missing 6 9.0% 2 3.0% 8 11.9%
Years 2 & 3
Treatment Given 60 53.1% 53 46.9% 113 100.0%
Surgery 6 5.3% 4 3.5% 10 8.8%
Radical Radiotherapy 7 6.2% 5 4.4% 12 10.6%
Palliative Radiotherapy 18 15.9% 21 18.6% 39 34.5%
Chemotherapy 13 11.5% 14 12.4% 27 23.9%
Supportive Care 13 11.5% 9 8.0% 22 19.5%
Combined 3 2.7% 0 0.0% 3 2.7%
Missing 2 1.8% 14 12.4% 16 14.2%
Q1  within 6 months of diagnosis
All years combined, n=247 Number % Number % Number %
Treatment Given 116 52.7% 104 47.3% 220 100.0%
Surgery 8 3.6% 11 5.0% 19 8.6%
Radical Radiotherapy 9 4.1% 6 2.7% 15 6.8%
Palliative Radiotherapy 45 20.5% 38 17.3% 83 37.7%
Chemotherapy 29 13.2% 33 15.0% 62 28.2%
Supportive Care 21 9.5% 16 7.3% 37 16.8%
Combined 4 1.8% 0 0.0% 4 1.8%
Missing 9 4.1% 18 8.2% 27 12.3%
Year 1
Treatment Given 44 50.0% 44 50.0% 88 100.0%
Surgery 2 2.3% 5 5.7% 7 8.0%
Radical Radiotherapy 1 1.1% 1 1.1% 2 2.3%
Palliative Radiotherapy 22 25.0% 14 15.9% 36 40.9%
Chemotherapy 11 12.5% 17 19.3% 28 31.8%
Supportive Care 7 8.0% 7 8.0% 14 15.9%
Combined 1 1.1% 0 0.0% 1 1.1%
Missing 6 6.8% 3 3.4% 9 10.2%
Years 2 & 3
Treatment Given 72 54.5% 60 45.5% 132 100.0%
Surgery 6 4.5% 6 4.5% 12 9.1%
Radical Radiotherapy 8 6.1% 5 3.8% 13 9.8%
Palliative Radiotherapy 23 17.4% 24 18.2% 47 35.6%
Chemotherapy 18 13.6% 16 12.1% 34 25.8%
Supportive Care 14 10.6% 9 6.8% 23 17.4%
Combined 3 2.3% 0 0.0% 3 2.3%
Missing 3 2.3% 15 11.4% 18 13.6%
TotalFemaleMale
Treatments delivered by time of Q1 from diagnosis, year groups and gender
 
Table 23: Treatments by gender in those with first questionnaire completed within six weeks, three 
months and six months from diagnosis in all years and year 1 and years 2/3. 
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6.1.5 Discussion 
The population attending the lung multidisciplinary clinic in Stobhill is in keeping with 
lung cancer populations reported within the literature and in comparison to the national 
lung cancer audit (Table 24).  
Chracteristic Stobhill lung cancer service
Data sourced from 
national lung cancer 
audit
Gender
Male 49.30% 53%
Female 50.70% 47%
Age
50 years and less 2.80% 6.15%
51-69 46.50% 35.31%
70 years and more 50.70% 58.54%
Histology
NSCLC 68% 60.90%
SCLC 13% 15%
No/Negative histology 19% 19.80%
Other na 2.80%
Stage
1a 0.80% 3.31%
1b 5.80% 3.94%
2a 5.00% 0.55%
2b 1.70% 2.29%
3a 5.00% 4.42%
3b 25.60% 8.18%
4 38.00% 22.99%
Treatment
Surgery 19.3%* 9.88%
Chemotherapy 25.20% 25.24%
Radiotherapy 37.60% 22.04%
Palliative Care 15.20% 17.61%
Active monitoring na 12.86%
Performance status
0 14.40% 13.19%
1 34.30% 21.24%
2 19.30% 13.66%
3 22.90% 11.17%
4 3.40% 3.72%
5 na 16.76%
Missing 5.70% 20.27%
*Note discussion  
Table 24: Comparison of evaluation sample population characteristics to national audit. 
 
The patients tended to be over 65 years old, with half over the age of 70 years. Gregor et 
al41 reported a similar age spread in 1995 from a Scottish lung cancer population 
(median 70 years, range 34-97). 
 
Histological types are represented in expected proportions with around 70% of patients 
having NSCLC and 13% known to be SCLC. The 19% of patients with a clinico-
radiological diagnosis is also in keeping with the literature. In 1995 Gregor et al41 
reported 23.7% SCLC, 58.2% NSCLC and 18% unknown or other. The recent national 
lung cancer audit reported histological rates in Scotland as 60.9% NSCLC, 15% SCLC 
and 19.8% without histology.3  
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Advanced disease is common in each cell type. It is of note that out of the 353 patients, 
185 (52.4%) had advanced incurable disease (> stage 3A or extensive SCLC). The 
national lung cancer audit reports 40.9% of patients with advanced incurable disease in 
England and Wales.3 Furthermore, one third of patients attending the clinic had 
metastatic disease. This is in keeping with the 31.2% of metastatic disease at 
presentation reported in 199541 and the 29.8% in England and Wales reported in the 
national lung cancer audit.3  
 
It is of note that there were slightly more females (50.7%) than males (49.3%). This is 
less usual in lung cancer care and within the literature. Gregor et al41 reported 60.7% of 
the study population were male in 1995, and this is similar to the 59% males reported in 
England and Wales in 2007.3 Other studies have reported smaller differences between 
proportions of genders.164, 286 Furthermore, the clinic at Stobhill has seen an increase in 
referrals of females. This has been found within both in-house audits and as part of 
other studies within the same time period as this study.189, 190 This may reflect the 
increase within Scotland of lung cancer in the female population.36 Between 1995 and 
2005 there has been a 23.7% decrease in age-standardised incidence in lung cancer in 
men and a 3.5% increase in females.36 
 
There is a bias in year one with more completing Q1 as returning patients rather than 
newly diagnosed patients. This is to be expected as the LCQ is completed for the first 
time by any patient in year one. After the first year, most of the returning patients would 
have already completed a Q1 or would be deceased and therefore more newly diagnosed 
patients predominate in years 2/3. As such, the overall treatment rates and patient 
representation will be biased towards survivors returning to the clinic within the first 
year. This bias was accounted for by sub-group analysis. 
 
Overall survival of this lung cancer population was 11.47 months when evaluating all 
patients who returned a single questionnaire. This median survival is higher than the 
expected due to the bias towards including survivors in the sample. When considering 
overall survival in newly diagnosed patients only, the median was 9.13 months. Median 
survival from lung cancer in Scotland has been reported as 3.6 months,41, 42 5.2 
months,43 6 months,44 and 9.1 months45 dependent on area of Scotland and patient 
selection. It is likely there is some participation bias towards longer survivors in this 
study. 
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The majority of patients presenting with lung cancer have disease not amenable to 
surgical resection.41 In this study 19.3% of all patients completing a questionnaire had 
undergone surgery (24.1% of year one population and 14.1% years 2/3 population; see 
Table 22). However, when considering newly diagnosed patients only (excluding 
routine returns), 6.8% of patients underwent surgery (Table 23). This is in keeping with 
the national audit proportions of patients undergoing surgical resection: 9.26% in 
England and Wales and 9.7% in Scotland.3 
 
In newly diagnosed patients, 6.8% underwent radical radiotherapy and a further 39.2% 
received palliative radiotherapy (Table 23). Overall, 18.2% of patients undertook 
curative intent treatments (surgical resection, radical radiotherapy and chemotherapy in 
limited stage SCLC). In 2007, 62.3% of newly diagnosed lung cancer patients in 
Scotland received active anti-cancer treatments (including curative and non-curative 
intent treatments).3 In this study, around 79% of newly diagnosed patients received anti-
cancer treatment, with the palliative radiotherapy being delivered in 39.2% of patients 
(Table 23). 
 
In keeping with the out-patient study setting, most patients have a performance status 
doctor-rated at diagnosis as 2 or less (84.4%). The national lung cancer audit found 
48.09% of patients had a PS of 2 or less.3 However, 20.2% of patients had no recorded 
PS in the national audit and in-patients were also audited. 
 
The deprivation within the lung cancer population at this clinic is high. This is in 
keeping with expectation as the Stobhill Hospital catchment area covers several 
deprived areas within North Glasgow. Furthermore, deprivation has been found to be an 
independent risk factor for developing lung cancer in several countries,333-335 including 
Scotland.52 Survival from diagnosed lung cancer may also be reduced in those with 
higher deprivation, even within the population undergoing curative intent surgery.336 
There is also some evidence that a lower baseline quality of life in lung cancer is 
associated with deprivation.53 This is of particular note for this study which evaluates 
supportive care needs within a population with short survival rates. This study provides 
a focused view of a largely deprived population in which supportive care needs may 
require rapid identification to allow sufficient and timely care provision to meet those 
needs. 
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6.1.6 Conclusions 
Patients included in this analysis are in keeping with the expected range of histology 
and stages of lung cancer in an out-patient clinic. There are more females in this 
population than previously published articles, but this may reflect the changing trends 
within lung cancer incidence in Scotland and reflects the current situation in Stobhill. 
Median survival in this population is high compared to previously published studies. It 
is likely there is some participation bias towards survivors in this study. Other 
demographic variables are in keeping with published literature. When considering 
newly diagnosed patients, curative intent treatments were undertaken in 18.2% of 
patients. There is a high level of deprivation within this patient group and this may be 
associated with increased supportive care needs and shortened survival. This will be 
evaluated in subsequent sections.  
 
6.2 Descriptive Analysis of LCQ Responses 
In keeping with the primary aim of this study (Section 2), the prevalence of supportive 
care needs within Stobhill Hospital’s lung cancer multidisciplinary clinic and overall 
supportive care needs are considered in three groupings: 
1. All patients attending the lung cancer clinic population (all first questionnaires 
returned (Q1)). Filter: Q1 selected from Q1 or not Q1. 
2. Patients with newly diagnosed lung cancer (Q1 < six weeks post-diagnosis). 
Filter: as above AND additional criteria Q1 < six weeks from diagnosis. 
3. Those within three months of death from any cause. Filter: vital status=dead 
AND QF selected AND death within three months of QF. 
In keeping with Aims 1, 4 and 5 (Section 2), responses to the additional questions are 
presented in the same three groupings. 
 
As described in Section 3 both descriptive statistics of centrality are given to allow 
comparison with other published symptom assessment data and results have been 
further evaluated in terms of three categories: ‘none or mild’, ‘moderate’ and ‘severe to 
overwhelming’, and 95% confidence intervals for POS scores were calculated.  
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6.2.1 All patients Attending the Lung Cancer Clinic 
6.2.1.1 Responses to POS Questions 
Overall, 303 (85.8%) patients completed all the POS questions, thus allowing a 
summary score out of 40 to be calculated (n=353). Fifty (14.2%) patients did not fully 
complete the POS questions but some have responded to a proportion of individual 
questions. Summary statistics are tabulated below (Table 25). 
N Percentage Mean Standard Deviation 95% CI of mean Median Range
Palliative outcome scale summary score 303 85.8% 9.81 5.87 0.66 9 0-27
Pain 341 96.6% 1.28 1.18 0.13 1 0-4
Other symptoms 332 94.1% 0.65 0.97 1.04 0 0-4
Personal anxiety 334 94.6% 1.63 1.31 0.14 1 0-4
Perceived anxiety within support network 332 94.1% 2.17 1.40 0.15 2 0-4
Ability to share 332 94.1% 0.75 1.19 0.13 0 0-4
Life-worth 320 90.7% 0.55 0.90 0.10 0 0-4
Self-worth 325 92.1% 1.26 1.20 0.13 1 0-4
Information 309 87.5% 0.72 1.19 0.13 0 0-4
Practical issues 315 89.2% 0.52 0.88 0.10 0 0-3
Time use 321 90.9% 0.14 0.45 0.05 0 0-2
Form completion 331 93.8% 0.53 0.53 0.06 1 0-2  
Table 25: Summary statistics of overall and individual POS scores. 
 
POS individual question responses and summary scores alongside patient-rated PS are 
displayed in Figure 11. Individual bar charts of responses to each question with 95% CI 
are displayed in Appendix 5 (Figure 21A and B). A table showing patient responses 
categorised into none-mild, moderate and severe-overwhelming is displayed (Table 26). 
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Figure 11: Stacked bar charts showing POS scores, PS and responses to POS questions for all patients. Percentages adjusted to account for missing data. 
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Number % Number % Number %
Questionnaires
Number of lung cancer clinic questionnaires completed 174 49.3% 179 50.7% 353 100.0%
Number of fully completed POS questions 148 41.9% 155 43.9% 303 85.8%
Incomplete POS questions 26 7.4% 24 9.4% 50 14.2%
Summary POS score 148 41.9% 155 43.9% 303 85.8%
0-4 36 10.2% 24 6.8% 60 17.0%
5-9 51 14.4% 54 15.3% 105 29.7%
10-15 35 9.9% 39 11.0% 74 21.0%
≥15 26 7.4% 38 10.8% 64 18.1%
Missing 26 7.4% 24 6.8% 50 14.2%
Have you been affected by pain? 167 47.3% 174 49.3% 341 96.6%
None or slight 93 26.3% 104 29.5% 197 55.8%
Moderately 42 11.9% 42 11.9% 84 23.8%
Severe or overwhelming 32 9.1% 28 7.9% 60 17.0%
Missing 7 2.0% 5 1.4% 12 3.4%
Have any other symptoms been affecting how you feel? 161 45.6% 171 48.4% 332 94.1%
None or slight 130 36.8% 142 40.2% 272 77.1%
Moderately 20 5.7% 16 4.5% 36 10.2%
Severe or overwhelming 11 3.1% 13 3.7% 24 6.8%
Missing 13 3.7% 8 2.3% 21 5.9%
Have you felt anxious or worried about your illness or treatment? 162 45.9% 172 48.7% 334 94.6%
None or slight 92 26.1% 81 22.9% 173 49.0%
Moderate 34 9.6% 36 10.2% 70 19.8%
High anixiety (severe-overwhelming) 36 10.2% 55 15.6% 91 25.8%
Missing 12 3.4% 7 2.0% 19 5.4%
Have any of your friends or family about your illness or treatment? 162 45.9% 170 48.2% 332 94.1%
None or slight 68 19.3% 63 17.8% 131 37.1%
Moderate 12 3.4% 27 7.6% 39 11.0%
High anixiety (severe-overwhelming) 82 23.2% 80 22.7% 162 45.9%
Missing 12 3.4% 9 2.5% 21 5.9%
Have you been able to share how you are feeling with family or friends? 161 45.6% 171 48.4% 332 94.1%
Most or as much as wanted 130 36.8% 127 36.0% 257 72.8%
Sometimes 12 3.4% 27 7.6% 39 11.0%
Ocassionnally or not at all 19 5.4% 17 4.8% 36 10.2%
Missing 13 3.7% 8 2.3% 21 5.9%
Have you felt life was worthwhile? 154 43.6% 166 47.0% 320 90.7%
Yes to most of time 140 39.7% 137 38.8% 277 78.5%
Sometimes 8 2.3% 20 5.7% 28 7.9%
Occasionnally or not at all 6 1.7% 9 2.5% 15 4.2%
Missing 20 5.7% 13 3.7% 33 9.3%
Have you felt good about yourself? 158 44.8% 167 47.3% 325 92.1%
Yes to most of time 120 34.0% 101 28.6% 221 62.6%
Sometimes 21 5.9% 35 9.9% 56 15.9%
Occasionnally or not at all 17 4.8% 31 8.8% 48 13.6%
Missing 16 4.5% 12 3.4% 28 7.9%
How much information has been given? 152 43.1% 157 44.5% 309 87.5%
Full info to full info but some hard to understand 118 33.4% 109 30.9% 227 64.3%
Info on request but wanted more 24 6.8% 27 7.6% 51 14.4%
Very little to no information 10 2.8% 21 5.9% 31 8.8%
Missing 22 6.2% 22 6.2% 44 12.5%
Have practical matters, relating to your illness, been addressed? 153 43.3% 162 45.9% 315 89.2%
No issues or issues addressed 113 32.0% 131 37.1% 244 69.1%
Practical issues are currently being addressed 37 10.5% 28 7.9% 65 18.4%
Practical issues exist which have not been addressed 3 0.8% 3 0.8% 6 1.7%
Missing 21 5.9% 17 4.8% 38 10.8%
How much time do you feel has been wasted through healthcare? 158 44.8% 163 46.2% 321 90.9%
None at all 145 41.1% 142 40.2% 287 81.3%
Up to half a day wasted 10 2.8% 12 3.4% 22 6.2%
More than half a day wasted 3 0.8% 9 2.5% 12 3.4%
Unknown 16 4.5% 16 4.5% 32 9.1%
Form Completion 161 45.6% 170 48.2% 331 93.8%
Self 89 25.2% 71 20.1% 160 45.3%
Help from family 68 19.3% 97 27.5% 165 46.7%
Help from Staff 4 1.1% 2 0.6% 6 1.7%
Unknown 13 3.7% 9 2.5% 22 6.2%
Male Female Total
Analysis of Palliative Outcome Scale from First Questionnaire (Q1) 
 
Table 26: Responses to POS (summary score and individual questions) in categories compared 
across genders (n=353). Missing data presented.  
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In this analysis of all patients attending a lung cancer clinic, most respondents were able 
to complete the questionnaire by themselves (45.3%) or with help from family or 
friends (46.7%). Very few patients required help from staff to compete the form (1.7%).  
 
At least one supportive care need was recorded for 295 (97.4%) patients completing a 
full POS score (n=303). The overall mean POS score was 9.81 (SD 5.87, 95% CI 9.15-
10.47) and the median was 9. As such, when grouping patients into ‘higher’ or ‘lower’ 
supportive care needs, a cut off of ≥10 is used.  
 
Six out of ten of the issues assessed by POS had a median value of 0, and three issues 
(pain, personal anxiety and self-worth) had median values of 1. The only issue 
identified by POS with a median value rated moderate or above was ‘perceived anxiety 
within the patient’s support network’ ( x = 2.17, SD 1.40, median 2). 
 
Prevalences of moderate to overwhelming issues were as follows: 201 patients (56.9%, 
95% CI 51.7-62%) felt their support network was anxious, 161 (45.6%, 95% CI 40.5-
50.8%) reported personal anxiety, 144 (40.8%, 95% CI 35.8-46.0%) pain, 108 (30.5%, 
95% CI 26-35.6%) had information needs, 104 (29.6%, 95% CI 24.9-34.4%) reduced 
self-esteem, 75 (21.2%, 95% CI 17.3 – 25.8%) a low ability to share, 71 (20.1%, 95% 
CI 16.3-24.6%) reported unmet practical needs, 60 (17%, 95% CI 13.4-21.3%) affected 
by ‘other’ symptoms, 43 (12.1%, 95% CI 9.2-16%) felt life was worthwhile only 
sometimes to not at all and only 33 (9.6%, 95% CI 6.7%-12.8%) reported half or more 
of a day had been wasted through health care appointments. 
 
6.2.1.2 Responses to Respiratory Symptoms, Service Views and 
Other Questions 
All the respiratory symptom questions were completed by 334 (94.6%) patients out of 
353. Ten (2.8%) patients did not fully complete the respiratory questions but some have 
responded to a proportion of individual questions. A satisfaction score was completed 
by 131 (37.1%) patients. The questions relating to satisfaction were not included within 
the first 12 months and, therefore, 177 (50.1%) patients were not able to complete a 
satisfaction score in Q1. Thus, the 131 completed scores represent 74.4% of the number 
of possible scores (n=176). Forty-five (25.6%) patients did not fully complete the 
satisfaction questions but some have responded to a proportion of individual questions. 
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Summary statistics for respiratory symptom questions and service questions were 
tabulated (Table 27). 
 
N Percentage Mean Standard Deviation 95%  CI of mean Median Range
Overview of all patients attending clinic n=353
Respiratory symptom summary score 334 94.6% 3.00 1.91 0.20 3 0-10
Dypsnoea 342 96.9% 1.55 1.06 0.11 2 0-4
Cough 338 95.8% 1.23 0.98 0.10 1 0-4
Haemoptysis 334 94.6% 0.23 0.63 0.07 0 0-3
Overview of all patients attending clinic n=353
Satisfaction score 131 37.1% 1.27 1.49 0.25 1 0-7
Satisfaction with investigations 140 39.7% 0.47 0.68 0.11 0 0-3
Satisfaction with way diagnosis was given 139 39.4% 0.51 0.66 0.11 0 0-3
Satisfaction with follow-up 136 38.5% 0.36 0.54 0.09 0 0-2  
Table 27: Summary statistics of overall and individual respiratory and satisfaction scores for all 
Q1. 
 
Individual bar charts with 95% CI for all non-POS item responses for all patients’ Q1 
are displayed in Figure 12A and B. A table showing symptom responses categorised 
into none-mild, moderate and severe-overwhelming and also service question responses 
is displayed (Table 28). 
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Figure 12A: Histogram and bar charts of patient responses to respiratory symptom and other 
symptom-related questions (Q1). Percentages adjusted for missing data and 95% CI included. 
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Figure 12B: Histogram and bar charts of patient responses to service questions (Q1). 
Percentages adjusted for missing data and 95% CI included. 
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Male Female Total
Number % Number % Number %
Questionnaires
Number of lung clinic questionnaires completed 174 49.3% 179 50.7% 353 100.0%
Number of fully completed respiratory questions 164 46.5% 170 48.2% 334 94.6%
Incomplete respiratory questions 10 2.8% 9 2.5% 19 5.4%
Summary Respiratotry Score 164 46.5% 170 48.2% 334 94.6%
0-4 132 37.4% 137 38.8% 269 76.2%
5-8 30 8.5% 32 9.1% 62 17.6%
9-12 2 0.6% 1 0.3% 3 0.8%
Missing 10 2.8% 9 2.5% 19 5.4%
Have you been affected by dyspnoea? 167 47.3% 175 49.6% 342 96.9%
None or slight 84 23.8% 82 23.2% 166 47.0%
Moderate 56 15.9% 56 15.9% 112 31.7%
Severe or overwhelming 27 7.6% 37 10.5% 64 18.1%
Missing 7 2.0% 4 1.1% 11 3.1%
Have you been affected by cough? 166 47.0% 172 48.7% 338 95.8%
None or slight 102 28.9% 114 32.3% 216 61.2%
Moderate 46 13.0% 43 12.2% 89 25.2%
Severe or overwhelming 18 5.1% 15 4.2% 33 9.3%
Missing 8 2.3% 7 2.0% 15 4.2%
Have you been affected by haemoptysis? 163 46.2% 171 48.4% 334 94.6%
None or slight 151 42.8% 163 46.2% 314 89.0%
Moderate 8 2.3% 4 1.1% 12 3.4%
Severe or overwhelming 4 1.1% 4 1.1% 8 2.3%
Missing 11 3.1% 8 2.3% 19 5.4%
Have you had any new or worsening symptoms since last clinic? 166 47.0% 173 49.0% 339 96.0%
No 122 34.6% 127 36.0% 249 70.5%
Yes 44 12.5% 46 13.0% 90 25.5%
Missing 8 2.3% 6 1.7% 14 4.0%
Have you had to contact your GP since last clinic? 74 21.0% 77 21.8% 151 42.8%
No 32 9.1% 44 12.5% 76 21.5%
Yes 42 11.9% 33 9.3% 75 21.2%
Missing 100 28.3% 102 28.9% 202 57.2%
Satisfaction summary Score 66 18.7% 65 18.4% 131 37.1%
0-4 65 18.4% 63 17.8% 128 36.3%
5-8 1 0.3% 2 0.6% 3 0.8%
9-12 0 0.0% 0 0.0% 0 0.0%
Missing 108 30.6% 114 32.3% 222 62.9%
How satisfied were you with the way tests were carried out? 68 19.3% 72 20.4% 140 39.7%
Very satisfied or satisfied 65 18.4% 68 19.3% 133 37.7%
Unsatisfied or very unsatisfied 3 0.8% 4 1.1% 7 2.0%
Missing 106 30.0% 107 30.3% 213 60.3%
How satisfied were you with the way your diagnosis was given? 68 19.3% 71 20.1% 139 39.4%
Very satisfied or satisfied 66 18.7% 64 18.1% 130 36.8%
Unsatisfied or very unsatisfied 2 0.6% 7 2.0% 9 2.5%
Missing 106 30.0% 108 30.6% 214 60.6%
How satisfied were you with the way you are being followed-up? 68 19.3% 68 19.3% 136 38.5%
Very satisfied or satisfied 67 19.0% 65 18.4% 132 37.4%
Unsatisfied or very unsatisfied 1 0.3% 3 0.8% 4 1.1%
Missing 106 30.0% 111 31.4% 217 61.5%
Do you feel you are seeing to many health care professionals 158 44.8% 164 46.5% 322 91.2%
No 148 41.9% 149 42.2% 297 84.1%
Yes 10 2.8% 15 4.2% 25 7.1%
Missing 16 4.5% 15 4.2% 31 8.8%
How would you prefer to be followed-up? 137 38.8% 141 39.9% 278 78.8%
MDT clinic with routine review 87 24.6% 92 26.1% 179 50.7%
GP based system, referred back if symptoms occur 36 10.2% 29 8.2% 65 18.4%
Hospital-based specialist nurse 14 4.0% 20 5.7% 34 9.6%
Missing 37 10.5% 38 10.8% 75 21.2%
Who do you think is in over all charge of your care? 145 41.1% 160 45.3% 305 86.4%
GP 29 8.2% 32 9.1% 61 17.3%
Respiratory Consultant 79 22.4% 74 21.0% 153 43.3%
Oncologist 11 3.1% 18 5.1% 29 8.2%
Surgeon 1 0.3% 3 0.8% 4 1.1%
Palliative Care Consultant 2 0.6% 0 0.0% 2 0.6%
Specialist nurse 2 0.6% 2 0.6% 4 1.1%
Uncertain 13 3.7% 19 5.4% 32 9.1%
Other 8 2.3% 12 3.4% 20 5.7%
Missing 29 8.2% 19 5.4% 48 13.6%
Has palliative care been involved in care? 77 21.8% 77 21.8% 154 43.6%
No 49 13.9% 63 17.8% 112 31.7%
Yes 28 7.9% 14 4.0% 42 11.9%
Missing 97 27.5% 102 28.9% 199 56.4%
Analysis of Respiratory and other symptom questions from Q1 across gender
 
 
 
 
 
 
Table 28: Responses to respiratory and other symptom questions (summary score and individual 
questions) and service-related qeustions compared across gender from Q1. Note: satisfaction 
questions were not available in year 1. Missing data presented. 
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At least one respiratory symptom was reported for 312 (93.4%, n=334) patients 
completing a respiratory score. The only respiratory symptom identified as moderate or 
above was dyspnoea (median 2). Prevalence of moderate to overwhelming symptoms 
were as follows: dyspnoea 176 (49.8%, 95% CI 44.7-55.0%), cough 122 (34.5%, 95% 
CI 29.8-39.7%) and haemoptysis 20 (5.7%, 95% CI 3.7-8.6%).  
 
When satisfaction was assessed, the majority of patients were either very satisfied or 
satisfied with the investigation process (133; 75.6%), diagnosis disclosure (130; 73.9%) 
and follow-up (132; 80%).  
 
The majority (70.5%) of patients indicated no new or changing symptoms and 21.2% 
had contacted their GP since their last clinic review. Most (84.1%) did not feel they 
were seeing too many health care professionals and slightly more than half of patients 
(50.7%) preferred follow-up at the MDT clinic with routine review. However, 18.4% of 
patients would prefer a GP-led follow-up system and 9.6% a nurse-led follow-up; 
21.2% did not express an opinion. One hundred and twelve (72.7%, n=154) patients did 
not have documented palliative care input (this was only reviewed in year 2/3). Most 
(43.3%) patients identified the respiratory consultant as in charge of care, 17.3% GP, 
8.2% oncologist and 2.8% surgeon, palliative care or specialist nurse. Some (14.8%) 
were uncertain or suggested ‘other’, and 13.6% did not reply.  
 
6.2.2 Newly Diagnosed Patients 
6.2.2.1 Responses to POS Questions 
For 170 patients out of 353 (48.2%), Q1 was completed within six weeks of diagnosis. 
One hundred and forty-seven (86.5%) of these patients completed all of the POS 
questions, thus allowing a summary score out of 40 to be calculated. Twenty-three 
patients (13.5%) did not fully complete the POS questions but some have responded to a 
proportion of individual questions. Summary statistics are tabulated below (Table 29). 
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N Percentage Mean Standard Deviation 95% CI of mean Median Range
Palliative Outcome Scale summary score 147 86.5% 10.74 5.85 0.95 10 1-27
Pain 166 97.6% 1.33 1.23 0.19 1 0-4
Other symptoms 161 94.7% 0.63 0.97 0.15 0 0-4
Personal anxiety 162 95.3% 1.93 1.35 0.21 2 0-4
Perceived anxiety within support network 161 94.7% 2.63 1.23 0.19 3 0-4
Ability to share 161 94.7% 0.75 1.23 0.19 0 0-4
Life-worth 155 91.2% 0.55 0.94 0.15 0 0-4
Self-worth 158 92.9% 1.28 1.29 0.20 1 0-4
Information 154 90.6% 0.60 0.98 0.15 0 0-3
Practical issues 155 91.2% 0.66 0.98 0.15 0 0-2
Time use 155 91.2% 0.15 0.45 0.07 0 0-2
Form completion 161 94.7% 0.60 0.50 0.08 1 0-2  
Table 29: Summary statistics of overall and individual POS scores in recently diagnosed patients 
(Q1<6 weeks). 
 
POS individual question responses and summary scores alongside patient-rated PS are 
displayed in Figure 13. Individual bar charts of responses to each question with 95% CI 
are displayed in Appendix 6 (Figure 22A and B). A table showing responses categorised 
into none-mild, moderate and severe-overwhelming is displayed (Table 30). 
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Supportive care needs of all newly diagnosed patients
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Figure 13: Stacked bar chart showing newly diagnosed patients’ POS score, PS and responses to POS question. Percentages adjusted for missing data.
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Number % Number % Number %
Questionnaires
Number of lung cancer clinic questionnaires completed 84 49.4% 86 50.6% 170 100.0%
Number of fully completed POS questions 72 42.4% 75 44.1% 147 86.5%
Incomplete POS questions 12 7.1% 11 6.5% 23 13.5%
Summary POS score 72 42.4% 75 44.1% 147 86.5%
0-4 13 7.6% 10 5.9% 23 13.5%
5-9 26 15.3% 23 13.5% 49 28.8%
10-15 19 11.2% 19 11.2% 38 22.4%
≥15 14 8.2% 23 13.5% 37 21.8%
Missing 12 7.1% 11 6.5% 23 13.5%
Have you been affected by pain? 82 48.2% 84 49.4% 166 97.6%
None or slight 47 27.6% 46 27.1% 93 54.7%
Moderately 18 10.6% 21 12.4% 39 22.9%
Severe or overwhelming 17 10.0% 17 10.0% 34 20.0%
Missing 2 1.2% 2 1.2% 4 2.4%
Have any other symptoms been affecting how you feel? 79 46.5% 82 48.2% 161 94.7%
None or slight 66 38.8% 66 38.8% 132 77.6%
Moderately 8 4.7% 9 5.3% 17 10.0%
Severe or overwhelming 5 2.9% 7 4.1% 12 7.1%
Missing 5 2.9% 4 2.4% 9 5.3%
Have you felt anxious or worried about your illness or treatment? 80 47.1% 82 48.2% 162 95.3%
None or slight 39 22.9% 32 18.8% 71 41.8%
Moderate 15 8.8% 17 10.0% 32 18.8%
High anixiety (severe-overwhelming) 26 15.3% 33 19.4% 59 34.7%
Missing 4 2.4% 4 2.4% 8 4.7%
Have any of your friends or family about your illness or treatment? 80 47.1% 81 47.6% 161 94.7%
None or slight 21 12.4% 17 10.0% 38 22.4%
Moderate 7 4.1% 15 8.8% 22 12.9%
High anixiety (severe-overwhelming) 52 30.6% 49 28.8% 101 59.4%
Missing 4 2.4% 5 2.9% 9 5.3%
Have you been able to share how you are feeling with family or friends? 79 46.5% 82 48.2% 161 94.7%
Most or as much as wanted 62 36.5% 62 36.5% 124 72.9%
Sometimes 6 3.5% 12 7.1% 18 10.6%
Ocassionnally or not at all 11 6.5% 8 4.7% 19 11.2%
Missing 5 2.9% 4 2.4% 9 5.3%
Have you felt life was worthwhile? 76 44.7% 79 46.5% 155 91.2%
Yes to most of time 69 40.6% 64 37.6% 133 78.2%
Sometimes 4 2.4% 9 5.3% 13 7.6%
Occasionnally or not at all 3 1.8% 6 3.5% 9 5.3%
Missing 8 4.7% 7 4.1% 15 8.8%
Have you felt good about yourself? 78 45.9% 80 47.1% 158 92.9%
Yes to most of time 58 34.1% 49 28.8% 107 62.9%
Sometimes 12 7.1% 12 7.1% 24 14.1%
Occasionnally or not at all 8 4.7% 19 11.2% 27 15.9%
Missing 6 3.5% 6 3.5% 12 7.1%
How much information has been given? 75 44.1% 79 46.5% 154 90.6%
Full info to full info but some hard to understand 56 32.9% 60 35.3% 116 68.2%
Info on request but wanted more 15 8.8% 16 9.4% 31 18.2%
Very little to no information 4 2.4% 3 1.8% 7 4.1%
Missing 9 5.3% 7 4.1% 16 9.4%
Have practical matters, relating to your illness, been addressed? 75 44.1% 80 47.1% 155 91.2%
No issues or issues addressed 49 28.8% 61 35.9% 110 64.7%
Practical issues are currently being addressed 23 13.5% 16 9.4% 39 22.9%
Practical issues exist which have not been addressed 3 1.8% 3 1.8% 6 3.5%
Missing 9 5.3% 6 3.5% 15 8.8%
How much time do you feel has been wasted through healthcare? 76 44.7% 79 46.5% 155 91.2%
None at all 69 40.6% 69 40.6% 138 81.2%
Up to half a day wasted 6 3.5% 5 2.9% 11 6.5%
More than half a day wasted 1 0.6% 5 2.9% 6 3.5%
Unknown 8 4.7% 7 4.1% 15 8.8%
Form Completion 78 45.9% 83 48.8% 161 94.7%
Self 34 20.0% 32 18.8% 66 38.8%
Help from family 43 25.3% 51 30.0% 94 55.3%
Help from Staff 1 0.6% 0 0.0% 1 0.6%
Unknown 6 3.5% 3 1.8% 9 5.3%
Male Female Total
Analysis of Palliative Outcome Scale from First Questionnaire (Q1) in newly diagnosed patients
 
Table 30: Responses to POS (summary score and individual questions) in categories compared 
across gender for recently diagnosed patients (n=170). Missing data presented. 
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The majority (55.3%) of newly diagnosed patients completed the questionnaire with 
help from family or friends or by themselves (38.8%). Again very few patients required 
help from staff (0.6%).  
 
All of the patients completing a full POS score (n=147) recorded at least one supportive 
care need being present. The overall mean POS score of 10.74 (SD 5.85, 95% CI 9.79-
11.69) was higher in the newly diagnosed patients than the general clinic population. 
The median POS was 10. Comparison of newly diagnosed patients ( x =10.74) with 
those not diagnosed in the preceding six weeks ( x =8.93) demonstrated a significant 
mean POS difference of 1.81, 95% CI 0.49 to 3.13, p=0.007(Student’s t test, 2 tailed).  
 
Six out of ten of the issues assessed by POS had a median value of 0; two issues (pain 
and self-worth) had median values of 1. There were two issues identified by POS with a 
median value in the moderate or above category (personal anxiety and perceived 
support network anxiety). These issues were rated significantly higher in this newly 
diagnosed population compared to those outwith six weeks of diagnosis (Mann-
Whitney U test): personal anxiety ( x =1.93, SD 1.35, median 2, p<0.001) and perceived 
anxiety within the patient’s support network ( x =2.63, SD 1.23, median 3, p<0.001). 
The only other significant difference in POS items between newly diagnosed patients 
and patients who had not been diagnosed in the preceding six weeks was found to relate 
to practical matters requiring to be addressed (p=0.007). This latter difference may well 
relate to the initial lack of time for the service to identify and address such issues.  
 
Prevalences of moderate to overwhelming issues were as follows: 123 patients (72.4%, 
95%CI 65.2-78.5%) felt their support network was anxious, 91 (53.5%, 95% CI 46.0- 
60.9%) reported personal anxiety, 73 (42.9%, 95% CI 35.7-50.7%) pain, 60 (35.3%, 
95% CI 28.5-42.7%) unmet information needs, 51 (30%, 95% CI 23.6%-37.3%) 
reduced self-esteem, 45 (26.4%, 95%CI 20.4-33.6%) practical matters needing 
addressed, 37 (21.8%, 95% CI 16.2-28.6%) were able to share feelings occasionally or 
not at all, 29 (17.1%, 95%CI 12.1%-23.4%) affected by ‘other’ symptoms, 22 (12.9%, 
95% CI 8.7-18.8%) felt life was worthwhile only sometimes to not at all and only 17 
(10%, 95% CI 6.3-15.4%) felt half or more of a day had been wasted through health 
care appointments. 
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6.2.2.1.1 Responses to Respiratory Symptoms, Service Views and Other 
Questions 
Overall, 170 (48.2%) patients out of the total study population (n=353) completed an 
initial questionnaire within six weeks of diagnosis. Of these 170 patients, 160 (94.1%) 
competed all the respiratory questions, thus allowing a summary score to be calculated. 
Ten (5.9%) patients did not fully complete the respiratory questions but some have 
responded to a proportion of individual questions. Eighty-one (22.9%) patients out of 
353 completed a satisfaction score. It should be noted that these questions were not 
included within year 1 and, as such, 177 (50.1%) patients did not complete a satisfaction 
score in year 1. Thus the 81 completed scores represent (76.4%) of the number of 
possible scores when Q1 < six weeks from diagnosis (n=106). Twenty-five out of 106 
patients (23.6%) did not complete a full satisfaction score but some have completed a 
proportion of the individual questions. Summary statistics for respiratory symptom 
questions and service questions were tabulated (Table 31). 
 
N Percentage Mean Standard Deviation 95% CI of mean Median Range
Patients with recent diagnosis (Q1<6 weeks from diagnosis) n=170
Respiratory symptom summary score 160 94.1% 3.12 2.03 0.31 3 0-10
Dypsnoea 166 97.6% 1.56 1.07 0.16 2 0-4
Cough 163 95.9% 1.27 0.98 0.15 1 0-3
Haemoptysis 161 94.7% 0.32 0.76 0.12 0 0-3
Patients with recent diagnosis (Q1<6 weeks from diagnosis) n=106
Satisfaction score 81 76.4% 1.27 1.47 0.32 1 0-7
Satisfaction with investigations 88 83.0% 0.48 0.73 0.15 0 0-3
Satisfaction with way diagnosis was given 88 83.0% 0.55 0.71 0.15 0 0-3
Satisfaction with follow-up 82 77.4% 0.30 0.46 0.10 0 0-1  
Table 31: Summary statistics of overall and individual respiratory and satisfaction scores. 
 
Percentage of responses to questions about respiratory symptoms, satisfaction, symptom 
occurrence, GP use, preferences regarding follow-up responses and perception of who is 
in charge have been displayed. Bar charts with 95% CI for responses to each item are 
displayed in Figure 14A and B. 
 
A table showing symptom responses categorised into none-mild, moderate and severe-
overwhelming and also service question responses is displayed (Table 32). 
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Figure 14A: Histogram and bar charts of patient responses to respiratory symptom and other 
symptom related questions (Q1<6 weeks of diagnosis). Percentages adjusted for missing data. 
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Figure 14B: Histogram and bar charts of patient responses to service questions (Q1<6 weeks of 
diagnosis). Percentages adjusted for missing data and 95% CI included. 
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Number % Number % Number %
Questionnaires
Number of lung clinic questionnaires completed 84 49.4% 86 50.6% 170 100.0%
Number of fully completed respiratory questions 79 46.5% 81 47.6% 160 94.1%
Incomplete respiratory questions 5 2.9% 5 2.9% 10 5.9%
Summary Respiratotry Score 79 46.5% 81 47.6% 160 94.1%
0-4 60 35.3% 65 38.2% 125 73.5%
5-8 18 10.6% 15 8.8% 33 19.4%
9-12 1 0.6% 1 0.6% 2 1.2%
Missing 5 2.9% 5 2.9% 10 5.9%
Have you been affected by dyspnoea? 82 48.2% 84 49.4% 166 97.6%
None or slight 42 24.7% 40 23.5% 82 48.2%
Moderate 27 15.9% 23 13.5% 50 29.4%
Severe or overwhelming 13 7.6% 21 12.4% 34 20.0%
Missing 2 1.2% 2 1.2% 4 2.4%
Have you been affected by cough? 81 47.6% 82 48.2% 163 95.9%
None or slight 48 28.2% 55 32.4% 103 60.6%
Moderate 23 13.5% 19 11.2% 42 24.7%
Severe or overwhelming 10 5.9% 8 4.7% 18 10.6%
Missing 3 1.8% 4 2.4% 7 4.1%
Have you been affected by haemoptysis? 79 46.5% 82 48.2% 161 94.7%
None or slight 71 41.8% 75 44.1% 146 85.9%
Moderate 5 2.9% 3 1.8% 8 4.7%
Severe or overwhelming 3 1.8% 4 2.4% 7 4.1%
Missing 5 2.9% 4 2.4% 9 5.3%
Have you had any new or worsening symptoms since last clinic? 80 47.1% 81 47.6% 161 94.7%
No 65 38.2% 64 37.6% 129 75.9%
Yes 15 8.8% 17 10.0% 32 18.8%
Missing 4 2.4% 5 2.9% 9 5.3%
Have you had to contact your GP since last clinic? 42 24.7% 52 30.6% 94 55.3%
No 22 12.9% 28 16.5% 50 29.4%
Yes 20 11.8% 24 14.1% 44 25.9%
Missing 42 24.7% 34 20.0% 76 44.7%
Satisfaction summary Score 38 22.4% 43 25.3% 81 47.6%
0-4 37 21.8% 42 24.7% 79 46.5%
5-8 1 0.6% 1 0.6% 2 1.2%
9-12 0 0.0% 0 0.0% 0 0.0%
Missing 46 27.1% 43 25.3% 89 52.4%
How satisfied were you with the way tests were carried out? 39 22.9% 49 28.8% 88 51.8%
Very satisfied or satisfied 37 21.8% 45 26.5% 82 48.2%
Unsatisfied or very unsatisfied 2 1.2% 4 2.4% 6 3.5%
Missing 45 26.5% 37 21.8% 82 48.2%
How satisfied were you with the way your diagnosis was given? 39 22.9% 49 28.8% 88 51.8%
Very satisfied or satisfied 37 21.8% 44 25.9% 81 47.6%
Unsatisfied or very unsatisfied 2 1.2% 5 2.9% 7 4.1%
Missing 45 26.5% 37 21.8% 82 48.2%
How satisfied were you with the way you are being followed-up? 38 22.4% 44 25.9% 82 48.2%
Very satisfied or satisfied 38 22.4% 44 25.9% 82 48.2%
Unsatisfied or very unsatisfied 0 0.0% 0 0.0% 0 0.0%
Missing 46 27.1% 42 24.7% 88 51.8%
Do you feel you are seeing to many health care professionals 76 44.7% 81 47.6% 157 92.4%
No 70 41.2% 75 44.1% 145 85.3%
Yes 6 3.5% 6 3.5% 12 7.1%
Missing 8 4.7% 5 2.9% 13 7.6%
How would you prefer to be followed-up? 68 40.0% 69 40.6% 137 80.6%
MDT clinic with routine review 40 23.5% 44 25.9% 84 49.4%
GP based system, referred back if symptoms occur 16 9.4% 12 7.1% 28 16.5%
Hospital-based specialist nurse 12 7.1% 13 7.6% 25 14.7%
Missing 16 9.4% 17 10.0% 33 19.4%
Who do you think is in over all charge of your care? 68 40.0% 78 45.9% 146 85.9%
GP 8 4.7% 7 4.1% 15 8.8%
Respiratory Consultant 38 22.4% 33 19.4% 71 41.8%
Oncologist 3 1.8% 11 6.5% 14 8.2%
Surgeon 0 0.0% 2 1.2% 2 1.2%
Palliative Care Consultant 2 1.2% 0 0.0% 2 1.2%
Specialist nurse 1 0.6% 0 0.0% 1 0.6%
Uncertain 11 6.5% 17 10.0% 28 16.5%
Other 5 2.9% 8 4.7% 13 7.6%
Missing 16 9.4% 8 4.7% 24 14.1%
Has palliative care been involved in care? 39 22.9% 45 26.5% 84 49.4%
No 28 16.5% 36 21.2% 64 37.6%
Yes 11 6.5% 9 5.3% 20 11.8%
Missing 45 26.5% 41 24.1% 86 50.6%
Total
Analysis of Respiratory and other symptom questions from Q1 < 6 weeks across gender
Male Female
 
Table 32: Responses to respiratory and other symptom questions (summary score and individual 
questions) and service-related questions compared across genders from Q1<6 weeks of diagnosis. 
Note: satisfaction questions not available in year 1.  
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One hundred and fifty-one of the 160 patients (94.4%) completed a respiratory score 
and reported at least one respiratory symptom. The only respiratory symptom identified 
as moderate or above was dyspnoea (median 2). The prevalences of moderate to 
overwhelming symptoms were as follows: dyspnoea 84 (49.4%, 95% CI 42.0-56.9%), 
cough 60 (35.3%, 95% CI 28.5-42.7%) and haemoptysis 15 (8.8%, 95% CI 5.4-14.0%).  
 
When satisfaction was assessed, the majority of patients were either very satisfied or 
satisfied with the investigation process (82, 77%), diagnosis disclosure (81, 76%) and 
follow-up (82, 77%). 
 
Most patients (75.9%) indicated no new or changing symptoms, and 25.9% had 
contacted their GP since their last clinic review. Most (145, 85.3%) did not feel they 
were seeing too many health care professionals, and almost half of patients (49.4%) 
preferred follow-up at the MDT clinic with routine review. However, 16.5% of patients 
would prefer a GP-led follow-up system and 14.7% a nurse-led follow-up; 19.4% did 
not express an opinion. Sixty-four (76.2%) patients did not have documented palliative 
care input (this was reviewed only in year 2/3, n=84). Most patients (41.8%) identified 
the respiratory consultant as in charge of care, 8.8% GP, 8.2% oncologist and 3.0% 
surgeon, palliative care or specialist nurse, 24.1% were uncertain or suggested ‘other’ 
and 14.1% did not reply. 
 
6.2.3 Last Questionnaires Completed Within Three Months 
Prior to All-Cause Death 
6.2.3.1 Responses to POS Questions 
Of the 215 patients who died, 121 (56.3%) had completed a questionnaire within the 
three months prior to death. Out of these 121, 109 (90.1%) completed all the POS 
questions allowing a summary score out of 40 to be calculated. Twelve (9.9%) patients 
did not fully complete the POS questions but some responded to a proportion of 
individual questions. Summary statistics are tabulated below (Table 33). 
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N Percentage Mean Standard Deviation 95% CI of mean Median Range
Palliative Outcome Scale summary score 109 90.1% 11.40 6.30 1.18 11 0-27
Pain 117 96.7% 1.68 1.33 0.24 2 0-4
Other symptoms 113 93.4% 1.00 1.10 0.20 1 0-4
Personal anxiety 113 93.4% 1.79 1.34 0.25 2 0-4
Perceived anxiety within support network 114 94.2% 2.40 1.35 0.25 3 0-4
Ability to share 115 95.0% 0.91 1.23 0.23 0 0-4
Life-worth 114 94.2% 0.75 1.05 0.19 0 0-4
Self-worth 115 95.0% 1.63 1.40 0.26 1 0-4
Information 114 94.2% 0.72 1.20 0.22 0 0-4
Practical issues 114 94.2% 0.68 0.98 0.18 0 0-3
Time use 115 95.0% 0.16 0.45 0.08 0 0-2
Form completion 115 95.0% 0.67 0.54 0.10 1 0-2  
Table 33: Summary statistics of overall and individual POS scores in patients less than three 
months prior to death (from any cause). 
 
POS individual question responses and summary scores alongside patient-rated PS are 
displayed in Figure 15. Individual bar charts of responses to each question with 95% CI 
are displayed in Appendix 7 (Figure 23A and B).  
 
Responses categorised into none-mild, moderate and severe across groupings of Q1=QF 
and when Q1≠QF are tabulated. Comparisons across the groupings are included (Table 
34). 
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Figure 15: Stacked bar chart showing POS scores, PS and POS responses for patients three months from death. Percentages adjusted for missing data. 
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Number % Χ2 Number % Χ2 Number %
POS
Number of Questionnaires completed 54 44.6% 67 55.4% 121 100.0%
Number of fully completed POS questions 46 38.0% 63 52.1% 109 90.1%
Incomplete POS questions 8 4 12 9.9%
Summary POS Score 46 38.0% 63 52.1% 109 90.1%
0-4 5 4.1% 1.14 14 11.6% 0.83 19 15.7%
5-9 11 9.1% 0.07 13 10.7% 0.05 24 19.8%
10-14 13 10.7% 0.06 20 16.5% 0.05 33 27.3% Χ2= 3.376
≥15 17 14.0% 0.68 16 13.2% 0.50 33 27.3% df= 3
Missing 8 6.6% 4 3.3% 12 9.9% p= 0.34
Have you been affected by pain? 52 43.0% 65 53.7% 117 96.7%
None or slight 24 19.8% 0.33 24 19.8% 0.27 48 39.7%
Moderately 13 10.7% 0.56 23 19.0% 0.45 36 29.8% Χ2= 1.626
Severe or overwhelming 15 12.4% 0.01 18 14.9% 0.01 33 27.3% df= 2
Missing 2 1.7% 2 1.7% 4 3.3% p= 0.44
Have any other symptoms been affecting how you feel? 50 41.3% 63 52.1% 113 93.4%
None or slight 32 26.4% 0.02 42 34.7% 0.01 74 61.2%
Moderately 9 7.4% 0.55 17 14.0% 0.43 26 21.5% Χ2= 3.828
Severe or overwhelming 9 7.4% 1.36 4 3.3% 1.46 13 10.7% df= 2
Missing 4 3.3% 4 3.3% 8 6.6% p= 0.15
Have you felt anxious or worried about your illness or treatment? 50 41.3% 63 52.1% 113 93.4%
None or slight 14 11.6% 2.98 36 29.8% 2.37 50 41.3%
Moderate 14 11.6% 0.35 13 10.7% 0.28 27 22.3% Χ2= 10.133
High anixiety (severe-overwhelming) 22 18.2% 2.31 14 11.6% 1.84 36 29.8% df= 2
Missing 0 0.0% 4 3.3% 4 3.3% p= 0.01
Have any of your friends or family about your illness or treatment? 50 41.3% 64 52.9% 114 94.2%
None or slight 8 6.6% 9.61 44 36.4% 7.51 52 43.0%
Moderate 7 5.8% 0.03 8 6.6% 0.02 15 12.4% Χ2= 28.987
High anixiety (severe-overwhelming) 35 28.9% 3.97 12 9.9% 7.84 47 38.8% df= 2
Missing 4 3.3% 3 2.5% 7 5.8% p= 0.00
Have you been able to share how you are feeling with family or friends? 51 42.1% 64 52.9% 115 95.0%
Most or as much as wanted 39 32.2% 0.13 44 36.4% 0.10 83 68.6%
Sometimes 8 6.6% 0.12 8 6.6% 0.09 16 13.2% Χ2= 2.868
Ocassionnally or not at all 4 3.3% 1.35 12 9.9% 1.08 16 13.2% df= 2
Missing 3 2.5% 3 2.5% 6 5.0% p= 0.24
Have you felt life was worthwhile? 50 41.3% 64 52.9% 114 94.2%
Yes to most of time 37 30.6% 0.28 55 45.5% 0.22 92 76.0%
Sometimes 5 4.1% 0.09 5 4.1% 0.07 10 8.3% Χ2= 3.184
Ocassionnally or not at all 8 6.6% 1.42 4 3.3% 1.11 12 9.9% df= 2
Missing 4 3.3% 3 2.5% 7 5.8% p= 0.20
Have you felt good about yourself? 51 42.1% 64 52.9% 115 95.0%
Yes to most of time 26 21.5% 0.69 43 35.5% 0.55 69 57.0%
Sometimes 6 5.0% 0.01 7 5.8% 0.01 13 10.7% Χ2= 3.599
Ocassionnally or not at all 19 15.7% 1.30 14 11.6% 1.04 33 27.3% df= 2
Missing 3 2.5% 3 2.5% 6 5.0% p= 0.17
How much information has been given? 50 41.3% 64 52.9% 114 94.2%
Full info to full info but some hard to understand 34 28.1% 0.16 49 40.5% 0.12 83 68.6%
Info on request but wanted more 10 8.3% 0.33 9 7.4% 0.26 19 15.7% Χ2= 1.060
Very little to no information 6 5.0% 0.10 6 5.0% 0.08 12 9.9% df= 2
Missing 4 3.3% 3 2.5% 7 5.8% p= 0.59
Have practical matters, relating to your illness, been addressed? 50 41.3% 64 52.9% 114 94.2%
No issues or issues addressed 33 27.3% 0.24 49 40.5% 0.19 82 67.8%
Practical issues are currently being addressed 16 13.2% 1.46 11 9.1% 1.14 27 22.3% Χ2= 4.192
Practical issues exist which have not been addressed 1 0.8% 0.65 4 3.3% 0.51 5 4.1% df= 2
Missing 4 3.3% 3 2.5% 7 5.8% p= 0.12
How much time do you feel has been wasted through healthcare? 51 42.1% 64 52.9% 115 95.0%
None at all 44 36.4% 0.01 57 47.1% 0.01 101 83.5%
Up to half a day wasted 4 3.3% 0.04 6 5.0% 0.03 10 8.3% Χ2= 1.624
More than half a day wasted 3 2.5% 0.85 1 0.8% 0.68 4 3.3% df= 2
Unknown 3 2.5% 3 2.5% 6 5.0% p= 0.44
Form Completion 51 42.1% 64 52.9% 115 95.0%
Self 17 14.0% 0.14 25 20.7% 0.11 42 34.7%
Help from family 33 27.3% 0.19 36 29.8% 0.15 69 57.0% Χ2= 1.200
Help from Staff 1 0.8% 0.34 3 2.5% 0.27 4 3.3% df= 2
Unknown 3 2.5% 3 2.5% 6 5.0% p= 0.55
Analysis of Palliative Outcome Scale from Final Questionnaire (QF) when death occurs within 3months from POS
Final Questionniare when =Q1 Final Questionnaire when not =Q1 Total
 
Table 34: Responses to POS (summary score and individual questions) in categories compared 
between all final questionaires (QF), and final questionnaires from patients completing greater 
than one (QF≠Q1) in patients who died within three months of questionnaire completion.  
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In final questionnaires completed within three months of death by any cause, 69 (57%) 
patients had help from family and friends and 42 (34.7%) completed the form 
themselves.  
 
A difference between questionnaire grouping (QF=Q1 versus QF≠Q1) was observed for 
both personal anxiety (Χ2=10.133, df=2, p=0.01) and perceived support network anxiety 
(Χ2=28.987, df=2, p<0.01). For both items, more anxiety was recorded in the group in 
whom their first questionnaire was also QF. No other differences were observed in POS 
responses between the questionnaire groups.  
 
One hundred and eight (99.1%) patients completing a full POS score recorded at least 
one supportive care need being present. The overall mean POS score was 11.40 (SD 
6.3, 95% CI 10.22-12.58) and the median was 11. Mean POS scores were higher from 
QF in those with three months or less to live ( x =11.40 SD=6.304) than QF completed 
by patients with greater than three months to live but who subsequently died ( x =9.69 
SD=5.656). However, this did not reach statistical significance: mean difference 1.716 
(95% CI -0.009 to 2.441, p=0.51).  
 
Five out of ten of the issues assessed by POS had a median value of 0; two issues (self-
worth and ‘other’ symptoms) had a median value of 1. There were three issues 
identified by POS with a median value in the moderate or above category: personal 
anxiety (median 2), support network anxiety (median 3) and pain (median 2).  
 
Prevalences of moderate to overwhelming issues were as follows: pain 69 (57.1%, 95% 
CI 48.1-65.5%), personal anxiety 63 (52.1%, 95% CI 43.2-60.8%), perception of 
support network anxiety 62 (51.2%, 95%CI 42.4-60.0%), self-esteem 46 (38.0%, 95% 
CI 29.9-46.9%), ‘other’ symptoms 39 (32.2%, CI 95% 24.6-41.0%), ability to share 32 
(26.4%, 95% CI 19.4-34.9%), practical issues 32 (26.4%, 95% CI 19.4-34.9%), 
information 31 (25.6%, 95% CI 18.7-34.1%), life-worth 22 (18.2%, 95% CI 12.3-26%) 
and time wasted 14 (11.6%, 95% CI 7.0-18.5%). Thus, pain was found to be the most 
prevalent issue in this group of patients. 
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6.2.3.2 Responses to Respiratory Symptoms, Service Views and 
Other Questions 
Overall, 215 patients (60.1%) out of 353 died during the study period. Of these 215 
patients, 121 (56.20%) completed a QF within three months prior to death. One hundred 
and fourteen (94.2%) patients completed all the respiratory questions allowing a 
summary score to be calculated. Seven (5.3%) patients did not fully complete the 
respiratory questions but some responded to a proportion of individual questions. 
 
Fifty-six (15.9%) patients out of 353 completed a satisfaction score. It should be noted 
that these questions were not included within year 1 and, as such, 177 (50.1%) patients 
did not complete a satisfaction score in year 1. Thus, the 56 completed scores represent 
74.7% of the number of possible scores for QF<3 months from any cause of death 
(n=75). Nineteen out of 75 (25.3%) patients did not complete a full satisfaction score 
but some have completed a proportion of individual questions. Summary statistics for 
respiratory symptom questions and service questions were tabulated (Table 35). 
 
N Percentage Mean Standard Deviation 95% CI of mean Median Range
Deceased patients with QF<3months from death n=121
Respiratory symptom summary score 114 94.2% 3.54 2.24 0.41 4 0-10
Dypsnoea 117 96.7% 1.92 1.23 0.22 2 0-4
Cough 115 95.0% 1.40 1.19 0.22 1 0-4
Haemoptysis 113 93.4% 0.25 0.62 0.11 0 0-3
Deceased patients with QF<3months from death n=121
Satisfaction score 56 46.3% 1.71 1.47 0.39 1 0-6
Satisfaction with investigations 59 48.8% 0.47 0.63 0.16 0 0-3
Satisfaction with way diagnosis was given 59 48.8% 0.68 0.54 0.14 1 0-2
Satisfaction with follow-up 56 46.3% 0.52 0.57 0.15 0 0-2  
Table 35: Summary statistics of overall and individual respiratory and satisfaction scores. 
 
Individual bar charts with 95% CI for all non-POS item responses are displayed (Figure 
16A and B). A table showing symptom responses categorised into none-mild, moderate 
and severe-overwhelming and also service question responses is displayed (Table 36). 
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Figure 16A: Histogram and bar charts of patient responses to respiratory symptom and other 
symptom related questions (QF completed in patients who died of any cause within three months of 
completing QF). Percentages adjusted for missing data. 
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Figure 16B: Patient responses to service questions (QF in patients who completed QF within three 
months of death). Percentages adjusted for missing data and 95% CI included. 
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Number % Χ2 Number % Χ2 Number %
Questionnaires
Number of lung clinic questionnaires completed 54 44.6% 67 55.4% 121 100.0%
Number of fully completed respiratory questions 50 41.3% 64 52.9% 114 94.2%
Incomplete respiratory questions 4 3.3% 3 2.5% 7 5.8%
Summary Respiratotry Score 50 41.3% 64 52.9% 114 94.2%
0-4 32 26.4% 0.02 43 35.5% 0.02 75 62.0%
5-8 17 14.0% 0.01 21 17.4% 0.01 38 31.4% Χ2= 1.34
9-12 1 0.8% 0.72 0 0.0% 0.56 1 0.8% df= 2
Missing 4 3.3% 3 2.5% 7 5.8% p= 0.51
Have you been affected by dyspnoea? 52 43.0% 65 53.7% 117 96.7%
None or slight 19 15.7% 0.01 23 19.0% 0.00 42 34.7%
Moderate 14 11.6% 0.16 21 17.4% 0.12 35 28.9% Χ2= 0.44
Severe or overwhelming 19 15.7% 0.08 21 17.4% 0.07 40 33.1% df= 2
Missing 2 1.7% 2 1.7% 4 3.3% p= 0.80
Have you been affected by cough? 51 42.1% 64 52.9% 115 95.0%
None or slight 24 19.8% 0.01 40 33.1% 0.01 64 52.9%
Moderate 15 12.4% 0.10 21 17.4% 0.06 36 29.8% Χ2= 0.24
Severe or overwhelming 12 9.9% 0.03 21 17.4% 0.02 33 27.3% df= 2
Missing 3 2.5% 3 2.5% 6 5.0% p= 0.89
Have you been affected by haemoptysis? 50 41.3% 63 52.1% 113 93.4%
None or slight 46 38.0% 0.02 60 49.6% 0.01 106 87.6%
Moderate 3 2.5% 0.28 2 1.7% 0.22 5 4.1% Χ2= 0.56
Severe or overwhelming 1 0.8% 0.01 1 0.8% 0.01 2 1.7% df= 2
Missing 4 3.3% 4 3.3% 8 6.6% p= 0.76
Have you had any new or worsening symptoms since last clinic? 51 42.1% 66 54.5% 117 96.7%
No 34 28.1% 1.33 30 24.8% 1.03 64 52.9% Χ2= 5.22
Yes 17 14.0% 1.61 36 29.8% 1.25 53 43.8% df= 1
Missing 28 23.1% 31 25.6% 59 48.8% p= 0.03
Have you had to contact your GP since last clinic? 26 21.5% 36 29.8% 62 51.2%
No 9 7.4% 0.01 13 10.7% 0.00 22 18.2% Χ2= 0.01
Yes 17 14.0% 0.00 23 19.0% 0.00 40 33.1% df= 1
Missing 28 23.1% 31 25.6% 59 48.8% p= 1.00
Satisfaction summary Score 22 18.2% 34 28.1% 56 46.3%
0-4 21 17.4% 34 28.1% 55 45.5%
5-8 1 0.8% 0 0.0% 1 0.8% Χ2= na
9-12 0 0.0% 0 0.0% 0 0.0% df= 2
Missing 32 26.4% 33 27.3% 65 53.7% p= na
How satisfied were you with the way tests were carried out? 25 20.7% 34 28.1% 59 48.8%
Very satisfied or satisfied 24 19.8% 0.00 33 27.3% 0.00 57 47.1% Χ2= 0.05
Unsatisfied or very unsatisfied 1 0.8% 0.03 1 0.8% 0.02 2 1.7% df= 1
Missing 29 24.0% 33 27.3% 62 51.2% p= 1.00
How satisfied were you with the way your diagnosis was given? 25 20.7% 34 28.1% 59 48.8%
Very satisfied or satisfied 25 20.7% 0.03 32 26.4% 0.02 57 47.1% Χ2= 1.52
Unsatisfied or very unsatisfied 0 0.0% 0.85 2 1.7% 0.62 2 1.7% df= 1
Missing 29 24.0% 33 27.3% 62 51.2% p= 0.50
How satisfied were you with the way you are being followed-up? 22 18.2% 34 28.1% 56 46.3%
Very satisfied or satisfied 22 18.2% 0.03 32 26.4% 0.02 54 44.6% Χ2= 1.34
Unsatisfied or very unsatisfied 0 0.0% 0.79 2 1.7% 0.51 2 1.7% df= 1
Missing 32 26.4% 33 27.3% 65 53.7% p= 0.51
Do you feel you are seeing to many health care professionals 50 41.3% 62 51.2% 112 92.6%
No 46 38.0% 0.02 59 48.8% 0.01 105 86.8% Χ2= 0.47
Yes 4 3.3% 0.25 3 2.5% 0.20 7 5.8% df= 1
Missing 4 3.3% 5 4.1% 9 7.4% p= 0.49
How would you prefer to be followed-up? 38 31.4% 60 49.6% 98 81.0%
MDT clinic with routine review 21 17.4% 0.10 37 30.6% 0.06 58 47.9%
GP based system, referred back if symptoms occur 11 9.1% 0.01 18 14.9% 0.00 29 24.0% Χ2= 1.32
Hospital-based specialist nurse 6 5.0% 0.71 5 4.1% 0.45 11 9.1% df= 2
Missing 16 13.2% 7 5.8% 23 19.0% p= 0.52
Who do you think is in over all charge of your care? 48 39.7% 61 50.4% 109 90.1%
GP 13 10.7% 0.03 18 14.9% 0.02 31 25.6%
Respiratory Consultant 17 14.0% 0.03 20 16.5% 0.02 37 30.6%
Oncologist 1 0.8% 3.90 12 9.9% 3.07 13 10.7%
Surgeon 0 0.0% 0.50 1 0.8% 0.35 1 0.8%
Palliative Care Consultant 1 0.8% 0.66 4 3.3% 0.52 5 4.1%
Specialist nurse 0 0.0% na 0 0.0% na 0 0.0%
Uncertain 9 7.4% 1.30 5 4.1% 1.03 14 11.6% Χ2= na
Other 7 5.8% 3.43 1 0.8% 2.70 8 6.6% df= 7
Missing 6 5.0% 6 5.0% 12 9.9% p= na
Has palliative care been involved in care? 28 23.1% 29 24.0% 57 47.1%
No 12 9.9% 0.22 16 13.2% 0.22 28 23.1% Χ2= 0.86
Yes 16 13.2% 0.22 13 10.7% 0.21 29 24.0% df= 1
Missing 26 21.5% 38 31.4% 64 52.9% p= 0.43
Final Questionnaire when =Q1 Final Questionnaire when not equal to Q1
Analysis of Respiratory and other symptom questions from Qf within 3 months of when death (all cause) has occurred within study period
Total
 
Table 36: Responses to respiratory and other symptom questions (summary score and individual 
questions) and service related questions compared between QF when equal to Q1 
and when not. QF in patients who died within three months of completing QF.  
Note: satisfaction questions not available in year 1. 
 
A respiratory score was completed and at least one respiratory symptom reported for for 
104 (91.0%) of the 114. The only respiratory symptom identified as moderate or above 
was dyspnoea (median 2).  
 
Prevalences of moderate to overwhelming symptoms were: dyspnoea 75 (62.0%, 95% 
CI 53.1-70.1%), cough 69 (57.1%, 95% CI 48.1-65.5%) and haemoptysis 7 (5.8%, 95% 
CI 2.8-11.5%). Many (52.9%) patients indicated no new or changing symptoms and 
43.8% had contacted their GP since their last clinic review. A significant difference 
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across questionnaire groups (QF and QF≠Q1) was observed in ‘new or changed 
symptoms’ (p=0.03) 
 
When satisfaction was assessed, the majority of patients were either very satisfied or 
satisfied with the investigation process: diagnosis disclosure 57 (76%) and follow-up 54 
(72%). Most (105, 86.8%) did not feel they were seeing too many health care 
professionals, and just under half of patients (47.9%) preferred follow-up at the MDT 
clinic with routine review. However, 24.0% of patients would prefer a GP-led follow-up 
system and 9.1% a nurse-led follow-up; 19% did not express an opinion. In those 
reviewed, 28 (49%) patients did not have documented palliative care input (this was 
reviewed only in year 2, n=57). Many (30.6%) patients identified the respiratory 
consultant as in charge of care, 25.6% GP, 10.7% oncologist and 4.9% surgeon, 
palliative care or specialist nurse, 18.2% were uncertain or suggested ‘other’ and 9.9% 
did not reply. 
 
6.2.4 Main Issues Indicated by Free Text in POS 
Within the POS questionnaire, the free text question ‘If any, what have been your main 
problems in the last 4 weeks?’ invites the patients to record the main issues affecting 
them. The responses to this question have been tabulated (Table 37). 
 
Number Percentage Number Percentage Number Percentage
Dyspnoea 20 5.7% 14 8.2% 15 12.4%
Pain 16 4.5% 8 4.7% 9 7.4%
Cough 4 1.1% 0 0.0% 4 3.3%
Fatigue 7 2.0% 5 2.9% 3 2.5%
Nausea 4 1.1% 3 1.8% 3 2.5%
Anxiety 1 0.3% 1 0.6% 0 0.0%
Depression 0 0.0% 0 0.0% 0 0.0%
Treatment Side effects 1 0.3% 0 0.0% 0 0.0%
Weight loss 2 0.6% 1 0.6% 0 0.0%
Sweats 1 0.3% 1 0.6% 1 0.8%
Constipation 0 0.0% 0 0.0% 1 0.8%
Altered appetite 1 0.3% 0 0.0% 0 0.0%
Other 3 0.8% 2 1.2% 3 2.5%
All patients who died 
and QF within 3 
months of death 
n=121
All patients' initial 
Questionnaire (Q1) 
n=353
Recent diagnosis (Q1 
<6 weeks from 
diagnosis) n=170
 
Table 37: Summarised free text responses to the question ‘If any, what have been your main 
problems in the last 4 weeks?’ for different groupings of patients. 
 
Within the category of ‘other’, free text responses included: bleeding, toe fracture, 
altered speech, oedema, balance issues, memory problems and difficulty walking (some 
patients reported more than one issue). Dyspnoea was the most frequently cited ‘main 
issue’ in each grouping. The second most frequent issue cited was pain. 
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6.2.5 Free Text Responses Outwith POS 
Within the non-POS sections of the questionnaire, the free text question ‘Have you had 
to contact your GP in the last 4 weeks? If so, why?’ invites the patients to record the 
main reasons for attending their GP. The responses to this question have been tabulated 
(Table 38). 
Number Percentage Number Percentage Number Percentage
Dyspnoea 5 1.4% 3 1.8% 7 5.8%
Pain/Analgesics 11 3.1% 5 2.9% 6 5.0%
Cough 4 1.1% 2 1.2% 1 0.8%
Fatigue 0 0.0% 0 0.0% 0 0.0%
Nausea 1 0.3% 1 0.6% 2 1.7%
Anxiety 0 0.0% 0 0.0% 0 0.0%
Depression 0 0.0% 0 0.0% 0 0.0%
Treatment Side effects 0 0.0% 0 0.0% 0 0.0%
Weight loss 2 0.6% 1 0.6% 1 0.8%
Other 5 1.4% 5 2.9% 0 0.0%
Routine Follow-up 7 2.0% 2 1.2% 8 6.6%
Vaccination 4 1.1% 2 1.2% 0 0.0%
Practical conerns 1 0.3% 0 0.0% 1 0.8%
Discussion/Information 3 0.8% 2 1.2% 0 0.0%
Chest Infection 4 1.1% 2 1.2% 2 1.7%
Other Infections 3 0.8% 1 0.6% 2 1.7%
"Unwell" 2 0.6% 1 0.6% 1 0.8%
Medication/Script 8 2.3% 6 3.5% 2 1.7%
All patients' initial 
Questionnaire (Q1)
Recent diagnosis (Q1 
<6 weeks from 
diagnosis)
All patients who died 
and QF within 3 
months of death
 
Table 38: Summarised free text responses to the question ‘Have you had to contact your GP in the 
last 4 weeks? If so, why?’ evaluated within different groupings of patients. 
 
Within the ‘other’ category, responses included: rash, new lumps, bleeding, dyspepsia, 
high potassium, road accident, insomnia, smoking cessation advice, co-morbid 
conditions, jaundice and sick lines. 
 
6.2.6 Comparison of LCQ Items Across Groupings 
The median scores and their 95% CI for individual items in each grouping have been 
compared to the general population using Mann-Whitney U tests. The results are 
tabulated below (Table 39). 
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Physical Median 95% CI Median 95% CI p value Median 95% CI p value Median 95% CI p value
Pain 1 1-1 1 1-2 0.55 2 1-2 0.13 2 1-2 0.01
Other 0 0-0 0 0-0 0.59 0 0-1 0.38 1 0-1 0.03
Dyspnoea 2 1-2 2 1-2 0.89 2 2-2 <0.01 2 2-2 0.02
Cough 1 1-1 1 1-1 0.51 1 1-1 0.87 1 1-2 0.65
Haemoptysis 0 0-0 0 0-0 0.02 0 0-0 0.74 0 0-0 0.40
Psycho-emotional
Personal anxiety 1 1-2 2 1-2 <0.001 2 1-2 0.29 2 1-2 0.31
Support anxiety 2 2-3 3 3-3 <0.001 2 2-3 0.05 3 2-3 0.28
Self worth 1 1-1 1 0-0 0.79 1 1-1 0.15 1 1-1 0.37
Life worth 0 0-0 0 1-1 0.75 0 0-1 0.03 0 0-1 0.97
Ability to share 0 0-0 0 0-0 0.60 0 0-0 0.17 0 0-1 0.04
Social
Practical 0 0-0 0 0-0 0.01 0 0-0 1.00 0 0-0 0.38
Information 0 0-0 0 0-0 0.37 0 0-0 0.89 0 0-0 0.41
Time 0 0-0 0 0-0 0.83 0 0-0 0.66 0 0-0 0.98
Satisfaction
Investigations 0 0-0 0 0-0 0.76 0 0-1 0.50 0 0-1 0.92
Diagnosis 0 0-1 0 0-0 0.59 1 0-1 0.01 1 1-1 0.01
Follow-up 0 0-0 0 0-0 0.29 0 0-1 0.03 0 0-1 0.12
Performance Status 1 1-2 1 1-2 0.73 2 2-3 <0.001 2 2-3 <0.001
QF <3 months from all death
Grouping of patients
New diagnosis QF all cause mortalityGeneral
 
Table 39: Comparison of physical symptoms, psycho-emotional issues, social issues, satisfaction and performance status of 
different groupings to overall general clinic population (comparison by Mann-Whitney U tests). 
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6.2.7 Performance Status 
Performance status is not evaluated in the patient version of POS. It can be assessed if 
the staff version is used concurrently. Patients in this study were asked to rate their own 
current performance status using the ECOG scale within the LCQ. Within the clinic, 
333 patients (94.3%) and 160 (94.1%) newly diagnosed patients completed this item in 
their first questionnaire. One hundred and twelve (92.6%) patients who died within 
three months of QF completion responded to this item. These have been displayed in 
Figure 17. A table showing PS categorised into 0-2 and 3-4 is shown below; Fisher’s 
exact test was used to assess for difference of each grouping from all patients (Table 
40). 
Compared Compared
Count % Count % to general to new
All patients 240 72.1% 93 27.9% p=1.0
Newly diagnosed 116 72.5% 44 27.5% p=1.0
All cause death (<3 months) 60 53.6% 52 46.4% p<0.001 p<0.001
0-2 3-4
Performance Status Category
 
Table 40: Table of current ECOG PS, patient-rated. 
 
0% 20% 40% 60% 80% 100%
Percentage of each response
All pat ients
Newly diagnosed
All cause death (<3
months)
Current performance status (patient-rated)
4
3
2
1
0
 
Figure 17: Stacked bar chart showing percentage response for each category of patient-rated, 
current ECOG performance status (4, 3, 2, 1, 0) for each grouping of patients. Percentages adjusted 
for missing data. 
 
There was no difference found between the general clinic and newly diagnosed patients’ 
PS. Those who subsequently died within three months of completing the LCQ had 
significantly poorer PS than the general clinic population and newly diagnosed patients. 
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6.3 Discussion 
6.3.1 Questionnaire Response 
There was a good response to the questionnaire with 353 patients returning at least one 
questionnaire. Around 200-250 new patients are referred to Stobhill each year for 
investigation of lung cancer. Of these referrals, approximately 130 are diagnosed with 
lung cancer. Therefore, in 30 months around 325 new diagnoses may be made. (Audit 
figures from Stobhill lung cancer service in 2008 reported 155 new patients, of which 
128 had confirmed lung cancer (28 NSCLC, 25 SCLC and 25 clinical lung cancer)). 
Over the 30 months studied, 170 patients diagnosed within the previous six weeks 
responded (approximately 52% of possible newly diagnosed patients) and 121 patients 
completed the LCQ within three months of death. The majority of patients completed 
the forms by themselves or with some help from their family or friends. In comparison 
to many studies assessing symptoms and supportive care needs of patients with lung 
cancer, both the total number of patients participating and the response rate were good.  
 
6.3.2 Supportive Care Needs Measured by the Palliative 
Outcome Scale 
Previous studies using POS have reported findings in different ways and have studied 
heterogeneous groups of patients (i.e. multiple cancer sites, different settings and some 
non-cancer). The majority of previous POS study populations contain a proportion of 
lung cancer patients. Lung cancer patients have been reported to have high levels of 
symptom burden and unmet supportive care needs.13, 157 In the current study, at least one 
unmet supportive care need was reported in 97.4% of all patients attending clinic, 100% 
of new diagnosis patients and 99.1% of those within three months of death. The mean 
scores for POS were 9.81 (CI 9.15-10.47), 10.74 (CI 9.79-11.69) and 11.40 (CI 10.22-
12.58) for all patients, newly diagnosed patients and patients who died within three 
months of LCQ completion, respectively. Mean POS scores have been previously 
reported in the cancer setting of 15.9 by Bausewein et al219 (22 lung cancer patients in a 
study group of 118 German cancer patients) and 8.04 by Higginson215 (11 lung cancer 
patients in a study population of 66 palliative care patients). Other studies utilising POS 
do not report a mean summative score. No previous study has reported a median for the 
summative POS score. In this study, the median POS summative scores were 9, 10 and 
11 for all patients, newly diagnosed patients and patients who died within three months 
of completing the LCQ, respectively. Bausewein et al219 also report a range of 
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summative POS scores of 3-31; in this study we observed an overall range of 0-27. The 
findings from this study and previous studies have been tabulated below (Table 41). 
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Eisenchlas et al, 2008 Bausewein et al, 2005 Stevens et al,  2005 Higginson,  2004 Hearn & Higginson, 1999 All Patients Q1<6 weeks from Diagnosis Qf<3months from death
(Current Study) (Current Study) (Current Study)
Patient group studied Argentina, Cancer German, Cancer UK, Cancer UK, mainly cancer, some non-cancer UK, Palliative care patients Lung Cancer Lung Cancer Lung Cancer
Number of lung cancer patients 11of 65 22 of 118 3 of 30 11 of 66 26 of 145 353 170 121
POS Summative score
Mean 15.9 8.04 9.81 10.74 11.4
Median POS 9 10 11
POS Range 3-31 0-27 1-27 0-27
Pain
Median 2 1 1 2
Mean 1.41 1.28 1.33 1.68
Percentage severe-overwhelming 39 57 43.3 24.3 17 20 27.3
Other symptoms
Median 2 0 0 1
Mean 1.1 0.65 0.63 1
Percentage severe-overwhelming 33.3 30 4.2 27.2 6.8 7.1 10.7
Personal Anxiety
Median 2 1 2 2
Mean 0.8 1.63 1.93 1.79
Percentage severe-overwhelming 39.7 55 43.3 23.6 25.8 34.7 29.8
Family anxiety
Median 3 2 3 3
Mean 1.56 2.17 2.63 2.4
Percentage severe-overwhelming 62.3 79 56.6 49.6 45.9 59.4 38.8
Information needs
Median 0 0 0 0
Mean 0.09 0.72 0.6 0.72
Percentage severe-overwhelming 11.7 8 3.3 12.6 8.8 4.1 9.9
Ability to share
Median 0 0 0 0
Mean 0.85 0.75 0.75 1.23
Percentage severe-overwhelming 10.4 11 6.7 10.4 10.2 11.2 13.2
Life-worth
Median 1 0 0 0
Mean 0.64 0.55 0.55 1.05
Percentage severe-overwhelming 15.8 43 16.7 13.6 4.2 5.3 9.9
Self-worth
Median 1 1 1 1
Mean 1.09 1.2 1.29 1.63
Percentage severe-overwhelming 26.3 31 16.7 15.9 13.6 15.9 27.3
Time use
Median 0 0 0 0
Mean 0.07 0.14 0.15 0.16
Percentage severe-overwhelming 31.6 3 10 5.9 3.4 3.5 3.3
Practical issues
Median 0 0 0 0
Mean 0.43 0.52 0.66 0.68
Percentage severe-overwhelming 10.5 9 6.7 7.8 1.7 8.8 4.1
 
Table 41: Previously published data for POS items and summative scores, as well as the current study’s data. 
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A wide range of summative POS scores and item scores have previously been reported 
(Table 41). No previous study has reported POS responses from lung cancer patients 
only; however, the figures reported and the responses patterns are similar to previous 
work. The current study has a relatively low prevalence of reported severe to 
overwhelming pain. This may reflect that the patients are in the out-patient setting of a 
lung cancer clinic rather than within a palliative care service. The figures from the 
current study are percentages including missing values and most of the other studies 
quoted exclude missing values. It is of particular note that, in each study, anxiety 
perceived in the support network is the highest-rated problem no matter which 
descriptive statistic is used.  
 
The reported impact on patients’ lives of most items measured by POS appears to be 
relatively low when assessed by median response. However, median values for each 
item do not evaluate the specific prevalence of moderate to overwhelming symptoms. 
Three items from POS (anxiety perceived in support network, personal anxiety and 
pain) had a median value equal to or greater than two (moderate) in each of the different 
groupings studied. In addition to those three, dyspnoea was also rated as troubling in the 
respiratory questions (median 2 in all groupings). Previous reports within the literature 
regarding POS scores were mainly related to validation of the tool. However, the 
Stevens et al218 descriptive study of patients with advanced cancer (on admission to a 
hospital based palliative care unit) also found apparently low levels of baseline 
supportive care needs measured by median POS values. Of the 30 patients studied by 
Stevens et al,218, six out of ten issues had a median value of 0 or 1, with four main areas 
scoring higher: patients’ perception of family anxiety (median 3), personal anxiety 
(median 2), pain (median 2) and ‘other’ symptoms (median 2). Again, both family and 
personal anxiety were rated the highest in this study. Higginson215 explored the factors 
contributing to an overall POS score in a heterogeneous population and found that four 
main factors explained 67% of the variability of POS scores – life-worth combined with 
self-worth, information needs, family anxiety and pain combined with other symptoms. 
This study215 also evaluated two other patient-reported outcome measures. 
 
Despite the use of an adapted version of POS within the LCQ, the pattern of responses 
and levels of symptoms identified would suggest the questions retained face, content 
and construct validity. However, this was not formally assessed and therefore remains 
speculative. The palliative outcome questions within the LCQ also retained internal 
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consistency with a Cronbach’s alpha value of 0.79 (This compares to 0.65 reported 
during POS development147). Validation and development of the LCQ was beyond the 
scope and resources of the current project. The lack of formal validation limits the 
conclusions that can be drawn. 
 
6.3.3 Physical Symptoms and Function 
Pain is a key symptom in the lung cancer population (see Sections 5 and 6.2). An 
overall clinic prevalence of 40.8% of pain, that is either moderate (23.8%) or severe-
overwhelming (17%), is in keeping with the high symptom burden expected within the 
lung cancer population. The prevalence of pain in patients with lung cancer ranges from 
20-86% depending on the phase of illness evaluated (Table 11 to Table 15). In this 
study, 42.9% of newly diagnosed patients rated pain as moderate, severe or 
overwhelming. The pain burden within the last three months of life was significantly 
higher than in the general clinic population. Pain has been reported to be an adverse 
prognostic indicator in advanced cancer in previous studies.135, 337 
 
Although POS records the presence and severity of pain, it does not explore location or 
cause. However, from a supportive care perspective, the main issue is to identify the 
existence of the problem, to further elucidate the details and to establish subsequent 
management clinically. The high prevalence of pain in lung cancer patients attending 
for routine review, new patients’ appointments and near end of life in lung cancer is 
confirmed here and should be considered as part of the clinical assessment on each 
review. 
 
‘Other’ symptoms did not rate highly in any of the groupings in this study. Overall in 
the clinic, 6.8% of patients rated ‘other’ symptoms as severe or overwhelming. This is 
in contrast to most previously published studies (Table 41). However, it should be noted 
that the response in the ‘other’ symptoms section cannot be related directly to previous 
studies using only POS without any additional questions. The LCQ asks patients to rate 
the effects of dyspnoea, cough and haemoptysis in addition to the symptom of pain. As 
such, these additional symptoms are less likely to be rated as ‘other’ symptoms. The 
fact that Higginson reported dyspnoea as the most frequently cited symptom in the free 
text of ‘other’ symptoms in version 1 of POS reinforces this postulate.147 
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The presence of at least one respiratory symptom was observed in over 90% of patients, 
irrespective of phase of illness. Median respiratory summary scores (possible score = 0-
12) were similar for all patient groupings, although in the last three months of life 
higher scores were observed (median 4). In every group, the respiratory symptoms were 
ranked the same by median scores: dyspnoea (median 2), cough (median 1) and 
haemoptysis (median 0).  
 
Low levels of haemoptysis are in keeping with previous findings regarding lung cancer 
symptoms throughout the cancer journey (Section 5). Overall, 89% of patients had no or 
slight problems with haemoptysis, and only 5.7% rated this symptom as moderate-
overwhelming. Slightly more patients rated this symptom as moderate-overwhelming in 
the last three months of life (5.8%) and within six weeks of diagnosis (8.8%). Despite 
the low levels of haemoptysis in this population, it remains a cardinal symptom of 
diagnostic importance (often a presenting symptom)83, 86 and can generate great anxiety 
and fear for patients.338 
 
Moderate to overwhelming cough was present in 34.5% of the general clinic population 
and 35.3% of the newly diagnosed patients; it increased in prevalence in the last three 
months of life (57.1%). However, comparison of median scores did not show a 
significant difference in cough in any phase of illness compared to the general study 
population. Cough has not been identified as an adverse prognostic indicator in lung 
cancer, and its utility in diagnosis is reduced by low specificity.82 
 
Dyspnoea was identified as the most troublesome respiratory symptom in this study; it 
was present in over 80% of all patients irrespective of phase of illness, and the 
prevalence of moderate to overwhelming dyspnoea in the general study population was 
49.8%, in newly diagnosed patients 49.4% and in patients who died within three months 
of LCQ completion 62%. Furthermore, in the free text sections of the LCQ indicating 
‘main issues’, dyspnoea was the most frequently rated of all the responses in each 
grouping (Table 37). Dyspnoea, again, was most frequently rated as a reason for visiting 
the general practioner between clinic appointments (with the exception of collecting 
prescriptions; Table 38). This is in keeping with previous studies looking at the 
prevalence of breathlessness in lung cancer patients utilising a variety of assessment 
tools (Section 1.5.2).  
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Comparison of median scores showed a significant increase in dyspnoea in patients who 
died than in the general study population (p<0.01) and in patients in the last three 
months of life (p=0.02). There was no difference between dyspnoea reported by the 
general study population and dyspnoea reported by newly diagnosed patients (Table 
39). Dyspnoea has been previously identified as an adverse prognostic indicator in 
advanced cancer and within lung cancer.135, 337, 339 Increased symptom frequency and 
severity in lung cancer patients in the last three months of life has been reported by Lutz 
et al.297 
 
Poor performance status is a well defined adverse prognostic indicator in lung cancer 
(see Section 1.4.5). In this study, patient-rated performance status was significantly 
poorer in those who died within three months of completing the LCQ. This will be 
explored further in Section 8. 
 
6.3.4 Psycho-Emotional Issues  
Psychosocial distress may occur in 10-40% of cancer patients.340, 341 In a study of 96 
newly diagnosed patients, Steinberg et al160 reported a prevalence of clinically 
significant distress in 51% of patients and also high levels of depression and/or 
nervousness in 26.5% of patients. Montazeri et al342 found post diagnosis levels of 
depression were significantly greater than pre-diagnosis levels in lung cancer patients. 
POS considers several aspects of personal psycho-emotional distress in three specific 
questions: ‘have you felt anxious or worried about your illness or treatment?’, ‘have you 
felt life was worthwhile?’ and ‘have you felt good about yourself?’ The question ‘have 
any of your friends or family been worried about your illness or treatment?’ evaluates 
the patients’ perception of how much worry is present in the support network. A final 
question ‘have you been able to share about how you are feeling with family or 
friends?’ evaluates the degree of support perceived to be available to the patients from 
that support network. In this study, we found high levels of moderate to overwhelming 
personal anxiety within the overall clinic population (45.6%), and a prevalence of 
moderate to overwhelming reduced self-esteem of 29.5%, as assessed by the question 
‘have you felt good about yourself?’. An overall prevalence of reduced life-worth of 
12.1% was identified. 
 
The median level of anxiety perceived in the support network (median 2) shows this as 
the highest-rated concern within the POS responses. Personal anxiety was also highly 
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rated (median 1). In all other studies of cancer patients using POS, this has been a 
common finding. There have been no studies to confirm that patients’ perception of 
worry and anxiety amongst friends and family truly reflects reality; however, in studies 
utilising concurrent staff POS questionnaires, there is concordance. The finding that 
lung cancer patients are concerned about the worries of their support network has also 
been identified by Li and Girgis.157 In their study of 888 patients with a variety of 
cancers, the authors reported that those with lung cancer had significantly more unmet 
supportive care needs than those with other cancers. Furthermore, the main reported 
increased needs were in the psychological and daily living domains of the evaluation 
tool. It is of interest that lung cancer patients rated ‘concerns about the worries of those 
close to you’ as the most frequent unmet psychological need (53.4%), followed by 
‘fears about the cancer spreading’ (52%) and ‘fears about physical disability or 
deterioration’ (49.5%). In contrast, these three psychological concerns were rated in 
reverse order and at lower frequencies by patients with other cancers: ‘fears about 
physical disability or deterioration’ (36.6%), ‘fears about the cancer spreading’ (36.1%) 
and ‘concerns about the worries of those close to you’ (33%).157 
 
The majority of patients (72.8%) in the clinic were able to share how they were feeling 
with family or friends, but 21.2% were only able to share ‘sometimes’ (11%) or 
‘occasionally’ to ‘not at all’ (10.2%). Within the group of 91 patients experiencing high 
anxiety (severe-overwhelming), 11% were only able to share their feelings occasionally 
or not at all. Of the 15 patients who felt life was worthwhile ‘occasionally or not at all’, 
three (20%) were not able to share feelings. In this minority of patients with high 
psychosocial distress and high social isolation, targeted supportive care may benefit 
overall care goals and reduce symptom burden. Psycho-emotional aspects are further 
explored in Section 9. 
 
6.3.5 Information Needs and Practical Aspects of Care 
Information needs within the lung cancer population may be high, with many patients 
desiring information to be consistent, individualised and actively offered.12, 343 Meredith 
et al344 found that 79% of cancer patients in the West of Scotland (n=269) wanted ‘as 
much information as possible’. Krishnasamy et al13 reported that although many lung 
cancer patients ‘feel able’ to ask questions at time of diagnosis in out-patients settings 
(34%), some did not wish to or felt too upset to ask questions. A recent audit of 
information needs in Glasgow showed that up to 91% of patients gain their main 
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information from the doctor.345 Within the Stobhill general clinic population, 64.3% of 
patients felt they had been given full information (although sometimes hard to 
understand); a further 14.4% gained information on request but still wished more; 
16.1% stated that they gained little or no information despite wanting to know more. It 
may be that some of those who wished more information did not actively seek it or felt 
they should not seek it in the clinic setting.14 Of these 57 patients receiving little or no 
information, four (7%) also reported they were able to share how they were feeling with 
no one or only occasionally. Over one third of the patients attending the lung cancer 
clinic had unmet information needs. This is particularly important for a hospital-based 
service, as Edmonds et al178 reported lung cancer patients were significantly more likely 
than those with chronic lung disease to ask for information from a hospital doctor. 
 
Lung cancer patients may also have practical matters that require support as a result of 
the cancer or due to other factors. In this study, only 1.7% (6) of clinic patients reported 
having any unaddressed practical matters.  
 
6.3.6 Satisfaction 
The majority of respondents were satisfied or very satisfied overall with investigations, 
with the way diagnosis was delivered and with follow-up (Figure 12B). No difference 
was observed between each of the groupings in median scores for either investigations 
or follow-up (median 0 for all). A significantly higher median of 1 was observed for 
satisfaction in the ‘way diagnosis was given’ in the groupings of patients who died 
within three months of completing QF compared to the general clinic population. This 
may relate to overall distress as a patient nears the end of life. However, it is of note that 
very few patients expressed dissatisfaction with any of the areas assessed. 
 
As discussed in Section 3 there are many issues that surround the measurement of 
satisfaction that limit the scope of conclusions. Satisfaction evaluation has evolved from 
consumer survey models within the private sector and may have been driven through 
public policy rather than stemmed from patients’ agenda.232, 238, 346 The importance of 
patient satisfaction and it’s potential relevance to the quality agenda has been 
recognised.235, 236, 240, 241, 265, 347 However, issues including a lack of accepted 
definition,346 a poor understanding its theoretical basis,237, 238 heterogeneity in 
evaluation methodologies and an apparent bias towards reporting high levels of 
satisfaction requires satisfaction surveys to be considered at most exploratory.236 Gill 
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and White238 summarise some possible theoretical models for underpinning satisfaction 
evaluations. One definition that has been offered states satisfaction is ‘a recipient's 
reaction to salient aspects of the context, process and result of the service experience'. 
The reaction can be considered in cognitive, emotional and affective terms.236 In an 
effort to address the bias that may result from patients not wishing to criticise a service 
the ‘discrepancy model’ places value on responses that indicate dissatisfaction. 242.241 
The major component of these theories link satisfaction to achieving previous 
expectations in a way that ties with patients’ own beliefs, personal approaches and 
views of quality.  
 
Recognising these limitations, it is interesting to observe that there were high levels of 
satisfaction reported in this study. This is in keeping with a previous study in the 
Stobhill clinic231 and in Williamson et al’s265 audit of satisfaction with nurse-led lung 
cancer follow-up. Viewed from a sceptical point of view this may only reflect the bias 
of against providing critical responses described above. Viewed at face value, these 
responses could represent the reporting of high satisfaction with service (irrespective of 
the reasons for why this assessment is being made).Viewed from a discrepancy model, 
the lack of dissatisfaction may serve to affirm that patients are accepting of the current 
level of service in Stobhill. Furthermore, from the discrepancy viewpoint that there was 
a significantly lower level of satisfaction in patients who died within 3 months may be 
of great importance. This area would need further study and may require the taxonomy 
of satisfaction research to be further defined before any such research is possible. It has 
been argued that satisfaction research is a waste of time. In the context of improving 
quality and involving service users, it is likely that an increased understanding of the 
relationships between quality, expectation and satisfaction will be beneficial to service 
provision.  
 
6.3.7 Service Use and Preferences 
Some patients may feel that their time is being used inefficiently through clinic 
attendances and waiting room times.343 In this clinic population, 81.3% of patients felt 
no time had been wasted, 6.3% up to half a day and only 3.4% more than half a day. 
There was little change in these ratings throughout the phases of the lung cancer 
journey. These findings are in keeping with the views expressed regarding how many 
health care professionals are involved in care. Most patients did not feel they were 
‘seeing too many healthcare professionals’ in any of the groupings. 
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Attendance at the patient’s general practitioner (GP) between clinic appointments 
varied. This question was asked in the LCQ after the first 12 months. The majority 
(though not statistically significant) of respondents from the general clinic population 
had not seen their GP between visits (Figure 12A). This was also the case for newly 
diagnosed patients (Figure 14A). However, a significant majority of patients who 
completed a LCQ in the last three months of life had attended their GP (Figure 16A). 
This may relate to the finding that there was an increase in new or changing symptoms 
since the last review reported in the patients who died within three months of LCQ 
completion compared to both the general clinic and newly diagnosed patients (see 
Figure 12A, Figure 14A and Figure 16A). It is of interest to note that the main reasons 
for attending the GP in the final three months of life were recorded in the free text 
sections as dyspnoea and pain (Table 38). This may represent an increasing symptom 
burden in the advanced stages of lung cancer and, therefore, an increased usage of 
community health care services. Edmonds et al178 found that in the final year of life, the 
majority of lung cancer patients attended their GP ten or more times, and 53% of lung 
cancer patients were seen by their GP within the last seven days of life. In addition, 
74% of lung cancer patients felt the GP care was excellent or good, but only 60% of 
relatives felt the GP’s understanding of the deceased’s problems was good. 
 
The BTS guidelines for organisation of care for patients with lung cancer state that the 
patient should be aware of who is in charge of their care.69 In this study there was a 
wide variation in who the patient regarded as the lead healthcare professional. Some of 
this variation may reflect the different phases of the lung cancer journey and/or the 
strength of relationship between the patient and GP. However, at least 10% of patients 
in each grouping documented that they were ‘uncertain’ of who was in charge. This 
finding may have implications in these patients seeking help at the optimal time.  
 
The analysis of documented referrals showed that around half the patients in the last 
three months of life had been referred to palliative care. This is a lower than expected 
referral rate, but it should be noted that only documented referrals were identified. As 
such, telephone referrals were not identified in this study. Only around 20% of the 
general clinic and 20% of newly diagnosed patients had documented palliative care 
referrals (see Figure 12B, Figure 14B and Figure 16B). This is likely to reflect clinical 
practice of referring when it is felt the end of life is approaching. However, given the 
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short survival of many lung cancer patients from point of diagnosis, it may be that 
earlier referral to palliative care would be appropriate. 
 
The role of routine follow-up appointments is not well evidence-based. It is also unclear 
when and if routine imaging should be used in follow-up. There is little evidence 
regarding patients’ own views about follow-up (see Section 4.3) We found that the 
majority of patients wished to continue with routine MDT clinic review appointments 
compared to GP follow-up or nurse specialist follow-up (see Figure 12B, Figure 14B 
and Figure 16B). There was, however, an increase in the number of patients preferring 
GP-led follow-up in those who died within three months of LCQ completion with less 
preferring nurse-led follow-up. Cox et al267 evaluated this issue in more detail, reporting 
that standard or nurse-led follow-up was preferred to GP-led follow-up by selected lung 
cancer patients of PS<2 with no active medical issues. However, patients also describe 
the need to access medical advice when appropriate. Cox et al267 concluded that around 
20% of the lung cancer clinic population studied could be eligible and accepting of 
nurse-led follow-up. Moore et al264, 270, 271, 348 also described the acceptability and 
effectiveness of nurse-led follow-up (see Section 4.3). Only 17% of patients receiving 
nurse-led follow-up would have preferred to return to medical only follow-up if forced 
to choose. Stent273 reported that four out of five patients undertaking qualitative 
interviews regarding follow-up wished hospital-based care to continue rather than being 
discharged to the care of the their GP. In a recent article, Krishnasamy et al272 surveyed 
30 lung cancer patients at a single treatment centre regarding follow-up preferences. 
They found that most patients expected to be seen for follow-up within two weeks of 
any treatment, and that the majority (75%) strongly agreed they would like follow-up by 
a ‘cancer specialist’ with few wishing follow-up by GP or specialist nurse. However, 
when alternative modes of follow-up (GP or nurse) were co-ordinated with a defined 
route of returning to a ‘cancer specialist’ if necessary, more patients strongly agreed 
with these options (48% and 41%, respectively). 
 
6.4 Conclusions 
Lung cancer patients face a disease of high symptom burden from diagnosis, including 
physical and psychosocial issues. This study of lung cancer patients attending the 
Stobhill lung cancer clinic demonstrates that despite current service provision there 
remains unmet need in this population. The three main issues identified were: anxiety, 
pain and dyspnoea. These three key issues are evaluated further in Sections 9-11. 
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Anxiety is a major issue for lung cancer patients from diagnosis throughout their lung 
cancer journey. In keeping with previous reports, lung cancer patients perceive that their 
support network is highly anxious throughout the cancer journey. Furthermore, lung 
cancer patients also report high levels of personal anxiety. Low self-esteem and reduced 
sense of life-worth is present in a few patients and is of particular concern for those who 
describe little access support through sharing their worries or anxieties.  
 
Performance status is reduced as lung cancer advances, and many lung cancer patients 
have significantly reduced physical function. However, practical aspects of patient care 
are well addressed, but there is a lack of information for a large percentage of patients. 
Most patients are satisfied with the service they are receiving. However, the lower 
satisfaction reported nearer the end of life merits further exploration but this may be 
limited by the available methodologies for satisfaction research. 
 
Most patients are also satisfied with the current follow-up structure. However, this is 
designed to mainly address bio-physical aspects of care and may not fully address 
potentially important psychosocial issues. Earlier and more frequent referral to 
palliative care services may be appropriate. Nurse-led services may also be acceptable 
and could aid in assessment and management of supportive care issues. However, many 
patients prefer routine medical reviews. The LCQ appears to allow the identification of 
these issues and could potentially be used to monitor the success of interventions 
established to address them. This demonstrates the validity of systemic assessment of 
supportive care issues within a clinical service. The approach to this could be 
strengthened by utilising fully validated instruments targeted towards the key issues. It 
would be important to avoid instrument burden and to identify tools that could function 
in a busy clinical service. Utilising a screening tool with a broad range of questions, 
such as POS may allow this balance to be struck. More detailed tools could be used 
when individual issues are identified. 
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7 Predictors of Supportive Care Needs in Lung 
Cancer 
In keeping with Aim 4a, this section reports an evaluation of possible predictors of 
supportive care needs as measured by POS. The predictors evaluated were all readily 
available within the Stobhill clinical service and may serve to allow effective and 
efficient targeting of supportive care within the service. The methods and statistical 
approach are outlined in Section 3. 
 
7.1 Introduction 
‘Supportive care’ can be defined as: 
Care that helps the patient and their family to cope with cancer and the 
treatment of it – from pre-diagnosis, through the process of diagnosis and 
treatment, to cure, continuing illness or death and into bereavement. It 
helps maximise the benefits of treatment and to live as well as possible with 
the effects of the disease. It is given equal priority alongside diagnosis and 
treatment.141  
 
Providing supportive care is now considered to be part of good management of lung 
cancer.10, 139 Furthermore, ‘best supportive care’ is a term now often utilised to describe 
the default or standard arm of many clinical trials within the oncology setting140 
(Section 1.4.7). Despite this, patients with lung cancer continue to have unrecognised 
supportive care needs (Section 6.2). Hill et al11 described the experience of 89 patients 
with lung cancer at diagnosis who were treated by a health care team focusing only on 
physical symptoms; none of the patients’ psychosocial or emotion concerns were 
addressed. There is some evidence that systematic assessment of symptoms and unmet 
needs can aid the identification and management of these issues.264, 270, 276 Sanders et 
al216 confirmed that the majority of lung cancer patients do wish supportive care needs 
to be addressed and are willing to take up offers of support and appropriate referrals to 
supportive care services. Identification of unmet needs and subsequent referrals may be 
enhanced by focusing attention on those found to be most in need. In a multivariate 
study of 109 lung cancer patients, Sanders et al216 described poorer physical function, 
increased symptom burden, problem-focused coping and low satisfaction with health 
care as the four independent factors associated with higher levels of supportive care 
needs. The current study utilised POS to assess supportive care needs and evaluated 
predictors of higher needs in three groupings: all patients attending the lung cancer 
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clinic, newly diagnosed patients and patients within the last three months of life when 
they complete the LCQ. 
 
7.2 Results 
7.2.1 Supportive Care Needs in All Patients Attending the 
Lung Cancer Clinic 
A total of 303 (85.5%) patients completed all the POS questions allowing a summary 
score to be calculated. The factors tabulated below were evaluated for significant 
differences across lower and higher supportive care needs (Table 42). The factors 
identified as significant were: age, TNM stage of lung cancer in NSCLC (but not in 
SCLC), performance status rated by patients during LCQ completion, PS rated by a 
doctor at diagnosis, treatment type delivered, respiratory symptom score and frequency 
of review. 
 
There were no significant differences found for gender, presence of metastases 
(comparison of TNM stage 4/extensive stage SCLC to all other stages), histological 
types, time from diagnosis, deprivation level, satisfaction score and attendance at the 
patient’s GP between lung cancer clinic appointments. 
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 87 58.8 61 41.2
Female 78 50.3 77 49.7 2.19 1.00 0.166
Age
<65 years 43 45.7 51 54.3
≥65 years 122 58.4 87 41.6 4.17 1.00 0.046 *
Histology
Clinical 28 51.9 26 48.1
NSCLC 116 55.2 94 44.8
SCLC 21 53.8 18 46.2 0.21 2.00 0.902
Stage NSCLC and clinicoradiological
1A 15 68.2 7 31.8
1B 33 76.7 10 23.3
2A 6 31.6 13 68.4
2B 7 50.0 7 50.0
3A 13 52.0 12 48.0
3B 33 50.0 33 50.0
4 34 48.6 36 51.4 15.97 6.00 0.014 *
Stage SCLC
Limited 8 61.5 5 38.5
Extensive 12 48.0 13 52.0 0.63 1.00 0.428
Presence or absence of metastases
None 119 57.2 89 42.8
Metasases 46 48.4 49 51.6 2.03 1.00 0.172
Time from diagnosis to POS
Within 3 weeks 50 47.6 55 52.4
3-6 weeks 22 52.4 20 47.6
6 weeks to 3 months 17 58.6 12 41.4
3-6 months 20 57.1 15 42.9
6-12 months 19 54.3 16 45.7
> 12 months 35 63.6 20 36.4 4.21 5.00 0.520
Performance status rated by patients
0-1 120 74.1 42 25.9
2 24 40.0 36 60.0
3-4 21 25.9 60 74.1 56.78 2.00 <0.001 **
Diagnosis PS, assessed by doctor
0-1 120 62.8 71 37.2
2 29 40.8 42 59.2
3-4 1 16.7 5 83.3 56.78 6.00 0.001 **
Treatment delivered
Surgery 37 67.3 18 32.7
Radical Radiotherapy 11 50.0 11 50.0
Palliative Radiotherapy 33 41.8 46 58.2
Chemotherapy 41 56.9 31 43.1
Supportive Care 21 53.8 18 46.2
Combined 7 87.5 1 12.5 12.65 5.00 0.027 *
Deprivation
Dep Cat 1-5 81 57.9 59 42.1
Dep cat 6 or 7 83 52.2 76 47.8 0.96 1.00 0.353
Respiratory Score
0-4 151 62.7 90 37.3 Mann Whitney U
5-8 12 21.1 45 78.9 two tailed test
9-12 1 33.3 2 66.7 na <0.001 ***
Satisfaction score
0-4 63 55.8 50 44.2 Mann Whitney U
5-8 0 .0 3 100.0 two tailed test
9-12 0 .0 0 .0 na 0.852
Last Clinic appointment
1st Appointment 34 44.7 42 55.3
<4 weeks 52 51.5 49 48.5
4-8 weeks 20 48.8 21 51.2
2-4 months 22 62.9 13 37.1
>4 months 35 76.1 11 23.9 13.46 4.00 0.009 ***
GP attendance between clinics
No 39 60.0 26 40.0
Yes 26 41.9 36 58.1 4.14 1.00 0.051
POS <10 POS ≥ 10
 
Table 42: All patients attending the lung cancer clinic. Univariate analysis of factors across groups 
of higher and lower supportive care needs as measured by POS. Percentages adjusted for missing 
data. *p<0.05, **p<0.01 and ***p<0.001 
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Significant factors were entered into a backwards logistic regression model to test for 
independent effects. Frequency of review was not entered as this was likely to be related 
to ongoing active issues rather than a useful predictor of increased supportive care 
needs. Thus, the following factors were added to the model: patients-rated PS, doctor-
rated PS at diagnosis, age, respiratory score and treatment delivered. Treatment 
delivered was considered a dichotomous variable for active anti-cancer treatment or not. 
In addition to these significant variables, additional factors of interest (factors identified 
in previous studies) were included in the model: gender, presence of metastases and 
deprivation. Results are shown in Table 43.  
 
b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 28.855 2 <0.001
Performance status 2 1.383 .398 12.100 1 .001 3.99 1.83 8.70
Performance status 3-4 2.030 .398 26.031 1 <0.001 7.62 3.49 16.62
Respiratory score -.989 .341 8.430 1 0.00 1.48 1.23 1.78
Age >65 .392 .094 17.228 1 <0.001 0.37 0.19 0.73
Constant -1.567 .374 17.609 1 <0.001 0.21
95% CI for Odds Ratios
 
R2=0.283 (Cox and Snell); 0.379 (Nagelkerke) Model Χ2=82.97, df=4, p<0.001 
Hosmer-Lemeshow test: Χ2=11.38, df=8, p=0.181 
Table 43: Independent factors associated with higher supportive care needs identified through 
backwards logistic regression for all patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=82.97, df=4, p<0.001). Nagelkerke’s R2 of 0.379 indicated that around 38% of 
variance was explained by the model. Overall prediction success was 74.7% (79.6% for 
POS<10 and 68.8% for POS>10). This compares to the null model overall prediction 
success of 55%. Each of the predictors in the final model was significant at the p<0.05 
level. As such, higher levels of supportive care needs were independently associated 
with reduced performance status, higher respiratory symptom scores and a younger age. 
There were no significant effects from the other variables, which were excluded from 
the final model. For a fixed age and respiratory score, a patient with a PS of 3-4 is 7.62 
(95% CI 3.49-16.62) times more likely to have higher supportive care needs (POS>10). 
For a fixed PS and age, each unit increase in respiratory score increases the likelihood 
of increased supportive care needs by 1.48 (95% CI 1.23-1.78) times. 
 
Respiratory score was an independent predictor of higher supportive care needs. This 
was further examined to assess which variables making up the respiratory score were 
the significant factors. Dyspnoea, cough and haemoptysis were dichotomised into 
absent (0) or present (1) categories and entered into the original model instead of the 
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summated respiratory score. This identified cough and haemoptysis as significant 
factors but dyspnoea as non-significant (Table 44). 
 
b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 44.48 2 <0.01
Performance status 2 1.67 0.39 18.54 1 <0.01 5.31 2.48 11.34
Performance status 3-4 2.44 0.39 39.81 1 <0.01 11.42 5.36 24.35
Age >65 -0.95 0.34 7.81 1 0.01 0.39 0.20 0.75
Cough 0.97 0.40 6.05 1 0.01 2.65 1.22 5.76
Haemoptysis 0.85 0.44 3.74 1 0.05 2.34 0.99 5.56
Constant -1.47 0.44 11.24 1 <0.01 0.23
95% CI for Odds Ratios
R2=0.259 (Cox and Snell); 0.347 (Nagelkerke) Model Χ2=74.68, df=5, p<0.001 
Hosmer-Lemeshow test: Χ2=2.58, df=8, p=0.958 
Table 44: Independent factors associated with higher supportive care needs identified through 
backwards logistic regression using individual respiratory factors for all patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=74.68, df=5, p<0.001). Nagelkerke’s R2 of 0.347 indicated that around 35% of 
variance was explained by the model. Overall prediction success was 74.3% (74.5% for 
POS<10 and 74.3% for POS>10). This compares to the null model overall prediction 
success of 55%. Each of the predictors in the final model was significant at the p<0.05 
level. As such, higher levels of supportive care needs were independently associated 
with reduced performance status, presence of cough, presence of haemoptysis and a 
younger age. There were no significant effects from the other variables, which were 
excluded from the final model (i.e. doctor-rated PS at diagnosis, active anti-cancer 
treatment, gender, deprivation, presence of metastases and dyspnoea). 
 
Correlations between individual POS items and PS, respiratory score and age are 
tabulated below (Table 45). 
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POS items Performance Status 
Respiratory 
symptom score Dyspnoea Cough Haemoptysis Age
Correlation Coefficient .331** .301** .331** .148** .106 -.086
Sig. (2-tailed) .000 .000 .000 .006 .053 .113
N 331 332 340 336 332 341
Correlation Coefficient .386** .386** .341** .294** .158** -.037
Sig. (2-tailed) .000 .000 .000 .000 .004 .506
N 328 329 332 330 330 332
Correlation Coefficient .278** .353** .259** .263** .183** -.240**
Sig. (2-tailed) .000 .000 .000 .000 .001 .000
N 331 330 334 332 331 334
Correlation Coefficient .279** .298** .242** .255** .102 -.160**
Sig. (2-tailed) .000 .000 .000 .000 .065 .003
N 329 329 332 331 329 332
Correlation Coefficient .195** .181** .145** .143** .077 -.048
Sig. (2-tailed) .000 .001 .009 .167 .379
N 326 324 331 329 325 332
Correlation Coefficient .370** .243** .207** .212** .058 .005
Sig. (2-tailed) .000 .000 .000 .000 .306 .927
N 314 314 320 317 315 320
Correlation Coefficient .549** .459** .406** .329** .170** -.013
Sig. (2-tailed) .000 .000 .000 .000 .002 .813
N 319 318 324 322 319 325
Correlation Coefficient .168** .212** .180** .211** .021 -.043
Sig. (2-tailed) .003 .000 .002 .000 .713 .448
N 303 302 308 306 303 309
Correlation Coefficient .250** .150** .096 .165** .061 -.144*
Sig. (2-tailed) .000 .009 .091 .004 .288 .010
N 309 308 314 312 309 315
Correlation Coefficient .077 .078 .057 .061 -.046 .002
Sig. (2-tailed) .175 .170 .309 .279 .413 .968
N 314 312 320 317 313 321
Pain
Other symptoms
Personal anxiety
Family anxiety
Practical
Time use
Ability to share
Life worth
Self esteem
Information
 
**Correlation significant at 0.01 level, *Correlation significant at 0.05 level (2 tailed) 
Table 45: Spearman Rho correlations for POS items and PS, respiratory symptoms and age (all 
Q1). 
 
PS and respiratory symptoms were positively correlated with pain, ‘other’ symptoms, 
personal anxiety, perceived support network anxiety, ability to share, life-worth, self-
esteem, information needs and practical concerns. In particular, dyspnoea and cough 
were correlated with all POS items except time use. Haemoptysis was only correlated 
with ‘other’ symptoms, personal anxiety and low self-esteem. Age was negatively 
correlated to personal anxiety, perceived support network anxiety and practical needs. 
None of the variables was correlated to time use. 
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7.2.2 Supportive Care Needs in Newly Diagnosed Patients 
A total of 147 of 170 newly diagnosed patients (86.5%) completed all POS questions 
allowing a summary score to be calculated. The factors tabulated below were evaluated 
for significant differences across lower and higher supportive care needs (Table 46). 
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Factor χ2 Df p value Significant
Number Percentage Number Percentage
Gender
Male 39 54.2 33 45.8
Female 33 44.0 42 56.0 1.52 1 0.250
Age
≤50 years 0 .0 5 100.0
51-69 years 30 44.8 37 55.2
≥70 years 42 56.0 33 44.0 6.75 2 0.034 *
Histology
Clinical 14 42.4 19 57.6
NSCLC 48 52.2 44 47.8
SCLC 10 45.5 12 54.5 1.05 2 0.591
Stage NSCLC and clinicoradiological
1A 3 42.9 4 57.1
1B 17 77.3 5 22.7
2A 13 38.2 21 61.8
2B 3 60.0 2 40.0
3A 16 55.2 13 44.8
3B 26 51.0 25 49.0
4 31 49.2 32 50.8 8.89 6 0.180
Stage SCLC
Limited 6 75.0 2 25.0
Extensive 4 28.6 10 71.4 4.43 1 0.074
Presence or absence of metastases
None 49 54.4 41 45.6
Metasases 23 40.4 34 59.6 2.77 1 0.127
Time from diagnosis to POS
Within 3 weeks 50 47.6 55 52.4
3-6 weeks 22 52.4 20 47.6
6 weeks to 3 months 0 .0 0 .0
3-6 months 0 .0 0 .0
6-12 months 0 .0 0 .0
> 12 months 0 .0 0 .0 0.27 1 0.602
Performance status rated by patients
0 17 73.9 6 26.1
1 35 64.8 19 35.2
2 10 35.7 18 64.3
3 8 25.8 23 74.2
4 1 12.5 7 87.5 24.02 4 <0.001 **
Diagnosis PS, assessed by doctor
0 3 37.5 5 62.5
1 47 66.2 24 33.8
2 15 34.9 28 65.1
3 1 20.0 4 80.0 13.51 3 0.004 **
4
Treatment delivered
Surgery 5 55.6 4 44.4
Radical Radiotherapy 4 44.4 5 55.6
Palliative Radiotherapy 19 39.6 29 60.4
Chemotherapy 20 54.1 17 45.9
Supportive Care 11 52.4 10 47.6
Combined 2 100.0 0 .0 4.47 5 0.483
Deprivation
Dep Cat 1-5 40 54.1 34 45.9
Dep cat 6 or 7 32 45.1 39 54.9 1.17 1 0.320
Respiratory Score
0-4 63 55.8 50 44.2 Mann Whitney U
5-8 7 22.6 24 77.4 two tailed test
9-12 1 50.0 1 50.0 na <0.001 ***
Satisfaction score
0-4 34 50.0 34 50.0 Mann Whitney U
5-8 0 .0 2 100.0 two tailed test
9-12 0 .0 0 .0 na 0.050
GP attendance between clinics
No 23 54.8 19 45.2
Yes 12 33.3 24 66.7 3.60 1 0.070
POS <10 POS ≥ 10
 
Table 46: Newly diagnosed patients. Univariate analysis of factors across groups of higher and 
lower supportive care needs as measured by POS. Percentages adjusted for missing data.  
*p<0.05, **p<0.01 and ***p<0.001 
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There were no significant differences found for gender, presence of metastases, 
histological types, stages, treatment delivered, time from diagnosis, deprivation level, 
satisfaction score and attendance at the patient’s GP between lung cancer clinic 
appointments. The factors identified as significant were: age, performance status rated 
by patients during LCQ completion, PS rated by a doctor at diagnosis and respiratory 
symptom score. As in the previous section, the respiratory symptom variables were 
dichotomised and the model was repeated to assess the main factors (Table 47). 
 
b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 19.18 2 <0.01
Performance status 2 1.53 0.57 7.22 1 0.01 4.63 1.51 14.14
Performance status 3-4 2.22 0.54 16.97 1 <0.01 9.23 3.21 26.57
Age >65 -1.28 0.47 7.35 1 0.01 0.28 0.11 0.70
Constant 0.05 0.38 0.02 1 0.90 1.05
95% CI for Odds Ratios
R2=0.212 (Cox and Snell); 0.282 (Nagelkerke) Model Χ2=27.34, df=3, p<0.001 
Hosmer-Lemeshow test: Χ2=0.699, df=3, p=0.874 
Table 47: Independent factors associated with higher supportive care needs identified through 
backwards logistic regression using individual respiratory factors for newly diagnosed patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=27.34, df=3, p<0.001). Nagelkerke’s R2 of 0.282 indicated that around 28% of 
variance was explained by the model. Overall prediction success was 68.7% (54.4% for 
POS<10 and 82.8% for POS>10). This compares to the null model overall prediction 
success of 50.4%. Each of the predictors in the final model was significant at the p<0.05 
level. As such, higher levels of supportive care needs in newly diagnosed lung cancer 
patients were independently associated with reduced performance status and a younger 
age. For a fixed age, a patient with a PS of 3-4 is 9.23 (95% CI 3.21-26.57) times more 
likely to have higher supportive care needs (POS>10). There were no significant effects 
from the other variables which were excluded from the final model (i.e. doctor-rated PS 
at diagnosis, active anti-cancer treatment, deprivation, gender, presence of metastases, 
dyspnoea, cough and haemoptysis). 
 
Correlations between individual POS items and PS, age and individual respiratory 
symptoms are tabulated below (Table 48). 
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POS items Performance Status Age Dyspnoea Cough Haemoptysis
Correlation .403** -.156* .286** .116 .140
Sig. (2-tailed) .000 .045 .000 .139 .077
N 160 166 166 163 161
Correlation .410** -.088 .300** .291** .193*
Sig. (2-tailed) .000 .265 .000 .000 .014
N 159 161 161 160 160
Correlation .214** -.263** .165* .221** .104
Sig. (2-tailed) .007 .001 .036 .005 .189
N 160 162 162 161 161
Correlation .179* -.223** .177* .176* .078
Sig. (2-tailed) .024 .004 .025 .025 .325
N 159 161 161 161 160
Correlation .297** -.054 .186* .204* .124
Sig. (2-tailed) .000 .497 .018 .010 .122
N 156 161 161 159 157
Correlation .353** .009 .153 .263** .095
Sig. (2-tailed) .000 .911 .057 .001 .246
N 150 155 155 153 152
Correlation .498** -.031 .334** .257** .165*
Sig. (2-tailed) .000 .702 .000 .001 .040
N 153 158 158 156 155
Correlation -.024 -.110 -.020 .135 -.033
Sig. (2-tailed) .772 .176 .807 .098 .691
N 149 154 154 152 150
Correlation .288** -.216** .133 .234** .009
Sig. (2-tailed) .000 .007 .098 .004 .909
N 150 155 155 153 152
Correlation .080 .047 .052 .013 .000
Sig. (2-tailed) .329 .563 .522 .876 .998
N 149 155 155 152 150
Practical
Time use
Ability to share
Life worth
Self esteem
Information
Pain
Other symptoms
Personal anxiety
Family anxiety
 
** Correlation significant at 0.01 level, *Correlation significant at 0.05 level (2 tailed) 
Table 48: Spearman Rho correlations for POS items and PS and age (Q1<six weeks from diagnosis) 
 
PS was positively correlated with pain, ‘other’ symptoms, personal anxiety, perceived 
support network anxiety, ability to share, life-worth, self-esteem, information needs and 
practical concerns. Age was negatively correlated to pain, personal anxiety, perceived 
support network anxiety and practical needs. 
 
7.2.3 Supportive Care Needs in Patients in the Last Three 
Months of Life 
A total of 109 of 121 patients (90.1%) in the last three months of life completed all the 
POS questions allowing a summary score to be calculated. The factors tabulated below 
were evaluated for significant differences across lower and higher supportive care needs 
(Table 49). 
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Factor χ2 Df p value Significant
Number Percentage Number Percentage
Gender
Male 24 40.0 36 60.0
Female 19 38.8 30 61.2 0.02 1 0.896
Age
≤50 years 1 25.0 3 75.0
51-69 years 15 31.9 32 68.1
≥70 years 27 46.6 31 53.4 2.69 2 0.260
Histology
Clinical 7 46.7 8 53.3
NSCLC 27 36.0 48 64.0
SCLC 9 47.4 10 52.6 1.20 2 0.549
Stage NSCLC and clinicoradiological
1A 0 0.00 1.00 100.00
1B 4 57.40 3.00 42.90
2A 1 16.70 5.00 83.30
2B 0 0.00 2.00 100.00
3A 3 50.00 3.00 50.00
3B 11 36.70 19.00 63.30
4 14 37.80 23.00 62.20 4.49 6 0.611
SCLC
Limited 1 25.0 3 75.0
Extensive 8 53.3 7 46.7 1.02 1 0.582
Presence or absence of metastases
None 21 36.8 36 63.2
Metasases 22 42.3 30 57.7 0.34 1 0.560
Time from diagnosis to POS
Within 3 weeks 9 33.3 18 66.7
3-6 weeks 1 20.0 4 80.0
6 weeks to 3 months 7 38.9 11 61.1
3-6 months 7 41.2 10 58.8
6-12 months 9 37.5 15 62.5
> 12 months 10 55.6 8 44.4 3.23 5 0.664
Performance status rated by patients
0 6 85.7 1 14.3
1 13 54.2 11 45.8
2 7 26.9 19 73.1
3 13 32.5 27 67.5
4 2 22.2 7 77.8 12.14 4 0.016 *
Performance status rated by doctor
0 4 36.4 7 63.6
1 22 46.8 25 53.2
2 16 42.1 22 57.9
3 0 .0 5 100.0
4 42 41.6 59 58.4 4.22 3 0.239
Treatment delivered
Surgery 2 33.3 4 66.7
Radical radiotherapy 0 .0 1 100.0
Palliative radiotherapy 16 33.3 32 66.7
Chemotherapy 11 47.8 12 52.2
Supportive care 8 47.1 9 52.9
Combined 1 50.0 1 50.0 2.68 5 0.749
Deprivation
Dep Cat 1-5 22 37.9 36 62.1
Dep cat 6 or 7 21 41.2 30 58.8 0.12 1 0.729
Respiratory Score
0-4 38 52.8 34 47.2
5-8 4 11.4 31 88.6
9-12 0 .0 1 100.0 na <0.001 ***
Satisfaction score
0-4 22 44.0 28 56.0 Mann Whitney U
5-8 0 .0 1 100.0 two tailed test
9-12 0 .0 0 .0 na 0.070
Last clinic appointment
1st appointment 6 31.6 13.0 68.4
<4 weeks 12 41.4 17.0 58.6 Mann Whitney U
4-8 weeks 13 39.4 20.0 60.6 two tailed test
2-4 months 8 42.1 11.0 57.9
>4 months 3 42.9 4.0 57.1 0.63 4 0.960
GP attendance between clinics
No 10 47.6 11 52.4
Yes 13 36.1 23 63.9 0.73 1 0.393
POS <10 POS ≥ 10
 
Table 49: Patients who died within three months of questionnaire completion. Univariate analysis 
of factors across groups of higher and lower supportive care needs as measured by POS. 
Percentages adjusted for missing data. *p<0.05, **p<0.01 and ***p<0.001 
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The only significant factors identified as significant were: patient-rated performance 
status and respiratory symptom score. As in the previous section, the respiratory 
symptom variables were dichotomised and the model was repeated to assess the main 
factors (Table 50). 
b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 7.48 2 0.02
Performance status 2 1.74 0.70 6.17 1 0.01 5.73 1.45 22.67
Performance Status 3-4 1.33 0.59 5.05 1 0.02 3.80 1.19 12.17
Dyspnoea 2.71 1.11 6.00 1 0.01 14.99 1.72 130.88
Haemoptysis 1.82 0.83 4.82 1 0.03 6.20 1.22 31.55
Constant -3.32 1.16 8.22 1 0.00 0.04
95% CI for Odds Ratios
 
R2=0.269 (Cox and Snell); 0.363 (Nagelkerke) Model Χ2=28.14, df=4, p<0.001 
Hosmer-Lemeshow test: Χ2=1.025, df=5, p=0.960 
 
Table 50: Independent factors associated with higher supportive care needs identified through 
backwards logistic regression using individual respiratory factors for patients who died within 
three months of questionnaire completion. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=28.14, df=4, p<0.001). Nagelkerke’s R2 of 0.363 indicated that around 36% of 
variance was explained by the model. Overall prediction success was 77.8% (61.1% for 
POS<10 and 88.9% for POS>10). This compares to the null model overall prediction 
success of 60%. Each of the predictors in the final model was significant at the p<0.05 
level. As such, higher levels of supportive care needs in patients who died within three 
months of questionnaire completion were independently associated with presence of 
dyspnoea, reduced performance status and presence of haemoptysis. There were no 
significant effects from the other variables which were excluded from the final model, 
(doctor-rated PS, age, active anti-cancer treatment, deprivation, gender, presence of 
metastases and presence of cough). For a fixed performance status and symptomatic 
state of haemoptysis, patients with dyspnoea present are 14.99 (95% CI 1.72-130.88) 
times more likely to have higher supportive care needs (POS>10). 
 
Correlations between individual POS items and respiratory symptoms are tabulated 
below. 
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POS items
Performance 
Status 
Respiratory 
symptom score Dyspnoea Cough Haemoptysis
Correlation Coefficient .172 .307** .339** .144 .193*
Sig. (2-tailed) .070 .001 .000 .125 .040
N 112 114 117 115 113
Correlation Coefficient .217* .302** .243** .222* .261**
Sig. (2-tailed) .022 .001 .009 .018 .005
N 112 113 113 113 113
Correlation Coefficient .199* .305** .317** .215* .138
Sig. (2-tailed) .035 .001 .001 .022 .145
N 112 113 113 113 113
Correlation Coefficient .260** .252** .222* .194* .030
Sig. (2-tailed) .006 .007 .017 .039 .751
N 112 114 114 113 113
Correlation Coefficient .167 .190* .126 .173 .164
Sig. (2-tailed) .080 .044 .178 .066 .084
N 111 113 115 114 112
Correlation Coefficient .171 .284** .262** .253** .259**
Sig. (2-tailed) .073 .002 .005 .007 .006
N 110 112 114 113 111
Correlation Coefficient .321** .368** .374** .280** .144
Sig. (2-tailed) .001 .000 .000 .003 .130
N 111 113 115 114 112
Correlation Coefficient .103 .386** .249** .393** .120
Sig. (2-tailed) .286 .000 .008 .000 .209
N 110 112 114 113 111
Correlation Coefficient .140 .143 .076 .133 .095
Sig. (2-tailed) .145 .133 .423 .160 .322
N 110 112 114 113 111
Correlation Coefficient .147 .267** .164 .143 .231*
Sig. (2-tailed) .126 .004 .079 .130 .015
N 110 112 115 113 111
Practical
Time wasted
Ability to share
Life worth
Self esteem
Information
Pain
Other symptoms
Personal anxiety
Family anxiety
 
** Correlation significant at 0.01 level, *Correlation significant at 0.05 level (2 tailed) 
Table 51: Spearman Rho correlations for POS items and PS and age (QF<three months from 
death). 
 
PS was positively correlated with ‘other’ symptoms, personal anxiety, perceived 
support network anxiety and self-esteem. Respiratory symptoms were negatively 
correlated to pain, personal anxiety, perceived support network anxiety, ability to share, 
life-worth, self-esteem, information needs, practical needs and time use. Dyspnoea was 
correlated with all items except practical issues and time use. Cough was correlated with 
‘other’ symptoms, personal anxiety, perceived support network anxiety, life-worth, self-
esteem and information needs. Haemoptysis was correlated to pain, ‘other’ symptoms, 
life-worth and time wasted. 
 
7.3 Discussion 
The potential predictors of increased supportive care needs in lung cancer patients 
remain poorly understood. The situation is complicated by the use of different 
assessment tools, outcome measures (e.g. distress, symptom distress, quality of life or 
supportive care needs) and methodologies. The only previous study to look directly at 
predictors of supportive care needs of lung cancer patients found higher levels of need 
associated with worse physical functioning (measured using a ten question subscale 
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from the SF-36), greater symptom burden and lower satisfaction with health care.216 
Sanders et al216 reported that age, gender, marital status, time from diagnosis and cancer 
stage were not associated with supportive care needs. 
 
In the current study, the key clinical variable that allows identification of patients with 
higher supportive care needs is PS. Increased PS was a significant predictor of higher 
supportive care needs in all three clinical groups. Respiratory symptoms were also 
significantly associated with higher supportive care needs: in particular, cough and 
haemoptysis in the general clinic population and dyspnoea and haemoptysis in the last 
three months of life. 
 
Those who were younger (<65 years) had increased supportive care needs in both the 
general study population and in newly diagnosed patients but not when evaluated within 
the last three months of life. There was no significant association found for other factors 
in any of the clinical groups including gender, presence of metastases, histology, time 
from diagnosis, deprivation or active anti-cancer treatments. 
 
7.3.1 Performance Status 
Performance status is a global assessment of a patient’s ability for self-care and 
ambulation. The use of functional assessment to aid management of cancer patients was 
first developed in 1948 by David Karnofsky.314 The use of ECOG PS in elderly patients 
has been reported to overestimate function and may be less sensitive more in-depth 
functional assessment tools.226, 228 A reduced function measured by ECOG PS has been 
used to aid clinical decisions, for research stratification, prognostication and as a 
predictor of increased symptom burden.103 Furthermore, its use in lung cancer has been 
well validated over many years.10  
 
Ferreira et al323 utilised several symptom assessment tools, the EORTC cancer quality 
of life score and doctor-rated Karnofsky performance status assessment to evaluate the 
relationship between symptoms and PS in cancer patients. They found that a high 
symptom burden was independently associated with lower performance status (odds 
ratio 4.1, 95% CI 1.77-8.66, p=0.001) when controlled for gender, presence of 
metastases and hormone therapy. Ferreira et al323 also reported that gender had no 
independent effect but the presence of metastases was associated with reduced PS. 
Presence and severity of pain in cancer patients has been correlated with reduced PS. 
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Martins et al113 also reported an inverse relationship between symptom distress and 
physical function measured by Karnofsky PS. In their study of lung cancer patients, 
Martins et al113 reported that increased global symptom distress (measured by the lung 
cancer symptom scale) was predicted by reduced PS independent of age, histology or 
clinical stage. Snyder et al349 utilised the supportive care needs survey (SCNS) and 
EORTC-QLQ-C30 to assess concordance between cancer patients’ supportive care 
needs, physical function and symptoms. They reported that patients with high function 
usually have low symptoms and low supportive care needs. When function is reduced 
there is an increase in symptoms, but this is not always perceived by the patient or 
reported by the patient as a ‘need’. Kurtz  et al111 reported that reduced physical 
function in lung cancer patients (>65 years) was independently related to increased 
symptom severity, prior physical function and age (younger patients had greater loss of 
function). It was noted that older patients were more likely to have increased co-
morbidities and reduced function at diagnosis than younger patients. There was no 
relationship between function and gender, stage or treatment delivered. Ostlund  et al172 
assessed global quality of life in lung cancer patients and reported emotional 
functioning and fatigue to be independent predictors of reduced QOL but physical 
functioning was not a significant factor. However, there did appear to be a relationship 
between fatigue and physical function that made interpretation of the regression model 
difficult. Skaug et al303 undertook multivariate analyses of 247 lung cancer patients in 
the last two months of life. They reported that initial PS was not a significant predictor 
of terminal symptoms. In the current study, patient-rated performance status within 
three months of death was an independent predictor of higher supportive care needs. 
Sanders et al216 evaluated predictors of higher supportive care needs in lung cancer 
patients and found that physical function was a strong independent factor. Physical 
function was assessed by a subscale from the medical outcomes study short form. This 
ten item subscale assesses the impact of health on a patient’s functional ability and 
activities of daily living. Better physical function was negatively correlated with total 
supportive care needs, physical and daily living needs, health system and information 
needs, patient care support needs and psychological needs.324 
 
The finding that reduced physical function is associated with higher supportive care 
needs was confirmed in the current study. In those patients in whom ECOG PS is 3 or 4, 
the likelihood of having higher supportive care needs is 11 times compared to PS 0 or 1 
patients. In newly diagnosed patients the increased likelihood is around nine times. In 
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the last three months of life the increased likelihood of higher supportive care needs for 
PS 3 or 4 was around four. For patients reporting PS of 2 in the last three months of life, 
there was a higher likelihood of around six times that of PS 0 or 1.  
 
In the general population and in newly diagnosed patients, PS was not only a predictor 
of global higher supportive care needs, but reduced physical function was significantly 
correlated with each individual POS item with the exception of time use. In the last 
three months of life, PS was correlated with ‘other’ symptoms, personal anxiety, 
perceived anxiety in the support network and self-esteem but no other POS item. It is 
not clear why there is a difference amongst the clinical groups, but it is possible that in 
the last three months of life patients with advancing disease and reduced PS were less 
able to attend an out-patient review. As such, some patients with higher supportive care 
needs and PS of 3 or 4 may have been underrepresented in the sample. It is interesting 
to note this easily assessed, widely used clinical variable could aid targeting of 
supportive care within the lung cancer clinic. PS is used within the multidisciplinary 
setting to aid decisions about fitness for treatment. This may be the key time to identify 
patients in whom a more detailed evaluation of supportive care needs would be 
appropriate.  
 
7.3.2 Respiratory Symptoms 
Symptom burden has been associated with increased supportive care needs,216 reduced 
quality of life121, 172, 323 and distress350 (see Section 5). The presence and severity of 
respiratory symptoms have a clear role in the diagnosis of lung cancer. It is expected 
that a cancer of the respiratory system leads to the development and experience of 
respiratory symptoms; for instance, lung cancer patients are more likely to experience 
dyspnoea than patients with other cancers.351, 352  
 
Dyspnoea is strongly related to distress in lung cancer patients.353 Furthermore, 
increased prevalence of respiratory symptoms in the general public is associated with 
increasing prevalence of lung cancer diagnoses,353 and the relative risk of lung cancer is 
related to the number and type of respiratory symptoms.66, 354 Lung cancer patients 
experience high levels of distressing dyspnoea and cough in the final year of life.202 
Although many lung cancer patients can be managed as out-patients, the second most 
frequent symptom leading to in-patient admission has been reported to be dyspnoea; 
pain was the most frequent.281 Furthermore, lung cancer patients may also have 
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concurrent chronic obstructive pulmonary disease (COPD).189, 190, 268 COPD itself is 
associated with a high respiratory symptom burden in the last year of life.178 
 
The continuation of respiratory symptoms after curative intent surgery for lung cancer 
has been reported by Sarna et al269 who noted that co-morbidity was the main factor 
predicting symptom distress. The reduction in lung function secondary to surgical 
resection also increases the likelihood of respiratory symptoms irrespective of the result 
of the surgery. Sarna et al115 previously reported that, in long-term survivors of NSCLC, 
dyspnoea is the only respiratory symptom to be independently related to reduced QOL. 
Again, the presence of dyspnoea was related in part to the presence of co-morbidities. 
The presence of dyspnoea in lung cancer patients has been reported to be correlated to 
reduced QOL and anxiety but was not significant as part of a multivariate model.302 
Smith et al355 found that pain and anxiety scores were significantly higher in lung 
cancer patients with increased dyspnoea. They found no relationship between dyspnoea 
and PS, histology, stage of disease or gender. 
 
In the current study, high levels of both dyspnoea and cough were confirmed in the 
general population, newly diagnosed patients and patients in the last three months of 
life. Haemoptysis is a lower level symptom but of particular diagnostic relevance (see 
Section 6.2). In the general clinic population, the presence of dyspnoea was correlated 
with all POS items except time use. In the last three months of life, dyspnoea was 
correlated with all POS items except ability to share, practical issues and time use. 
Cough was correlated with all items in the general population and all items except pain, 
ability to share, practical issues and time use in patients who died within three months. 
Although overall respiratory score is not associated with increased supportive care 
needs in newly diagnosed patients, bivariate correlation shows a relationship between 
dyspnoea and all POS items except life-worth, information needs, practical issues and 
time use. Cough was correlated to all items except pain, information needs and time use. 
Haemoptysis was only correlated with ‘other’ symptoms and life-worth.  
 
Although cough is a prevalent symptom in the lung cancer population, it appears to be 
less important in terms of supportive care needs. Sarna et al269 reported higher 
prevalence of severe cough than dyspnoea in NSCLC survivors, but only dyspnoea 
significantly contributed to reduced QOL. Less than 50% of cancer patients with cough 
rated this as distressing, but around 70% of those with dyspnoea considered the 
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symptom distressing.224 This is in keeping with the concept of symptom burden relating 
not just to the presence of a symptom but also the severity, frequency and subjective 
distress related to that symptom121, 162, 165, 169, 309, 324 (see Section 1.5). 
 
7.3.3 Age 
The age of a patient with lung cancer may have implications for management decisions 
and the treatment options available. Although age itself should not exclude any patient 
from being offered any specific treatments,227 it has been reported that older patients are 
less likely to receive active anti-cancer treatments than younger patients in both 
NSCLC227 and SCLC.356 However, when age was controlled for, the major determinants 
of treatment delivered were found to be PS and presence of co-morbidity.228 Graves et 
al350 reported a higher level of distress (measured by 0-10 visual analogue distress scale) 
in younger patients with lung cancer (odds ratio 0.97, 95% CI 0.94-0.99, p=0.36). 
Graves et al350 found no other demographic factor evaluated was related to distress (i.e. 
gender, race, stage or treatment type). Kirkova et al224 found symptom-related distress 
and symptom severity in cancer patients (24% patients had lung cancer) were 
independently associated with younger age, lower performance status and gender. 
Degner and Sloan119 reported a weak negative correlation between age and symptom 
distress (r=-0.11, p=0.026), with older patients experiencing less symptom distress. 
Skaug et al303 reported that younger age (<65 years) was a significant independent 
predictor of psychological symptoms in the last two months of life in lung cancer 
patients. However, Ferreira  et al323 reported no independent effect of age on overall 
quality of life. Sanders et al216 found no independent relationship between age and 
supportive care needs (measured by the supportive care needs survey) in lung cancer 
patients. None of the subscales were significantly associated with age in this study (i.e 
physical, information, psychological or patient care needs). 
 
In contrast to Sanders et al,216 in the current study age was a significant factor in the 
general clinic population and newly diagnosed patients. It was not significant in the last 
three months of life. In particular, younger age was correlated with increased personal 
anxiety, perceived support network anxiety and practical needs in these clinical groups. 
In newly diagnosed patients, pain was also correlated to lower age. The finding that 
younger patients experience more psychological distress in cancer is well documented 
for several cancer types.224, 341, 357 The relationship between psychological distress and 
age has been most studied in the setting of breast cancer care. It has been suggested that 
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for younger patients the potential losses due to a diagnosis of cancer are greater; that is, 
work, fertility and time with children. Others have argued that, through life experience, 
resilience develops and older patients have greater psychological resources to draw on 
at the time of cancer diagnosis.357 Furthermore, Jorm358 reviewed the literature to 
evaluate whether old age reduces the risk of anxiety and depression in the general 
population. He concluded that a clear answer is difficult due to multiple possible 
confounding variables, but overall there may be evidence of reduced psychological and 
emotional responsiveness as age increases. This age-related effect could be explained by 
increased emotional control and ‘psychological immunisation’ to stressful events 
through prior exposure. In a further community survey of participants aged between 20 
and 64, Jorm et al359 reported a reduction in both anxiety and depression overall as age 
increases. It appears that, in lung cancer, younger patients are more likely to experience 
anxiety but the reasons for this require further elucidation. This finding is important and 
suggests that, in lung cancer care, increased vigilance should be adopted in assessment 
of psychological supportive care needs of younger patients. 
 
7.3.4 Non-Significant Factors 
7.3.4.1 Time from Diagnosis 
It has been reported that psychological and spiritual distress in lung cancer varies over 
different phases of the lung cancer journey. Weisman and Worden4 first described a 
peak symptom distress in the first 100 days of lung cancer. In their qualitative study, 
Murray et al180 have described peaks of psycho-spiritual distress at diagnosis, at 
discharge from hospital and at times of recurrence. In this study, physical function and 
social distress declined as lung cancer advanced. Worden360 also went on to describe the 
distress experienced during recurrence of any cancer type. A peak in psychological 
distress around diagnosis has also been described by Cooley et al174 Furthermore, 
Montazeri et al342 reported significant pre-diagnosis depression in lung cancer patients 
that reduced during follow-up.  
 
Physical symptoms have been reported to increase as lung cancer advances.12, 178, 179, 297 
However, Sanders et al216 found no independent relationship between time from 
diagnosis and supportive care needs in lung cancer patients when controlling for 
physical function, coping mechanism, symptom bother, distress, healthcare satisfaction 
and depression in a stepwise logistic regression. It should be noted that time from 
diagnosis does not necessarily imply progressive or advanced lung cancer. Survivors of 
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lung cancer will be increasingly represented in any sample that is distant from diagnosis 
date, and this is likely to lead to a bias in cross-sectional studies of heterogeneous lung 
cancer populations. Thus, time from diagnosis should be considered separately from 
stage of lung cancer. Survivors of lung cancer are likely to continue to have supportive 
care needs.361 Physical symptoms may have been a legacy of the curative treatments 
provided115, 269 or may relate to significant co-morbidities.361 Psychosocial distress may 
continue from the previous diagnosis, reflect altered physical function115 despite cure or 
result from use of resources during the lung cancer.361, 362 In the current study, 
supportive care needs were independent of ‘time from diagnosis’ and this is an 
important finding affirming the need for supportive care from early on in the lung 
cancer journey. Therefore, time from diagnosis should not alter supportive care needs 
being evaluated and addressed. 
 
7.3.4.2 Gender 
Degner and Sloan119 utilised univariate analysis to evaluate patients with a variety of 
cancers. They found significantly higher symptom distress in females compared to 
males and again in advanced stage disease compared to early stage cancers. Increased 
symptom distress in females was also reported by Cooley et al.174 However, Graves et 
al350 reported no difference between genders in relation to symptom distress and 
psychosocial distress, and Ferreira et al323 reported no independent effect of gender on 
overall quality of life. Skaug et al303 reported that in the last two months of life gender 
had no relationship to physical or psychological symptoms. Sanders et al216 also found 
no independent relationship between gender and supportive care needs (measured by the 
supportive care needs survey) in lung cancer patients. In the current study, the level of 
supportive care needs was not dependent on gender. Although some previous studies 
have suggested females experience more symptom and psychological distress, this was 
not observed in many other studies. Supportive care should, therefore, be available, 
targeted and offered to both males and females with lung cancer. 
 
7.3.4.3 Stage 
In studies of lung cancer patients, Cooley et al174 found no relationship between 
symptom distress and stage of disease at diagnosis, three months or six months post-
diagnosis. Graves et al350 reported no relation between stage and symptoms or 
psychosocial distress in lung cancer patients. Sanders et al216 found no independent 
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relationship between stage and supportive care needs. However, Skaug et al303 reported 
differences in self-reported pain and nausea in the last two months of life in relation to 
stage of lung cancer. Lutz et al297 also reported increased symptom burden in those with 
advanced lung cancer and those patients in the last few months of life. 
In the current study, there was no direct relationship between stage of lung cancer and 
level of supportive care needs. In particular, the presence of metastases did not 
necessarily mean higher supportive care needs. Stage of disease should not be used to 
target supportive care in the lung cancer clinic. 
 
7.3.4.4 Histology 
Cooley et al174 also described an independent association between symptom distress and 
histology in newly diagnosed patients (NSCLC > SCLC symptom distress) but not at 
six months post-diagnosis. Skaug et al303 reported that patients with SCLC were more 
likely to have nausea and psychological symptoms in the last two months of life than 
those with NSCLC or no histology. Graves et al350 reported no relation between 
histology and symptoms or psychosocial distress in lung cancer patients. Differences 
between physical symptoms, function and psychosocial distress between histological 
types in lung cancer reflect a complex of potential variables. NSCLC and SCLC have 
different patterns of disease burden, different treatment protocols, possible differences 
in paraneoplastic syndromes and different mortality rates. As such, it is difficult to pin-
point particular reasons for described differences in supportive care needs. In the current 
study, histology was not independently related to levels of supportive care needs. Thus, 
histology in itself should not be used as a means of targeting supportive care.  
 
7.3.4.5 Treatment 
Sarna et al284 reported increased symptom distress in patients receiving chemotherapy 
and those not receiving surgery. Cooley et al174 did not find any association between 
symptom distress and treatment delivered at diagnosis (first 100 days) or at six months 
post-diagnosis. However, at three months post-diagnosis, patients who had undergone 
surgery had significantly less symptom distress than those who received radiotherapy or 
chemotherapy. Graves et al350 reported no relationship between treatment type and 
symptoms or psychosocial distress in lung cancer patients.  
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In the current study, the delivery of active anti-cancer treatment did not predict the 
levels of supportive care needs. This is consistent with the current trend to integrate 
palliative and supportive care early into lung cancer management, including those who 
are receiving active treatment (see Section 1.4.7). 
 
7.3.4.6 Deprivation 
Lung cancer is more prevalent in deprived populations; it has been postulated that this 
relates to a higher smoking prevalence.333, 334 This association has also been observed in 
Scotland.52 Deprivation has been associated with reduced survival52, 336 and increased 
symptom burden in lung cancer.53 Montazeri et al53 reported that deprivation level was 
associated with increased pain, increased dyspnoea, increased peripheral neuropathy, 
reduced functioning, reduced role functioning and reduced energy in lung cancer 
patients. This univariate analysis also found that the differences between socio-
economic groups were less apparent during follow-up than at diagnosis. However, 
several other studies have found no independent association between deprivation level 
and symptom distress174, 323, 350 or quality of life in lung cancer.323 
 
In the current study, there was a high level of deprivation within the lung cancer 
population. However, no relationship between deprivation and supportive care needs 
was identified. Thus, it could be recommended that deprivation levels should not be 
used to target supportive care. This was an unexpected finding, but it can be speculated 
that because most patients were deprived on the whole (to varying degrees), potential 
differences in supportive care needs within the study population were not identifiable. 
 
7.4 Conclusions 
Comparisons with previous studies show inconsistencies that reflect the variability in 
methodology, selection criteria, assessment tools, co-variates evaluated and outcome 
measures. However, a clear role is identified for the use of ECOG PS and respiratory 
symptoms as helpful clinical markers indicating possible higher supportive care needs at 
any stage of the lung cancer journey. Younger patients may also experience higher 
psychosocial distress, and vigilance for this should be adopted when caring for patients 
under 65 years. In contrast to the Sanders et al216 conclusion that supportive needs are 
not predicted by readily available clinical information, the current study establishes that 
ECOG PS and presence or absence of respiratory symptoms identify many patients with 
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higher needs. Respiratory symptom assessment remains an integral part of lung cancer 
follow-up, and ECOG PS is already used to direct clinical decisions regarding fitness 
for active anti-cancer treatments in many multidisciplinary clinics. As such, these two 
practical clinical approaches could be utilised within a clinic setting, perhaps 
incorporated into a nurse-led follow-up protocol or to allow community based follow-up 
of patients not undergoing hospital-based interventions.  
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8 Supportive Care Needs and Survival 
In keeping with Aim 4b, this section evaluates possible predictors of reduced survival 
within the Stobhill lung cancer population. The predictors evaluated were all readily 
available within the Stobhill clinic and may serve to allow effective and efficient 
targeting of supportive care for those who have less time. The methodology and 
statistical approach are outlined in Section 3.  
 
8.1 Introduction 
Lung cancer is a disease of short survival and high mortality3 (see Section 1). 
Treatments are employed to improve survival, provide palliation or both. The most 
consistent and useful predictors of survival are extent of disease, performance status, 
weight loss and tumour histology.100, 126, 128 However, a variety of other factors have 
been identified to be adverse prognostic factors in lung cancer. These include raised C-
reactive protein, reduced albumin, age, gender, smoking status and a variety of 
physiological markers.100, 363 There is also some evidence that symptom burden and 
quality of life may affect prognosis.1, 183, 309 The relationship between survival and 
supportive care needs, as measured by POS, are explored here.  
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8.2 Results 
8.2.1 Survival of All Patients Attending the Lung Cancer 
Clinic 
Factor Median SE Lower Upper χ2 Df p value Significant
Overall survival
319 0.25 269.27 368.73 na
Gender
Male 274 30.41 214.41 333.59 2.92 1 0.088
Female 354 45.41 264.99 443.01 2.92 1 0.088
Age
<65 years 307 29.17 249.83 364.17
≥65 years 319 41.90 236.88 401.12 0.12 1 0.729
Histology
Clinical 422 109.20 207.97 636.03
NSCLC 326 35.91 255.62 396.38
SCLC 181 57.25 68.80 293.20 7.68 2 0.022 *
Presence or absence of metastases
None 441 77.92 288.27 593.73
Metasases 136 23.50 89.94 182.06 42.01 1 <0.001 ***
Weight loss since diagnosis?
No 394 82.70 231.91 556.09
Yes 255 38.47 179.59 330.41 6.00 1 0.014 *
Performance status rated by patients
0-1 394 65.99 264.65 523.35
2-4 229 26.94 176.20 281.80 14.40 1 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 394 52.02 292.03 495.97
2-4 198 49.42 101.14 294.86 12.57 1 <0.001 ***
Palliative outcome scale
<10 360 49.91 262.17 457.83
>10 248 45.99 157.86 338.14 5.47 1 0.019 *
Active anti-cancer treatment
Yes 354 35.74 283.95 424.05
No 198 45.24 109.34 286.66 5.68 1 0.017 *
Deprivation
Dep Cat 1-5 280 31.39 218.47 341.53
Dep cat 6 or 7 338 43.33 253.06 422.94 0.41 1 0.524
Respiratory symptom score
0-4 331 37.44 257.62 404.38
5-8 283 69.71 146.36 419.64
9-12 252 187.79 0.00 620.08 5.15 2 0.076
Survival in days 95% Confidence interval Log Rank comparison
 
Table 52: Comparisons of median survival and confidence intervals for all patients attending the 
lung cancer clinic.  *p<0.05, **p<0.01 and ***p<0.001 
 
Overall median survival from LCQ completion in this heterogeneous population of all 
patients (newly diagnosed and returning patients) was 319 days (10.6 months). Factors 
that were significantly associated with reduced survival from time of LCQ completion 
were: histology (SCLC worst survival), presence of metastases, weight loss since 
diagnosis, reduced PS (patient or doctor-rated), POS score greater than ten, not 
receiving active anti-cancer treatment (Figure 18A and B). There was no difference in 
survival between genders, higher and lower deprivation level, younger and older 
patients and respiratory symptom score groups. However, for increasing respiratory 
symptom score, there was a trend toward poorer survival. 
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Figure 18A: Kaplan-Meier curves for survival from questionnaire completion until death or censor 
for all patients attending the lung cancer clinic. 
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Figure 18B: Kaplan-Meier curve for survival from questionnaire completion until death or censor 
for all patients attending the lung cancer clinic. 
 
 
b SE Wald df p value Hazard Ratio Lower Upper
PS = 0 14.235 2 .010
PS = 1-2 .428 .230 3.465 1 .063 1.534 .978 2.408
PS = 3-4 .735 .197 13.938 1 <0.001 2.085 1.418 3.065
Weight loss .431 .178 5.865 1 .150 1.539 1.086 2.182
Metastatic disease .942 .178 27.842 1 <0.001 2.564 1.807 3.638
95% CI for Hazard Ratios
 
Model Χ2 = 49.957, df = 4, p>0.001 
Table 53: Backwards Cox regression. Factors identified as independently associated with reduced 
survival in all patients attending the lung cancer clinic. 
 
Factors identified as independent predictors of reduced survival from LCQ completion 
were: Poorer ECOG PS, weight loss from diagnosis and presence of metastatic disease. 
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8.2.2 Survival of Newly Diagnosed Patients Attending the 
Lung Cancer Clinic 
 
Factor Median SE Lower Upper χ2 Df p value Significant
Overall survival
266 33.69 199.96 332.04
Gender
Male 235 58.53 120.28 349.72
Female 277 44.40 189.98 364.02 1.05 1 0.305
Age
<65 years 277 53.77 171.61 382.39
≥65 years 252 42.52 168.66 335.34 0.00 1 0.988
Histology
Clinical 422 103.68 218.79 625.21
NSCLC 232 47.92 138.08 325.92
SCLC 248 24.62 199.74 296.26 3.87 2 0.145
Presence or absence of metastases
None 422 110.97 204.50 639.50
Metasases 103 28.35 47.44 158.56 25.47 1 <0.001 ***
Weight loss since diagnosis?
No 349 92.43 167.84 530.16
Yes 240 56.01 130.21 349.79 2.08 1 0.149
Performance status rated by patients
0-1 389 55.95 279.33 498.67
2-4 178 25.06 128.88 227.12 7.63 1 0.006 **
Diagnosis PS, assessed by doctor
0-1 360 61.76 238.95 481.05
2-4 151 47.14 58.61 243.39 8.87 1 0.003 **
Palliative outcome scale
<10 360 75.93 211.17 508.83
>10 201 47.86 107.20 294.80 4.39 1 0.036 *
Active anti-cancer treatment
Yes 326 36.61 254.24 397.76
No 138 64.91 10.78 265.22 3.80 1 0.051
Deprivation
Dep Cat 1-5 248 46.59 156.68 339.32
Dep cat 6 or 7 277 55.00 169.19 384.81 0.07 1 0.786
Respiratory symptom score
0-4 277 51.74 175.58 378.42
5-8 252 96.12 63.60 440.40
9-12 22 . . . 3.31 2 0.209
Survival in days 95% Confidence interval Log Rank comparison
 
Table 54: Comparisons of median survival and confidence intervals for newly diagnosed patients 
attending the lung cancer clinic.  *p<0.05, **p<0.01 and ***p<0.001 
 
Overall median survival from LCQ completion in this population of newly diagnosed 
patients was 266 days (8.87 months). Factors identified as significantly associated with 
reduced survival from time of LCQ completion were: presence of metastases, reduced 
PS (patient or doctor-rated) and POS score greater than ten (Figure 19). 
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Figure 19: Kaplan-Meier curves for survival from questionnaire completion until death or censor 
for newly diagnosed patients. 
 
 
b SE Wald df p value Hazard Ratio Lower Upper
Metastatic disease .667 .235 8.086 1 .004 3.19 2.00 5.10
PS = 0 7.115 2 .029
PS = 1-2 .350 .313 1.248 1 .264 1.419 .768 2.622
PS = 3-4 .706 .265 7.105 1 .008 2.025 1.205 3.403
95% CI for Hazard Ratios
 
Model Χ2 = 37.053, df = 3, p>0.001 
Table 55: Backwards Cox regression. Factors identified as independently associated with reduced 
survival in newly diagnosed patients attending the lung cancer clinic. 
 
Factors identified as independent predictors of reduced survival from LCQ completion 
were: presence of metastatic disease and the ECOG PS.  
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8.2.3 Survival of Patients in the Last Three Months of Life  
Overall median survival from LCQ completion in this population of patients in the last 
three months of life was 41 days. Factors identified as significantly associated with 
reduced survival from time of LCQ completion were: increased dyspnoea, pain, 
personal anxiety and increased ability to share (Figure 20). 
Factor Median SE Lower Upper χ2 Df p value Significant
Overall survival
41 3.54 34.07 47.93 na
Gender
Male 33 6.32 20.62 45.38
Female 44 3.71 36.73 51.27 0.01 1 0.904
Age
<65 years 44 5.48 33.26 54.74
≥65 years 41 4.33 32.51 49.49 0.25 1 0.620
Histology
Clinical 49 6.53 36.20 61.80
NSCLC 40 3.60 32.94 47.06
SCLC 36 6.10 24.04 47.96 1.00 1 0.606
Presence or absence of metastases
None 39 10.33 18.76 59.24
Metasases 42 4.39 33.39 50.61 0.02 1 0.876
Weight loss since diagnosis?
No 47 7.65 32.01 61.99
Yes 45 2.92 39.27 50.73 0.00 1 0.969
Performance status rated by patients
0-1 38 11.86 14.76 61.24
2-4 41 3.50 34.14 47.86 0.01 1 0.927
Diagnosis PS, assessed by doctor
0-1 42 5.10 32.00 52.00
2-4 44 3.99 36.18 51.82 1.15 1 0.283
Palliative outcome scale
<10 39 5.24 28.72 49.28
>10 43 5.08 33.05 52.95 0.07 1 0.788
Active anti-cancer treatment
Yes 37 4.61 27.97 46.03
No 49 3.99 41.17 56.83 1.07 1 0.300
Deprivation
Dep Cat 1-5 44 5.18 33.84 54.16
Dep cat 6 or 7 39 3.74 31.67 46.33 0.89 1 0.344
Respiratory symptom score
0-4 44 4.72 34.75 53.25
5-8 42 4.32 33.54 50.46
9-12 22 . . . 1.66 2 0.435
Dyspnoea
Lower 50 9.18 32.01 67.99
Higher 38 6.25 25.74 50.26 4.27 1 0.039 *
Cough
Lower 45 5.33 34.55 55.45
Higher 41 4.46 32.27 49.73 1.67 1 0.196
Haemoptysis
Lower 41 3.56 34.01 47.99
Higher 66 24.88 17.24 114.76 2.89 1 0.089
Pain
Lower 45 6.93 31.42 58.58
Higher 37 7.12 23.05 50.95 8.00 1 0.005 **
Other symptoms
Lower 45 4.84 35.52 54.48
Higher 41 4.37 32.43 49.57 0.24 1 0.622
Personal anxiety
Lower 47 2.53 42.05 51.95
Higher 37 3.97 29.22 44.78 4.45 1 0.035 *
Support network anxiety
Lower 46 6.03 34.18 57.82
Higher 41 3.03 35.05 46.95 0.87 1 0.351
Ability to share
Lower 37 3.19 30.75 43.25
Higher 49 5.66 37.91 60.09 6.94 1 0.008 **
Self-esteem
Lower 46 5.34 35.53 56.47
Higher 36 6.78 22.72 49.28 0.93 1 0.336
Life-worth
Lower 44 3.20 37.73 50.27
Higher 26 6.45 13.36 38.64 0.11 1 0.736
Survival in days 95% Confidence interval Log Rank comparison
 
Table 56: Comparisons of median survival and confidence intervals for patients in the last 3 
months of life.  *p<0.05, **p<0.01 and ***p<0.001 
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Figure 20: Kaplan-Meier curves for survival from questionnaire completion until death or censor 
for patients who died within three months of questionnaire completion 
 
 
b SE Wald df p value Hazard Ratio Lower Upper
Dyspnoea (higher) .401 .204 3.851 1 .050 1.493 1.001 2.229
Pain (higher) .490 .205 5.719 1 .017 1.633 1.093 2.441
Reduced ability to share -.557 .217 6.567 1 .010 .573 .374 .877
95% CI for Hazard Ratios
 
Model Χ2 = 20.388, df = 2, p>0.001 
Table 57: Backwards Cox regression. Factors identified as independently associated with reduced 
survival in patients in last 3 months of life. 
 
Factors identified by logistic regression as independent predictors of reduced survival 
from LCQ completion were: increased pain, dyspnoea and increased ability to share. 
 
8.3 Discussion 
Lung cancer is a disease of reduced survival. Prognostication in lung cancer serves 
several purposes and includes aiding decision-making regarding treatments offered, 
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helping patients make decisions regarding accepting treatments,364 affording some 
guidance to patients regarding survival outlook, influencing goals of treatments and 
identifying the most appropriate healthcare professional to lead care provision. Despite 
the median survival of lung cancer remaining relatively unchanged for the last 25 years, 
determining prognosis on an individual level remains difficult but no less important. 
The main clinical indicators of prognosis that have previously been identified are stage 
of disease, performance status and weight loss. Additional refinement of the prognosis 
estimate is informed by additional clinical markers (e.g. LDH) and laboratory markers 
of systemic inflammation or nutritional status. In addition to these, there have been 
several reports regarding the potential prognostic value of patient-derived indices such 
as quality of life, symptom burden and supportive care needs.  
 
In the current study, several factors have been confirmed as independent adverse 
prognostic factors. In the general population attending the Stobhill lung cancer clinic, 
performance status, presence of metastases and weight loss were all independent 
adverse prognostic factors. This is in keeping with previous reports which have 
identified these factors as key in both prognostication and decision-making in lung 
cancer (see Section 1.4.5). In newly diagnosed patients, ECOG PS and the presence of 
metastases were significant. In the final three months of life, none of the above factors 
was significant, but instead increased pain, increased dyspnoea and increased ability to 
share were independent predictors of reduced survival time. It is possible that as 
patients near the end of life, reduced PS and weight loss are so common that these 
factors lose discriminating prognostic power.  
 
In the general clinic population and in newly diagnosed patients, increased supportive 
care needs as measured by POS (POS≥10) were associated with reduced survival time 
on univariate analysis. This association was not maintained when controlling for other 
factors in multivariate analysis. In Section 7, it was established that the key predictor of 
supportive care needs was performance status. Given this strong relationship and the 
knowledge that performance status is also a strong predictor of survival, it is not 
surprising to find that supportive care needs are not significant predictors of survival 
when controlling for the effect of PS and other known adverse prognostic factors.  
 
Although POS≥10 was not a significant factor in the last three months of life, the 
previously documented adverse prognostic physical symptoms of pain and dyspnoea 
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were found to be the main independent factors in this population of lung cancer patients. 
Furthermore, PS, presence of metastatic disease and weight loss were not found to be 
significant predictive factors. It has previously been described that in the terminal phase, 
histology and stage of disease have less importance in predicting prognosis.133, 134 
 
8.3.1 Symptoms, Supportive Care Needs and Survival in Lung 
Cancer 
Symptoms may be predictive of mortality in cancer.1, 183, 309 In lung cancer there is 
specific evidence of a relationship between increased symptom distress and decreased 
survival. The Degner & Sloan119 analysis of 82 lung cancer patients in a wider cohort of 
434 ambulatory, newly diagnosed cancer patients showed a significant negative 
correlation between symptom distress (measured by the SDS) and survival. This 
relationship held true when symptom distress was measured any time in the six months 
following diagnosis. However, they reported three patients with high symptom distress 
but greater than five years’ survival. On further review, these patients had undergone 
thoracotomies and had significant post-surgical pain at time of testing. This was noted 
as a limitation of symptom assessment for aiding prognostication. Kasaa et al120 had 
previously found that inoperable lung cancer patients with low symptom distress 
survived longer than those with higher levels of distress, irrespective of treatment. 
Kukull et al181 also found a negative correlation with higher symptom distress 
(measured by the SDS) and survival when controlling for age, personality traits (e.g. 
coping ability) and functional status.  
 
It has recently been reported that Korean patients with lung cancer who were 
asymptomatic at presentation survived longer than those who were symptomatic at 
presentation.173 In this large, national survey of 8788 patients diagnosed with lung 
cancer in 2005, only 6.5% presented with no symptoms, and 60% of asymptomatic 
patients underwent curative intent surgery. Furthermore, those asymptomatic patients 
with NSCLC had reduced risk of death from lung cancer regardless of age, gender, 
stage at diagnosis, smoking history and whether treatment was given. Interestingly, this 
was not the case for the asymptomatic patients with SCLC in this cohort. 
 
Global QOL or domains from within QOL assessment may also be an independent 
predictor of mortality in lung cancer at different stages of disease.115, 117, 120, 325-331 The 
relationship between QOL and symptom burden is complex and ill-defined. There are 
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many tools available for assessing QOL in cancer in general and in lung cancer 
specifically.322 Although many of these contain physical symptom components,323 they 
differ from symptom (or symptom distress) assessment and needs assessment. Symptom 
burden may predict overall QOL,121, 323 but it is not clear if this is an independent effect 
or relates to the functional effects of symptoms.172 In some chemotherapy trials, global 
QOL did not change, but symptom burden measures did show a response to 
treatment.324 During active treatment, symptom burden may vary due to occurrence of 
treatment-related symptoms and improved or worsening disease-related symptoms. 
Supportive care needs assessment is likely to overlap with both QOL and symptom 
burden assessment, incorporating physical symptoms, psychosocial domains and 
functional status dependent domains.216 
 
To date there have been no studies specifically examining the relationship between 
supportive care needs and survival in lung cancer. Furthermore, there have been no 
studies evaluating the relationship between POS and survival in lung cancer.  
 
In the current study, increased supportive care needs as measured by the Palliative 
Outcome Scale (POS≥10) were associated with reduced survival in the general clinic 
population and newly diagnosed patients on univariate analyses. In those who died 
within three months of questionnaire completion, no relationship was identified between 
POS and survival. On multivariate analysis, increased supportive care needs were not 
found to be independent predictors of reduced survival in any of the groupings. 
 
In the last three months of life, increased ability to share was associated with reduced 
survival; it is not clear why this is the case. It may be that as patients enter the terminal 
phase, they consider sharing thoughts and worries more and therefore increase the 
perception of feeling listened to. It may also be that patients nearing death are given 
more opportunities to discuss their worries and feelings about their illness. 
 
It has been shown that PS is a strong predictor of both increased supportive care needs 
(see Section 7) and reduced mortality. It is not surprising, therefore, that when 
controlling for the effects of PS and other known adverse prognostic factors, increased 
supportive care needs do not predict reduced survival. 
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In the current study, PS was not a significant predictor of survival in the last three 
months of life. Instead, dyspnoea and pain were identified as the main predictors of 
survival in the last three months of life. This partly contrasts to previous studies that 
reported functional status as an important prognostic factor in the terminal stage of 
cancer.135 Dyspnoea has been previously reported as a predictor in the terminal phase.135 
This physical symptom is incorporated into prognostic scoring systems used within the 
palliative setting. Pain has also been found to be associated with reduced survival in 
some bivariate cancer studies.135 Vigano et al,135 in their review of prognostic factors in 
terminal cancer, reported that only one study found pain to be an independent predictor 
of reduced survival. However, it is of note that this finding was reported in a study of 
lung cancer patients in the last months of life.365 It has been reported that the type, stage 
and histology of cancer matter much less in survival prediction in the terminal phase.135, 
366 The current study supports these previous findings.  
 
8.3.2 Additional Factors and Survival in Lung Cancer 
Survival from questionnaire completion was not associated with gender, age or 
deprivation level in any group using univariate analysis. In NSCLC, Albain et al367 
described patients with good performance status, female gender and age of less than 70 
years having improved survival. In the current study, there was no significant survival 
difference between levels of deprivation. Reduced survival in deprived cancer patients 
has been previously described, and it has been postulated that it may reflect: delays in 
presentation, reduced access to services, decreased compliance with treatment, 
increased co-morbidities and life-style factors.368 Cancer Research UK statistics show 
that there is a significant difference in relative survival between affluent and deprived 
lung cancer patients. However, it is noted that this difference of around 1% is only 
statistically significant due to the large number of patients evaluated.51 The current 
study was unlikely to show such a small effect with the relatively small number of 
patients and the large number of deprived patients. 
 
Those receiving active anti-cancer treatment survived significantly longer overall and 
there was a trend toward significance in the newly diagnosed population. This analysis 
includes those who received palliative intent anti-cancer treatments. There was no 
significant difference found in the last three months of life. It is unlikely that a survival 
difference derived from treatment would be identified in a group of patients who were 
all within the last three months of life. 
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8.4 Conclusions 
Increased supportive care needs were associated with reduced survival on univariate 
analysis, but there was no independent relationship between reduced survival and 
increased supportive care needs as measured by POS. As such, although patients with a 
shorter estimated prognosis should receive prompt attention patients at any stage of the 
lung cancer journey may have unmet supportive care needs. Therefore supportive care 
issues should be assessed at in all phases of lung cancer patients attending Stobhill 
Hospital, not just those near the end of life. 
 
ECOG PS is integrated within lung cancer care in Stobhill and many other cancer 
services. The role of ECOG PS status in predicting survival in lung cancer is key. 
Furthermore, it has been established that reduced PS is associated with increased 
supportive care needs (see Section 7). Thus, evaluation of supportive care needs in 
patients with poor PS should be timely and efficient, so as to identify and manage the 
unmet needs of this population who also have reduced survival. 
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9 Anxiety in Lung Cancer – A Key Supportive 
Care Need 
In keeping with Aim 4c, this section evaluates possible predictors of increased anxiety. 
The predictors evaluated were all readily available within the Stobhill lung cancer 
service. The methodology and statistical approach are outlined in Section 3.  
 
9.1 Introduction 
Anxiety (both personal and that of a support network) has been identified as a key issue 
in this study. This is in keeping with previous studies utilising POS.218 Furthermore, 
perceived support network anxiety has also been consistently rated the highest issue in 
previous studies.218  
 
Anxiety and worry within the lung cancer population are common, underestimated and 
impact significantly on quality of life.2, 13, 107, 176, 369 The impact of anxiety and worry on 
day-to-day life is reflected in the etymology of both words: ‘anxiety’ derives from the 
Latin anxius meaning to choke; ‘worry’ originates from the Anglo-Saxon wyrgan 
meaning to strangle.163 Manifestations of anxiety can be classed as physical (e.g. 
sweats, palpitation, gastrointestinal disturbance, panic attacks and dyspnoea), 
behavioural (e.g. unease, restlessness and reassurance-seeking) and psycho-emotional 
(e.g. apprehension, recurrent and intrusive thoughts and loss of concentration).370-372 A 
spectrum of anxiety is observed within both the general and cancer populations. This 
includes adaptive anxiety, maladaptive anxiety and classifiable anxiety disorders (such 
as phobias, panic attacks, generalised anxiety disorders and post-traumatic distress).373-
375 Maladaptive anxiety is out of proportion to the stimulus, and it persists and disrupts 
function and quality of life.376 
 
9.1.1 Anxiety in Cancer 
Cancer is a threatening diagnosis. The word ‘cancer’ has been used in studies to 
provoke anxiety.372 Within the cancer population, there is a higher prevalence of anxiety 
and mixed anxiety-depression than in the general population.371  It can be difficult to 
assess for anxiety in cancer as the changing illness trajectory, effect and side effects of 
treatment and the persistent threat of the diagnosis and associated prognostic uncertainty 
lead to a dynamic situation.372 However, anxiety can become a significant, identifiable 
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problem requiring specific assessment and management. Once identified, management 
of anxiety in cancer includes good communication, information giving, psychological 
support and pharmacological interventions.370-372 
 
9.1.2 Anxiety in Lung Cancer 
Physical decline in advanced cancer in general and lung cancer specifically has been 
well characterised.372 Lung cancer is often a short illness with rapid physical decline, 
high symptom burden and prognosis of weeks or a few months.1, 157 Anxiety and 
distress are not predictable by gender, age or stage of lung cancer but may peak at 
certain stages of disease: diagnosis, identification of disease progression and the 
beginning of the terminal phase.129, 180 There is some evidence that anxiety in cancer is 
associated with poor PS and high symptom burden.371 As such, lung cancer patients are 
likely to be at risk of anxiety. The small body of research into this area provides some 
consistent evidence that psychosocial distress is high in the lung cancer population.119, 
164, 168, 178 
 
9.1.3 Support Network Anxiety 
Individual patients cope with illness and symptoms within the context of relationships 
with significant others.12, 377 It has been suggested that sharing feelings with trusted and 
supportive people can improve emotional and cognitive processing of illness.378 Lack of 
positive support may adversely affect this process. In tobacco-related disease, there may 
be additional elements with guilt or blame related to cigarette smoking. This may also 
affect ability to discuss issues within the support network.378 
 
The concept of distinguishing symptom distress from symptom occurrence is gaining 
ground.121, 165, 169 Assessment of symptom occurrence and symptom distress may differ 
between individuals, caregivers and significant others.165, 167, 169 Lack of concordance in 
distress recognition and identification of its cause, between patients and others, may 
influence a patient’s perception of support. 
 
Patient perception of family’s or friends’ worry may affirm presence of support or may 
drive personal anxiety. Perceiving high anxiety within your support network may 
impact on freedom to discuss illness or symptoms within the support network. 
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Conversely, if this perceived anxiety is recognised as appropriate and reflective of care, 
then it may affirm feelings of support and facilitate shared feelings. 
 
This section further examines anxiety felt by lung cancer patients and the anxiety that 
they perceive in their support network.  
 
9.2 Results 
9.2.1 Anxiety in All Patients Attending the Lung Cancer Clinic 
Personal anxiety felt (mean 1.63, median 1, range 0-4, SD 1.31) was reported to be low 
(0-1) in 49% (n=173/353) of patients. Higher anxiety levels (2-4), were described in 
46% of patients (n=161/353). Perceived support network anxiety (mean 2.17, SD 1.40, 
median 2, range 0-4) was reported to be low (0-1) by 37.1% (n=131/353) of patients and 
high (2-4) by 56.9% (n=201/353). Being able to share feelings (mean 0.75, SD 1.19, 
median 0, range 0-4) was reported to be felt possible ‘as much as I want’ (0) or ‘most of 
the time’ (1) in 72.8% (n=257/353) of patients. 
 
9.2.1.1 Personal Anxiety (All Patients) 
Personal anxiety was categorised as low (0-1) and high (2-4). Differences between the 
lower and higher anxiety patients were examined in relation to the factors listed in Table 
58. Statistical significance of any difference was assessed (using Pearson Χ2 or Fisher’s 
exact test).  
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 92 56.8% 70 43.2%
Female 81 47.1% 91 52.9% 3.142 1 0.81
Age
<65 years 39 41.1% 56 58.9%
≥65 years 134 56.1% 105 43.9% 6.138 1 0.015 *
Histology
Clinical 31 50.8% 30 49.2%
NSCLC 123 53.0% 109 47.0%
SCLC 19 46.3% 22 53.7% 0.65 2 0.722
Stage NSCLC
1A 14 58.3% 10 41.7%
1B 32 69.6% 14 30.4%
2A 11 52.4% 10 47.6%
2B 13 65.0% 7 35.0%
3A 11 42.3% 15 57.7%
3B 31 44.9% 38 55.1%
4 38 46.9% 43 53.1% 10.625 6 0.101
Stage SCLC
Limited 7 50.0% 7 50.0%
Extensive 11 42.3% 15 57.7% 0.218 1 0.641
Presence or absence of metastases
None 124 54.6% 103 45.4%
Metasases 49 45.8% 58 54.2% 2.272 1 0.159
Time from diagnosis to POS
Within 3 weeks 43 38.7% 68 61.3%
3-6 weeks 28 54.9% 23 45.1%
6 weeks to 3 months 17 53.1% 15 46.9%
3-6 months 22 57.9% 16 42.1%
6-12 months 21 53.8% 18 46.2%
> 12 months 39 65.0% 21 35.0% 12.589 5 0.028 *
Performance status rated by patients
0-1 111 64.2% 62 35.8%
2 35 51.5% 33 48.5%
3-4 27 29.0% 66 71.0% 29.9 2 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 121 57.9% 88 42.1%
2 24 31.6% 52 68.4%
3-4 6 66.7% 3 33.2% 16.321 2 <0.001 ***
Active anti-cancer treatment
Yes 134 51.1% 128 48.9%
No 25 55.6% 20 44.4% 0.299 1 0.63
Deprivation
Dep Cat 1-5 76 50.3% 75 49.7%
Dep cat 6 or 7 94 53.1% 83 46.9% 0.252 1 0.658
Satisfaction score
0-4 67 53.6% 58 46.4%
5-8 1 33.3% 2 66.7%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 41 55.4% 33 44.6%
Yes 35 48.6% 37 51.4% 0.675 1 <0.001 ***
Dysnoea
No 39 63.9% 22 36.1%
Yes 134 49.1% 139 50.9% 4.40 1.00 0.047 *
Cough
No 52 65.0% 28 35.0%
Yes 119 47.2% 133 52.8% 7.68 1.00 0.007 **
Haemoptysis
No 157 55.5% 126 44.5%
Yes 14 29.2% 34 70.8% 11.38 1.00 0.001 **
Dysnoea
Lower 101 62.3% 61 37.7%
Higher 72 41.9% 100 58.1% 14.02 1.00 <0.001 ***
Cough
Lower 130 61.6% 81 38.4%
Higher 41 33.9% 80 66.1% 23.67 1.00 <0.001 ***
Haemoptysis
Lower 166 53.4% 145 46.6%
Higher 5 25.0% 15 75.0% 6.51 1.00 0.019 *
Pain
Lower 113 58.5% 80 41.5%
Higher 59 42.4% 80 57.6% 8.39 1.00 0.004 **
Other symptoms
Lower 156 57.6% 115 42.4%
Higher 15 25.4% 44 74.6% 20.05 1.00 <0.001 ***
Personal anxiety
Lower 114 87.7% 16 12.3%
Higher 57 28.4% 144 71.6% 111.29 1.00 <0.001 ***
Less ability to share
Lower 139 55.2% 113 44.8%
Higher 31 41.3% 44 58.7% 4.43 1.00 0.048 **
Reduced life-worth
Lower 155 56.8% 118 43.2%
Higher 8 18.6% 35 81.4% 21.67 1.00 <0.001 ***
Reduced self-esteem
Lower 142 65.7% 74 34.3%
Higher 24 23.1% 80 76.9% 51.18 1.00 <0.001 ***
Information needs
Lower 126 56.8% 96 43.2%
Higher 30 36.6% 52 63.4% 9.75 1.00 0.002 **
Practical needs
Lower 135 56.5% 104 43.5%
Higher 27 38.0% 44 62.0% 7.47 1.00 0.007 **
Time wasted
Lower 161 53.0% 143 47.0%
Higher 4 36.4% 7 63.6% 1.17 1.00 0.362
Lower Anxiety Higher Anxiety
 
Table 58: All patients attending the lung cancer clinic. Univariate analysis of factors across groups 
of higher and lower anxiety. Percentages adjusted for missing data.  
*p<0.05, **p<0.01 and ***p<0.001 
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The significant factors identified by univariate analysis were younger age, time from 
diagnosis, PS, GP attendance, dyspnoea, cough, haemoptysis, pain, ‘other’ symptoms, 
perceived anxiety in support network, reduced ability to share, reduced life-worth, low 
self-esteem, information needs and practical needs. Patient-rated PS was selected for 
this model. In addition, other factors of interest from the literature were included in the 
backwards logistic regression model: gender and presence of metastases. GP attendance 
was excluded, as this is likely to be a consequence of increased anxiety. The initial 
model included the factor of perceived anxiety in the support network, and this was the 
strongest contributor to the model’s predictive power. As this perception may have been 
driven by personal anxiety, the model was repeated excluding this factor. The results of 
both models are tabulated in Table 59 and Table 60 below.  
b SE Wald df p value Odds Ratio Lower Upper
Cough (higher) .701 .326 4.615 1 .032 2.015 1.063 3.818
Family anxiety 2.849 .376 57.313 1 <0.001 17.274 8.261 36.120
Low self-esteem 1.375 .346 15.768 1 <0.001 3.956 2.007 7.798
Constant -2.692 .371 52.765 1 <0.001 .068
95% CI for Odds Ratios
 
      R2=0.377 (Cox and Snell); 0.503 (Nagelkerke) Model Χ2=135.38, df=3, p<0.001 
      Hosmer-Lemeshow test: Χ2=3.642, df=3, p=0.457 
Table 59: Independent factors associated with higher personal anxiety identified through 
backwards logistic regression for all patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=135.38, df=3, p<0.001). Nagelkerke’s R2 of 0.503 indicated that around 50% of 
variance was explained by the model. Overall prediction success was 78% (64.1% for 
lower anxiety and 92.2% for higher anxiety). This compares to the null model overall 
prediction success of 50.7%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of personal anxiety in all patients attending the 
lung cancer clinic were independently associated with perception of increased support 
network anxiety, increased severity of cough and reduced self-esteem. There were no 
significant effects from the other variables which were excluded from the final model. 
For a fixed level of cough and self-esteem, patients who perceived increased anxiety in 
their support network were 17.274 (95% CI 8.261-36.120) times more likely to have 
higher levels of personal anxiety (i.e. anxiety which is moderate to overwhelming). 
 
The regression was repeated without including the factor of perceived support network 
anxiety.  
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b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 7.422 2 .024
Performance status 2 .071 .342 .043 1 .835 1.074 .549 2.099
Performance Status 3-4 .948 .359 6.956 1 .008 2.580 1.276 5.217
Cough (higher) .782 .288 7.377 1 .007 2.185 1.243 3.840
Low self-esteem 1.379 .323 18.197 1 <0.001 3.970 2.107 7.480
Time from diagnosis >6 months -.877 .383 5.256 1 .022 .416 .196 .880
Constant -.859 .203 17.873 1 <0.001 .423  
R2=0.214 (Cox and Snell); 0.286 (Nagelkerke) Model Χ2=69.47, df=5, p<0.001 
Hosmer-Lemeshow test: Χ2=7.545, df=7, p=0.374 
Table 60: Independent factors associated with higher personal anxiety identified through 
backwards logistic regression for all patients, excluding perceived support network anxiety. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=69.47, df=5, p<0.001). Nagelkerke’s R2 of 0.286 indicated that around 29% of 
variance was explained by the model. Overall prediction success was 67.7% (77.6% for 
lower anxiety and 57.4% for higher anxiety). This compares to the null model overall 
prediction success of 51%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of personal anxiety in all patients attending the 
lung cancer clinic were independently associated with reduced physical function (higher 
PS), increased cough, lower self-esteem and shorter time from diagnosis. There were no 
significant effects from the other variables which were excluded from the final model. 
For a fixed level of cough, self-esteem and time from diagnosis, patients with 
performance status 3-4 were 2.58 (95% CI 1.276-5.217) times more likely to have 
higher levels of personal anxiety than those of PS=0. 
 
9.2.1.2 Anxiety Perceived in the Support Network (All Patients) 
Anxiety in the support group as perceived by the patient was categorised as low (never 
anxious to sometimes anxious) and high (most of the time to preoccupied). The analysis 
was repeated to assess differences between these categories (Table 61).  
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 92 56.8% 70 43.2%
Female 81 47.1% 91 52.9% 3.142 1 0.81
Age
<65 years 39 41.1% 56 58.9%
≥65 years 134 56.1% 105 43.9% 6.138 1 0.015 *
Histology
Clinical 31 50.8% 30 49.2%
NSCLC 123 53.0% 109 47.0%
SCLC 19 46.3% 22 53.7% 0.65 2 0.722
Stage NSCLC
1A 14 58.3% 10 41.7%
1B 32 69.6% 14 30.4%
2A 11 52.4% 10 47.6%
2B 13 65.0% 7 35.0%
3A 11 42.3% 15 57.7%
3B 31 44.9% 38 55.1%
4 38 46.9% 43 53.1% 10.625 6 0.101
Stage SCLC
Limited 7 50.0% 7 50.0%
Extensive 11 42.3% 15 57.7% 0.218 1 0.641
Presence or absence of metastases
None 124 54.6% 103 45.4%
Metasases 49 45.8% 58 54.2% 2.272 1 0.159
Time from diagnosis to POS
Within 3 weeks 43 38.7% 68 61.3%
3-6 weeks 28 54.9% 23 45.1%
6 weeks to 3 months 17 53.1% 15 46.9%
3-6 months 22 57.9% 16 42.1%
6-12 months 21 53.8% 18 46.2%
> 12 months 39 65.0% 21 35.0% 12.589 5 0.028 *
Performance status rated by patients
0-1 111 64.2% 62 35.8%
2 35 51.5% 33 48.5%
3-4 27 29.0% 66 71.0% 29.9 2 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 96 46.2% 112 53.8%
2 17 22.4% 59 77.6%
3-4 4 44.4% 5 55.6% 13.02 2 0.001 **
Active anti-cancer treatment
Yes 134 51.1% 128 48.9%
No 25 55.6% 20 44.4% 0.299 1 0.63
Deprivation
Dep Cat 1-5 76 50.3% 75 49.7%
Dep cat 6 or 7 94 53.1% 83 46.9% 0.252 1 0.658
Albumin at diagnosis
<35 51 50.0% 51 50.0%
≥35 117 52.9% 104 47.1% 0.242 1 0.634
CRP at diagnosis
<10 84 56.4% 65 43.6%
≥10 89 48.1% 96 51.9% 2.259 1 0.152
Glasgow Prognostic Score
CRP <10 and Albumin >35 66 56.4% 51 43.6%
CRP >10 or Albumin <35 58 50.4% 57 49.6%
CRP >10 and Albumin <35 38 46.9% 43 53.1% 1.856 2 0.395
Satisfaction score
0-4 67 53.6% 58 46.4%
5-8 1 33.3% 2 66.7%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 41 55.4% 33 44.6%
Yes 35 48.6% 37 51.4% 0.675 1 <0.001 ***
Dysnoea
No 39 63.9% 22 36.1%
Yes 134 49.1% 139 50.9% 4.40 1.00 0.047 *
Cough
No 52 65.0% 28 35.0%
Yes 119 47.2% 133 52.8% 7.68 1.00 0.007 **
Haemoptysis
No 157 55.5% 126 44.5%
Yes 14 29.2% 34 70.8% 11.38 1.00 0.001 **
Pain
Lower 113 58.5% 80 41.5%
Higher 59 42.4% 80 57.6% 8.39 1.00 0.004 **
Other symptoms
Lower 156 57.6% 115 42.4%
Higher 15 25.4% 44 74.6% 20.05 1.00 <0.001 ***
Support network anxiety
Lower 114 87.7% 16 12.3%
Higher 57 28.4% 144 71.6% 111.29 1.00 <0.001 ***
Less ability to share
Lower 139 55.2% 113 44.8%
Higher 31 41.3% 44 58.7% 4.43 1.00 0.048 *
Reduced life-worth
Lower 155 56.8% 118 43.2%
Higher 8 18.6% 35 81.4% 21.67 1.00 <0.001 ***
Reduced self-esteem
Lower 142 65.7% 74 34.3%
Higher 24 23.1% 80 76.9% 51.18 1.00 <0.001 ***
Information needs
Lower 126 56.8% 96 43.2%
Higher 30 36.6% 52 63.4% 9.75 1.00 0.002 **
Practical needs
Lower 135 56.5% 104 43.5%
Higher 27 38.0% 44 62.0% 7.47 1.00 0.007 **
Time wasted
Lower 161 53.0% 143 47.0%
Higher 4 36.4% 7 63.6% 1.17 1.00 0.362
Lower Anxiety Higher Anxiety
 
Table 61: All patients attending the lung cancer clinic. Univariate analysis of factors across groups 
of higher and lower perceived support network anxiety. Percentages adjusted for missing data.  
*p<0.05, **p<0.01 and ***p<0.001  
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The significant factors identified by univariate analysis were younger age, time from 
diagnosis, PS, GP attendance, dyspnoea, cough, haemoptysis, pain, ‘other’ symptoms, 
personal anxiety, reduced ability to share, reduced life-worth, low self-esteem, 
information needs and practical needs. In addition to these factors, gender and presence 
of metastases were entered into a backwards logistic regression model. Again, GP 
attendance was excluded. The initial model included the factor of personal anxiety, and 
it was repeated excluding this factor. The results for both models are tabulated in Table 
62 and Table 63. 
b SE Wald df p value Odds Ratio Lower Upper
Metastases present .727 .369 3.890 1 .049 2.069 1.005 4.259
Performance status 0-1 9.518 2 .009
Performance status 2 .758 .410 3.418 1 .064 2.135 .955 4.771
Performance Status 3-4 1.260 .446 7.982 1 .005 3.525 1.471 8.446
Time from diagnosis >6 months -1.367 .452 9.153 1 .002 .255 .105 .618
Personal anxiety (higher) 2.909 .383 57.759 1 <0.001 18.342 8.662 38.839
Constant -.924 .250 13.700 1 <0.001 .397
95% CI for Odds Ratios
 
     R2=0.380 (Cox and Snell); 0.520 (Nagelkerke) Model Χ2=137.80, df=5, p<0.001 
     Hosmer-Lemeshow test: Χ2=3.318, df=6, p=0.768 
Table 62: Independent factors associated with higher support network anxiety identified through 
backwards logistic regression for all patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=137.80, df=5, p<0.001). Nagelkerke’s R2 of 0.520 indicated that around 52% of 
variance was explained by the model. Overall prediction success was 81.3% (81.3% for 
lower anxiety and 81.3% for higher anxiety). This compares to the null model overall 
prediction success of 63.27%. Each of the predictors in the final model was significant 
at the p<0.05 level. As such, higher levels of perceived anxiety in the support network 
in all patients attending the lung cancer clinic were independently associated with 
presence of metastases, reduced physical function (increased PS), shorter time from 
diagnosis and higher personal anxiety. There were no significant effects from the other 
variables, which were excluded from the final model. For a fixed PS, time from 
diagnosis and stage of disease (metastatic or not), patients who rated personal anxiety 
higher were 18.342 (95% CI 8.662-38.839) times more likely to perceive  higher levels 
of anxiety in their support group (i.e. anxiety which is moderate to overwhelming). 
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b SE Wald df p value Odds Ratio Lower Upper
Metastases present .875 .325 7.235 1 .007 2.399 1.268 4.538
Performance status 0-1 11.939 2 .003
Performance status 2 .526 .361 2.122 1 .145 1.692 .834 3.432
Performance Status 3-4 1.430 .420 11.581 1 .001 4.180 1.834 9.526
Haemoptysis (higher) 2.033 1.096 3.442 1 .064 7.636 .891 65.416
Low self-esteem 1.129 .372 9.234 1 .002 3.093 1.493 6.407
Time from diagnosis >6 months -1.365 .379 12.992 1 <0.001 .255 .122 .536
Constant -.244 .206 1.402 1 .236 .784  
R2=0.227 (Cox and Snell); 0.310 (Nagelkerke) Model Χ2=74.538, df=6, p<0.001 
Hosmer-Lemeshow  test: Χ2=4.823, df=8, p=0.776 
Table 63: Independent factors associated with higher support network anxiety identified through 
backwards logistic regression for all patients. Personal anxiety excluded. 
 
A test of the full model against constant only model was statistically significant (Model 
Χ2=74.54, df=6, p<0.001). Nagelkerke’s R2 of 0.310 indicated that around 31% of 
variance was explained by the model. Overall prediction success was 72.7% (64.5% for 
lower anxiety and 77.5% for higher anxiety). This compares to the null model overall 
prediction success of 63.0%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of perceived anxiety in the support network in 
all patients attending the lung cancer clinic were independently associated with presence 
of metastases, reduced physical function (increased PS), increased haemoptysis, shorter 
time from diagnosis and reduced self-esteem. There were no significant effects from the 
other variables, which were excluded from the final model. For a fixed PS, time from 
diagnosis, presence of higher levels of haemoptysis and stage of disease (metastatic or 
not), patients who rated reduced self-esteem were 3.093 (95% CI 1.493-6.4079) times 
more likely to perceive higher levels of anxiety in their support group. 
 
9.2.2 Anxiety in Newly Diagnosed Patients 
Personal anxiety felt (mean 1.93, median 2, range 0-4, SD 1.35) was reported to be low 
(0-1) in 41.8% (n=71/170) of newly diagnosed patients. Higher anxiety levels (2-4) 
were described by 91 of 170 patients (53.5%). Anxiety perceived in the support network 
(mean 2.63, SD 1.23, median 3, range 0-4) was reported to be low (0-1) by 22.4% 
(n=38/170) of patients and described as high (2-4) by 72.4% (n=123/170). Being able to 
share feelings (mean 0.75, , SD 1.23, median 0.00, range 0-4) was reported to be felt 
possible ‘as much as I want’ (0) or ‘most of the time’ (1) in 72.9% (n=124/170) of 
patients. 
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9.2.2.1 Personal Anxiety (Newly Diagnosed Patients) 
Personal anxiety was categorised as low (0-1) and high (2-4). Differences between the 
lower and higher anxiety patients were examined in relation to the factors listed in Table 
64. Statistical significance of any difference was assessed. 
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 39 48.8% 41 51.3%
Female 32 39.0% 50 61.0% 1.556 1 0.268
Age
<65 years 16 34.8% 30 65.2%
≥65 years 55 47.4% 61 52.6% 2.135 1 0.163
Histology
Clinical 17 45.9% 20 54.1%
NSCLC 44 43.6% 57 56.4%
SCLC 10 41.7% 14 58.3% 0.116 2 0.944
Stage NSCLC
1A 0 .0% 3 100.0%
1B 8 50.0% 8 50.0%
2A 5 45.5% 6 54.5%
2B 4 80.0% 1 20.0%
3A 4 25.0% 12 75.0%
3B 16 48.5% 17 51.5%
4 21 42.0% 29 58.0% 7.926 6 0.244
Stage SCLC
Limited 6 66.7% 3 33.3%
Extensive 4 26.7% 11 73.3% 3.703 1 0.054
Presence or absence of metastases
None 46 47.4% 51 52.6%
Metasases 25 38.5% 40 61.5% 1.1269 1 0.332
Time from diagnosis to POS
Within 3 weeks 43 38.7% 68 61.3%
3-6 weeks 28 54.9% 23 45.1%
6 weeks to 3 months 0 .0% 0 .0%
3-6 months 0 .0% 0 .0%
6-12 months 0 .0% 0 .0%
> 12 months 0 .0% 0 .0% na
Performance status rated by patients
0-1 44 51.2% 42 48.8%
2 14 43.8% 18 56.3%
3-4 13 29.5% 31 70.5% 5.525 2 0.63
Diagnosis PS, assessed by doctor
0-1 43 50.0% 43 50.0%
2 12 26.7% 33 73.3%
3-4 5 71.4% 2 28.6% 8.889 2 0.012 *
Active anti-cancer treatment
Yes 48 40.7% 70 59.3%
No 13 54.2% 11 45.8% 1.481 1 0.262
Deprivation
Dep Cat 1-5 35 43.2% 46 56.8%
Dep cat 6 or 7 36 45.6% 43 54.4% 0.09 1 0.784
Satisfaction score
0-4 36 47.4% 40 52.6%
5-8 1 50.0% 1 50.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 25 52.1% 23 47.9%
Yes 17 39.5% 26 60.5% 1.437 1 0.231
Dysnoea
No 15 51.7% 14 48.3%
Yes 56 42.1% 77 57.9% 0.90 1.00 0.410
Cough
No 20 55.6% 16 44.4%
Yes 50 40.0% 75 60.0% 2.75 1.00 0.127
Haemoptysis
No 60 45.8% 71 54.2%
Yes 10 33.3% 20 66.7% 1.54 1.00 0.229
Dysnoea
Lower 42 53.2% 37 46.8%
Higher 29 34.9% 54 65.1% 5.46 1.00 0.026 *
Cough
Lower 54 53.5% 47 46.5%
Higher 16 26.7% 44 73.3% 11.00 1.00 0.001 **
Haemoptysis
Lower 66 45.2% 80 54.8%
Higher 4 26.7% 11 73.3% 1.90 1.00 0.274
Pain
Lower 49 52.7% 44 47.3%
Higher 22 31.9% 47 68.1% 6.96 1.00 0.010 *
Other symptoms
Lower 65 49.2% 67 50.8%
Higher 6 20.7% 23 79.3% 7.86 1.00 0.007 **
Support network anxiety
Lower 34 89.5% 4 10.5%
Higher 36 29.3% 87 70.7% 42.82 1.00 <0.001 ***
Less ability to share
Lower 57 47.1% 64 52.9%
Higher 12 32.4% 25 67.6% 2.48 1.00 0.132
Reduced life-worth
Lower 62 47.7% 68 52.3%
Higher 4 18.2% 18 81.8% 6.67 1.00 0.011 **
Reduced self-esteem
Lower 56 53.8% 48 46.2%
Higher 12 23.5% 39 76.5% 12.77 1.00 0.001 **
Information needs
Lower 53 46.9% 60 53.1%
Higher 13 34.2% 25 65.8% 1.86 1.00 0.190
Practical needs
Lower 51 47.7% 56 52.3%
Higher 15 33.3% 30 66.7% 2.65 1.00 0.111
Time wasted
Lower 65 44.5% 81 55.5%
Higher 1 20.0% 4 80.0% 1.18 1.00 0.387
Lower Anxiety Higher Anxiety
 
Table 64: Newly diagnosed patients attending the lung cancer clinic. Univariate analysis of factors 
across groups of higher and lower anxiety. Percentages adjusted for missing data.  
*p<0.05, **p<0.01 and ***p<0.001 
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The significant factors identified by univariate analysis were younger age, time from 
diagnosis, doctor-rated PS at diagnosis, dyspnoea, cough, pain, ‘other’ symptoms, 
perceived anxiety in support network, reduced life-worth and low self-esteem. In 
addition to these factors, gender and presence of metastases were entered into a 
backwards logistic regression model. The initial model included the factor of perceived 
anxiety in the support network, and this was the strongest contributor to the model’s 
predictive power. As this perception may have been driven by personal anxiety, the 
model was repeated excluding this factor. The results of both models are tabulated 
below in Table 65 and Table 66. 
b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 (doctor rated) 4.849 2 .089
Performance status 2 (doctor rated) .612 .476 1.656 1 .198 1.844 .726 4.684
Performance Status 3-4 (doctor rated -2.377 1.467 2.624 1 .105 .093 .005 1.647
Family anxiety (higher) 2.488 .589 17.849 1 <0.001 12.042 3.796 38.198
Reduced life-worth 2.338 1.117 4.383 1 .036 10.363 1.161 92.500
Constant -2.023 .558 13.153 1 <0.001 .132
95% CI for Odds Ratios
 
        R2=0.308 (Cox and Snell); 0.413 (Nagelkerke) Model Χ2=47.549, df=4, p<0.001 
        Hosmer-Lemeshow test: Χ2=3.642, df=3, p=0.457 
Table 65: Independent factors associated with higher personal anxiety identified through 
backwards logistic regression for newly diagnosed patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=47.549, df=4, p<0.001). Nagelkerke’s R2 of 0.413 indicated that around 41% of 
variance was explained by the model. Overall prediction success was 76% (52.6% for 
lower anxiety and 94.4% for higher anxiety). This compares to the null model overall 
prediction success of 55.8%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of personal anxiety in newly diagnosed patients 
attending the lung cancer clinic were independently associated with PS at diagnosis 
(doctor-rated), perception of increased support network anxiety and reduced life-worth. 
There were no significant effects from the other variables, which were excluded from 
the final model. For a fixed PS and level of life-worth, patients who perceived increased 
anxiety in their support network were 12.042 (95% CI 3.796-38.198) times more likely 
to have higher levels of personal anxiety (i.e. anxiety which is moderate to 
overwhelming). 
 
The regression was repeated without including the factor of perceived support network 
anxiety.  
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b SE Wald df p value Odds Ratio Lower Upper
Cough (higher) .965 .385 6.273 1 .012 2.625 1.233 5.584
Low self-esteem 1.182 .396 8.902 1 .003 3.261 1.500 7.090
Constant -.415 .232 3.192 1 .074 .661  
      R2=0.121 (Cox and Snell); 0.163 (Nagelkerke) Model Χ2=19.46, df=2, p<0.001 
      Hosmer-Lemeshow test: Χ2=0.403, df=2, p=0.817 
Table 66: Independent factors associated with higher personal anxiety identified through 
backwards logistic regression for newly diagnosed patients, excluding perceived support network 
anxiety. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=19.46, df=2, p<0.001). Nagelkerke’s R2 of 0.286 indicated that around 29% of 
variance was explained by the model. Overall prediction success was 65.3(64.6% for 
lower anxiety and 65.9% for higher anxiety). This compares to the null model overall 
prediction success of 56.7%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of personal anxiety in newly diagnosed patients 
attending the lung cancer clinic were independently associated with higher cough and 
lower self-esteem. There were no significant effects from the other variables, which 
were excluded from the final model. For a fixed level of cough, patients with lower self-
esteem were 3.261 (95% CI 1.5-7.090) times more likely to have higher levels of 
personal anxiety. 
 
9.2.2.2 Anxiety Perceived in the Support Network (Newly Diagnosed 
Patients) 
Anxiety perceived by the patient in their support group was categorised as low (never 
anxious to sometimes anxious) and high (most of the time to preoccupied). The analysis 
was repeated to assess differences between these categories (Table 67). 
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 21 26.3% 59 73.8%
Female 17 21.0% 64 79.0% 0.618 1 0.463
Age
<65 years 7 15.2% 39 84.8%
≥65 years 31 27.0% 84 73.0% 2.511 1 0.15
Histology
Clinical 14 37.8% 23 62.2%
NSCLC 19 19.0% 81 81.0%
SCLC 5 20.8% 19 79.2% 5.435 2 0.066
Stage NSCLC
1A 1 33.3% 2 66.7%
1B 4 25.0% 12 75.0%
2A 3 27.3% 8 72.7%
2B 2 40.0% 3 60.0%
3A 5 31.3% 11 68.7%
3B 8 25.0% 24 75.0%
4 8 16.0% 42 84.0% 3.18 6 0.786
Stage SCLC
Limited 3 33.3% 6 66.7%
Extensive 2 13.3% 13 86.7% 1.364 1 0.326
Presence or absence of metastases
None 28 29.2% 68 70.8%
Metasases 10 15.4% 55 84.6% 4.083 1 0.058
Time from diagnosis to POS
Within 3 weeks 19 17.3% 91 82.7%
3-6 weeks 19 37.3% 32 62.7%
6 weeks to 3 months 0 .0% 0 .0%
3-6 months 0 .0% 0 .0%
6-12 months 0 .0% 0 .0%
> 12 months 0 .0% 0 .0% na
Performance status rated by patients
0-1 27 31.4% 59 68.6%
2 6 18.8% 26 81.3%
3-4 5 11.6% 38 88.4% 6.734 2 0.034 **
Diagnosis PS, assessed by doctor
0-1 25 29.1% 61 70.9%
2 6 13.3% 39 86.7%
3-4 3 42.9% 4 57.1% 5.285 2 0.063
Active anti-cancer treatment
Yes 23 19.7% 94 80.3%
No 9 37.5% 15 62.5% 3.613 1 0.066
Deprivation
Dep Cat 1-5 15 18.8% 65 81.3%
Dep cat 6 or 7 23 29.1% 56 70.9% 2.347 1 0.14
Albumin at diagnosis
<35 14 24.1% 44 75.9%
≥35 22 22.9% 74 77.1% 0.03 1 0.847
CRP at diagnosis
<10 19 28.8% 47 71.2%
≥10 19 20.0% 76 80.0% 1.668 1 0.257
Glasgow Prognostic Score
CRP <10 and Albumin >35 15 27.8% 39 72.2%
CRP >10 or Albumin <35 9 18.8% 39 81.3%
CRP >10 and Albumin <35 12 24.0% 38 76.0% 1.15 2 0.563
Satisfaction score
0-4 20 26.3% 56 73.7%
5-8 0 .0% 2 100.0%
9-12 0 .0% 0 .0% 0.708 2 na
GP attendance between clinics
No 13 27.1% 35 72.9%
Yes 9 21.4% 33 78.6% 0.388 1 0.626
Dysnoea
No 10 34.5% 19 65.5%
Yes 28 21.2% 104 78.8% 2.32 1.00 0.149
Cough
No 12 33.3% 24 66.7%
Yes 26 20.8% 99 79.2% 2.44 1.00 0.125
Haemoptysis
No 34 26.0% 97 74.0%
Yes 3 10.3% 26 89.7% 3.25 1.00 0.089
Dysnoea
Lower 24 30.8% 54 69.2%
Higher 14 16.9% 69 83.1% 4.31 1.00 0.043 *
Cough
Lower 32 31.7% 69 68.3%
Higher 6 10.0% 54 90.0% 9.81 1.00 0.002 **
Haemoptysis
Lower 37 25.3% 109 74.7%
Higher 0 .0% 14 100.0% 4.62 1.00 0.041 *
Pain
Lower 30 32.6% 62 67.4%
Higher 8 11.6% 61 88.4% 9.66 1.00 0.002 **
Other symptoms
Lower 35 26.7% 96 73.3%
Higher 3 10.3% 26 89.7% 3.52 1.00 0.089
Personal anxiety
Lower 34 48.6% 36 51.4%
Higher 4 4.4% 87 95.6% 42.82 1.00 <0.001 ***
Less ability to share
Lower 29 24.2% 91 75.8%
Higher 7 18.9% 30 81.1% 0.44 1.00 0.656
Reduced life-worth
Lower 33 25.6% 96 74.4%
Higher 1 4.5% 21 95.5% 4.77 1.00 0.028 **
Reduced self-esteem
Lower 31 30.1% 72 69.9%
Higher 4 7.8% 47 92.2% 9.62 1.00 0.002 **
Information needs
Lower 29 25.9% 83 74.1%
Higher 5 13.2% 33 86.8% 2.53 1.00 0.121
Practical needs
Lower 29 27.1% 78 72.9%
Higher 5 11.4% 39 88.6% 4.43 1.00 0.052
Time wasted
Lower 33 22.8% 112 77.2%
Higher 1 20.0% 4 80.0% 0.21 1.00 1.000
Lower Anxiety Higher Anxiety
 
Table 67: Newly diagnosed patients attending the lung cancer clinic. Univariate analysis of factors 
across groups of higher and lower perceived support network anxiety. Percentages adjusted for 
missing data. *p<0.05, **p<0.01 and ***p<0.001 
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The significant factors identified by univariate analysis were time from diagnosis, PS, 
dyspnoea, cough, haemoptysis, pain, personal anxiety, reduced life-worth and low self-
esteem. In addition to these factors, gender and presence of metastases were entered into 
a backwards logistic regression model. Initial modelling containing degree of 
haemoptysis could not be achieved due to the large standard error resulting from only a 
few ‘higher’ haemoptysis cases being present. Therefore, the model was repeated with 
presence or absence of haemoptysis as the variable entered. The initial model included 
the factor of personal anxiety, and the model was repeated excluding this factor. The 
results of both models are tabulated below in Table 68 and Table 69. 
b SE Wald df p value Odds Ratio Lower Upper
Pain (higher) 1.118 .512 4.762 1 .029 3.057 1.121 8.341
Personal anxiety (higher) 2.774 .576 23.219 1 <0.001 16.016 5.183 49.489
Constant -.188 .294 .406 1 .524 .829
95% CI for Odds Ratios
 
R2=0.254 (Cox and Snell); 0.387 (Nagelkerke) Model Χ2=44.151, df=2, p<0.001 
Hosmer-Lemeshow test: Χ2=0.006, df=2, p=0.997 
Table 68: Independent factors associated with higher support network anxiety identified through 
backwards logistic regression for newly diagnosed patients.  
 
A test of the full model against constant only model was statistically significant (model 
Χ2=44.151, df=2, p<0.001). Nagelkerke’s R2 of 0.417 indicated that around 42% of 
variance was explained by the model. Overall prediction success was 80.1 (70.6% for 
lower anxiety and 82.9% for higher anxiety). This compares to the null model overall 
prediction success of 77.5%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of perceived anxiety in the support network in 
newly diagnosed patients were independently associated with increased pain and 
increased personal anxiety. There were no significant effects from the other variables, 
which were excluded from the final model. For a fixed level of pain, patients who rated 
higher personal anxiety were 16.016 (95% CI 5.183-49.489) times more likely to 
perceive higher levels of anxiety in their support group (i.e. anxiety which is moderate 
to overwhelming). 
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b SE Wald df p value Odds Ratio Lower Upper
Cough (higher) 1.169 .538 4.723 1 .030 3.219 1.122 9.238
Pain (higher) 1.047 .482 4.712 1 .030 2.850 1.107 7.337
Low self-esteem 1.281 .584 4.814 1 .028 3.600 1.146 11.307
Constant .266 .272 .955 1 .328 1.305  
R2=0.140 (Cox and Snell); 0.213 (Nagelkerke) Model Χ2=22.693, df=3, p<0.001 
Hosmer-Lemeshow test: Χ2=5.204, df=6, p=0.518 
Table 69: Independent factors associated with higher support network anxiety identified through 
backwards logistic regression for newly diagnosed patients. Personal anxiety excluded. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=22.69, df=3, p<0.001). Nagelkerke’s R2 of 0.213 indicated that around 21% of 
variance was explained by the model. Overall prediction success was 77.5% (0% for 
lower anxiety and 100% for higher anxiety). This compares to the null model overall 
prediction success of 77.5%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of perceived anxiety in the support network of 
newly diagnosed patients were independently associated with higher cough, higher pain 
and reduced self-esteem. There were no significant effects from the other variables, 
which were excluded from the final model. For a fixed level of cough and pain, patients 
with reduced self-esteem were 3.6 (95% CI 1.46-11.307) times more likely to perceive 
higher levels of anxiety in their support group. 
 
9.2.3 Anxiety in Patients in the Last Three Months of Life 
Personal anxiety felt (mean 1.79, median 1, range 0-4, SD 1.34) was reported to be low 
(0-1) in 41.3% (n=50/121) of patients within the last three months of life. Higher 
anxiety levels (2-4) were described by 51.2% (n=63/121) of patients. Anxiety perceived 
in the support network (mean 2.40, SD 1.35, median 3, range 0-4) was reported to be 
low (0-1) by 43.0% (n=52/121) of patients and described as high (2-4) by 52.1% 
(n=62/121). Being able to share feelings (mean 0.91, SD 1.23, median 0, range 0-4) was 
reported to be felt possible ‘as much as I want’ (0) or ‘most of the time’ (1) in 68.6% 
(n=83/170) of patients. 
 
9.2.3.1 Personal Anxiety (Patients in the Last Three Months of Life) 
Personal anxiety was categorised as low (0-1) and high (2-4). Differences between the 
lower and higher anxiety patients were examined in relation to the factors listed in Table 
70. Statistical significance of any difference was assessed.  
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 27 45.0% 33 55.0%
Female 23 43.4% 30 56.6% 0.03 1 1.000
Age
<65 years 10 35.7% 18 64.3%
≥65 years 40 47.1% 45 52.9% 1.10 1 0.381
Histology
Clinical 9 56.3% 7 43.8%
NSCLC 32 42.1% 44 57.9%
SCLC 9 42.9% 12 57.1% 1.09 2 0.579
Stage NSCLC
1A 0 .0% 1 100.0%
1B 3 42.9% 4 57.1%
2A 5 83.3% 1 16.7%
2B 1 50.0% 1 50.0%
3A 4 66.7% 2 33.3%
3B 10 35.7% 18 64.3%
4 17 41.5% 24 58.5% 6.73 6 0.347
Stage SCLC
Limited 2 33.3% 4 66.7%
Extensive 7 46.7% 8 53.3% 0.31 1 0.577
Presence or absence of metastases
None 26 45.6% 31 54.4%
Metasases 24 42.9% 32 57.1% 0.87 1 0.850
Time from diagnosis to POS
Within 3 weeks 7 25.0% 21 75.0%
3-6 weeks 3 50.0% 3 50.0%
6 weeks to 3 months 10 55.6% 8 44.4%
3-6 months 8 47.1% 9 52.9%
6-12 months 13 52.0% 12 48.0%
> 12 months 9 47.4% 10 52.6% 5.96 5 0.310
Performance status rated by patients
0-1 19 59.4% 13 40.6%
2 10 34.5% 19 65.5%
3-4 21 40.4% 31 59.6% 4.40 2 0.111
Diagnosis PS, assessed by doctor
0-1 27 45.0% 33 55.0%
2 16 43.2% 21 56.8%
3-4 5 71.4% 2 28.6% 1.96 2 0.370
Active anti-cancer treatment
Yes 34 41.5% 48 58.5%
No 12 60.0% 8 40.0% 2.23 1 0.210
Deprivation
Dep Cat 1-5 25 42.4% 34 57.6%
Dep cat 6 or 7 25 46.3% 29 53.7% 0.18 1 0.708
Satisfaction score
0-4 25 47.2% 28 52.8%
5-8 1 100.0% 0 .0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 10 45.5% 12 54.5%
Yes 17 44.7% 21 55.3% 0.00 1 1.000
Dysnoea
No 12 66.7% 6 33.3%
Yes 38 40.0% 57 60.0% 4.36 1 0.042 *
Cough
No 15 46.9% 17 53.1%
Yes 35 43.2% 46 56.8% 0.13 1 0.834
Haemoptysis
No 44 46.8% 50 53.2%
Yes 6 31.6% 13 68.4% 1.49 1 0.312
Dysnoea
Lower 23 57.5% 17 42.5%
Higher 27 37.0% 46 63.0% 4.41 1 0.048 *
Cough
Lower 35 55.6% 28 44.4%
Higher 15 30.0% 35 70.0% 7.38 1 0.008 **
Haemoptysis
Lower 47 44.3% 59 55.7%
Higher 3 42.9% 4 57.1% 0.01 1 1.000
Pain
Lower 26 55.3% 21 44.7%
Higher 24 36.4% 42 63.6% 4.00 1 0.056
Other symptoms
Lower 38 51.4% 36 48.6%
Higher 12 30.8% 27 69.2% 4.39 1 0.470
Support network anxiety
Lower 27 90.0% 3 10.0%
Higher 23 27.7% 60 72.3% 34.66 1 <0.001 ***
Less ability to share
Lower 36 45.0% 44 55.0%
Higher 13 40.6% 19 59.4% 0.18 1 0.833
Reduced life-worth
Lower 45 50.0% 45 50.0%
Higher 4 19.0% 17 81.0% 6.62 1 0.014 *
Reduced self-esteem
Lower 40 59.7% 27 40.3%
Higher 9 20.0% 36 80.0% 17.24 1 <0.001 ***
Information needs
Lower 38 46.9% 43 53.1%
Higher 10 33.3% 20 66.7% 1.65 1 0.281
Practical needs
Lower 39 49.4% 40 50.6%
Higher 10 31.3% 22 68.8% 3.03 1 0.095
Time wasted
Lower 49 45.4% 59 54.6%
Higher 0 .0% 3 100.0% 2.44 1 0.254
Lower Anxiety Higher Anxiety
 
Table 70: Patients within three months of death. Univariate analysis of factors across groups of 
higher and lower personal anxiety. Percentages are adjusted for missing data.   
*p<0.05, **p<0.01 and ***p<0.001  
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The significant factors identified by univariate analysis were dyspnoea, cough, ‘other’ 
symptoms, perceived anxiety in support network, reduced life-worth and low self-
esteem. In addition to these factors, gender, age and presence of metastases were 
entered into a backwards logistic regression model. The initial model included the factor 
of perceived anxiety in the support network, and the model was repeated excluding this 
factor. The results for both models are tabulated below in Table 71 and Table 72. 
b SE Wald df p value Odds Ratio Lower Upper
Family anxiety (higher) 2.882 .673 18.317 1 <0.001 17.851 4.769 66.812
Low self-esteem 1.362 .509 7.174 1 .007 3.904 1.441 10.577
Constant -2.478 .637 15.136 1 <0.001 .084
95% CI for Odds Ratios
 
R2=0.338 (Cox and Snell); 0.453 (Nagelkerke) Model Χ2=45.773, df=2, p<0.001 
Hosmer-Lemeshow test: Χ2=0.000, df=2, p=1.000 
Table 71: Independent factors associated with higher personal anxiety identified through 
backwards logistic regression for patients who died within three months. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=45.773, df=2, p<0.001). Nagelkerke’s R2 of 0.453 indicated that around 45% of 
variance was explained by the model. Overall prediction success was 77.5% (55.2% for 
lower anxiety and 95.2% for higher anxiety). This compares to the null model overall 
prediction success of 55.9%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of personal anxiety in patients who died within 
three months were independently associated with perception of increased support 
network anxiety and reduced self-esteem. There were no significant effects from the 
other variables, which were excluded from the final model. For a fixed level of self-
esteem, patients who perceived increased anxiety in their support network were 17.851 
(95% CI 4.796-66.812) times more likely to have higher levels of personal anxiety (i.e. 
anxiety which is moderate to overwhelming). 
 
The regression was repeated without including the factor of perceived support network 
anxiety.  
b SE Wald df p value Odds Ratio Lower Upper
Low self-esteem 1.817 .450 16.317 1 <0.001 6.154 2.548 14.861
Constant -.431 .252 2.924 1 .087 .650  
R2=0.156 (Cox and Snell); 0.209 (Nagelkerke) Model Χ2=18.813, df=1, p<0.001 
Hosmer-Lemeshow test: Χ2=0.000, df=0 
Table 72: Independent factors associated with higher personal anxiety identified through 
backwards logistic regression for patients who died within three months, excluding perceived 
support network anxiety. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=18.813, df=1, p<0.001). Nagelkerke’s R2 of 0.286 indicated that around 29% of 
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variance was explained by the model. Overall prediction success was 68.5 (81.6% for 
lower anxiety and 58.1% for higher anxiety). This compares to the null model overall 
prediction success of 56.7%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of personal anxiety in patients who died within 
three months were independently associated with reduced self-esteem. There were no 
significant effects from the other variables which were excluded from the final model. 
Patients with lower self-esteem were 6.154 (95% CI 2.545-14.861) times more likely to 
have higher levels of personal anxiety. 
 
9.2.3.2 Anxiety Perceived in the Support Network (Patients in the 
Last Three Months of Life) 
Anxiety perceived by the patient in their support group was categorised as low (never 
anxious to sometimes anxious) and high (most of the time to preoccupied). The analysis 
was repeated to assess differences between these categories (Table 73). 
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 17 27.9% 44 72.1%
Female 14 26.4% 39 73.6% 0.3 1 1
Age
<65 years 8 28.6% 20 71.4%
≥65 years 23 26.7% 63 73.3% 0.36 1 1
Histology
Clinical 6 35.3% 11 64.7%
NSCLC 18 23.7% 58 76.3%
SCLC 7 33.3% 14 66.7% 1.436 2 0.488
Stage NSCLC
1A 0 .0% 1 100.0%
1B 2 28.6% 5 71.4%
2A 1 16.7% 5 83.3%
2B 1 50.0% 1 50.0%
3A 2 33.3% 4 66.7%
3B 7 24.1% 22 75.9%
4 10 24.4% 31 75.6% 1.512 6 0.959
Stage SCLC
Limited 1 16.7% 5 83.3%
Extensive 6 40.0% 9 60.0% 1.05 1 0.306
Presence or absence of metastases
None 15 25.9% 43 74.1%
Metasases 16 28.6% 40 71.4% 0.106 1 0.834
Time from diagnosis to POS
Within 3 weeks 3 10.7% 25 89.3%
3-6 weeks 3 50.0% 3 50.0%
6 weeks to 3 months 5 27.8% 13 72.2%
3-6 months 6 33.3% 12 66.7%
6-12 months 6 24.0% 19 76.0%
> 12 months 8 42.1% 11 57.9% 8.025 5 0.155
Performance status rated by patients
0-1 15 45.5% 18 54.5%
2 5 17.2% 24 82.8%
3-4 11 21.2% 41 78.8% 7.967 2 0.019 *
Diagnosis PS, assessed by doctor
0-1 16 26.7% 44 73.3%
2 11 28.9% 27 71.1%
3-4 4 57.1% 3 42.9% 2.808 2 0.246
Active anti-cancer treatment
Yes 21 25.3% 62 74.7%
No 7 35.0% 13 65.0% 0.766 1 0.408
Deprivation
Dep Cat 1-5 14 23.3% 46 76.7%
Dep cat 6 or 7 17 31.5% 37 68.5% 0.953 1 0.401
Satisfaction score
0-4 19 35.8% 34 64.2%
5-8 0 .0% 1 100.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 8 36.4% 14 63.6%
Yes 12 31.6% 26 68.4% 0.144 1 0.78
Dysnoea
No 7 38.9% 11 61.1%
Yes 24 25.0% 72 75.0% 1.48 1.00 0.253
Cough
No 9 28.1% 23 71.9%
Yes 21 25.9% 60 74.1% 0.57 1.00 0.817
Haemoptysis
No 26 27.7% 68 72.3%
Yes 4 21.1% 15 78.9% 0.35 1.00 0.777
Dysnoea
Lower 15 36.6% 26 63.4%
Higher 16 21.9% 57 78.1% 2.85 1.00 0.124
Cough
Lower 23 36.5% 40 63.5%
Higher 7 14.0% 43 86.0% 7.24 1.00 0.010 *
Haemoptysis
Lower 30 28.3% 76 71.7%
Higher 0 .0% 7 100.0% 2.70 1.00 0.187
Pain
Lower 18 37.5% 30 62.5%
Higher 13 19.7% 53 80.3% 4.45 1.00 0.054
Other symptoms
Lower 25 33.8% 49 66.2%
Higher 5 12.8% 34 87.2% 5.58 1.00 0.024 *
Personal anxiety
Lower 27 54.0% 23 46.0%
Higher 3 4.8% 60 95.2% 34.66 1.00 <0.001 ***
Less ability to share
Lower 24 29.6% 57 70.4%
Higher 7 21.9% 25 78.1% 0.69 1.00 0.487
Reduced life-worth
Lower 27 29.7% 64 70.3%
Higher 4 19.0% 17 81.0% 0.96 1.00 0.423
Reduced self-esteem
Lower 27 39.7% 41 60.3%
Higher 4 8.9% 41 91.1% 12.92 1.00 <0.001 ***
Information needs
Lower 28 34.1% 54 65.9%
Higher 2 6.7% 28 93.3% 8.46 1.00 0.003 **
Practical needs
Lower 22 27.5% 58 72.5%
Higher 9 28.1% 23 71.9% 0.00 1.00 1.000
Time wasted
Lower 31 28.4% 78 71.6%
Higher 0 .0% 3 100.0% 1.18 1.00 0.559
Lower Anxiety Higher Anxiety
 
Table 73: Patients within three months of death. Univariate analysis of factors across groups of 
higher and lower perceived support network anxiety. Percentages adjusted for missing data.  
*p<0.05, **p<0.01 and ***p<0.001 
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The significant factors identified by univariate analysis were PS, cough, ‘other’ 
symptoms, personal anxiety, low self-esteem and information needs. In addition to these 
factors, gender and presence of metastases were entered into a backwards logistic 
regression model. The initial model included the factor of personal anxiety, and the 
model was repeated excluding this factor. The results of both models are tabulated 
below (Table 74 and Table 75). 
b SE Wald df p value Odds Ratio Lower Upper
Personal anxiety (higher) 3.215 .676 22.594 1 <0.001 24.898 6.614 93.724
Information needs (higher) 2.060 .834 6.109 1 .013 7.848 1.532 40.204
Constant -.559 .334 2.796 1 .095 .572
95% CI for Odds Ratios
R2=0.335 (Cox and Snell); 0.491 (Nagelkerke) Model Χ2=45.333, df=2, p<0.001 
Hosmer-Lemeshow test: Χ2=0.216, df=2, p=0.898 
Table 74: Independent factors associated with higher support network anxiety identified through 
backwards logistic regression for patients who died within three months. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=45.333, df=2, p<0.001). Nagelkerke’s R2 of 0.491 indicated that around 49% of 
variance was explained by the model. Overall prediction success was 82.9% (82.8% for 
lower anxiety and 82.9% for higher anxiety). This compares to the null model overall 
prediction success of 73.9%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of perceived anxiety in the support network in 
patients who died within three months were independently associated with increased 
personal anxiety and increased information needs. There were no significant effects 
from the other variables which were excluded from the final model. For a fixed level of 
information need, patients who rate higher personal anxiety were 24.898 (95% CI 
6.614-93.724) times more likely to perceive higher levels of anxiety in their support 
group (i.e. anxiety which is moderate to overwhelming). 
 
b SE Wald df p value Odds Ratio Lower Upper
Other symptoms (higher) 1.097 .578 3.604 1 .058 2.996 .965 9.303
Low self-esteem 1.575 .605 6.787 1 .009 4.833 1.477 15.812
Information needs (higher) 1.901 .793 5.741 1 .017 6.692 1.413 31.691
Constant -.074 .311 .057 1 .811 .928
R2=0.198 (Cox and Snell); 0.290 (Nagelkerke) Model Χ2=24.464, df=3, p<0.001 
Hosmer-Lemeshow test: Χ2=9.095, df=4, p=0.059 
Table 75: Independent factors associated with higher support network anxiety identified through 
backwards logistic regression for patients who died within three months. Personal anxiety was 
excluded. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=24.464, df=3, p<0.001). Nagelkerke’s R2 of 0.213 indicated that around 21% of 
variance was explained by the model. Overall prediction success was 79.3% (75.9% for 
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lower anxiety and 80.5% for higher anxiety). This compares to the null model overall 
prediction success of 73.9%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of perceived anxiety in the support network of 
patients within three months of death were independently associated with increased 
information needs, ‘other’ symptoms and reduced self-esteem. There were no 
significant effects from the other variables which were excluded from the final model. 
For a fixed level of information need and ‘other’symptoms, patients with reduced self-
esteem were 4.833 (95% CI 1.477-16.812) times more likely to perceive higher levels 
of anxiety in their support group. 
 
9.3 Discussion 
The current study demonstrates the high prevalence within the Stobhill lung cancer 
clinic of anxiety in both patients themselves and as perceived in the support network. 
There is a strong relationship between these factors. Furthermore, reduced self-esteem is 
a strong predictor of increased anxiety. Other physical and psychosocial factors 
contribute at different stages within the lung cancer journey. 
 
Anxiety is a common and normal response to a diagnosis of cancer.342 It can become 
maladaptive for some patients, impacting on quality of life, function and symptom 
burden. Maladaptive anxiety is characterised as being persistent, intrusive and 
disproportionate to the stimulus. Assessing anxiety within the context of a real and 
persistent but dynamic threat such as cancer is a challenge.2, 342, 350, 370-372 
 
Lung cancer is a serious diagnosis that often heralds high symptom burden, decline in 
physical health and short survival. Patients diagnosed with lung cancer may not have 
their supportive care needs fully identified or met.12, 104, 157, 281, 379 It has been recognised 
that patients deal with illness in the context of a social environment and that this may 
positively or negatively influence their ability to cope.302, 378 
 
The concept of symptom distress, encompassing symptom occurrence, intensity and 
impact on patients, is gaining ground.121 Congruence between patient perception of 
symptom distress and that of their support network or professional carers may also 
influence their ability to cope with and discuss their illness.164, 169 
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9.3.1 Anxiety 
This study confirms that anxiety is a significant issue within the lung cancer population. 
Around 46% of patients within the lung cancer clinic experienced moderate to 
overwhelming personal anxiety. Over half of these patients felt anxious about their 
illness ‘most of the time’ or were ‘completely preoccupied’. This is consistent with 
findings of moderate to overwhelming anxiety ranging between 10-45% in other lung 
cancer studies.342, 379, 380 Sanders et al216 found that around 50% of lung cancer patients 
reported anxiety as a troubling issue. Furthermore, they identified that half of the 
patients were interested in receiving psychological support through at least one service. 
Steinberg et al160 described that 22% of newly diagnosed lung cancer patients 
experience ‘nervousness’ as part of clinically relevant ‘distress’. In the current study, 
anxiety was a significant issue from the point of diagnosis until the end of life. Personal 
anxiety was more prevalent in the newly diagnosed patients and in those within the last 
three months of life than in the general clinic population. Fifty three percent of newly 
diagnosed patients reported moderate to overwhelming anxiety and 52.1% of patients 
reported the same within the last three months of life. This is in keeping with the 
qualitative study by Murray et al180 which identified peaks of psychological distress at 
diagnosis, discharge and points of recurrence or progression in lung cancer. Particular 
attention should be given to these identified junctures in the lung cancer journey to 
ensure that suitable support is provided for those with distressing personal anxiety.  
 
The affects of anxiety and depression on quality of life at the time of diagnosis have 
also been described by Montazeri et al.342 They describe potential anxiety issues 
identified by the Hospital Anxiety and Depression Scale in 6% of lung cancer patients 
during the investigation phase; this increased to 11% at follow-up later in their illness. 
Depression was potentially an issue in 11% at diagnosis, increasing to 22% at follow-
up. The authors also noted that global quality of life (measured by EORTC QLQ-C30) 
was significantly reduced in those with increased anxiety or depression. In the current 
study, time from diagnosis (i.e. greater versus less than six months from diagnosis) was 
a significant factor in predicting higher personal anxiety; those surviving greater than 
six months were less likely to express higher personal anxiety.  
 
9.3.2 Anxiety, Age, Gender, Stage, Deprivation and Histology 
Anxiety in lung cancer patients has been previously described to be higher in females, 
younger patients and those with more advanced stage disease.2 However, these findings 
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have not been consistently described, and opposing findings have also been reported.2 
In the current study, no relationship was found between either personal anxiety or 
perceived support network anxiety and gender. In univariate analysis, younger age was 
found to be associated with higher personal anxiety and higher perceived support 
network anxiety in the general clinic population and in newly diagnosed patients. Using 
logistic regression, age was not a significant independent predictor of anxiety in any of 
the clinical groupings. Previous studies have found increased distress relating to stage of 
disease, whereas others reported no difference across stage of disease.2 Given the likely 
dynamic nature of anxiety in lung cancer,180 it is possible to understand how conflicting 
results can arise.  
 
In the current study, no relationship was found between the presence of metastatic 
disease and personal anxiety (using both univariate and multivariate analyses). The 
presence of metastases did influence the perception of higher support network anxiety in 
the general clinic population but not at diagnosis or at the end of life. Histology was not 
a significant factor in any of the analyses. Deprivation level also did not influence 
anxiety levels.  
 
9.3.3 Personal Anxiety and Perceived Support Network 
Anxiety 
As a patient’s own anxiety increased, they also perceived increased anxiety within their 
own support network.381 It is of note that patients in this study perceived higher levels 
of anxiety in their support network than the level of personal anxiety they described. 
Previous studies utilising POS have also found this to be the case.147, 218-220 The 
perception of increased anxiety within the support network was the strongest predictor 
of higher personal anxiety in each of the clinical groupings (Table 59, Table 65 and 
Table 71). A reciprocal relationship was observed, with personal anxiety being the 
strongest predictor of increased support network anxiety (Table 62, Table 68 and Table 
74). This congruence of psycho-emotional response may influence the support felt by 
the patient and their willingness to discuss their illness or feelings.382 
 
In their review article, Pitceathly and Macguire383 outlined the reasons for increased 
distress in carers and noted a well-documented correlation between the psychological 
adjustment of couples irrespective of cancer type or stage. This relationship held true 
whether or not the significant other was a spouse. It could be hypothesised that patients 
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who feel support network anxiety that mirrors their personal anxiety demonstrate 
recognition and understanding. Other patients may wish to withhold their own worries 
in an attempt to protect the significant other.384 
 
A patient’s support network is important in aiding them to cope and face their cancer 
diagnosis.12, 384 The concept of caring for the support network has been tested for 
feasibility348, 377 and purpose in the lung cancer setting.385 In the current study, the 
majority of patients felt that they were able to share how they were feeling as much as 
they wanted or most of the time, irrespective of the phase of lung cancer journey. 
However, a sizable minority of patients (10.2%) felt only occasionally able to share or 
not able to share at all. Reduced ability to share was associated with higher personal 
anxiety and support network anxiety in univariate analysis in the general clinic. 
Increased psychosocial distress may be associated with reduced support or social 
functioning in lung cancer.2 In the current study, eight patients in the general clinic 
population described higher anxiety and also felt unable to share their feelings with 
anyone at all. Although this is a relatively small number of patients, it is important to 
identify psychosocial distress in individuals who have such low levels of support. Early 
identification of patients with low levels of perceived support may be important to allow 
targeted supportive care measures to meet this deficit in a timely fashion. This may help 
prevent the development of psychosocial distress or aid the treatment of anxiety or other 
psychological issues. 
 
9.3.4 Anxiety and Self-Worth 
The univariate analyses of personal anxiety (Table 58, Table 64 and Table 70) in each 
clinical grouping confirm previous studies (including a published interim analysis from 
the current study;381 see Appendix 9) that there is a strong relationship between anxiety 
and depression or reduced self-worth (‘have you felt your life-worthwhile?’ and ‘have 
you felt good about yourself?’).379, 381, 386 This relationship is observed for perceived 
anxiety in the support network for both reduced self-worth and reduced life-worth in 
each clinical grouping except the last three months of life group (reduced life-worth not 
significant). Logistic regression identified low self-esteem (‘have you felt good about 
yourself?’) as a major predictor of high personal anxiety and increased perceived 
anxiety in the support network in each of the clinical groupings.  
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Self-esteem can be defined as ‘the degree to which an individual holds attitudes of 
acceptance or rejection towards themselves’.387 There is a well documented relationship 
between anxiety and self-esteem in non-cancer and general population studies.387-389 
The relationship between self-esteem and anxiety in the cancer setting has also been 
explored.390, 391 In both cancer and non-cancer settings, it remains unclear whether low 
self-esteem leads to increased anxiety or whether increased anxiety leads to reduced 
self-worth.387 However, both anxiety and reduced self-esteem can be addressed through 
well-established psychotherapeutic methods.371, 392 Thus, given the strong relationship 
identified between anxiety and reduced self-esteem in the current study, identification of 
either problem should prompt further evaluation to assess the presence of the second 
unmet need. 
 
9.3.5 Anxiety, Symptoms and Performance Status 
Increased patient anxiety has been described in advanced cancer when symptom burden 
is high.2 Univariate analysis confirmed this for specific physical symptoms of dyspnoea, 
cough, haemoptysis, pain and ‘other’ symptoms in the general clinic population (Table 
58). Furthermore, worse patient-rated PS was also associated with higher personal and 
support network anxiety. In newly diagnosed patients, the main physical variables 
associated with increased anxiety were dyspnoea, cough, pain and ‘other’ symptoms but 
not patient-rated PS (Table 64). In the last three months of life, the only physical 
symptoms related to increased anxiety identified were dyspnoea and cough (Table 70). 
On logistic regression, no physical factors predicted increased personal anxiety at the 
end of life. In newly diagnosed patients and in the general clinic, reduced performance 
status and cough were the major physical contributors to the models.  
 
Cough may be underrated by carers and healthcare workers as a cause of distress.168, 176 
In the Lobchuk et al168 study of congruence between symptom distress rated by lung 
cancer patients and their carers, cough was rated as the second most distressing 
symptom by patients (fatigue was most distressing) but only the fourth most distressing 
symptom by carers (below fatigue, psychological outlook and insomnia). However, 
other studies have reported the opposite finding: carers and healthcare professionals 
rated cough as more distressing than the patient.169 Increased support network anxiety 
was associated with pain and cough in newly diagnosed patients, ‘other’ symptoms at 
the end of life and haemoptysis in the general clinic population. Dyspnoea has been 
previously associated with anxiety in lung cancer.355, 393 It is interesting to note that 
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although dyspnoea was associated with increased anxiety in univariate analysis, it was 
not an independent predictor in any of the regression models. 
Worse PS (patient-rated) was a predictor of increased anxiety in the general clinic 
population when perceived anxiety was excluded from the model. Conversely, in newly 
diagnosed patients, worse PS (doctor-rated) was an independent predictor of lower 
anxiety, and patient-rated PS did not contribute to the model. It is not clear why this 
would be the case, although it is well-documented that PS assessment by healthcare 
professionals and patients differ.103 
 
9.3.6 Anxiety, Survival and Active Treatment 
The relationship between anxiety and cancer survival is unclear and remains 
controversial.370 The effect of anxiety on survival was studied in the previous section 
(see Section 8). It has been reported that patients receiving no active anti-cancer 
treatment experience increased psychological distress.2 In the current study, no 
relationship was found between active anti-cancer treatment and anxiety levels.  
 
9.3.7 Anxiety and Information Needs 
Despite the existence of clear guidelines for delivering information to lung cancer 
patients,394 unmet information needs were apparent in around 30% of the general clinic 
population, 35% of newly diagnosed patients and 31% of patients within the last three 
months of life. Information needs strongly contributed to the models for prediction of 
both personal and support network anxiety in the last three months of life but not in the 
other clinical groupings. It is possible that as patients recognise physical decline and 
increasingly limited treatment options, their information needs gain a greater degree of 
importance despite the prevalence being similar to previous points within the cancer 
journey. Previous studies have suggested that ‘truth-telling’ is important to the well-
being of most patients near the end of life.395, 396 
 
9.4 Conclusions 
The presence of anxiety is an important issue in cancer care. It may reflect recognition 
of advancing disease or become disproportionate to the current condition. Maladaptive 
anxiety can ‘choke’ or ‘strangle’ the patient’s quality of life. 
 
 230
Within the Stobhill lung cancer service many patients report both personal anxiety and 
perceive high levels of worry within their support network. Most patients do perceive 
recognition within their support network that their condition merits increased concern 
when symptoms are high, personal distress is increased and at particular junctures of the 
lung cancer journey. The majority of patients felt able to share their worries and 
concerns with significant others, irrespective of their own anxiety levels. 
 
Lung cancer care operates within a dynamic and often rapidly declining situation. The 
presence of high personal anxiety was strongly related to increased perceived anxiety 
within the support network. Personal anxiety was not readily predicted by gender, age, 
stage or histology. ECOG PS and some specific symptoms such as cough, pain and 
haemoptysis may aid assessment. Early recognition of anxiety and facilitating further 
support – through significant others or members of the health care team – may help 
relieve the stranglehold of psychological distress. Prompt assessment and response to 
distress within this acute illness trajectory is necessary. 
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10 Pain in Lung Cancer 
In keeping with Aim 4c, this section evaluates the predictors of increased pain in the 
Stobhill lung cancer clinic population. The predictors evaluated were all readily 
available within the Stobhill clinical service and may serve to allow effective and 
efficient targeting of pain control within the service. The methodology and statistical 
approach are outlined in Section 3. 
 
10.1 Introduction 
Pain can be defined as ‘an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such’.397 In lung cancer, pain 
can result from the disease, treatments or unrelated co-morbidities.398-401 It is a common 
symptom401 and is often associated with distress399 (see Section 1.5). The majority of 
pains in cancer can be controlled by identification and subsequent management utilising 
the analgesic ladder.398, 402 Lung cancer patients consistently rate pain as one of their top 
concerns,401 and there is some evidence that they experience more pain than patients 
with other types of cancer.400, 401, 403 Furthermore, many lung cancer patients will 
experience mixed nociceptive-neuropathic pain401-403 which can be more difficult to 
control than other types of pain.383 In the current study, pain was identified as a 
significant physical problem for lung cancer patients. This troublesome symptom is 
further evaluated. 
 
10.2 Results 
10.2.1 Pain in All Patients Attending the Lung Cancer Clinic 
Pain felt (mean 1.28, SD 1.18, median 1, range 0-4) was reported to be low (0-1) in 
55.8% (n=197/353) of patients and high (2-4) in 40.1% (n=144/353) of patients. The 
factors tabulated below were evaluated for significant differences across lower and 
higher pain (Table 76).  
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 93 55.7% 74 44.3%
Female 104 59.8% 70 40.2% 0.582 1 0.511
Age
<65 years 46 47.9% 50 52.1%
≥65 years 151 61.6% 94 38.4% 5.319 1 0.028 *
Histology
Clinical 34 53.1% 30 46.9%
NSCLC 134 57.3% 100 42.7%
SCLC 29 67.4% 14 32.6% 2.239 2 0.326
Stage NSCLC
1A 16 69.6% 7 30.4%
1B 29 60.4% 19 39.6%
2A 8 38.1% 13 61.9%
2B 14 70.0% 6 30.0%
3A 16 59.3% 11 40.7%
3B 35 49.3% 36 50.7%
4 45 54.9% 37 45.1% 7.864 6 0.248
Stage SCLC
Limited 11 73.3% 4 26.7%
Extensive 17 65.4% 9 34.6% 0.278 1 0.598
Presence or absence of metastases
None 135 57.9% 98 42.1%
Metasases 62 57.4% 46 42.6% 0.009 1 1
Time from diagnosis to POS
Within 3 weeks 64 56.1% 50 43.9%
3-6 weeks 29 55.8% 23 44.2%
6 weeks to 3 months 21 65.6% 11 34.4%
3-6 months 24 58.5% 17 41.5%
6-12 months 22 57.9% 16 42.1%
> 12 months 34 55.7% 27 44.3% 1.11 5 0.953
Performance status rated by patients
0-1 129 71.7% 51 28.3%
2 31 45.6% 37 54.4%
3-4 37 39.8% 56 60.2% 30.716 2 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 131 61.8% 81 38.2%
2 45 57.0% 34 43.0%
3-4 5 55.6% 4 44.4% 0.65 2 0.723
Active anti-cancer treatment
Yes 153 57.5% 113 42.5%
No 28 60.9% 18 39.1% 0.181 1 0.747
Deprivation
Dep Cat 1-5 90 58.1% 65 41.9%
Dep cat 6 or 7 106 58.9% 74 41.1% 0.023 1 0.912
Satisfaction score
0-4 71 55.5% 57 44.5%
5-8 0 .0% 3 100.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 46 60.5% 30 39.5%
Yes 36 48.0% 39 52.0% 2.387 1 0.143
Dyspnoea
No 48 77.4% 14 22.6%
Yes 148 53.2% 130 46.8% 12.14 1 0.001 **
Cough
No 52 63.4% 30 36.6%
Yes 142 55.9% 112 44.1% 1.43 1 0.249
Haemoptysis
No 169 59.5% 115 40.5%
Yes 24 50.0% 24 50.0% 1.53 1 0.268
Dyspnoea
Lower 119 72.6% 45 27.4%
Higher 77 43.8% 99 56.3% 28.86 1 <0.001 ***
Cough
Lower 136 63.6% 78 36.4%
Higher 58 47.5% 64 52.5% 8.16 1 0.006 **
Haemoptysis
Lower 183 58.7% 129 41.3%
Higher 10 50.0% 10 50.0% 0.58 1 0.488
Other symptoms
Lower 180 66.7% 90 33.3%
Higher 12 20.0% 48 80.0% 43.94 1 <0.001 ***
Personal anxiety
Lower 113 65.7% 59 34.3%
Higher 80 50.0% 80 50.0% 8.39 1 0.004 **
Support network anxiety
Lower 90 69.8% 39 30.2%
Higher 102 50.7% 99 49.3% 11.68 1 0.001 **
Less ability to share
Lower 157 61.3% 99 38.7%
Higher 34 45.9% 40 54.1% 5.57 1 0.023 *
Reduced life-worth
Lower 167 60.7% 108 39.3%
Higher 18 41.9% 25 58.1% 5.44 1 0.030 *
Reduced self-esteem
Lower 144 65.8% 75 34.2%
Higher 44 42.3% 60 57.7% 15.93 1 <0.001 ***
Information needs
Lower 142 62.8% 84 37.2%
Higher 35 42.7% 47 57.3% 9.99 1 0.002 **
Practical needs
Lower 149 61.6% 93 38.4%
Higher 33 46.5% 38 53.5% 5.14 1 0.028 *
Time wasted
Lower 181 59.0% 126 41.0%
Higher 3 25.0% 9 75.0% 5.46 1 0.033 *
Lower Pain Higher Pain
 
Table 76: All patients attending the lung cancer clinic. Univariate analysis of factors across groups 
of higher and lower pain. Percentages adjusted for missing data. *p<0.05, **p<0.01 and ***p<0.001 
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Significant factors were entered into a backwards logistic regression model to test for 
independent effects. The following factors were added to the model: age, patient-rated 
PS, dyspnoea, cough, ‘other’ symptoms, personal anxiety, support network anxiety, 
ability to share, self-esteem, life-worth, information needs, practical needs and time 
wasted. In addition to these significant variables, additional factors of interest were 
included in the model: gender, presence of metastases and deprivation. Results are 
shown in Table 77. 
b SE Wald df p value Odds Ratio Lower Upper
Age >65 -.948 .311 9.302 1 .002 .388 .211 .713
Performance status 0-1 10.471 2 .005
Performance status 2 .468 .375 1.563 1 .211 1.597 .767 3.328
Performance Status 3-4 1.119 .346 10.470 1 .001 3.061 1.554 6.028
Dyspnoea (higher) 1.011 .286 12.478 1 .000 2.748 1.568 4.815
Other symptoms (higher) 1.670 .396 17.761 1 .000 5.313 2.443 11.552
Constant -.951 .289 10.808 1 .001 .386
95% CI for Odds Ratios
 
        R2=0.231 (Cox and Snell); 0.311 (Nagelkerke) Model Χ2=73.74, df=5, p<0.001 
        Hosmer-Lemeshow test: Χ2=3.069, df=6, p=0.800 
Table 77: Independent factors associated with higher pain identified through backwards logistic 
regression for all patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=73.74, df=5, p<0.001). Nagelkerke’s R2 of 0.311 indicated that around 31% of 
variance was explained by the model. Overall prediction success was 73.0% (78.0% for 
lower pain and 65.8% for higher pain). The null model overall prediction of success was 
58.4%. Each of the predictors in the final model was significant at the p<0.05 level. As 
such, higher levels of pain were independently associated with worse performance 
status, younger age, increased dyspnoea and increased ‘other’ symptoms. There were no 
significant effects from the other variables which were excluded from the final model. 
For a fixed age, level of dyspnoea and ‘other’ symptoms, a patient with a PS of 3-4 was 
3.06 (95% CI 1.55-6.03) times more likely to have increased pain levels. 
 
10.2.2 Pain in Newly Diagnosed Patients 
Pain felt (mean 1.33, SD 1.33, median 1, range 0-4) was reported to be ‘low’ (0-1) in 
54.7% (n=93/170) of newly diagnosed patients and high (2-4) in 42.9% (n=73/170). The 
factors tabulated below were evaluated for significant differences across lower and 
higher pain (Table 78).  
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 47 57.3% 35 42.7%
Female 46 54.8% 38 45.2% 0.11 1 0.757
Age
<65 years 20 43.5% 26 56.5%
≥65 years 73 60.8% 47 39.2% 4.065 1 0.055
Histology
Clinical 17 43.6% 22 56.4%
NSCLC 60 58.3% 43 41.7%
SCLC 16 66.7% 8 33.3% 3.758 2 0.153
Stage NSCLC
1A 16 69.6% 7 30.4%
1B 29 60.4% 19 39.6%
2A 8 38.1% 13 61.9%
2B 14 70.0% 6 30.0%
3A 16 59.3% 11 40.7%
3B 35 49.3% 36 50.7%
4 45 54.9% 37 45.1% 7.864 6 0.248
Stage SCLC
Limited 7 77.8% 2 22.2%
Extensive 9 60.0% 6 40.0% 0.8 1 0.371
Presence or absence of metastases
None 57 57.0% 43 43.0%
Metasases 36 54.5% 30 45.5% 0.97 1 0.873
Time from diagnosis to POS
Within 3 weeks 64 56.1% 50 43.9%
3-6 weeks 29 55.8% 23 44.2%
6 weeks to 3 months 0 .0% 0 .0%
3-6 months 0 .0% 0 .0%
6-12 months 0 .0% 0 .0%
> 12 months 0 .0% 0 .0% na
Performance status rated by patients
0-1 67 74.4% 23 25.6%
2 13 40.6% 19 59.4%
3-4 13 29.5% 31 70.5% 27.997 2 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 60 67.4% 29 32.6%
2 19 41.3% 27 58.7%
3-4 4 57.1% 3 42.9% 8.519 2 0.014 *
Active anti-cancer treatment
Yes 69 57.5% 51 42.5%
No 14 56.0% 11 44.0% 0.19 1 1
Deprivation
Dep Cat 1-5 50 60.2% 33 39.8%
Dep cat 6 or 7 43 53.1% 38 46.9% 0.855 1 0.431
Satisfaction score
0-4 44 55.7% 35 44.3%
5-8 0 .0% 2 100.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 28 56.0% 22 44.0%
Yes 23 52.3% 21 47.7% 0.131 1 0.836
Dyspnoea
No 23 76.7% 7 23.3%
Yes 70 51.5% 66 48.5% 6.33 1 0.014 *
Cough
No 22 59.5% 15 40.5%
Yes 70 55.6% 56 44.4% 0.18 1 0.710
Haemoptysis
No 79 60.3% 52 39.7%
Yes 14 46.7% 16 53.3% 1.86 1 0.219
Dyspnoea
Lower 57 69.5% 25 30.5%
Higher 36 42.9% 48 57.1% 11.97 1 0.001 **
Cough
Lower 63 61.2% 40 38.8%
Higher 29 48.3% 31 51.7% 3.54 1 0.141
Haemoptysis
Lower 86 58.9% 60 41.1%
Higher 7 46.7% 8 53.3% 0.84 1 0.417
Other symptoms
Lower 89 67.4% 43 32.6%
Higher 4 13.8% 25 86.2% 28.01 1 <0.001 ***
Personal anxiety
Lower 49 69.0% 22 31.0%
Higher 44 48.4% 47 51.6% 6.96 1 0.010 *
Support network anxiety
Lower 30 78.9% 8 21.1%
Higher 62 50.4% 61 49.6% 9.66 1 0.002 **
Less ability to share
Lower 75 60.5% 49 39.5%
Higher 16 43.2% 21 56.8% 3.45 1 0.088
Reduced life-worth
Lower 77 57.9% 56 42.1%
Higher 10 45.5% 12 54.5% 1.19 1 0.355
Reduced self-esteem
Lower 68 63.6% 39 36.4%
Higher 21 41.2% 30 58.8% 7.03 1 0.010 *
Information needs
Lower 72 62.1% 44 37.9%
Higher 14 36.8% 24 63.2% 7.39 1 0.008 **
Practical needs
Lower 65 59.1% 45 40.9%
Higher 22 48.9% 23 51.1% 1.35 1 0.286
Time wasted
Lower 84 56.4% 65 43.6%
Higher 1 16.7% 5 83.3% 3.67 1 0.091
Lower Pain Higher Pain
 
Table 78: Newly diagnosed patients. Univariate analysis of factors across groups of higher and 
lower pain. Percentages are adjusted for missing data. *p<0.05, **p<0.01 and ***p<0.001 
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The factors identified as significant were: dyspnoea, ‘other’ symptoms, personal 
anxiety, support network anxiety, self-esteem and information needs. Significant factors 
were entered into a backwards logistic regression model to test for independent effects. 
In addition to these significant variables, additional factors of interest were included in 
the model: patient-rated PS, presence of metastases, age, gender and deprivation. 
Results are shown in Table 79. 
b SE Wald df p value Odds Ratio Lower Upper
Age >65 -1.350 .477 8.029 1 .005 .259 .102 .660
Performance status 0-1 18.564 2 .000
Performance status 2 1.658 .566 8.587 1 .003 5.251 1.732 15.923
Performance Status 3-4 2.183 .539 16.406 1 .000 8.875 3.086 25.527
Other symptoms (higher) 2.087 .638 10.707 1 .001 8.058 2.309 28.122
Information needs (higher) 1.102 .498 4.892 1 .027 3.011 1.134 7.998
Constant -.969 .418 5.366 1 .021 .380
95% CI for Odds Ratios
 
    R2=0.340 (Cox and Snell); 0.457 (Nagelkerke) Model Χ2=60.64, df=5, p<0.001 
    Hosmer-Lemeshow test: Χ2=3.311, df=6, p=0.769 
Table 79: Independent factors associated with higher pain identified through backwards logistic 
regression for newly diagnosed patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=60.64, df=5, p<0.001). Nagelkerke’s R2 of 0.457 indicated that around 46% of 
variance was explained by the model. Overall prediction success was 78.1% (88.2% for 
lower pain and 63.9% for higher pain). This compares to the null model overall 
prediction success of 58.2%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of pain were independently associated with 
younger age, worse performance status, higher ‘other’ symptoms and increased 
information needs. There were no significant effects from the other variables which 
were excluded from the final model. For a fixed age, level of information needs and 
‘other’ symptoms, a patient with a PS of 3-4 was 8.875(95% CI 3.09-25.53) times more 
likely to have higher pain.  
 
10.2.3 Pain in Patients in the Last Three Months of Life 
Pain felt (mean 1.68, SD 1.33, median 2, range 0-4) was reported to be ‘low’ (0-1) in 
39.7% (n=48/121) of patients within the last three months of life and high (2-4) in 
57.1% (n=69/121). The factors tabulated below were evaluated for significant 
differences across lower and higher pain (Table 80).  
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 26 41.3% 37 58.7%
Female 22 40.7% 32 59.3% 0.03 1 1
Age
<65 years 9 31.0% 20 69.0%
≥65 years 39 44.3% 49 55.7% 1.591 1 0.277
Histology
Clinical 7 41.2% 10 58.8%
NSCLC 29 36.7% 50 63.3%
SCLC 12 57.1% 9 42.9% 2.863 2 0.239
Stage NSCLC
1A 1 100.0% 0 .0%
1B 4 57.1% 3 42.9%
2A 0 .0% 6 100.0%
2B 0 .0% 3 100.0%
3A 2 33.3% 4 66.7%
3B 11 35.5% 20 64.5%
4 17 40.5% 25 59.5% 7.915 6 0.244
Stage SCLC
Limited 3 50.0% 3 50.0%
Extensive 9 60.0% 6 40.0% 0.175 1 0.676
Presence or absence of metastases
None 22 36.7% 38 63.3%
Metasases 26 45.6% 31 54.4% 0.967 1 0.352
Time from diagnosis to POS
Within 3 weeks 11 36.7% 19 63.3%
3-6 weeks 4 66.7% 2 33.3%
6 weeks to 3 months 10 55.6% 8 44.4%
3-6 months 9 50.0% 9 50.0%
6-12 months 9 34.6% 17 65.4%
> 12 months 5 26.3% 14 73.7% 6.177 5 0.289
Performance status rated by patients
0-1 19 52.8% 17 47.2%
2 12 41.4% 17 58.6%
3-4 17 32.7% 35 67.3% 3.549 2 0.17
Diagnosis PS, assessed by doctor
0-1 27 43.5% 35 56.5%
2 16 42.1% 22 57.9%
3-4 3 42.9% 4 57.1% 0.2 2 0.99
Active anti-cancer treatment
Yes 33 38.8% 52 61.2%
No 11 55.0% 9 45.0% 1.74 1 0.214
Deprivation
Dep Cat 1-5 24 39.3% 37 60.7%
Dep cat 6 or 7 24 42.9% 32 57.1% 0.149 1 0.711
Albumin at diagnosis
<35 24 46.2% 28 53.8%
≥35 23 37.1% 39 62.9% 0.957 1 0.346
CRP at diagnosis
<10 18 43.9% 23 56.1%
≥10 30 39.5% 46 60.5% 0.216 1 0.696
Glasgow Prognostic Score
CRP <10 and Albumin >35 13 48.1% 14 51.9%
CRP >10 or Albumin <35 12 27.3% 32 72.7%
CRP >10 and Albumin <35 21 50.0% 21 50.0% 5.412 2 0.067
Satisfaction score
0-4 20 36.4% 35 63.6%
5-8 0 .0% 1 100.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 11 50.0% 11 50.0%
Yes 12 30.0% 28 70.0% 2.433 1 0.17
Dyspnoea
No 12 63.2% 7 36.8%
Yes 36 36.7% 62 63.3% 4.59 1 0.042 *
Cough
No 15 45.5% 18 54.5%
Yes 32 39.0% 50 61.0% 0.40 1 0.537
Haemoptysis
No 44 46.8% 50 53.2%
Yes 3 15.8% 16 84.2% 6.26 1 0.020 *
Dyspnoea
Lower 26 61.9% 16 38.1%
Higher 22 29.3% 53 70.7% 11.81 1 0.001 **
Cough
Lower 29 45.3% 35 54.7%
Higher 18 35.3% 33 64.7% 1.18 1 0.341
Haemoptysis
Lower 45 42.5% 61 57.5%
Higher 2 28.6% 5 71.4% 0.52 1 0.697
Other symptoms
Lower 40 54.1% 34 45.9%
Higher 7 17.9% 32 82.1% 13.71 1 <0.001 ***
Personal anxiety
Lower 26 52.0% 24 48.0%
Higher 21 33.3% 42 66.7% 4.00 1 0.056
Support network anxiety
Lower 18 58.1% 13 41.9%
Higher 30 36.1% 53 63.9% 4.45 1 0.054
Less ability to share
Lower 36 43.4% 47 56.6%
Higher 11 34.4% 21 65.6% 0.77 1 0.406
Reduced life-worth
Lower 40 43.5% 52 56.5%
Higher 7 31.8% 15 68.2% 1.00 1 0.347
Reduced self-esteem
Lower 32 46.4% 37 53.6%
Higher 15 32.6% 31 67.4% 2.17 1 0.176
Information needs
Lower 34 41.0% 49 59.0%
Higher 12 38.7% 19 61.3% 0.05 1 1.000
Practical needs
Lower 31 37.8% 51 62.2%
Higher 16 50.0% 16 50.0% 1.41 1 0.291
Time wasted
Lower 47 42.3% 64 57.7%
Higher 0 .0% 4 100.0% 2.86 1 0.144
Lower Pain Higher Pain
 
Table 80: Patients who died within three months of questionnaire completion. Univariate analysis 
of factors across groups of higher and lower pain. Percentages are adjusted for missing data. 
*p<0.05, **p<0.01 and ***p<0.001 
 237
The factors identified as significant were: dyspnoea, haemoptysis and ‘other’ 
symptoms. These factors were entered into a backwards logistic regression model to test 
for independent effects. In addition to these significant variables, additional factors of 
interest were included in the model: gender, age, patient-rated PS, presence of 
metastases and deprivation. Results are shown in (Table 81).  
b SE Wald df p value Odds Ratio Lower Upper
Dyspnoea (higher) 1.092 .435 6.294 1 .012 2.981 1.270 6.997
Other symptoms (higher) 1.463 .492 8.829 1 .003 4.320 1.646 11.340
Constant -.783 .351 4.971 1 .026 .457
95% CI for Odds Ratios
 
R2=0.170 (Cox and Snell); 0.229 (Nagelkerke) Model Χ2=21.06, df=2, p<0.001 
Hosmer-Lemeshow test: Χ2=0.141, df=2, p=0.932 
Table 81: Independent factors associated with higher pain identified through backwards logistic 
regression for patients in the last three months of life. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=21.06, df=2, p<0.001). Nagelkerke’s R2 of 0.229 indicated that around 23% of 
variance was explained by the model. Overall prediction success was 69.9% (48.9% for 
lower pain and 84.8% for higher pain). This compares to the null model overall 
prediction success of 58.4%. Each of the predictors in the final model was significant at 
the p<0.05 level. As such, higher levels of pain were independently associated with 
increased dyspnoea and increased ‘other’ symptoms. There were no significant effects 
from the other variables which were excluded from the final model. For a fixed level of 
‘other’ symptoms, a patient with increased dyspnoea was 2.981 (95% CI 1.27-6.99) 
times more likely to have higher pain. 
 
10.3 Discussion 
The current study confirms the high prevalence of pain in the Stobhill lung cancer 
population. Furthermore, pain was rated as moderate, severe or overwhelming by four 
out of ten patients attending the lung cancer clinic (Section 6.2.1.1). Pain in lung cancer 
is well recognised to cause patients distress and be one their main concerns.401 Despite 
this, pain remains undertreated in the lung cancer population.404 Pain can result from the 
cancer itself, treatment-related effects or from co-morbidity. In lung cancer, pain can be 
present from early stage404 until later stage.399 Irrespective of its origin, pain can usually 
be managed once identified.400 
 
In lung cancer, increased pain has been reported to be associated with a variety of 
factors including: histological subtype, stage of disease, gender, younger age and 
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treatment received. However, these reports are variable and inconsistent with underlying 
differences in methodology, sample characteristics and assessment tools.401 Potter and 
Higginson401 undertook a systematic review of such studies and reported on pain 
profiles in lung cancer. In this review, they reported the prevalence of pain as 27% 
(range 8-85%) in outpatients, 36% (range 9-58%) in general hospital in-patients, 76% 
(range 63-88%) in patients referred to palliative care and 100% in patients referred to 
pain teams with an overall prevalence of 47% (6-100%) in the lung cancer 
population.401 
 
In the current study, pain was a highly rated physical symptom: 40.1% of patients 
overall, 42.9% of newly diagnosed patients and 57.1% of patients in the last three 
months of life described moderate to overwhelming pain. The potential predictors of 
increased pain (moderate-overwhelming) were explored utilising univariate and 
multivariate analyses. The main factors identified associated with increased pain were:  
younger age, worse PS, physical symptoms of dyspnoea and ‘other’symptoms. 
Information needs were also found to be significant in newly diagnosed patients. 
Factors that were not related to the level of pain on univariate analyses included gender, 
histology, stage, active treatment and deprivation level. 
 
10.3.1 Performance Status 
PS is a global assessment of function.405 In the current study, worse PS rated by the 
patient was strongly related to increased pain levels. In multivariate analysis, this study 
revealed PS was an independent predictor of increased pain in the whole clinic 
population and in newly diagnosed patients. Performance status was not an independent 
factor in the last three months of life. It may be that within the current study population 
there were insufficient numbers to detect a difference between PS groups, especially 
given the finding that poorer PS is strongly correlated with reduced survival.  
 
In their multivariate study, Lin et al406 reported significantly lower PS (measured by 
Karnofsky PS) in Taiwanese lung cancer patients experiencing pain. Pain intensity and 
pain interference with life were both significantly correlated with worse performance 
status. This is in keeping with the higher pain prevalence reported in patients with PS 2 
compared to PS 0-1 in Italian patients with NSCLC.407 Ferreira et al323 identified that a 
number of symptoms may relate to reduced functional status in cancer. They further 
elucidated the most important predictor of reduced PS was fatigue but pain was the next 
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most important predictor. The two symptoms together explained 38% of variance in the 
model predicting reduced functional status. Gift et al285 also reported reduced 
functioning relating to six main symptoms including pain and fatigue in lung cancer 
patients.  
 
Vallerand et al408 explored the relationship between pain occurrence, pain-related 
distress, functioning and perceived control over pain. They reported that a patient’s pain 
level is related to increased distress and reduced control over pain and functional status. 
Through further modelling, they reported that symptom distress mediated this 
relationship. This in keeping with ‘The Theory of Unpleasant Symptoms’409 discussed 
and assessed by Gift et al298 in a lung cancer population. This theoretical framework 
considered the relationship between symptom occurrence, distress, timing and quality 
alongside additional symptoms, performance, psycho-emotional environment and 
contextual factors (such as cancer recurrence, entering the terminal phase or previous 
experience of such symptoms). In such a complex interplay of factors, pain and pain-
related distress can relate to reduction in performance status leading to worsening 
psycho-emotional state and further increase in distress. Increased distress can, in turn, 
lead to an increase in perceived pain.298, 409 
 
10.3.2 Age 
In the current study, increased pain levels were independently associated with younger 
patients (<65 years) in the general clinic population and newly diagnosed patients. This 
finding has been previously reported.401 Maio et al407 reported increased moderate-
severe pain in younger patients with NSCLC than older patients. De Maria et al287 
described significantly increased pain in lung cancer patients less than 70 years old. 
Kuo et al410 also reported an increased level of pain at diagnosis in younger patients (40 
years and younger) compared to elderly patients (>80years) with lung cancer. 
 
10.3.3 Physical Symptoms 
Lung cancer patients often experience multiple symptoms (see Section 1.5) However, in 
the current study, increased pain was associated with the physical symptoms of 
increased dyspnoea and ‘other’ symptoms. In the general lung cancer clinic population, 
other significant factors in the model included PS and age; in newly diagnosed patients, 
PS, age and information needs were included; in the last three months of life, however, 
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the only significant predictors of increased pain were increased dyspnoea and ‘other’ 
symptoms.  
 
Pain has been associated with increased dyspnoea in seriously ill patients in a previous 
hospital based study.411 In a large hospital based study (n=1556), Desbiens et al411 
controlled for depression, anxiety, disease type and severity, location of patient and 
QOL and reported that increased dyspnoea was an independent predictor of increased 
pain levels. Furthermore, in lung cancer patients, Tanaka et al412 reported that pain was 
an independent predictor of increased breathlessness alongside cough, psychological 
distress and ‘organic causes’. It is not clear what underlies this association between pain 
and dyspnoea. This may be a simple co-occurrence in lung cancer or there may be a 
direct link through altered sensitivity to pain in dyspnoeic patients.411 It has recently 
been postulated that both pain and dyspnoea share common pathways within the 
nervous system and that the ‘unpleasantness’ associated with both these common 
symptoms is mediated through an aversive signalling pathway.413-416 
 
In the current study, the other predictive factor for increased pain was ‘other’ 
symptoms. Unfortunately, despite the questionnaire allowing patients to detail what the 
‘other’ symptoms were, very few reported what was that was troubling them. In 
previous cancer symptom studies, pain has been associated with the presence of 
constipation.417 It has been postulated that this relationship may be mediated through the 
prescription of constipating analgesics such as opioids.417 Other symptoms associated 
with pain in the cancer population include fatigue418 and nausea.411 It is not clear in this 
study what the ‘other’ symptoms associated with pain are, but it is relevant to note that 
the presence of pain in a lung cancer patient should prompt further assessment for the 
presence of dyspnoea and other symptoms. This is in keeping with the finding of 
multiple studies that lung cancer patients experience multiple symptoms throughout 
their cancer journey (see Section 5). 
 
10.3.4 Information Needs 
Hsu et al419 reported on the relationship between pain, uncertainty and hope in 
Taiwanese patients with lung cancer. Pain severity itself was associated with uncertainty 
in either univariate or multivariate analysis. A relationship was identified between 
uncertainty and the level of interference with normal life that pain was causing. In this 
study, the Mishel uncertainty illness scale was used to evaluate the individual’s 
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perception of uncertainty regarding symptoms, diagnosis, treatment, prognosis and 
personal relationships. In the current study, increased unmet information needs were 
independently associated with increased pain in newly diagnosed patients. This may 
relate to the relationship between uncertainty and pain described by Hsu et al.419 It is 
also possible that the presence of pain itself creates uncertainty or the desire for 
increased information. In newly diagnosed patients with increased pain, there may, 
therefore, be increased information needs which should be elicited and addressed.  
 
10.3.5 Non-Significant Factors 
In the current study, multivariate analysis found no significant relationships between 
increased pain and gender, histology, stage of disease, deprivation level, albumin, CRP, 
time from diagnosis, active anti-cancer treatments, cough, haemoptysis, anxiety, ability 
to share, self-esteem, life-worth, practical needs and time use. 
 
Previous studies have also reported that gender has no influence on pain levels in lung 
cancer.216, 300, 407, 418, 420 Huhti et al421 reported no difference in short term symptoms 
(less than six months in duration) between men and women with lung cancer, with the 
exception of increased sputum production in females. They did find increased long term 
pain in females. Overall, the literature is consistent with the finding that gender does not 
appear to influence pain in lung cancer.  
 
The current study found no difference in pain experience between histological subtypes 
of lung cancer. There has been conflicting evidence reported regarding this previously. 
One study reported increased pain levels at presentation in patients with NSCLC 
compared to SCLC;292 another study reported the opposite finding with increased pain 
in SCLC.421 Consistent with the current study, Chute et al422 report no difference in pain 
between histological subtypes. 
 
Increased pain has been previously described in relation to increased stage of lung 
cancer.401 The situation is complicated through studies considering patients in different 
settings and at different points of their cancer journey. In their systematic review, Potter 
et al401 reported that weighted mean prevalence of pain at presentation was 41% (range 
30-71%). Pain prevalence in the palliative setting was higher. However, in keeping with 
the 100% prevalence of pain in patients referred to pain services in this review, there is 
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likely to be some bias towards active symptoms in patients referred to palliative care 
services. 
 
The current study also found no relationship between time from diagnosis and pain. 
Chute et al422 reported that chest pain did not predict stage but the presence of extra-
thoracic pain was predictive of stage 3 disease. Maio et al407 described significantly 
increased pain on univariate analysis in patients with stage 4 NSCLC compared to 
patients with stage 3 NSCLC. Further research is needed to elucidate the relationship 
between pain and stage of disease, taking into account confounding variables. In 
keeping with the current study, many of the previous studies were not able to provide 
data on analgesic use or response to their analgesics. It remains unclear whether pain is 
a good clinical marker of advanced disease, disease progression or if increasing 
analgesic load may also act as a surrogate for evidence of advanced disease. 
 
No previous studies have reported on the relationship between pain and deprivation in 
lung cancer patients. In the current study, there was no significant relationship found 
between level of deprivation and pain reported in any of the clinical groups studied. No 
previous studies have evaluated the relationship between albumin level or CRP level 
and pain in lung cancer patients. There was no significant relationship found in this 
study.  
 
Treatment type has been previously described as influencing pain experienced. Post-
thoracotomy pain is well described in lung cancer patients,269 and both chemotherapy423 
and radiotherapy400 can cause painful neuropathy. However, each of these modalities 
can also provide improved symptom control including control of pain.97 Furthermore, 
patients receiving active treatments are under active surveillance for toxicities and 
treatment response. Such increased monitoring may also have a beneficial effect on 
overall symptom control. Potter  et al401 reported that most pain in lung cancer is multi-
factorial but the majority does relate to the disease itself. In their review, the weighted 
mean prevalence of pain attributable to anti-cancer treatments (irrespective of type) was 
13% (range 5-17%). Despite this, they note that there is little evidence that prevalence 
of pain is related to treatment modality.401 
 
Previous studies in the non-cancer setting have described a relationship between pain 
and psychological variables such as depression424-427 and anxiety.424, 428-430 In cancer, a 
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similar relationship between increased pain and increased anxiety178, 370, 381, 431-433 or 
increased depression376, 380, 431, 432, 434, 435 has been described. Furthermore, functional 
MRI scanning studies have suggested specific demonstrable links between pain and 
depression436 and pain and anxiety.437 
 
In their multivariate analysis of pain, depression and cancer type, Fischer et al432 
described increased pain levels and distress in lung cancer patients compared to those 
with head and neck cancers or prostate cancer. They also found that increased anxiety, 
increased depression and having lung cancer were all independent predictors of higher 
pain levels. However, research in this area is difficult due to probable relationships 
between anxiety and depression themselves,386, 424, 438 multiple assessment tools,439 
confounding variables and crossover features in the assessment of anxiety, pain and 
depression.435, 440 In Section 9 in the current study, the strong relationship between low 
self-esteem and anxiety in lung cancer has already been described. Section 9 also makes 
clear that anxiety is a key supportive care need in lung cancer patients. However, its 
relationship to pain remains unclear.  
 
In the current study, for all patients attending the clinic and for newly diagnosed 
patients, strong bivariate relationships were found between increased pain and both 
increased personal anxiety and increased perceived anxiety in the support network. 
Neither of these relationships was found in the last three months of life. This may 
reflect the lack of numbers within the three month grouping or that this relationship was 
modified by the use of symptom control measures targeted within the last three months 
of life. On multivariate analysis, anxiety (either personal or support network) was not a 
significant independent predictor of increased pain in any of the clinical groupings. 
Previous studies in lung cancer have also described high levels of anxiety at different 
stages of the illness.2 There are few published studies examining the relationship 
between pain and anxiety specifically in lung cancer. The study of Fischer et al432 in a 
variety of cancer types further examined interdependent relationships within the lung 
cancer population. Although other studies in the cancer setting do describe a 
relationship, many are univariate analyses and may not be directly applicable to lung 
cancer patients. However, from the emerging physiological evidence of linkage between 
anxiety and increased pain,437 the background of non-cancer studies, the evidence of 
some cancer studies and the high prevalence of both pain and anxiety in lung cancer, 
this is clearly an area which merits further research. 
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There is also a high prevalence of depression in the lung cancer population.2, 342 Laird et 
al435 carried out a systematic review of evidence for an interdependent relationship 
between cancer pain and depression in 2009. Fourteen studies were identified which 
contained information indentifying a relationship between pain and depression. 
However, none of these studies identified were specifically designed to examine this 
relationship. Prevalence of depression ranged from 22.1% to 46% but this was 
complicated through the use of multiple different assessment methods. A positive 
statistical relationship was identified between increased pain and increased depression 
in nine studies, of which only one utilised multivariate analysis. The authors concluded 
that, although there is some evidence of an association between depression and 
increased cancer related pain, there is insufficient evidence to conclude a causal 
relationship.  
 
In lung cancer, there are no studies looking specifically at the relationship between pain 
and depression. Hopwood et al380 reported on depression and risk factors derived from 
quality of life data obtained in trials involving lung cancer patients. They reported a 
strong independent relationship between reduced performance status and increased 
depression. They also described increased levels of depression independently associated 
with higher overall symptom burden. Further detailed evaluation of the data showed that 
increased depression was associated with certain symptoms at presentation, including 
general pain, chest pain, fatigue, dyspnoea and cough.  
 
In the current study, increased pain was associated with reduced self-esteem (p<0.001) 
and reduced life-worth (p=0.03) in the general clinic population. This relationship 
between reduced self-esteem and increased pain was also observed in newly diagnosed 
patients (p=0.01), but there was no significant relationship between pain and self-worth. 
Neither of these psychosocial variables was significantly associated with increased pain 
in the last three months of life. Again, this may relate to under-powering for this group. 
On multivariate analysis, neither reduced self-worth nor reduced life-worth were 
independent predictors of increased pain. Again, given the lack of current evidence but 
the high prevalence of both pain and depression in lung cancer, and the emerging 
physiological evidence of a possible link between the two factors,436 further research 
into this area is necessary to elucidate the relationship between pain and depression in 
the lung cancer setting. 
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10.4 Conclusions 
Pain is an important issue in lung cancer care. Lung cancer patients experience high 
levels of pain and associated distress. Pain can be managed, once identified, in the 
majority of patients with cancer. In lung cancer, a significant proportion of patients may 
have complex pain requiring particular attention and individually tailored approaches to 
analgesia. The current study confirms the significant prevalence of pain within the 
Stobhill lung cancer out-patient population.  
 
On multivariate analyses, increased levels of pain were not predicted by gender, stage, 
histology, deprivation, active treatment, anxiety or depression. However, in the general 
clinic population, increased pain was independently related to poorer performance 
status, younger age, dyspnoea and ‘other’ symptoms. In newly diagnosed lung cancer 
patients, increased pain was related to the same variables and increased unmet 
information needs. In the last three months of life, increased pain was associated with 
dyspnoea and ‘other’ symptoms but no other variables in this study. 
 
For lung cancer patients, pain is consistently rated as one of their highest concerns. 
Although a systematic approach to assessing symptoms should include pain assessment, 
the findings in the current study suggest it would be appropriate to focus attention on 
those with reduced performance status, younger patients and those with dyspnoea to 
identify any uncontrolled pain.  
 246
11 Dyspnoea in Lung Cancer 
In keeping with Aim 4c, this section evaluates the predictors of increased dyspnoea in 
the Stobhill lung cancer clinic population. The predictors evaluated were all readily 
available within the Stobhill clinical service and may serve to allow effective and 
efficient targeting of dyspnoea management within the service. The methodology and 
statistical approach is outlined in Section 3. 
 
11.1 Introduction 
Dyspnoea has been defined as: 
A subjective experience of breathing discomfort that consists of qualitatively 
distinct sensations that vary in intensity. The experience derives from 
interactions among multiple physiological, psychological, social, and 
environmental factors, and may induce secondary physiological and 
behavioural responses.441 
 
This broad definition has been designed to encompass a variety of sensations that can be 
reported as ‘breathlessness’ and to aid in the understanding of dyspnoea as a complex 
symptom that is influenced by physical, psychosocial and emotional factors.442 
Dyspnoea is a common symptom in lung cancer and is associated with high distress442 
(see Section 1.5). Furthermore, chronic obstructive airways disease is a common co-
morbidity in lung cancer patients,190, 228 and this is also associated with a high 
prevalence of distressing breathlessness.178 In the current study, dyspnoea was rated as 
the most troubling physical symptom. A further evaluation of dyspnoea in lung cancer 
has been completed.  
 
11.1.1 Dyspnoea in All Patients Attending the Lung Cancer 
Clinic 
Dyspnoea felt (mean 1.55, SD 1.06, median 2, range 0-4) was reported to be low (0-1) 
in 47% (n=166/353) of all patients and high (2-4) in 49.8% (n=176/353). The factors 
tabulated below were evaluated for significant differences across lower and higher 
dyspnoea (Table 82). 
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 84 50.3% 83 49.7%
Female 82 46.9% 93 53.1% 0.405 1 0.589
Age
<65 years 45 46.4% 52 53.6%
≥65 years 121 49.4% 124 50.6% 0.25 1 0.633
Histology
Clinical 30 46.9% 34 53.1%
NSCLC 115 48.7% 121 51.3%
SCLC 21 50.0% 21 50.0% 0.11 2 0.946
Stage NSCLC
1A 9 37.5% 15 62.5%
1B 28 58.3% 20 41.7%
2A 11 52.4% 10 47.6%
2B 12 60.0% 8 40.0%
3A 11 40.7% 16 59.3%
3B 33 46.5% 38 53.5%
4 28 45.8% 45 54.2% 5.215 6 0.517
Stage SCLC
Limited 8 53.3% 7 46.7%
Extensive 13 50.0% 13 50.0% 0.042 1 0.837
Presence or absence of metastases
None 115 49.4% 118 50.6%
Metasases 51 46.8% 58 53.2% 0.196 1 0.728
Time from diagnosis to POS
Within 3 weeks 55 48.2% 59 51.8%
3-6 weeks 27 51.9% 25 48.1%
6 weeks to 3 months 17 53.1% 15 46.9%
3-6 months 15 36.6% 26 63.4%
6-12 months 21 53.8% 18 46.2%
> 12 months 28 45.9% 33 54.1% 3.441 5 0.632
Performance status rated by patients
0-1 114 63.0% 67 37.0%
2 19 27.9% 49 72.1%
3-4 33 35.5% 60 64.5% 33.014 2 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 111 52.1% 102 47.9%
2 32 40.5% 47 59.5%
3-4 5 55.6% 4 44.4% 3.257 2 0.196
Active anti-cancer treatment
Yes 130 48.7% 137 51.3%
No 22 47.8% 24 52.2% 0.914 1 1
Deprivation
Dep Cat 1-5 79 50.6% 77 49.4%
Dep cat 6 or 7 85 47.2% 95 52.8% 0.391 1 0.585
Satisfaction score
0-4 72 56.3% 56 43.8%
5-8 2 66.7% 1 33.3%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 47 61.8% 29 38.2%
Yes 36 48.0% 39 52.0% 2.922 1 0.103
Cough
No 55 66.3% 28 33.7%
Yes 108 42.5% 146 57.5% 14.12 1 <0.001 ***
Haemoptysis
No 140 49.0% 146 51.0%
Yes 21 43.8% 27 56.3% 0.45 1 0.536
Cough
Lower 128 59.3% 88 40.7%
Higher 35 28.9% 86 71.1% 28.58 1 <0.001 ***
Haemoptysis
Lower 150 47.8% 164 52.2%
Higher 11 55.0% 9 45.0% 0.39 1 0.646
Pain
Lower 119 60.7% 77 39.3%
Higher 45 31.3% 99 68.8% 28.86 1 <0.001 ***
Other symptoms
Lower 146 53.7% 126 46.3%
Higher 15 25.0% 45 75.0% 16.18 1 <0.001 ***
Personal anxiety
Lower 101 58.4% 72 41.6%
Higher 61 37.9% 100 62.1% 14.02 1 <0.001 ***
Support network anxiety
Lower 77 58.8% 54 41.2%
Higher 83 41.3% 118 58.7% 9.71 1 0.002 **
Less ability to share
Lower 130 50.8% 126 49.2%
Higher 31 41.3% 44 58.7% 2.07 1 0.189
Reduced life-worth
Lower 142 51.3% 135 48.7%
Higher 13 30.2% 30 69.8% 6.59 1 0.013 *
Reduced self-esteem
Lower 132 60.0% 88 40.0%
Higher 26 25.0% 78 75.0% 34.62 1 <0.001 ***
Information needs
Lower 120 53.1% 106 46.9%
Higher 30 36.6% 52 63.4% 6.57 1 0.014 **
Practical needs
Lower 123 50.6% 120 49.4%
Higher 33 46.5% 38 53.5% 0.38 1 0.590
Time wasted
Lower 155 50.3% 153 49.7%
Higher 1 8.3% 11 91.7% 8.15 1 0.006 **
Lower Dyspnoea Higher Dyspnoea
 
Table 82: All patients attending the lung cancer clinic. Univariate analysis of factors across groups 
of higher and lower dyspnoea. Percentages adjusted for missing data. *p<0.05, **p<0.01 and 
***p<0.001 
 
Significant factors were entered into a backwards logistic regression model to test for 
independent effects. Thus the following factors were added to the model: histology, 
cough, pain, ‘other’ symptoms, personal anxiety, support network anxiety, life-worth, 
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self-esteem, information needs and time wasted. Time wasted was not included in the 
final model due to the large confidence interval. In addition to these significant 
variables, additional factors of interest were included in the model: age, gender, 
presence of metastases, deprivation and patient-rated performance status. Results are 
shown in Table 83.  
b SE Wald df p value Odds Ratio Lower Upper
Performance status 0-1 7.645 2 .022
Performance status 2 .973 .352 7.642 1 .006 2.645 1.327 5.273
Performance Status 3-4 .289 .357 .658 1 .417 1.335 .664 2.686
Cough (higher) .731 .285 6.573 1 .010 2.078 1.188 3.634
Pain (higher) 1.007 .277 13.233 1 .000 2.739 1.591 4.713
Reduced self-esteem .918 .322 8.124 1 .004 2.505 1.332 4.711
Constant -1.149 .216 28.381 1 .000 .317
95% CI for Odds Ratios
 
      R2=0.194 (Cox and Snell); 0.258 (Nagelkerke) Model Χ2=62.40, df=5, p<0.001 
      Hosmer-Lemeshow test: Χ2=3.685, df=6, p=0.719 
Table 83: Independent factors associated with higher dyspnoea identified through backwards 
logistic regression for all patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=62.40, df=5, p<0.001). Nagelkerke’s R2 of 0.258 indicated that around 26% of 
variance was explained by the model. Overall prediction success was 70.3% (71.9% for 
lower dyspnoea and 68.9% for higher dyspnoea). This compares to the null model 
overall prediction success of 52.1%. Each of the predictors in the final model was 
significant at the p<0.05 level. As such, higher dyspnoea levels were independently 
associated with reduced performance status, increased cough, increased pain and 
reduced self-esteem. There were no significant effects from the other variables which 
were excluded from the final model. For a fixed level of cough, pain and self-esteem, a 
patient with a PS of 3-4 was 1.34 (95% CI 0.664-3.634) times more likely to have 
higher dyspnoea. 
 
11.1.2 Dyspnoea in Newly Diagnosed Patients 
Dyspnoea felt (mean 1.56, SD 1.07, median 2, range 0-4) was reported to be low (0-1) 
in 48.2% (n=82/170) of newly diagnosed patients and high (2-4) in 49.4% (n=84/170). 
The factors tabulated below were evaluated for significant differences across lower and 
higher dyspnoea (Table 84). 
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Factor Number Percentage Number Percentage χ 2 Df p value Significant
Gender
Male 42 51.2% 40 48.8%
Female 40 47.6% 44 52.4% 0.215 1 0.756
Age
<65 years 23 50.0% 23 50.0%
≥65 years 59 49.2% 61 50.8% 0.009 1 1
Histology
Clinical 19 48.7% 20 51.3%
NSCLC 51 49.5% 52 50.5%
SCLC 12 50.0% 12 50.0% 0.011 2 0.994
Stage NSCLC
1A 2 66.7% 1 33.3%
1B 12 70.6% 5 29.4%
2A 7 63.6% 4 36.4%
2B 2 40.0% 3 60.0%
3A 8 47.1% 9 52.9%
3B 13 38.2% 21 61.8%
4 24 47.1% 27 52.9% 6.324 6 0.388
Stage SCLC
Limited 5 55.6% 4 44.4%
Extensive 7 46.7% 8 53.3% 0.178 1 0.673
Presence or absence of metastases
None 51 51.0% 49 49.0%
Metasases 31 47.0% 35 53.0% 0.258 1 0.637
Time from diagnosis to POS
Within 3 weeks 55 48.2% 59 51.8%
3-6 weeks 27 51.9% 25 48.1%
6 weeks to 3 months 0 .0% 0 .0%
3-6 months 0 .0% 0 .0%
6-12 months 0 .0% 0 .0%
> 12 months 0 .0% 0 .0% na
Performance status rated by patients
0-1 59 65.6% 31 34.4%
2 8 25.0% 24 75.0%
3-4 15 34.1% 29 65.9% 21.145 1 <0.001 ***
Diagnosis PS, assessed by doctor
0-1 50 56.2% 39 43.8%
2 17 37.0% 29 63.0%
3-4 4 57.1% 3 42.9% 4.633 2 0.099
Active anti-cancer treatment
Yes 60 50.0% 60 50.0%
No 12 48.0% 13 52.0% 0.033 1 1
Deprivation
Dep Cat 1-5 42 50.6% 41 49.4%
Dep cat 6 or 7 39 48.1% 42 51.9% 0.099 1 0.758
Satisfaction score
0-4 45 57.0% 34 43.0%
5-8 1 50.0% 1 50.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 33 66.0% 17 34.0%
Yes 19 43.2% 25 56.8% 4.93 1 0.037 *
Cough
No 25 67.6% 12 32.4%
Yes 55 43.7% 71 56.3% 6.55 1 0.015 *
Haemoptysis
No 68 51.9% 63 48.1%
Yes 11 36.7% 19 63.3% 2.27 1 0.158
Cough
Lower 63 61.2% 40 38.8%
Higher 17 28.3% 43 71.7% 16.35 1 <0.001 ***
Haemoptysis
Lower 72 49.3% 74 50.7%
Higher 7 46.7% 8 53.3% 0.04 1 1.000
Pain
Lower 57 61.3% 36 38.7%
Higher 25 34.2% 48 65.8% 11.97 1 0.001 **
Other symptoms
Lower 70 53.0% 62 47.0%
Higher 9 31.0% 20 69.0% 4.60 1 0.040 *
Personal anxiety
Lower 42 59.2% 29 40.8%
Higher 37 40.7% 54 59.3% 5.46 1 0.026 *
Support network anxiety
Lower 24 63.2% 14 36.8%
Higher 54 43.9% 69 56.1% 4.31 1 0.043 *
Less ability to share
Lower 65 52.4% 59 47.6%
Higher 15 40.5% 22 59.5% 1.61 1 0.261
Reduced life-worth
Lower 69 51.9% 64 48.1%
Higher 8 36.4% 14 63.6% 1.82 1 0.250
Reduced self-esteem
Lower 61 57.0% 46 43.0%
Higher 18 35.3% 33 64.7% 6.52 1 0.017 *
Information needs
Lower 59 50.9% 57 49.1%
Higher 19 50.0% 19 50.0% 0.01 1 1.000
Practical needs
Lower 58 52.7% 52 47.3%
Higher 20 44.4% 25 55.6% 0.88 1 0.380
Time wasted
Lower 75 50.3% 74 49.7%
Higher 1 16.7% 5 83.3% 2.62 1 0.210
Lower Dyspnoea Higher Dyspnoea
 
Table 84: Newly diagnosed patients. Univariate analysis of factors across groups of higher and 
lower dyspnoea. Percentages are adjusted for missing data. *p<0.05, **p<0.01 and ***p<0.001 
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The factors identified as significant were: PS rated by patients during LCQ completion, 
GP attendance, cough, pain, ‘other’ symptoms, personal anxiety, support network 
anxiety and self-esteem. Significant factors were entered into a backwards logistic 
regression model to test for independent effects. Frequency of review was not entered as 
this was likely to be related to ongoing active issues rather than a useful predictor of 
increased dyspnoea. In addition to these significant variables, additional factors of 
interest were included in the model: age, gender, presence of metastases and 
deprivation. Results are shown in Table 85.  
b SE Wald df p value Odds Ratio Lower Upper
Cough (higher) 1.171 .376 9.723 1 .002 3.225 1.545 6.734
Pain (higher) 1.141 .360 10.027 1 .002 3.129 1.544 6.341
Constant -.831 .258 10.401 1 .001 .436
95% CI for Odds Ratios
 
     R2=0.143 (Cox and Snell); 0.191 (Nagelkerke) Model Χ2=23.33, df=3, p<0.001 
     Hosmer-Lemeshow test: Χ2=1.930, df=2, p=0.381 
Table 85: Independent factors associated with higher dyspnoea identified through backwards 
logistic regression for newly diagnosed patients. 
 
A test of the full model against constant only model was statistically significant (model 
Χ2=23.33, df=3, p<0.001). Nagelkerke’s R2 of 0.191 indicated that around 19% of 
variance was explained by the model. Overall prediction success was 69.5% (60.8% for 
lower dyspnoea and 77.9% for higher dyspnoea). This compares to the null model 
overall prediction success of 51%. Each of the predictors in the final model was 
significant at the p<0.05 level. As such, higher levels of dyspnoea were independently 
associated with increased cough and increased pain. There were no significant effects 
from the other variables which were excluded from the final model. For a fixed level of 
cough, a patient with higher pain was 3.129 (95% CI 1.54-6.34) times more likely to 
have increased dyspnoea.  
 
11.1.3 Dyspnoea in Patients in the Last Three Months of Life 
Dyspnoea felt (mean 1.92, SD 1.23, median 2, range 0-4) was reported to be low (0-1) 
in 34.7% (n=42/121) of patients within the last three months of life and high (2-4) in 
61.9% (n=75/121). The factors tabulated below were evaluated for significant 
differences across lower and higher dyspnoea (Table 86).  
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Factor Number Percentage Number Percentage χ 2 df p value Significant
Gender
Male 23 36.5% 40 63.5%
Female 19 35.2% 35 64.8% 0.022 1 1
Age
<65 years 11 37.9% 18 62.1%
≥65 years 31 35.2% 57 64.8% 0.069 1 0.826
Histology
Clinical 9 52.9% 8 47.1%
NSCLC 22 27.8% 57 72.2%
SCLC 11 52.4% 10 47.6% 6.85 1 0.033 *
Stage NSCLC
1A 0 .0% 1 100.0%
1B 4 57.1% 3 42.9%
2A 2 33.3% 4 66.7%
2B 0 .0% 2 100.0%
3A 2 33.3% 4 66.7%
3B 9 29.0% 22 71.0%
4 13 31.0% 29 69.0% 3.62 6 0.728
Stage SCLC
Limited 1 16.7% 5 83.3%
Extensive 10 66.7% 5 33.3% 4.295 1 0.038 *
Presence or absence of metastases
None 19 31.7% 41 68.3%
Metasases 23 40.4% 34 59.6% 0.958 1 0.343
Time from diagnosis to POS
Within 3 weeks 12 40.0% 18 60.0%
3-6 weeks 2 33.3% 4 66.7%
6 weeks to 3 months 6 33.3% 12 66.7%
3-6 months 7 38.9% 11 61.1%
6-12 months 10 38.5% 16 61.5%
> 12 months 5 26.3% 14 73.7% 1.19 5 0.946
Performance status rated by patients
0-1 19 52.8% 17 47.2%
2 10 34.5% 19 65.5%
3-4 13 25.0% 39 75.0% 7.167 2 0.028 *
Diagnosis PS, assessed by doctor
0-1 21 33.9% 41 66.1%
2 16 42.1% 22 57.9%
3-4 3 42.9% 4 57.1% 0.778 2 0.678
Active anti-cancer treatment
Yes 28 32.9% 57 67.1%
No 9 45.0% 11 55.0% 1.032 1 0.313
Deprivation
Dep Cat 1-5 20 32.8% 41 67.2%
Dep cat 6 or 7 22 39.3% 34 60.7% 0.536 1 0.536
Satisfaction score
0-4 19 34.5% 36 65.5%
5-8 0 .0% 1 100.0%
9-12 0 .0% 0 .0% na
GP attendance between clinics
No 8 36.4% 14 63.6%
Yes 12 30.0% 28 70.0% 0.263 1 0.777
Cough
No 17 51.5% 16 48.5%
Yes 24 29.3% 58 70.7% 5.08 1 0.032 *
Haemoptysis
No 36 38.3% 58 61.7%
Yes 4 21.1% 15 78.9% 2.06 1 0.193
Cough
Lower 32 50.0% 32 50.0%
Higher 9 17.6% 42 82.4% 12.95 1 <0.001 ***
Haemoptysis
Lower 37 34.9% 69 65.1%
Higher 3 42.9% 4 57.1% 0.18 1 0.697
Pain
Lower 26 54.2% 22 45.8%
Higher 16 23.2% 53 76.8% 11.81 1 0.001 **
Other symptoms
Lower 33 44.6% 41 55.4%
Higher 7 17.9% 32 82.1% 7.93 1 0.007 **
Personal anxiety
Lower 23 46.0% 27 54.0%
Higher 17 27.0% 46 73.0% 4.41 1 0.048 *
Support network anxiety
Lower 15 48.4% 16 51.6%
Higher 26 31.3% 57 68.7% 2.85 1 0.124
Less ability to share
Lower 31 37.3% 52 62.7%
Higher 11 34.4% 21 65.6% 0.09 1 0.831
Reduced life-worth
Lower 40 43.5% 52 56.5%
Higher 2 9.1% 20 90.9% 9.02 1 0.003 **
Reduced self-esteem
Lower 34 49.3% 35 50.7%
Higher 8 17.4% 38 82.6% 12.10 1 0.001 **
Information needs
Lower 36 43.4% 47 56.6%
Higher 5 16.1% 26 83.9% 7.27 1 0.008 **
Practical needs
Lower 31 37.8% 51 62.2%
Higher 11 34.4% 21 65.6% 0.12 1 0.830
Time wasted
Lower 40 36.0% 71 64.0%
Higher 2 50.0% 2 50.0% 0.33 1 0.622
Lower Dyspnoea Higher Dyspnoea
 
Table 86: Patients who died within three months of questionnaire completion. Univariate analysis 
of factors across groups of higher and lower dyspnoea. Percentages are adjusted for missing data. 
*p<0.05, **p<0.01 and ***p<0.001 
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The factors identified as significant were patient-rated PS, extent of SCLC, cough, pain, 
‘other’ symptoms, personal anxiety, life-worth, self-esteem and information needs. 
Significant factors were entered into a backwards logistic regression model to test for 
independent effects. Extent of SCLC was not entered as this was a subset of all the 
patients. In addition to these significant variables, additional factors of interest were 
included in the model: age, gender, presence of metastases and deprivation. Results are 
shown in Table 87.  
b SE Wald df p value Odds Ratio Lower Upper
Cough (higher) 1.251 .484 6.687 1 .010 3.493 1.354 9.013
Pain (higher) 1.358 .455 8.909 1 .003 3.887 1.594 9.478
Reduced self-esteem 1.717 .818 4.408 1 .036 5.566 1.121 27.640
Constant -.845 .381 4.910 1 .027 .430
95% CI for Odds Ratios
 
   R2=0.212 (Cox and Snell); 0.291 (Nagelkerke) Model Χ2=26.22, df=3, p<0.001 
   Hosmer-Lemeshow test: Χ2=3.604, df=5, p=0.608 
Table 87: Independent factors associated with higher dyspnoea identified through backwards 
logistic regression for patients in the last three months of life. 
 
A test of the full model against constant only model was statistically significant (Model 
Χ2=26.22, df=3, p<0.001). Nagelkerke’s R2 of 0.291 indicated that around 29% of 
variance was explained by the model. Overall prediction success was 72.7% (43.6% for 
lower dyspnoea and 88.7% for higher dyspnoea). This compares to the null model 
overall prediction success of 64.5%. Each of the predictors in the final model was 
significant at the p<0.05 level. As such, higher levels of dyspnoea were independently 
associated with increased cough, pain and reduced self-esteem. There were no 
significant effects from the other variables which were excluded from the final model. 
For a fixed level of cough and pain, a patient with reduced self-esteem was 5.57 (95% 
CI 1.12-27.64) times more likely to have higher dyspnoea. 
 
11.2 Discussion 
Dyspnoea in lung cancer can interfere with physical and psychological functioning.443 
Tanaka et al443 reported that ‘clinical dyspnoea’ (breathlessness interfering with 
activities of daily living) occurred in 55% of ambulatory patients with advanced lung 
cancer. O’Driscoll et al442 explored the lung cancer patients’ experience of 
breathlessness and described the strong relationship between this sensation and strongly 
felt emotions and fears. The language used to describe the sensation of dyspnoea moved 
between physical descriptors (such as ‘chest tightness’) to emotional descriptors (such 
as ‘frightened the life out of me…breath is more important than water’). In this 
qualitative study, patients reported that dyspnoea affected many domains of their 
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everyday life, including activities of daily living, social activities, being able to leave 
the house, relationships with family and friends and sexual relations.442 
 
The current study demonstrates the high prevalence of dyspnoea in the Stobhill clinic 
lung cancer population. Dyspnoea was rated as moderate, severe or overwhelming by 
50% of patients attending the lung cancer clinic (see Section 6.2.1.1).  
 
In cancer, dyspnoea has been previously reported to be independently associated with 
lung involvement of cancer130 (primary site or secondary spread), anxiety,130, 352 
smoking, coexistent airway disease, lung irradiation351 and reduced survival.136, 339 
In lung cancer, increased breathlessness has been reported to be associated with a 
variety of factors, including presence of discrete organic causes,444 cough,393, 444 pain,444 
reduced performance status, fatigue, ‘coping’ ability,393 anxiety,355, 445 psychological 
distress444, 445 and reduced quality of life.355332 
 
In the current study dyspnoea was a highly rated physical symptom: 49.8% of patients 
overall, 49.4% of newly diagnosed patients and 61.9% of patients in the last three 
months of life described moderate to overwhelming dyspnoea. Potential predictors of 
increased dyspnoea (moderate-overwhelming) were explored utilising univariate and 
multivariate analyses. The main factors associated with increased dyspnoea were 
reduced PS, increased cough, increased pain and reduced self-esteem. Factors that were 
not related to dyspnoea level on univariate analyses included gender, age, histology, 
stage, time from diagnosis, deprivation, active anti-cancer treatment, Glasgow 
Prognostic Scale and practical needs. Personal anxiety was found to be associated with 
increased dyspnoea on univariate analysis but not in multivariate analysis. 
 
11.2.1 Performance Status and Dyspnoea 
Worse PS was associated with increased dyspnoea in each of the three clinical 
groupings on univariate analysis. However, on multivariate analysis, a PS of 2 was the 
only significant predictor of increased dyspnoea and only within the whole clinic 
population grouping. It has been reported in previous studies that increased 
breathlessness may adversely affect function, activities of daily living412, 443 and 
functional status in lung cancer.442 Furthermore, there is evidence that targeted clinics to 
treat breathlessness in the palliative setting can improve both dyspnoea and functional 
ability in lung cancer patients.446 Utilising specific breathing exercises,447, 448 education, 
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medications449 (such as opioids and benzodiazepines) and a focused approach to 
dyspnoea can improve symptom control and quality of life in patients with lung 
cancer.446 Smith et al355 did not find a significant association between PS and dyspnoea 
on univariate analysis of 127 lung cancer patients, but in their study most patients were 
PS 0 or 1 with only five patients reported with PS 4 and 14 patients with PS 3. Henoch 
et al393 and Tanaka et al444 reported increased dyspnoea in lung cancer patients with 
reduced PS. It should also be noted that in the outpatient setting there is likely to be bias 
against patients with poorer PS and high dyspnoea as they may be less able to attend the 
clinic. As such, this segment of the population may be underrepresented in any 
outpatient study. 
 
11.2.2 Other Physical Symptoms and Dyspnoea 
Cough and pain were consistently found to be independent predictors of increased 
dyspnoea in the current study. This was found to be the case on multivariate analysis in 
each of the clinical groupings. Furthermore, these two physical symptoms were the only 
two factors left in the model for newly diagnosed patients and comprised two of the 
three significant factors left in the model for patients in the last three months of life. 
This finding is in keeping with Tanaka et al444 who, in a study of 171 consecutive 
patients with advanced lung cancer, reported that the four independent predictors of 
increased dyspnoea were pain, cough, psychological distress (anxiety or depression) and 
presence of an organic cause for dyspnoea (e.g. pleural effusion, lymphangitis, 
pneumothorax, anaemia, etc). Henoch et al393 also reported cough as an independent 
predictor of dyspnoea but did not find an association between pain and dyspnoea. Smith 
et al355 reported pain as associated with increased dyspnoea but did not investigate the 
relationship between cough and dyspnoea.  
 
The association between pain and dyspnoea may be explained by high prevalence of the 
two symptoms in the lung cancer population, the common link being the lung cancer 
itself. Lung cancer patients are at increased risk of dyspnoea due to the presence of 
direct organic causes for breathlessness, and pain is also highly prevalent in lung cancer 
(see Section 10). However, it can be speculated that a bi-directional causal relationship 
may exist between these symptoms. In lung cancer, pain is often located in the chest due 
to local effects of the tumour, invasion of or spread to the ribs, infiltration of inter-costal 
nerves or invasion or spread to the pleura.401 It is likely that pain in the chest itself will 
limit breathing and contribute to the sensation of breathlessness.444 As such, pain may 
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be causing dyspnoea. Furthermore, the presence of dyspnoea may affect pain sensitivity 
by diminishing serotoninergic functions or may decrease sensitivity through the release 
of endogenous opioids.444 There may also be a common central link between the 
symptoms of pain and dyspnoea. Emerging evidence has suggested there may be a 
common aversive signalling pathway within the brain through which the 
‘unpleasantness’ of symptoms such as pain and dyspnoea is mediated.414-416 The 
sensitivity of such a pathway to one symptom may be increased by the presence of 
another symptom.414 In the current study, increased dyspnoea was an independent 
predictor of increased pain in the general clinic population and in patients within the last 
three months of life. However, this study was not designed to elucidate any relationship 
between these two symptoms and as such the above must remain speculative.  
 
11.2.3 Psychological Factors and Dyspnoea 
The relationship between dyspnoea and anxiety has been described in a variety of 
settings.416, 449, 450 Furthermore, addressing anxiety that occurs due to breathlessness, or 
triggers dyspnoea, is part of dyspnoea management.449 In the advanced cancer setting, 
increased dyspnoea has been described in patients who have increased anxiety.451 In 
lung cancer studies, the relationship between dyspnoea is less well defined. Most 
studies reported a positive relationship on univariate analysis, but this did not always 
remain on multivariate analysis. The situation is complicated by the heterogeneous 
populations studied, varying phases of the lung cancer journey being reported and the 
impact of other potential confounding variables. Tanaka et al444 did describe 
psychological distress (anxiety or depression) as being an independent predictor of 
increased dyspnoea in ambulatory lung cancer patients with advanced disease. Henoch 
et al393 reported that reduced coping ability was related to increased dyspnoea. They 
also reported anxiety and depression were associated with increased dyspnoea. 
However, only coping ability remained in the model after multivariate analysis. Chan et 
al445 studied 27 patients with advanced lung cancer to evaluate the possible symptom 
cluster of anxiety, fatigue and dyspnoea. They reported that there was some evidence 
for such a cluster but the significant correlations were low in strength. Smith et al355 
also described an increase in dyspnoea reported by patients with a high anxiety trait. 
 
In the current study, increased breathlessness was significantly associated with both 
increased personal and support network anxiety on univariate analysis in each of the 
groupings. However, on multivariate analysis, anxiety was not an independent predictor 
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of dyspnoea. Likewise, on multivariate analysis, increased dyspnoea did not predict 
increased personal anxiety or support network anxiety in this study (see Section 9). 
Multivariate analysis is dependent on the factors identified and entered into any model. 
It does appear that there was an association between increased anxiety and dyspnoea, 
but this may not be causal or direct. Furthermore, anxiety in lung cancer may be 
described with relationship to a symptom, the disease itself, treatments or existential 
fears and concerns. The LCQ question specifically asks ‘have you been feeling anxious 
or worried about your illness or treatment?’ This formulation of the question may miss 
anxiety that is more diffuse or relates to a specific factor other than illness or treatment 
(e.g. investigations, symptoms, etc).  
 
Increased dyspnoea has been reported in depressed patients with chronic respiratory 
diseases.452, 453 Furthermore, in the advanced cancer setting, increased dyspnoea has also 
been described in patients who have increased depression.451 In lung cancer, increased 
risk of depression has been described in patients experiencing higher symptom burden 
and reduced performance status.380 Tanaka et al444 also reported that increased dyspnoea 
was independently predicted by increased psychological distress (including anxiety and 
depression). However, a relationship between depression and dyspnoea has not been 
previously described specifically in lung cancer patients.  
 
In the current study, reduced self-esteem (‘do you feel good about yourself?’) was an 
independent predictor of increased breathlessness in the whole clinic population and for 
those within the last three months of life. Reduced self-esteem was also an independent 
predictor of increased personal anxiety in each clinical grouping. This finding suggests 
that reduced self-esteem is a key part of any relationship between increased anxiety and 
dyspnoea that has been previously described. The association between self-esteem and 
anxiety is further explored in Section 9. Reduction in feeling life was worthwhile (‘have 
you felt life was worthwhile?’) was not associated with either increased anxiety or 
dyspnoea. It is difficult to make direct comparisons between the LCQ questions and 
previous studies. The LCQ focuses on self-esteem and life-worth, which are specific 
components of or related to depression.375, 454 Reduced self-esteem has been reported to 
be related to increased depression in population studies391 and in patients with head and 
neck cancer.455 There have been no previous reports evaluating self-esteem and 
depression in the lung cancer population. 
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11.2.4 Non-Significant Factors 
Previous studies have consistently reported no relationship between dyspnoea and 
histology, stage of lung cancer, gender, social status and age.393 There have been some 
reports of increased dyspnoea in patients receiving radiotherapy.456 These previous 
findings are in keeping with the current study. Dyspnoea has previously been identified 
as a prevalent symptom at diagnosis,82, 292 during treatment,174, 283 in the terminal 
phase303, 393 and in survivors of lung cancer whom have undergone surgery.115 These 
findings are in keeping with the current study, both in prevalence of severe dyspnoea 
and in absence of a relationship between time from diagnosis and dyspnoea. Despite 
this symptom prevalence throughout the lung cancer journey, increased breathlessness 
has also been identified as an adverse prognostic factor in advanced cancer.136 The 
current study did find that dyspnoea was an independent predictor of reduced survival in 
the last three months of life in patients with lung cancer (see Section 8.2.3). 
 
11.3 Conclusions 
The high prevalence of dyspnoea in lung cancer has been confirmed in patients 
attending the Stobhill lung cancer service. This troublesome symptom was not related to 
demographic factors, the type of lung cancer or the stage of lung cancer journey. 
Independent predictors of increased dyspnoea were reduced PS, increased cough, 
increased pain and reduced self-esteem. Full evaluation of an individual’s symptom 
burden is important to identify troublesome symptoms, but particular attention should 
be paid to identifying increased dyspnoea in patients with any of the above factors. The 
relationship of anxiety with dyspnoea has been previously described in the cancer 
setting. The current study did not demonstrate any independent relationship between 
personal anxiety and dyspnoea. However, reduced self-esteem was associated with 
increased dyspnoea and this may influence the findings in this study. Dyspnoea is an 
important symptom in the Stobhill lung cancer population and, when identified, should 
be evaluated fully for associated factors. 
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12 Discussion 
12.1 Introduction 
Patients who are diagnosed with lung cancer face a condition which is likely to be 
incurable and is associated with increased psychosocial burden,2, 457, 458 financial 
implications,459 high symptom distress1, 174, 283 and reduced survival.3 Lung cancer has 
been associated with greater unmet supportive care needs than other cancers since 
Weisman’s report in 1976.4 This finding has been confirmed in more recent studies, 
with lung cancer being identified as an independent predictor of increased physical and 
psychosocial distress.175 Despite this, high levels of unmet needs remain in lung cancer 
patients, particularly psychosocial needs.11  
 
In addition to these issues, patients may also receive palliative or curative intent 
treatments with known toxicities and face decisions which are difficult and provoke 
anxiety.180 A recent review of ‘100 years of lung cancer’ failed to make any mention of 
supportive care needs or symptom control in lung cancer.19 The introduction of formal 
supportive and palliative care guidance for lung cancer management has only occurred 
recently.275 It is clear that such patients require focused, consistent and structured 
support from the point of diagnosis and throughout their illnesses. It is not clear how 
best to provide such support and how best to integrate such support into 
multidisciplinary care.  
 
This study has evaluated the supportive care needs of patients within the Stobhill lung 
cancer service, identified key issues, further evaluated these key issues, explored 
clinical indices for utility in the targeting of supportive care and evaluated patients’ 
views on service provision. This section will discuss the clinical care of lung cancer 
patients in reference to the stated aims of the project (Section 2). 
 
The development of this project has balanced the service aims of developing an 
evidence base to inform improvements through clinically useful instruments and 
evaluation of supportive care needs within the context of the published literature. This 
balance can be difficult to achieve and has raised the previously discussed 
methodological issues and limitations (Section 3). Such issues can be considered in the 
context of internal and external validity.460 Internal validity refers to how well a study 
measures what it sets out to measure; external validity refers to how well findings in one 
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study can be generalised to other groups.460 There can be a trade off between internal 
and external validity. For example, in randomised controlled trials the outcomes relate 
to a highly selected, controlled sample open to participation bias. The resultant 
outcomes are often clear and well defined but, therefore, less generalisable.460, 461 
Observational studies are often less selected, evaluate more heterogeneous groups and, 
therefore, outcomes are more generalisable but less defined. The possible biases within 
this study and the resulting limitations will be further discussed in Section 12.7.462 
 
The response and characteristics of the population described in Section 6.1 will be 
summarised. The discussion within Sections 6-11 will also be summarised and further 
considered within the context of the stated aims (Section 2). In keeping with Aim 6, 
recommendations for service improvement and for future work will be discussed in 
Section 12.8. 
 
12.2 Characteristics and Response of the Stobhill Lung 
Cancer Service Population 
Three hundred and fifty three lung cancer patients attending the Stobhill lung cancer 
clinic responded within the 30 month long study period. This represents a good 
response in a service that diagnoses around 130 patients with lung cancer each year. 
 
The characteristics of this population were in keeping with the recent United Kingdom 
lung cancer national audit3 (Table 24). The main difference identified was the 
preponderance of females within this sample. A longer median survival than expected 
was also identified. In addition, a very high level of deprivation was found in this 
population.  
 
The majority of patients presented with NSCLC. Advanced disease is common in this 
population, with over one third of patients having metastatic disease at presentation. In 
keeping with the out-patient setting, most patients had a performance status of 2 or 
better at diagnosis. The proportions able to undergo surgical resection also reflect 
known, national data, as did the percentages of patients receiving other anti-cancer 
treatments. In keeping with expectations, over half the patients in the current study were 
aged 70 years or more.  
 
 260
It is of note that there were more females in this sample than males. This is not typical 
for lung cancer studies but may reflect some participation bias, as well as the increasing 
national incidence of lung cancers in females40 and local increases in the incidence of 
female lung cancer referrals.189, 190 Gender differences regarding supportive care needs 
and symptoms in lung cancer have been discussed in the literature and are likely to 
represent complex dynamics between biological sex and other social factors.286, 418 
Gender differences were controlled for during the multivariate analyses. 
 
The median survival of all patients attending the Stobhill clinic was 11.47 months. This 
was higher than expected. However, the whole clinic population included those who 
were under treatment and those attending for routine follow-up after potentially curative 
treatment. Evaluating the three different clinical groupings in this study allowed this 
bias to be partly addressed through stratification. When considering newly diagnosed 
patients, Overall survival from diagnosis in this population was 9.1 months. This is also 
higher than previously published studies. It is likely that this reflected the out-patient 
nature of the study population and a selection bias towards longer surviving patients.460 
Direct hospital admission is not an uncommon mode of presentation and diagnosis in 
lung cancer,80 and this study would not have included all patients who presented in this 
way. Some patients who present to hospital would have died and, therefore, never 
attended the clinic. These patients have not been evaluated and this represents a form of 
prevalence-incidence selection bias (Neyman bias).462 Patients who did survive the 
initial hospital admission may have subsequently attended the clinic beyond six weeks 
from their diagnosis with lung cancer. These patients would not have been included in 
the new patient analyses (defined as less than six weeks from diagnosis). It is possible 
that this has contributed to the observed median survival being greater than expected. 
Furthermore, those with a poorer performance status and a high symptom burden were 
less likely to be able to attend an out-patient clinic, and if they did, may have felt less 
inclined to complete the questionnaire. 
 
There was a marked level of deprivation in the lung cancer patients attending this clinic. 
Although an increased incidence of lung cancer is associated with deprivation,52, 333-335 
the degree of deprivation in this population is greater than would be anticipated from 
the literature. However, this was not an unexpected finding given the level of 
deprivation within the Stobhill Hospital catchment area (Section 6.1). It can be 
speculated that deprivation may affect both survival50, 52, 368 and supportive care needs53 
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in cancer patients. However, no differences were found in this population when 
evaluating survival or supportive care needs between the three most deprived groups 
and other more affluent patients (see Sections 7 and 8). 
 
12.3 Understanding Lung Cancer 
To review the literature regarding symptoms related to lung cancer  
(Aim 2 and Section 5). 
The literature review undertaken within this study confirms that there are unmet 
physical and psychosocial needs at each stage of the lung cancer journey, including at 
presentation, at diagnosis, during investigation, during treatment (palliative or curative 
intent), at the end of life and in survivors (see Section 5). Meeting this aim has allowed 
a good understanding of the likely symptoms and issues that may be of particular 
importance in the Stobhill lung cancer population. 
 
Symptoms are dynamic in nature and the distress (or lack of) associated with any given 
symptom results from a complex interplay of multiple factors162, 165 (Section 1.5). 
Furthermore, the concept of symptom burden recognises that multiple symptoms may 
influence each other and global distress in an equally dynamic fashion.121, 324 As such, 
symptoms are individual and subjective. It is recognised that measurement of symptoms 
is therefore also complex. Furthermore, the choice of instrument to measure any factor 
will influence the observations made. It has been noted that the reported validity of any 
instrument designed to measure subjective health issues is limited to describing the 
instrument plus the population studied plus the setting of the study plus the manner in 
which the population has been engaged plus any error within the study.463 When 
utilising such measurement tools, these constraints should be recognised.  
 
12.4 Identifying Unmet Need 
To evaluate the prevalence of supportive care needs within Stobhill Hospital’s lung 
cancer multidisciplinary clinic, to assess overall supportive care needs as measured by 
the Palliative Outcome Scale and to identify the key issues reported by patients in 
three groupings (Aim 1 and Section 6.2). 
Section 6.2 describes the supportive care needs identified using the Lung Cancer Clinic 
Questionnaire in the Stobhill lung cancer service. In keeping with reported high levels 
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of need in patients attending lung cancer outpatient clinics,11-13 more than 90% of 
patients identified at least one unmet need from the POS questions and at least one 
active respiratory symptom. Furthermore, over 40% of patients attending the Stobhill 
lung cancer clinic reported moderate to overwhelming perceived anxiety within their 
support network (56.9%), moderate to overwhelming personal anxiety (50.8%), 
moderate to overwhelming dyspnoea (49.8%) and moderate to overwhelming pain 
(40.8%). These same four issues were reported most often in each of the clinical 
groupings considered. Therefore, anxiety, pain and dyspnoea have been identified as 
key issues in this population of lung cancer patients attending the Stobhill outpatient 
clinic when utilising the LCQ to assess needs. 
 
To evaluate clinical indices used within the Stobhill service to help identify patients 
with increased supportive care needs overall as measured by POS  
(Aim 4a and Section 7). 
In Scotland, although the incidence of lung cancer has peaked, there has been an effort 
to improve time from presentation to treatment in recent years.37, 207, 464 With the 
increasing complexity of investigations and treatment options, there is increasing 
pressure on lung cancer services, and this can lead to reduced time available for each 
individual patient.465 Palliative and supportive care services in Scotland are also 
providing increased levels of care to a broader range of patients and higher numbers of 
patients.466, 467 It is clear that care must be appropriately targeted to most efficiently 
deploy resources in meeting these challenges.277  
 
The Palliative Outcome Scale can be utilised to identify individuals’ supportive care 
needs in a variety of settings. In keeping with Aim 4a, considered here are, firstly, the 
use of the adapted POS questions within the LCQ to systematically assess individuals’ 
supportive care needs and, secondly, whether or not clinically relevant indices could 
allow patients with increased needs to be identified more readily.  
 
Patients may well have unmet needs which have not been identified or met despite 
attending a lung cancer clinic.11, 216, 350 Steele et al14 described that many lung cancer 
patients do not volunteer unmet needs as they feel they have an ability to manage, 
assume symptoms are part of the disease and cannot be altered, utilise their own 
existing support networks, feel staff are already too busy and/or are unaware that help is 
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available. Despite this, most patients would like to take up offers of help with 
supportive care needs.14, 468 Systematic assessment of symptoms and needs have been 
demonstrated to be more effective in identifying unresolved problems than traditional 
clinic reviews.276 The only randomised controlled trial to examine the use of a protocol 
driven, systematic assessment in lung cancer care showed that such an approach, 
delivered by a specialist nurse, identified more issues, provided more palliative 
radiotherapy and allowed more patients to die at home but had no effect on overall 
survival.264 The Palliative Outcome Scale is a tool which provides patient-rated 
outcome measures and allows a systematic evaluation of supportive care needs.147, 204 
POS has been successfully adapted already to suit settings different from hospice 
only.217, 221  
 
The experience in the Stobhill lung cancer clinic demonstrates that POS can be 
successfully incorporated into clinical care within a busy outpatient clinic and obtain 
information regarding supportive care needs of individuals and clinic populations. POS 
population data may further allow service structures to be reviewed and improved to 
allow identified needs to be addressed.  
 
POS can highlight specific issues in physical, psychological and social domains for each 
individual patient. As a patient-reported outcome measure, POS has the benefit of 
describing the main issues from the perspective of the patient themselves. This allows 
issues, often psychosocial problems, not often elicited and managed by medical models 
of care11 to be highlighted. However, POS does not detail any of the problems reported 
(e.g. does not identify pain type or cause).  
 
Despite this, in the context of clinical care, the use of POS as a screening tool is 
attractive. It compares well to other instruments and maintains a broad range of 
supportive care domains while retaining brevity (Table 6). Identified issues could then 
be addressed clinically or further assessed using more specific validated tools, (e.g. The 
Brief Pain Inventory469, 470 for pain or the Hospital Anxiety and Depression Scale310 for 
anxiety).  
 
The reported supportive care needs within this study are in keeping with other studies 
utilising POS. Furthermore, the findings are in keeping with symptom and need 
prevalence studies utilising many other tools used in symptom distress screening, 
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supportive care needs evaluation and quality of life studies (see Sections 6.2 and 7-11). 
These findings support the utility of POS within the LCQ as a useful clinical tool, a 
valid method for service analysis and a potentially helpful tool for research into 
supportive care needs. However, there was no formal testing of the LCQ undertaken for 
reliability or face validity (section 12.3.2) and, as such, the comparisons must be limited 
in scope. This is further discussed in Section 12.7.  
 
In Section 7, possible predictors of increased supportive care needs (POS>10) were 
evaluated. The factors identified within the three groupings are tabulated below. 
All patients Newly Diagnosed patients Patients within 3 months of 
death 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Poorer PS 
Younger age 
Diagnosis 
Treatment  
Resp score 
Review 
frequency 
Stage 
(NSCLC) 
Poorer PS 
Younger age 
Resp. score 
 
Cough 
Haemoptysis 
Poorer PS 
Younger age 
Resp. score 
Poorer PS 
Younger Age 
Poorer PS 
Resp. score 
Poorer PS 
Dyspnoea 
Haemoptysis 
Table 88: Summarised significant univariate associations and independent predictors of increased 
supportive care needs (Section 7). 
 
It is of note that having a POS>10 was independently associated with reduced 
performance status in each of the groupings studied: general clinic population, newly 
diagnosed patients and patients in the last three months of life. ECOG PS is used 
extensively within cancer management within the UK,10 is used as part of inclusion 
criteria for clinical trials405, 471 and is integral to decision making within the Stobhill 
lung cancer service. As such, this clinical scale could be further utilised to identify 
patients who may benefit from greater supportive care provision. 
 
Importantly, there was no independent relationship between supportive care needs and 
type of lung cancer, stage of lung cancer, time from diagnosis, gender or deprivation 
level (see Section 7). This finding is supportive of the concept of integrating supportive 
care throughout the lung cancer journey (see Section 1.4.7). Therefore, it is important to 
try and identify patients in need by recognising the associations of high supportive care 
needs. However, systematic screening assessment may be necessary to identify all 
needs.  
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Recommendation 1: Supportive care needs should be systematically assessed 
within the Stobhill lung cancer services from the point of diagnosis throughout the 
lung cancer journey. 
 
12.4.1 Anxiety – A Key Supportive Care Need 
To evaluate clinical indices used within the Stobhill service to help identify patients 
with increased risk of key supportive care needs: anxiety (Aim 4c and Section 9). 
Anxiety has been identified as a key supportive care issue in the Stobhill lung cancer 
service. Anxiety is known to be common within the lung cancer population, is often 
underestimated and impacts significantly on the quality of life of patients.2, 13, 107, 168, 176, 
369 Within the lung cancer clinic population in the current study, around half of patients 
reported moderate, severe or overwhelming personal anxiety. Personal anxiety appeared 
higher in newly diagnosed patients and those within three months of death than in the 
general clinic population. In keeping with previous studies utilising POS, more patients 
reported perception of high levels of anxiety in their support networks than higher levels 
of personal anxiety (see Section 9). In Section 9, possible predictors of increased 
personal and support network anxiety were evaluated. The significant associations and 
predictive factors identified within the three groupings are tabulated below. 
 
All patients Newly Diagnosed patients Patients within 3 months of death 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Poorer PS 
Younger age 
Time from 
diagnosis 
GP attendance 
Dyspnoea 
Cough 
Haemoptysis 
Pain 
Other symptoms 
Supporter anxiety 
Low self-esteem 
Information 
needs 
Practical needs 
Model 1: 
Supporter 
anxiety 
Cough 
Low self-esteem 
 
Model 2: 
Poorer PS 
Cough 
Low self-esteem 
Time from 
diagnosis 
<6months 
Poorer PS 
Younger age 
Time from 
diagnosis 
Dyspnoea 
Cough 
Pain 
Other 
symptoms 
Supporter 
anxiety 
Low self-
esteem 
Low life-worth 
 
Model 1: 
Poorer PS 
Supporter 
anxiety 
Low self-worth 
 
Model 2: 
Cough 
Low self-esteem 
Dyspnoea 
Cough 
Other 
symptoms 
Supporter 
anxiety 
Low self-worth 
Low self-
esteem 
Model 1: 
Supporter 
anxiety 
Low self-esteem 
 
Model 2: 
Low self:-esteem 
Table 89: Summarised significant univariate associations and independent predictors of increased 
personal anxiety (Section 9). 
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All patients Newly Diagnosed patients Patients within 3 months of death 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Poorer PS 
Younger age 
Time from 
diagnosis 
Dyspnoea 
Cough 
Haemoptysis 
Pain 
Other symptoms 
Personal anxiety 
Low self-esteem 
Low self-worth 
Reduced ability 
to share 
Information 
needs 
Practical needs 
 
Model 1: 
Poorer PS 
Metastases 
present 
Time from 
diagnosis < 6 
months 
Personal anxiety 
 
Model 2: 
Poorer PS 
Metastases 
present 
Haemoptysis 
Low self-esteem 
Time from 
diagnosis <6 
months 
Poorer PS 
Time from 
diagnosis 
Dyspnoea 
Cough 
Haemoptysis 
Pain 
Personal anxiety 
Low self-esteem 
 
Model 1: 
Pain 
Personal anxiety 
 
Model 2: 
Cough 
Pain 
Low self-esteem 
Poorer PS 
Cough 
Other symptoms 
Personal anxiety 
Low self-esteem 
Information 
needs 
Model 1: 
Personal anxiety 
Information 
needs 
 
Model 2: 
Other symptoms 
Low self-esteem 
Information 
needs 
Table 90: Summarised significant univariate associations and independent predictors of increased 
perceived support network anxiety (Section 9). 
 
A strong relationship between personal anxiety and levels of anxiety perceived in the 
support network was demonstrated. However, despite these high levels of anxiety, most 
patients reported they felt able to share their feelings with others if they wished. This is 
important as possible models of care could include enabling existent support networks 
to address anxiety and other issues. There was no evidence that male or female patients 
were likely to be more anxious. No relationship was found between anxiety and age or 
presence of active anticancer treatments. Reduced self-esteem was identified as an 
independent predictor of increased anxiety in this study. This is of particular 
importance, as both anxiety and reduced self-esteem can be addressed through well 
established psychotherapeutic methods.371, 392 PS was identified as a key predictor of 
increased anxiety in the general clinic population and newly diagnosed patients.  
 
Recommendation 2: Anxiety is a key issue within the Stobhill lung cancer 
population. This issue should be assessed systematically to allow identification and 
further management at all phases of the lung cancer journey 
 
Recommendation 3: To address anxiety and worry, Stobhill lung cancer services 
should explore ways in which to further support patients and their support 
networks. 
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12.4.2 Pain in Lung Cancer 
To evaluate clinical indices used within the Stobhill service to help identify patients 
with increased risk of key supportive care needs: pain (Aim 4c and Section 10). 
Pain in lung cancer has been well described in a recent review by Potter et al.401 The 
current study confirms that there was a high prevalence of uncontrolled pain in lung 
cancer patients attending the Stobhill outpatient lung cancer clinic. Around four in ten 
patients rated pain as moderate, severe or overwhelming (see Section 10). POS does not 
evaluate pain in any great detail so it is not possible to identify pain type, frequency or 
aetiology from this data. However, POS does assess the prevalence of pain that is 
disturbing the patient’s routine activities. The significant associations and predictive 
factors identified within the three groupings are tabulated below. 
 
All patients Newly Diagnosed patients Patients within 3 months of death 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Poorer PS 
Younger age 
Dyspnoea 
Cough 
Other symptoms 
Personal anxiety 
Supporter 
anxiety 
Ability to share 
Low self-esteem 
Information 
needs 
Practical needs 
Time use 
Poorer PS 
Younger age 
Dyspnoea 
Other symptoms 
Poorer PS 
Dyspnoea 
Other symptoms 
Personal anxiety 
Supporter 
anxiety 
Low self-esteem 
Information 
needs 
Poorer PS 
Younger age 
Other symptoms 
Information 
needs 
Dyspnoea 
Haemoptysis 
Other symptoms 
Dyspnoea 
Other symptoms 
Table 91: Summarised significant univariate associations and independent predictors of increased 
pain (Section 10). 
 
There was no independent relationship identified between increased pain and gender, 
stage, histology, deprivation, anxiety, depression or presence of active anti-cancer 
treatments. Predictive factors for increased pain were poorer PS, younger age, dyspnoea 
and ‘other’ symptoms. In newly diagnosed patients, unmet information needs were also 
associated with increased pain. Again it was noted that poorer PS was a key predictor of 
increased pain. 
 
Recommendation 4: Pain is a key issue within the Stobhill lung cancer population. 
Pain should be assessed systematically to allow identification and further 
management at all phases of the lung cancer journey. In particular, those with a 
poorer performance status should have pain assessed within the clinic. 
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12.4.3 Dyspnoea in Lung Cancer 
To evaluate clinical indices used within the Stobhill service to help identify patients 
with increased risk of key supportive care needs: dyspnoea (Aim 4c and Section 11). 
It can be expected, and has been demonstrated, that dyspnoea is a prominent symptom 
in lung cancer. Tanaka et al444 recently described a variety of correlates with dyspnoea 
in lung cancer patients. This study emphasised that ‘clinical dyspnoea’ is a multi-
factorial experience441 and is best considered and managed with that understanding.442, 
446, 447 In the current study, dyspnoea was rated as moderate, severe or overwhelming by 
five in ten patients attending the Stobhill lung cancer clinic. Furthermore, 61.9% of 
patients in the last three months of life reported moderate to overwhelming 
breathlessness. The significant associations and predictive factors identified within the 
three groupings are tabulated below. 
 
All patients Newly Diagnosed patients Patients within 3 months of death 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Poorer PS 
Cough 
Pain 
Other symptoms 
Personal anxiety 
Supporter 
anxiety 
Low self-esteem 
Low life-worth 
Information 
needs 
Poorer PS 
Cough 
Pain 
Low self-esteem 
Poorer PS 
Cough 
Pain 
Other 
symptoms 
Personal 
anxiety 
Supporter 
anxiety 
Low self-
esteem 
GP attendance 
Cough 
Pain 
Poorer PS 
Histology 
Stage of SCLC 
Cough 
Pain 
Other symptoms 
Personal anxiety 
Low self-esteem 
Low self-worth 
Information 
needs 
GP attendance 
Cough 
Pain 
Low self-esteem 
Table 92: Summarised significant univariate associations and independent predictors of increased 
dyspnoea (Section 11). 
 
Through logistic regression, the main factors identified that predicted increased 
dyspnoea were reduced PS, increased cough, increased pain and reduced self-esteem. It 
was of note that there was no relationship between increased dyspnoea and gender, age, 
histology, stage, time from diagnosis, deprivation, active anti-cancer treatment or 
practical needs. Personal anxiety (about illness or treatment) was associated with 
increased breathlessness on univariate analysis but not multivariate analysis. PS may 
therefore be a useful predictor of increased dyspnoea. 
 
Recommendation 5: Dyspnoea is a key issue within the Stobhill lung cancer 
population. Dyspnoea should be assessed systematically to allow identification and 
further management at all phases of the lung cancer journey. In particular, those 
with a poorer performance status should have dyspnoea assessed within the clinic. 
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12.5 Understanding the Urgency 
In any life-limiting condition, prognosis plays an important role in decision-making for 
patients and healthcare staff. When a prognosis is likely to be short, it is likely that 
treatments with major toxicities would be avoided and a greater focus placed upon 
quality of life. Symptom distress and reduced quality of life have both been previously 
associated with reduced life expectancy.1, 183, 309 Lung cancer patients often present with 
incurable disease and have a short life expectancy from the point of diagnosis. It would 
be useful to be able to identify individual patients with shorter survival and higher 
supportive care needs early within the disease journey. In this way efficient, effective 
supportive care could be targeted and provided more rapidly. 
 
12.5.1 Survival and Supportive Care Needs in Lung Cancer 
To evaluate clinical indices used within the Stobhill service to help identify patients 
with a reduced survival (Aim 4b and Section 8) 
Unmet supportive care needs have been demonstrated at specific junctures in the cancer 
journey: in particular, at time of diagnosis, investigation, discharge from clinics, point 
of recurrence and the terminal phase.180 It is not clear whether there is any association 
between increased supportive care needs and reduced survival.369 If patients with shorter 
survival also have higher supportive care needs, then there is a greater impetus for 
increased speed of care provision. Conversely, it may be that all patients, irrespective of 
expected survival, could benefit from supportive care. This would be in keeping with 
suggested models of integrating supportive care throughout the disease journey. POS 
score and other known adverse prognostic factors were evaluated in Section 8. The 
significant associated and predictive factors identified within the three groupings are 
tabulated below. 
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All patients Newly Diagnosed patients Patients within 3 months of death 
Univariate Multivariate Univariate Multivariate Univariate Multivariate 
Poorer PS 
Histology 
(SCLC) 
Metastases 
present 
Weight loss 
POS >10 
No treatment 
 
Poorer PS 
Metastases 
present 
Weight loss 
Poorer PS 
Metastases 
present 
POS >10 
 
Metastases 
present 
 
Dyspnoea 
Pain 
Personal 
anxiety 
Increased 
ability to share 
 
Dyspnoea 
Pain 
Increased ability 
to share 
Table 93: Summarised significant univariate associations and independent predictors of reduced 
survival (Section 8). 
 
The adverse prognostic factors identified in the Stobhill lung cancer population are in 
keeping with the known main determinants of survival.100 It is of interest to note that the 
physical factors, such as performance status and metastases, were not independent 
factors in the last three months. This is in keeping with the reported significance of 
symptoms in the terminal phase of many cancers.136, 339 
 
Regarding supportive care needs, there was a significant association with increased POS 
scores and reduced survival from the time of questionnaire completion on univariate 
analysis. However, on multivariate analysis (controlling for PS, stage and other factors) 
there was no independent relationship between POS and survival. Given the high levels 
of unmet need reported above, this finding supports models of supportive care that are 
integrated throughout the lung cancer journey. In Section 7, the close relationship 
between poorer PS and increased supportive care needs was also identified. Given the 
strong relationship between poorer PS and reduced survival, it is understandable that 
POS did not add further independent information regarding survival. Despite this, the 
triad of reduced function, increased supportive care needs and reduced survival may be 
a useful aid to lung cancer services in targeting and timing referrals to supportive care 
teams for individual patients. Clearly, care should be prompt for those in whom time is 
short. 
 
Recommendation 6: Supportive care should not only be aimed at those near the 
end of life but should be available to all patients throughout the whole of the lung 
cancer journey.  
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Recommendation 7: Known adverse prognostic factors may be used to prioritise 
timing of care and enable appropriate decision making. However, further work is 
necessary to define the role of these factors, in particular performance status. 
 
12.6 Evaluate Service and Preferences 
To review the literature regarding the current guidance and evidence for follow-up in 
lung cancer (Aim 3 and Section 4). 
The literature review undertaken within this study confirms that the evidence for follow-
up in lung cancer is poor. There is great variability within the guidance and there is little 
emphasis on supportive care issues. Despite this, follow-up is likely to be a useful 
platform for the delivery of supportive care (see Section 4). Meeting this aim has 
allowed a good understanding of the current evidence and practices of follow-up in the 
lung cancer setting. It would be useful to develop evidenced based follow-up models in 
the future that also take into account patients’ wishes and needs.  
 
12.6.1 Current Service Use 
To evaluate the Stobhill lung cancer service regarding service usage  
(Aim 5a and Section 6.1). 
The median review interval at the Stobhill clinic is 11 weeks (Table 17). This, however, 
represents a wide range of types of review appointment, including those under active 
treatment, those receiving supportive care and those who have received potentially 
curative treatments. The majority of patients (70.5%) attending the Stobhill lung cancer 
clinic reported no new or changing symptoms within the interval between review 
appointments. The majority of studies evaluating follow-up in lung cancer have 
reported that scheduled appointments often do not identify new or changing symptoms. 
In contrast, unscheduled appointments are almost always triggered by symptoms 
(Section 4). In the last three months of life more patients did report active symptoms 
between appointments (43%). In keeping with these findings, attendance at the general 
practioner between appointments was low overall (21.2%) but increased in the last three 
months of life (33.1%). Edmonds reported that within the last year of life the majority 
of patients with lung cancer (52%) attended their general practioner more than ten times 
(ranging from never to greater than 20 times).178 Murray et al180 reported that discharge 
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from hospital services to the care of community services can leave patients feeling 
anxious and uncertain.  
 
Although there are well documented strengths of multidisciplinary team working, there 
is a risk of professional overload for patients. This may be through overuse of the 
patient’s time or seeing too many health care professionals, resulting in repetition of 
assessment and care.70, 223, 332, 343, 472 Within the Stobhill lung cancer service, the 
majority of patients (81.4%) reported that they did not feel they were seeing too many 
healthcare professionals, and a similar proportion (81.3%) felt none of their time had 
been wasted through healthcare attendances. Although these findings are encouraging, it 
is likely that answers to these questions may be biased towards positive responses. 
Similar to the positive skew often found in satisfaction studies,236, 237, 343 patients may 
feel a sense of gratitude or dependence upon the clinical service and, therefore, limit 
critical comment. Seen in this light, the fact that 20% of patients reported some issues 
with time use or number of professionals seen should be considered in any future 
development of lung cancer services within Stobhill.  
 
Palliative care services play an active role within the Stobhill lung cancer service. In 
this study, documented referrals to palliative care were higher in the last three months of 
life (Section 6). It may be that specialist advice was more necessary in this group of 
patients and that many of the referrals could have been for end of life care. It may also 
be that referrals were made by phone or through the multidisciplinary meeting and were 
not documented within the notes. However, given that supportive care needs are 
apparent throughout the lung cancer journey, this may represent underuse of palliative 
care services at earlier phases. If this is the case, then it may reflect concerns of 
appropriateness of referral, patients’ reluctance to be referred due to stigma or 
misperceptions over palliative care’s role outwith end of life care.473 It is of note that, in 
a study of early palliative care in patients with metastatic NSCLC, Temel et al474 found 
early palliative care involvement led to significant improvements in both quality of life 
and mood. Furthermore, patients receiving palliative care input had less aggressive 
therapies at the end of life but longer survival.266, 475 
 
Recommendation 8: Stobhill lung cancer services should consider the structure 
and mechanisms of supportive care provision to ensure timely and effective 
support. 
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12.6.2 Patients’ Satisfaction with the Current Service 
To evaluate the Stobhill lung cancer service regarding patients’ satisfaction with the 
service (Aim 5b and Section 6). 
The measurement of satisfaction is promoted by the Scottish Government as an 
important way of engaging patients’ views on the quality of service provision.230 There 
are difficulties regarding the use of this poorly defined and poorly understood measure 
(Section 3). One of the main issues relates to the common finding that patients report 
high satisfaction with services they receive. This almost blanket positive response has 
been critiqued as measuring something other than true satisfaction: a feeling of gratitude 
to the service, a dependence upon the service and fear of removal or an unwillingness to 
be critical.236, 241 As such, it has been suggested that responses of dissatisfaction should 
be taken more seriously.236 It has been suggested that satisfaction evaluation is not 
useful at all; however, the definition and theory underpinning satisfaction evaluation has 
improved over the last decade through such work. Furthermore, it could be argued that 
in asking for service assessment from patients in a systematic way, a more open 
dialogue between patients and service providers could be promoted in time.  
 
In this study, high levels of satisfaction were reported regarding how the diagnosis was 
given, the investigation process and the current follow-up arrangements. The latter of 
these relates well to the finding that most patients would like to continue with the 
current follow-up structure. There were increased numbers of patients reporting 
dissatisfaction when considering those in the last three months of life. This may reflect 
increased distress as they enter the terminal phase of their illness or it may be that 
service improvement is required to meet the needs of this patient group.  
 
Around one third of patients attending the clinic reported not receiving the level of 
information they wished. This is an issue that should be addressed and may link to the 
high levels of anxiety identified. 
 
Recommendation 9: Stobhill lung cancer services should continue to involve 
patients in service evaluation. This should include a measure of quality or 
satisfaction rated from the patient’s point of view. 
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Recommendation 10: Information should be available to all patients and 
communicated in a sensitive and paced manner. 
 
12.6.3 Follow-up: Patients’ Understanding and Preferences 
To evaluate the Stobhill lung cancer service regarding patients’ understanding of the 
follow-up provision and patients’ preferences for follow-up (Aim 5c-d and Section 6). 
The role of supportive care has not been emphasised in the care of lung cancer,19 and its 
place in follow-up has not been clearly defined. There remain questions regarding the 
utility of follow-up, its cost-effectiveness, optimal type of follow-up structure, who 
should provide follow-up, what type of follow-up is wished for by patients and the place 
of supportive care in follow-up (see Section 6).  
 
The current study demonstrates the high prevalence of unmet needs in this population of 
ambulatory lung cancer outpatients with reduced life expectancy. The challenge of 
meeting these needs and providing accessible, equitable care is beginning to be 
discussed within national guidelines.277 Different models of care have been suggested, 
including on-going medical follow-up, nurse-led follow-up, open access clinics with 
general practioner-led follow-up, integration of palliative care services into 
multidisciplinary clinics and utilising these different models of follow-up through active 
MDT decision-making for individuals at different stages of their journey. There is a 
lack of knowledge regarding patients’ wishes and preferences for follow-up (see 
Sections 4 and 6). 
 
The British Thoracic Society’s guidelines do state that patients should know who is in 
charge of their care.69 In the Stobhill lung cancer service, a notable proportion (10%) of 
patients were ‘uncertain’ as to who was co-ordinating their care. Furthermore, there was 
a wide variation in who patients thought was in charge. The lead clinician is likely to 
change throughout the lung cancer journey and this may be reflected in the varied 
responses. However, in keeping with the guidance, it should be clear both who is in 
charge and who to contact regarding care issues.  
 
When asked about models of follow-up, the majority of patients preferred to continue 
with routine MDT clinic follow-up rather than GP-led follow-up (with open access 
return) or hospital-based, specialist nurse-led follow-up. This finding is common in 
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surveys of patient preference, but in studies which allow patients to experience nurse-
led clinics there is also high a level of satisfaction reported (see Section 6.3).223, 264, 265, 
476 It does appear that a variety of models of care would be acceptable or preferred by 
different patients. This range of preference is again in keeping with the varied clinical 
priorities at different phases of the lung cancer journey. It is also in keeping with the 
British Thoracic Society model of follow-up277 which advocates several different tracks 
of care should be available to meet individual needs (Figure 7).  
 
Patients may also be able to draw on their own resources and support network to meet 
needs. If this is the case, then the role of supportive care services may be best extended 
to empower and sustain the existing support network. In the current study, most patients 
felt able to share worries and concerns with somebody (see Section 6.2). This may be 
one method of meeting need within limited resources. However, it has been clearly 
demonstrated that patients face lung cancer along with their support network and have 
worries and concerns that relate to their families and significant others (Section 9). The 
recognition that patients face illness within the context of a support network, and that 
the diagnosis of lung cancer can affect carers and families, has led to the recognition 
that proactive supportive care should be extended to families and significant others.384 
Such models of care have a low evidence base but are now beginning to be studied and 
implemented. 
 
Recommendation 11: Stobhill lung cancer services should offer a range of follow-
up models including clinic-based care, nurse-led care and community-based care. 
The multidisciplinary team and patient’s wishes should drive the choice of follow-
up. 
 
Recommendation 12: All patients attending the Stobhill lung cancer clinic should 
know who is in charge of their care and whom to contact for advice or support. 
  
12.7 Limitations of this Study 
In 1979, David Sackett462 catalogued 35 biases that can occur in research. These can be 
grouped under three main headings: selection bias, information bias and confounding.460 
Selection bias relates to factors which influence the membership of the population being 
studied including participation bias, selection bias and non-respondent bias. Information 
bias relates to factors which influence the response of participants (such as leading 
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questions, differing modes of questioning or dependence on clinical service being 
evaluated) and recall bias. Confounding relates to other factors blurring effects. In this 
case, it may be that one or more factors influence outcome indirectly through 
interactions or is simply a co-occurrence rather than part of a causative chain. One 
example of this would be the identification of cigarette lighters causing lung cancer 
through a correlation study. In this example, it is known that the smoking of cigarettes is 
the causative factor and the cigarette lighter is only associated by being part of the 
process of smoking. 
 
12.7.1 Selection Bias 
This study was conducted in a single centre and, thus, portrays a site-specific 
experience. Within this sample there were particular population characteristics that 
suggested selection bias and may limit generalisation of the findings.  
 
As discussed in Section 6, the population described had a higher median survival than 
expected, perhaps reflecting some participation bias towards survivors and the 
ambulatory outpatient population. The preponderance of females within this population 
may also have affected the responses obtained. These issues may have affected the 
prevalence of issues reported and univariate associations described. However, the 
multivariate regressions were performed controlling for the influence of both these 
factors. 
 
There was a high level of deprivation in the patient catchment area for the study, and 
this may have influenced the type of supportive care needs reported although it did not 
affect the overall POS score. The Stobhill catchment area covers a population of more 
than 200,000 people within the North of Glasgow and part of East Dumbartonshire. 
This population includes many of the most deprived people in Scotland, with Glasgow 
City containing almost half (48%) of the 15% most deprived local populations in 
Scotland.188 Although this could be considered as a limitation, it can also be seen as a 
strength of this study. As outlined previously, Glasgow has the highest incidence of 
lung cancer and the highest lung cancer-related death rate in Scotland. This places 
Glasgow as a lead in lung cancer experience within the United Kingdom. In global 
terms, Scotland has one of the highest incidences of lung cancer worldwide. Therefore, 
the evaluation of supportive care needs within the Stobhill service is likely to provide 
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valuable insights that could aid service improvement for lung cancer patients no only 
within but also outwith this catchment area. 
 
12.7.2 Information Bias 
Within this study, POS questions were adapted and incorporated within the Lung cancer 
questionnaire. The reasons for this have been outlined within Section 3 and were driven 
by the wish to minimise questionnaire burden and retain an instrument that was 
clinically useful. This may have reduced the validity and reliability of the instrument.477  
 
There are several forms of validity that can be assessed for any health measurement 
instrument. Face validity evaluates whether the tool makes sense and is generally 
obtained through user groups or experts making judgements on each item.477 Content 
validity is the judgement of a group of experts as to whether the instrument adequately 
covers the areas to be measured.193 Construct validity relates to assessing whether the 
tool relates to the underlying theory, what it actually measures and what does it not 
measure. Some statistical processes can be used to aid this assessment (e.g. factorial 
analysis).477 Concurrent validity compares the tool to other validated tools and measures 
the level of agreement. This requires the index tool to be well validated in a similar 
population and context. It has also been suggested that new tools should differ from 
previous tools or there is no value in the new development.463 Conversely, discriminate 
validity assesses to what degree the tool differs from other instruments or what items 
within the tool differ.477  
 
Reliability can be considered as relating to internal consistency and test-retest 
reliability. Internal consistency is assessed through measurement of the variance within 
item responses as a proportion of the variance between respondents. This can be 
measured statistically through different methods (e.g. Cronbach’s alpha).463 Test-retest 
reliability refers to how stable the results from the tool are over time. It has been noted 
that this type of reliability may not be suitable when considering dynamic variables such 
as symptoms.477 
 
Although the Palliative Outcome Scale is a validated instrument, the adaptations and 
addition of questions to construct the lung cancer questionnaire will have influenced the 
responses given. This is a form of informational bias. There were some clear influences 
on the POS responses as a result of adding questions related to respiratory symptoms. 
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This was likely to reduce the number of patients who report ‘other’ symptoms (i.e. they 
would no longer report cough, dyspnoea or haemoptysis in this section). Despite this, 
internal consistency did remain high in the POS items. However, less clear item 
interactions may have occurred within this study. Although POS has been used in an 
adapted form for other studies, for future work these adaptations would require an 
assessment of validity. The staged adaptation of adding satisfaction questions in years 
two and three may also have influenced responses. However, there were no significant 
differences between summated POS score or questionnaire items completed in year one 
compared to years two and three. Finally, for patients who completed more than one 
questionnaire, this may have influenced the responses obtained. Having seen the 
questions previously could alter scoring in either direction through multiple different 
mechanisms. This may have affected the results obtained for patients within the last 
three months of life.  
 
The alteration of the assessed period from three days to four weeks may also have 
influenced the findings of this study. The aim of this was to match the out-patient 
environment, to assess issues that were persistent and to filter acute issues. This may 
have altered some responses by introducing the need to remember issues. It has been 
reported that the description of symptoms such as pain can be influenced by memory 
and pain itself can influence ability to remember.478 
 
Another approach to this study could have been to use a battery of validated tools to 
address all of the points of interest. Although the process of questionnaire validation 
itself has been critiqued as being essentially subjective,463 validation may have allowed 
comparisons of similar items to assess for external validity of POS in this population. 
However, it was not feasible to achieve full validation of the Lung Cancer Clinic 
Questionnaire within the context of this busy clinic in terms of time use, resources 
available and considering the risk of questionnaire fatigue. Although validated lung 
cancer specific tools are available for gaining information regarding some of the issues 
evaluated, there is no single tool that addresses all of these issues. Combinations of 
validated tools could be open to the same critique of unknown interactions between 
items and possible reduced validity.463 In addition, respondent burden has been reported 
to relate to longevity of survey, repetition of questions and perceived irrelevance of 
questions.479, 480 
 
 279
12.7.3 Confounders 
It is possible to try and control for confounding variables through a process of 
restriction (i.e. patient selection through selection criteria which may limit the scope of 
conclusions), matching in case-control studies (which can be complex if multiple 
variables matched and these variables cannot be analysed for effect) or stratification (i.e. 
post hoc analysis using statistical techniques to control for factors). This study was 
restricted to lung cancer patients attending the Stobhill lung cancer clinic. No matching 
of cases and controls was undertaken but stratification was used to assess different 
groups of patients. The analysis was phased as descriptive, univariate and multivariate. 
The multivariate approach allowed for control of confounding variables. However, it is 
not possible to control for all confounders, and this is apparent because logistic 
regressions only explained a proportion of the variance in prediction of the outcome. 
 
Accepting these limitations of the current study and understanding some of the likely 
biases within it are important. However, it is also worth noting that approaches to 
clinically based evaluation can vary from a flexible design481 (allowing conditions and 
evolving issues to inform methodology) to a highly controlled, selected and randomised 
trial.481 Information gained from different approaches should be viewed in the context 
of the respective advantages and disadvantages of each method; nonetheless, each form 
retains value and can inform improvement. 
 
12.8 Future Work 
Meeting the supportive care needs of lung cancer patients remains a challenge and 
currently lacks a strong evidence base from which to proceed. Recent developments in 
lung cancer management include advances in anti-cancer treatment options (including 
second and third line treatments), recognition of the need for supportive care and 
delivering care using a multidisciplinary approach. It is unfortunate that many of these 
developments have been introduced without assessing efficacy, efficiency and 
superiority compared to existent care.70 This study has established a high level of unmet 
need within the Stobhill lung cancer clinic. However, further study and development is 
necessary to understand how best to provide care in meeting those needs. Several 
recommendations, detailed below, have been made from this study. 
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Recommendation 1: Supportive care needs should be systematically assessed within 
the Stobhill lung cancer services from the point of diagnosis throughout the lung cancer 
journey. 
Recommendation 2: Anxiety is a key issue within the Stobhill lung cancer population. 
This issue should be assessed systematically to allow identification and further 
management at all phases of the lung cancer journey 
Recommendation 3: To address anxiety and worry, Stobhill lung cancer services 
should explore ways in which to further support patients and their support networks. 
Recommendation 4: Pain is a key issue within the Stobhill lung cancer population. 
Pain should be assessed systematically to allow identification and further management 
at all phases of the lung cancer journey. In particular, those with a poorer performance 
status should have pain assessed within the clinic. 
Recommendation 5: Dyspnoea is a key issue within the Stobhill lung cancer 
population. Dyspnoea should be assessed systematically to allow identification and 
further management at all phases of the lung cancer journey. In particular, those with a 
poorer performance status should have dyspnoea assessed within the clinic. 
Recommendation 6: Supportive care should not only be aimed at those near the end of 
life but should be available to all patients throughout the whole of the lung cancer 
journey.  
Recommendation 7: Known adverse prognostic factors may be used to prioritise 
timing of care and enable appropriate decision making. However, further work is 
necessary to define the role of these factors, in particular performance status. 
Recommendation 8: Stobhill lung cancer services should consider the structure and 
mechanisms of supportive care provision to ensure timely and effective support. 
Recommendation 9: Stobhill lung cancer services should continue to involve patients 
in service evaluation. This should include a measure of quality or satisfaction rated from 
the patient’s point of view. 
Recommendation 10: Information should be available to patients and communicated in 
a sensitive and paced manner. 
Recommendation 11: Stobhill lung cancer services should offer a range of follow-up 
models including clinic-based care, nurse-led care and community-based care. The 
multidisciplinary team and patients’ wishes should drive the choice of follow-up. 
Recommendation 12: All patients attending the Stobhill lung cancer clinic should 
know who is in charge of their care and whom to contact for advice or support. 
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12.8.1 Service Development 
The ongoing use of a supportive care need instrument within the Stobhill lung cancer 
clinic is recommended to allow systematic assessment of need. This tool could continue 
to be the Palliative Outcome Scale or another lung cancer specific instrument. It is 
important that this tool remains clinically viable in terms of resource and time available. 
However, it may add to future evaluations if the instrument was used in its validated 
form or, if adaptations are made, these are fully validated. 
 
The key issues of anxiety, pain and dyspnoea could be addressed through focusing of 
current resources. The role of the specialist lung cancer nurse is likely to be pivotal, and 
formal links between this person and palliative care services may streamline 
approaches.  
 
The role of support in tackling anxiety has been well established. Furthermore, 
supporting carers may add benefit.482 The formation of a support group within Stobhill 
may help tackle this issue and this has now been established. Lung cancer is a condition 
that is very likely to cause anxiety. It is noted that anxiety is increased at times in the 
journey when patients are likely to be meeting healthcare professionals. It is vital that 
these professionals do not add to anxiety through poor interaction and communication. 
The British Thoracic Society guidance on communication394 in lung cancer should be 
made available in the clinic, and staff could attend communication courses to improve 
skills. This may enable more information to be shared with patients in a sensitive and 
paced manner. 
 
Patient education regarding non-pharmacological techniques to control breathlessness 
may be advantageous and help address dyspnoea. This may be provided by clinic 
nursing staff or through referral to specialist palliative care services 441, 446  
 
Cancer pain can often be controlled utilising the analgesic ladder.402 Pain, and the cause 
of pain, must first be identified before it can be managed. The ongoing use of a 
screening tool could be augmented by a more detailed assessment through a pain-
specific instrument. Education regarding pain control should be provided to staff within 
the clinic. For pain that is not controlled by this approach, a clear and efficient referral 
pathway to palliative care services could be established.  
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12.8.2 Research and Further Work 
Complex, multi-modal supportive care measures can be difficult to evaluate, but there is 
a move to attempt clearer definitions of ‘best supportive care’ and ‘standard care’ within 
cancer trials.140 A better understanding of the cancer journey for different tumour types 
and treatment pathways may allow the development and testing of tumour-specific 
models of care. In lung cancer, such models of care will benefit from the improved 
understanding of symptom distress,162, 309 the pathophysiology of symptoms401 and 
effective palliative therapies.483 However, research into this area remains at a low level 
and future work is required to increase the knowledge base to allow the development of 
lung cancer care.  
 
Although patients prefer the option of hospital-based clinics, it is not clear that this is 
the best way of meeting need. Possible options for follow-up models include hospital-
based interval assessment, home-based interval assessment or perhaps real time 
assessment for selected patients utilising newer technology.484 There is a need for 
adequately powered randomised controlled trials to investigate both models of care and 
specific supportive care interventions. 
 
The key issues of anxiety, pain and dyspnoea in lung cancer patients merit further 
investigation. Understanding potential predictors of these issues may help target finite 
resources to aid their management. 
 
The utility of performance status as a decision-making and prognostic aid is already 
integrated into oncological care. The current study suggests that this clinical indicator 
could also be utilised to aid timely, proactive supportive care interventions. Further 
work is needed to evaluate how this could be integrated into lung cancer care and which 
health professions could best provide the interventions required  
 
Finally, the utility of the Palliative Outcome Scale in lung cancer care could be further 
evaluated and compared to other validated tools. This study could be developed to 
assess which tools can be used in combination and continue to retain clinical relevance.  
 
12.9 Conclusions and Recommendations 
In meeting the aims of this service evaluation, a high supportive care needs prevalence 
within lung cancer patients attending the Stobhill lung cancer clinic has been 
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demonstrated and recommendations regarding future service development have been 
made. 
 
Increased anxiety has been identified as a key psychosocial issue, including personal 
anxiety and, particularly anxiety within the support network. The physical symptoms of 
pain and dyspnoea are particularly prevalent in this population.  
 
In keeping with the importance of performance status in decision-making in lung cancer 
treatments, performance status has an important role in the targeting of referrals to 
supportive care services for individual assessment. However, supportive care needs are 
apparent at all stages of the lung cancer journey and are not predicted by histology, 
stage, gender or deprivation. Increased supportive care needs did not predict survival in 
multivariate analyses when controlled for performance status and other factors.  
 
Lung cancer remains the leading cause of cancer-related death in Scotland. Over 4000 
patients are diagnosed each year and, despite some treatment advances, overall survival 
remains poor. The psychosocial and physical symptom burden of lung cancer patients is 
greater than many other cancers and conditions. Systematic review of symptoms, 
psychosocial issues, spiritual needs and carers’ needs remains vital to identifying those 
individuals who would most benefit from focused care. 
 
Specific attention to supportive care in future service planning, service delivery, 
research and investment is required for people who will be diagnosed with lung cancer 
in Glasgow and elsewhere in the coming years. 
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Appendix 3: The Lung Multidisciplinary Clinic Questionnaire 
Please answer the following questions by ticking the box next to the answer that is most true for you. Your 
answers will help us to keep improving your care and will be analysed to further develop service and help 
in the care of others. If possible, please complete one each clinic visit. Thank you. 
Name: _____________________ Date of Birth: ____________     Weight: ____ 
Date: ___________   Age: ________ 
1. How long ago was your last clinic review? 
 This is my first appointment 
 Less than 4 weeks 
 4 - 8 weeks 
 2-4 months 
 Greater than 4 months 
 
2. Have you experienced any new or worsening symptoms since last being at clinic? 
 No 
 Yes 
 
3. If any, what have been your main problems in the last 4 weeks? 
a)_____________________________________________ 
 
b)_____________________________________________ 
 
4. Have you had to contact your GP in the last 4 weeks? If so Why? 
 No 
 Yes   Why? ______________________________ 
 
5. Over the past 4 weeks, have you been affected by pain? 
 Not at all, no effect 
 Slightly – but not bothered to be rid of it 
 Moderately – pain limits some activity 
 Severely – activities or concentration markedly affected 
 Overwhelmingly – unable to think of anything else 
 
6. Over the past 4 weeks, have you been affected by shortness of breath? 
 Not at all, no effect 
 Slightly – but not bothered to be rid of it 
 Moderately – breathlessness limits some activity 
 Severely – activities or concentration markedly affected 
 Overwhelmingly – unable to think of anything else 
7. Over the past 4 weeks, have you been affected by cough? 
 Not at all, no effect 
 Slightly – but not bothered to be rid of it 
 Moderately – cough limits some activity 
 Severely – activities or concentration markedly affected 
 Overwhelmingly – unable to think of anything else 
 313
8. Over the past 4 weeks, have you been affected by coughing up blood? 
 
 Not at all, no effect 
 Slightly – but not bothered to be rid of it 
 Moderately –happens quite often 
 Severely – happens a lot 
 Overwhelmingly – unable to think of anything else 
 
9. Over the past 4 weeks, have any other symptoms e.g. Nausea or constipation been 
affecting how you feel?                     (If Yes then please write symptoms) 
 
 No, not at all 
 Slightly   What Symptom(s)? ___________________ 
 Moderately 
 Severely 
 Overwhelmingly 
 
10. 6 months ago - How would you describe your ability to be active? 
 
 Fully active, no difference from my normal 
 Restricted in strenuous activity, can manage most other things with ease 
 Up and about for the majority of the day, can care for myself but cannot 
carry out normal activities (e.g. Shopping or cleaning by myself) 
 Can only do some things for myself, have to rest for more than half the day 
 I do not get out of bed or my chair and I need help with everything 
 
11. Over the past 4 weeks - how would you describe your ability to be active? 
 
 Fully active, no difference from my normal 
 Restricted in strenuous activity, can manage most other things with ease 
 Up and about for the majority of the day, can care for myself but cannot 
carry out normal activities (e.g. Shopping or cleaning by myself) 
 Can only do some things for myself, have to rest for more than half the day 
 I do not get out of bed or my chair and I need help with everything 
 
12. Over the past 4 weeks, have you been feeling anxious or worried about your illness 
or treatment? 
 
 No, not at all 
 Occasionally 
 Sometimes – affects my concentration now and then 
 Most of the time – often affects my concentration 
 Can’t think of anything else – completely pre-occupied by worry and anxiety 
 
13. Over the past 4 weeks, have any of your family or friends been anxious or worried 
about you? 
 
 No, not at all 
 Occasionally 
 Sometimes – it seems to affect their concentration 
 Most of the time 
 Yes, always pre-occupied with worry about me 
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14. Over the past 4 weeks, have you been able to share how you are feeling with your 
family or friends? 
 
 Yes, as much as I wanted to 
 Most of the time 
 Sometimes 
 Occasionally 
 Not at all with anyone 
 
15. Over the past 4 weeks, have you felt life was worthwhile? 
 
 Yes, all the time 
 Most of the time 
 Sometimes 
 Occasionally 
 Not at all 
 
16. Over the past 4 weeks, have you felt good about yourself? 
 
 Yes, all the time 
 Most of the time 
 Sometimes 
 Occasionally 
 No, not at all 
 
17. Over the past 4 weeks, how much information have you and your family or friends 
been given? 
 
 Full information or as much as wanted – always feel free to ask 
 Information given but hard to understand 
 Information given on request but would have liked more 
 Very little given and some questions were avoided 
 None at all – when we wanted information 
 
18. Over the last 4 weeks, have any practical matters resulting from your illness, either 
financial or personal, been addressed? 
 
 I have had no practical problems 
 Practical problems have been addressed and my affairs are as up to date as I 
would wish 
 Practical problems are in the process of being addressed 
 Practical problems exist which were not addressed 
 
19. Over the past 4 weeks, how much time do you feel has been wasted on 
appointments relating to your healthcare, e.g. Waiting round for transport or 
repeating tests? 
 
 None at all 
 Up to half a day wasted 
 More than half a day wasted 
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20. Do you feel you are seeing too many different Health care Professionals? 
 No 
 Yes 
 
21. How satisfied were you with the way tests were carried out  
      (Taking into account time taken, discomfort and side effects) 
 
 Very Satisfied 
 Satisfied 
 Unsatisfied 
 Very Unsatisfied                      Main reason : ______________________ 
 
22. How satisfied were you with the way in which you were told what was wrong? 
 
 Very Satisfied 
 Satisfied 
 Unsatisfied 
 Very Unsatisfied                      Main reason : ______________________ 
 
23. How satisfied are you with the way in which you are being followed up at the 
hospital clinic? 
 
 Very Satisfied 
 Satisfied 
 Unsatisfied 
 Very Unsatisfied                      Main reason : ______________________ 
 
24. How would prefer your on-going follow up to be organised? 
 
 Regular, routine appointments at this clinic even if you have no new or changing 
symptoms 
 If new or changing symptoms develop then an arranged, rapid return to this 
clinic through your own GP  
 By a hospital-based specialist nurse-led service with return to this clinic only if 
there were new issues to be assessed 
 
25. Who do you think is the main person in overall charge of your care? 
           (Please pick one main person) 
 General Practitioner 
 Respiratory Consultant 
 Oncologist 
 Surgeon 
 Palliative Care Consultant 
 Specialist Nurse 
 Uncertain 
 Other ______________ 
 
26. How did you complete this questionnaire? 
 
 On my own 
 With the help of a friend or relative 
 With help from a member of staff 
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Appendix 4: The Palliative Outcome Scale, Version 1 
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Appendix 5: POS Responses For All Q1 
 
 
  
  
  
Figure 21A: Histogram and bar charts of patient responses to POS questions (Q1);  
95% confidence intervals included. 
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Figure 21B: Bar charts of patient responses to POS questions and self-rated performance status 
(Q1); 95% confidence intervals included. 
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Appendix 6: POS Responses for All Newly Diagnosed Patients 
 
 
 
 
 
 
  
Figure 22A: Histogram and bar charts of recently diagnosed (<6 weeks) patients’ responses to POS 
questions (Q1); 95% confidence intervals included. 
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Figure 22B: Bar charts of recently diagnosed patients’ responses to POS questions and self-rated 
performance status (Q1); 95% confidence intervals included. 
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Appendix 7: POS Responses for Patients Within Last Three Months 
  
 
 
 
 
  
Figure 23A: Histogram and bar charts of patients’ responses to POS questions (QF) within three 
months of death (from any cause); 95% confidence intervals included. 
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Figure 23B: Bar charts of patients’ responses to POS questions (QF) and self-rated performance 
status within three months of death (any cause); 95% confidence intervals included. 
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Appendix 8: Outline of Statistical Tests 
Student’s t Test 
When comparing two independent groups of data, it is important to know the 
distribution of the data. This will determine which tests are appropriate to use.  
 
For normally (Gaussian) distributed data, any significant difference between the two 
groups can be assessed using Student’s t test. This test calculates a t statistic based on 
standard deviations (using standard error, s.e.) and the difference between the means of 
the two groups compared to an expected difference if the null hypothesis is true. (This 
would be zero if no difference.) 
 
means samplebetween  diff of s.e. of estimate
means popbetween  diff exp -means samplebetween  diff obs=t  
 
This t statistic describes the probability of that difference occurring by chance (the 
probability, or p value, can be obtained from published tables or by computation 
through, for example, SPSS). By convention, if the probability is less than 5% (p<0.05), 
this is considered a significant result and the null hypothesis (that there is no difference 
between the groups) can be rejected. 
 
Mann Whitney U Test 
When data is not normally distributed (non-parametric), then the t test cannot be used. 
To compare groups of non-parametric data, the Mann Whitney U test can be used. This 
is based on ranking the data. As such, large scores are represented by high ranks and 
low scores are represented by lower ranks. The analysis is then carried out on the ranks. 
If the null hypothesis is true (that there is no difference between the two groups) then 
there is also no difference in the ranking of the two groups. If there is a difference, then 
this should be represented in a difference of ranking and in the sum of the ranks. 
Repeating numbers (that would be normally ranked the same) are assigned increasing 
ranks for each occurrence and then averaged to produce a single rank for all occurrences 
(e.g. three occurrences of the value 6 could be ranked 3,4 and 5 but would be assigned 
the average rank of 4). The test statistic (U) is calculated from the sample sizes and the 
summed rank of group 1: 
1
11
21 2
)1( RnnnnU −++=  
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n1 and n2 are sample sizes for group 1 and 2, respectively 
R1 is sum of ranks for group 1 
 
The significance (p<0.05) of the difference can be evaluated by calculating a z score 
from the test statistic (lowest sum of ranks), the mean of test statistic (calculated 
knowing group sizes) and the standard error of the test statistic.  
 
statistictest ofe.s.
statistic test ofmean  - statistictest =z  
 
The significance of the z score can be obtained from published tables or computed by 
the statistics programme.  
 
The Wilcoxon rank-sum test can also be used to compare ranked non-parametric data. 
In this case the test statistic is the value obtained for the group with the lowest sum of 
ranks. This method is closely related to the Mann-Whitney U test and gives similar 
results through similar methods.  
 
Chi Squared Testing 
Chi squared (Χ2) testing compares categorical data in one (or more) group and another. 
The observed data can be compared to expected data determining if the null hypothesis 
(that there is no difference) can be rejected or accepted. Expected frequencies for each 
cell are calculated by assuming the null hypothesis that the proportions of the numbers 
in each cell are the same and constructing a contingency table to that effect.  
 
n
alcolumn tot   totalrow ∗=E  
 
E= expected frequency and n= total number of observations 
 
From these observed and expected frequencies, the Χ2 statistic can be calculated. 
( )∑ ∗= EEOX
2
2  
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The probability of attaining this value can then be looked up from the appropriate Χ2 
distribution table.  
 
Fisher’s Exact Testing 
Comparison of a 2x2 table can be limited if the frequencies are too small for the Χ2 test. 
The sampling distribution of the Χ2 statistic has an appropriate Χ2 distribution. The 
larger the sample, the closer the approximation; the smaller the sample, the less good 
the approximation.  
 
The exact probability test devised by Fisher, Irwin and Yates allows this situation to be 
resolved. The method describes the probability of observing a set of frequencies if the 
totals of both rows and columns in a 2x2 table are kept at their observed values. The 
probability of gaining a more extreme set of data (i.e. greater disparity in frequencies 
between the two groups) is then considered. This is akin to examining the tails of the 
distribution of continuous data. The 2x2 contingency tables are rearranged in each 
possible sequence that maintains the same row and column totals. The exact probability 
for each of these tables can be calculated. The addition of probabilities from these tables 
allows the overall probability for each array plus any more extreme array to be 
calculated. 
 
Correlation 
When evaluating whether two variables are associated, the simplest approach is to 
consider their covariance. Variance of a single variable is the average amount that the 
data vary from the mean.  
( )
1
Variance
2
−
−= ∑
N
xxi  
(note: the standard deviation is the square root of the variance) 
 
If we consider two variables, we are interested in what happens to the one variable when 
the other one deviates from the mean. By multiplying the standard deviations of two 
variables, we get the cross-product of the deviations. The covariance can be calculated 
from a similar formula to that for the variance above. 
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1
Covariance −
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N
yyxx ii  
 
As measures can be in different units, this is standardised using the standard deviations 
to give an r value which is the correlation coefficient. 
 
deviations standard xy ofproduct 
 xyof covariance=r  
 
Regression 
Regression techniques allow the relationship between two or more variables to be 
further examined than only correlation or association. Regression evaluates how well 
one variable (outcome) is predicted by another variable (predictor) and allows 
construction of a model of prediction. Such models can be conceptually considered as: 
Outcome = model + error 
 
Linear regression assumes a linear relationship between the variables and as such can be 
described using the equation of a line: 
y = b0 + b1x 
y = outcome, b0 = y intercept, b1= gradient and x=predictor 
 
The data is fitted with a line of best fit which is the line that minimises the vertical 
distance (the residual) from actual data point to fitted line the most for all points. As 
points will occur above and below the line (and summation of the positive and negative 
residuals would effectively cancel each other out), the sum of the squared residuals is 
used. This is the line of least squares. The equation of the line can be used to described 
the line and as the model of prediction. Not all lines will describe the data well as the 
error is too great. A regression line (or model) can be assessed for goodness of fit. This 
is done by comparing the best model to the most basic model. This basic model can be 
based on the mean and the sum of squares of differences around the mean. The 
improvement of the ability to predict by the model is calculated by the difference 
between the sum of squared residuals and the sum of squares around the mean. The 
difference is called the model sum of squares (SSm); if it is large, there is a big 
difference using the model compared to using the means. The exact proportional 
improvement from using means can be calculated by dividing SSm by the SS of the 
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mean. The resulting value is the R2 value which can be multiplied by 100 to give the 
percentage of variance that the model explains. 
 
R2 in regression is the same as the R2 obtained in correlation. 
 
Odds ratios 
The odds ratio is a ratio of the odds of an event in one group divided by the odds of that 
event in another group. The odds of an event is the ratio of the number of that event to 
the number of non-events (e.g. the odds of throwing a six with a standard die is 1:5 or 
0.2). An odds ratio of 1 means there is no change in odds as the predictor increases (or 
occurs); an odds ratio of less than one means as the predictor increases (or occurs) the 
odds of the outcome occurring decreases; for an odds ratio greater than one, the odds of 
the outcome occurring increases as the predictor increases (or occurs). 
 
Logistic Regression 
Linear regression is only suitable for continuous outcome variables and cannot be used 
to consider a dichotomous outcome (binary outcome), such as vital status. Logistic 
regression allows the relationship between multiple predictor variables and a 
dichotomous outcome variable to be examined. Therefore, logistic regression models 
allow the investigator to predict which of the two outcome categories each case is likely 
to belong to given certain other information. The impact of predictor variables is usually 
described in terms of the odds ratio.  
 
Logistic regression does not assume a linear relationship between outcome and 
predictor variables, and predictor variables can be categorical or continuous. It is non-
parametric but does require data to be independent and predictors should not be too 
highly correlated with each other. The outcome categories must be mutually exclusive.  
 
The significance of each variable within the model can be assessed through the Wald 
Statistic. This has a Χ2 distribution and is used to determine if the regression coefficient 
is significantly different from 0. Hosmer and Lemeshow’s statistic is utilised to evaluate 
that the overall model is significant. This is a ratio of what variance the new model can 
explain compared to the variance the baseline model explained. Hosmer and 
Lemeshow’s goodness of fit statistic is derived from an ordered grouping of the 
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observed outcomes and the predicted outcomes. The resulting test statistic has a Χ2 
distribution and a significance level can be derived. If the value is greater than 0.05 then 
we fail to reject the null hypothesis that there is no difference between observed and 
predicted values (i.e. the model predictions fit the data well).  
 
The additional technique of stepwise modelling can be used to identify the most 
significant factors in a predictive model. Backwards logistic regression is usually 
preferred for exploratory analysis to identify factors of significance when there is no 
clear theoretical understanding of important predictors. This involves entering all the 
predictors in the model and removing non-significant factors until the model is refined. 
By starting with all the predictors in the model this reduces the occurrence of suppressor 
effects (i.e. when a variable is significant only when another variable is held constant). 
Conversely, forwards logistic regression can be used when there is a strong theoretical 
basis for including certain predictors, but it is more open to suppressor effects.  
 
Kaplan-Meier  
Regression analysis describes the relationship between an outcome measure and one or 
more predictors. Survival analysis evaluates such a relationship and models the time it 
takes for events to occur. Kaplan-Meier cumulative survival curves can be used to 
model univariate survival (i.e. the probability of survival at any given time from a given 
point). Such survival curves can also be compared for survival differences across 
grouped survival (e.g. survival from diagnosis in males and female).  
 
In Kaplan-Meier analysis, the proportion of survivors from a given point and over a 
specified period of time can be calculated for a population. This estimate of the 
proportion surviving is also an estimated probability of survival to that time for a 
member of the population from which the sample has been drawn. Because the event 
may not have occurred for all patients within the study time, censoring is used. Over 
each survival time considered, the probability of survival is calculated by the product of 
those surviving at the beginning of the period examined and those surviving at the end 
of that period. For example, if 32 patients of 38 were alive at the end of one month 
(proportion alive = 0.842), and 27 of that 32 (proportion alive = 0.844) were still alive at 
the end of the second month, the probability of survival at two months is 0.842 x 0.844 
= 0.711. This can be repeated until the last event. Observations censored at any time 
will affect the number of patients included in the baseline survival proportion. These 
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survival probabilities can be graphed as ‘curves’ in which each step down occurs with 
an observed event. Censored events are also plotted on the curve. This is called the 
Kaplan-Meier curve. 
 
Comparison of two or more survival curves can be carried out using the log rank test. 
This tests the null hypothesis that there is no difference between the population survival 
curves (i.e. the probability of an event occurring at any given time is the same for both 
populations). The test statistic is calculated by: 
( ) ( )
2
2
22
1
2
112 rank) (log
E
EO
E
EOX −+−=  
O is the observed events and E is the expected number of events 
 
The expected number of events for a group is the sum of expected events for that group 
at each time interval. The expected number of events for each interval is calculated as 
the risk of that event (number of events/number of people in group) multiplied by the 
number in the group at the time concerned. The test statistic can be compared with a Χ2 
distribution with df=1 for significance. Where p is <0.05, there is a significant 
difference and the null hypothesis is rejected. The log rank test does not take any other 
variables into account.  
 
Cox’s Proportional Hazards Model (Cox Regression) 
Cox regression allows event-time analysis to consider multiple variables. One or more 
predictor variables (covariates) are used to predict a status variable (an event, usually 
death) over time. First described by D.R. Cox in 1972, this form of survival analysis is 
now used widely. Cox regression differs from logistic regression in that it describes the 
hazard ratio (rate of incidence of hazardous event) instead of the odds ratio (ratio of 
proportions of those who have experienced the hazardous event). In this regard, Cox 
regression is analogous to a multiple linear regression model except that the outcome 
variable is a hazard rate rather than a hazard state.  
 
Cox regression is regarded as semi-parametric and does not make assumptions about the 
distribution of the data or the probability distribution of the hazard (usually dying), and 
it can accommodate both discrete and continuous measures of event times. However, it 
is assumed in Cox regression that the risk of dying in one group at one time will be the 
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same at any other time, and that the effects of different variables on survival are 
constant over time. 
 
Stepwise procedure can be used to evaluate which predictor variables are significant 
contributors to the model. Both forwards and backwards stepwise methods can be 
utilised, but backwards modelling is preferred when there is no clear theoretical 
framework for variable selection (i.e. the work is exploratory).  
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Appendix 9: Publications 
 
The following paper was reproduced with permission from Supportive Care in Cancer 
18(1): 29-36. Copyright 2010 Springer.  
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Abstract
Introduction Lung cancer is a disease of high symptom
burden, major psychosocial impact and poor prognosis.
Although diagnosis is individual, each patient operates
within a social context. Patient perception of family’s or
friends’ concern may affirm the presence of support or may
drive personal anxiety. Perceived worry may impact on
freedom to discuss illness or symptoms within the support
network. The validated palliative outcome scale quantifies
physical and psychosocial needs. It also evaluates anxiety
felt and anxiety perceived in the support network. This study
examined lung cancer patients’ symptoms, performance
status, their supportive care needs and their perception of
family’s/friends’ anxiety.
Goals of work The aim of this study was to evaluate lung
cancer patients’ anxiety, physical symptoms, performance
status and their perception of anxiety within their support
network.
Patients and methods The study was a prospective obser-
vational evaluation of 170 lung cancer out-patients using an
adapted palliative outcome scale questionnaire. Comparison
was made between patients perceiving high anxiety within
their support network and those who perceiving low
anxiety.
Main results Perceived familial and self-rated personal
anxiety both increased as function declined (p<0.001; p=
0.001). Increased perceived worry was associated with
increased physical symptoms [dyspnoea (p<0.001), cough
(p=0.001), haemoptysis (p=0.009)], low self-esteem (p=
0.004) and feeling lack of worth (p=0.035). Perception of
increased worry did not influence whether patients felt able
to share their feelings (p=0.362).
Conclusions As physical function declines and symptoms
increase, patients are more worried themselves and perceive
increased anxiety within their support network. However,
this circle of anxiety did not impair the perception that
feelings could be shared within the support network.
Keywords Anxiety . Support network . Lung cancer .
Supportive care
Introduction
Lung cancer is the commonest cause of cancer-related
deaths worldwide. In Britain, it accounts for 25% of all
cancer deaths [36]. The prognosis remains poor with an
overall 5-year survival of around 7% [6, 15, 35]. Symptom
distress is higher than other cancers and there is a large
unmet psychosocial burden [7, 11, 20, 25, 30]. Anxiety and
worry within the lung cancer population are both common
and underestimated, and they impact significantly on
quality of life [1, 5, 7, 14, 27, 29, 32].
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The impact of anxiety and worry on day-to-day life is
reflected in the etymology of both words. Anxiety derives
from the Latin ‘anxius’ meaning ‘to choke’. Worry originates
from the Anglo-Saxon ‘wyrgan’ meaning ‘to strangle’ [10].
Manifestations of anxiety can be classed as physical
(including sweats, palpitation, gastrointestinal disturbance,
panic attacks and dyspnoea), behavioural (unease, restlessness
and reassurance seeking) and psycho-emotional (apprehen-
sion, recurrent and intrusive thoughts and loss of concentra-
tion) [3, 39, 42]. A spectrum of anxiety is observed within
both the general and cancer populations. This includes
adaptive anxiety, maladaptive anxiety and classifiable
anxiety disorders (such as phobias, panic attacks, generalised
anxiety disorders and post-traumatic distress) [24, 41, 46].
Maladaptive anxiety is out of proportion to the stimulus,
persists and disrupts function and quality of life [41].
Anxiety in cancer
Cancer is a threatening diagnosis. The word ‘cancer’ has been
used in studies to provoke anxiety [42]. Within the cancer
population, there is a higher prevalence of anxiety and mixed
anxiety–depression than the general population [39]. It can
be difficult to assess for anxiety in cancer as the changing
illness trajectory, effect and side effects of treatment, and the
persistent threat of the diagnosis and associated prognostic
uncertainty, lead to a dynamic situation [42]. However,
anxiety can become a significant identifiable problem
requiring specific assessment and management. Once
identified, management of anxiety in cancer includes good
communication, information giving, psychological support
and pharmacological interventions [3, 39, 42].
Anxiety in lung cancer
Physical decline in advanced cancer and lung cancer has been
well characterised [33]. Lung cancer is often an acute illness
with rapid physical decline, high symptom burden and short
prognosis [11, 25]. Anxiety and distress are not predictable
by gender, age or stage of lung cancer but may peak at
certain stages of disease—diagnosis, identification of disease
progression and the beginning of the terminal phase [33].
There is some evidence that anxiety in cancer is associated
with poor performance status (PS) and high symptom
burden [40]. As such, lung cancer patients are likely to be
at risk of anxiety. The small body of research into this area
provides some consistent evidence that psychosocial distress
is high in the lung cancer population [12, 13, 29, 44].
Support network anxiety
Individual patients cope with illness and symptoms within
the context of relationships with significant others [31, 38].
It has been suggested that sharing feelings with trusted and
supportive people can improve emotional and cognitive
processing of illness [21]. Lack of positive support may
adversely affect this process. In tobacco-related disease,
there may be additional elements with guilt or blame related
to cigarette smoking. This may also affect the ability to
discuss issues within the support network [21].
The concept of distinguishing symptom distress from
symptom occurrence is gaining ground [4, 9, 45]. Assess-
ment of symptom occurrence and symptom distress may
differ between individuals, caregivers and significant others
[4, 44, 45, 47]. Lack of concordance in distress recognition
and identification of its cause, between patients and others,
may influence the patients’ perceptions of support.
Patient perception of family’s or friends’ worry may
affirm presence of support or may drive personal anxiety.
Perceiving high anxiety within your support network may
impact on freedom to discuss illness or symptoms within
the support network. Conversely, if this perceived anxiety is
recognised as appropriate and reflective of care, then it may
affirm feelings of support and facilitate shared feelings.
Objectives
This paper examines lung cancer patients’ anxiety, physical
symptoms, PS and their perception of anxiety within their
support network. It utilises the validated Palliative Outcome
Scale (POS) [16].
Materials and methods
POS quantifies physical and psychosocial needs in terms of
impact on life. It quantifies patients’ perceptions about
worry within their support network and freedom to share
feelings with others [16, 17, 19]. Individual questions and
the summary score of POS have been shown to be valid
(content, consensus, face and construct validity) and
reliable (internal consistency and test/re-test reliability) in
a multicentre study encompassing inpatient, outpatient and
community care settings [16]. POS has been adapted for
local needs in a variety of settings and in this study was
applied in the ambulatory out-patient setting [16, 17, 23,
43]. POS asks patients to rate how different supportive care
issues have affected them over the previous 3 days. This
includes pain, ‘other symptoms’, their own anxiety, their
perception of their support network’s anxiety, mood and
self-worth, health-care time use, practical problems and
how much information has been given. In our question-
naire, the ‘3-day’ period was adapted to suit out-patient
review to consider ‘the last 4 weeks’. Using the POS model
of rating how affected the patient had been by symptoms as
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‘Not at all, no effect’, ‘Slightly—but not bothered to be rid
of it’, ‘Moderately—symptom limits some activity’, ‘Se-
verely—activities or concentration markedly affected’ and
‘Overwhelmingly—unable to think of anything else’, three
questions regarding dyspnoea, cough and haemoptysis were
introduced. Finally, a question self-rating performance status
was incorporated. This utilised the Eastern Co-operative
Oncology Group (ECOG) performance status scale. ECOG
quantifies function in patients from normal activity (0);
restricted in strenuous activity (1); self-caring, ambulatory
more than 50% of the day but unable to carry out work
activities (2); limited self-care and ambulatory less than
50% of the day (3); unable to self-care and non-ambulatory
(4); and dead (5) [34]. Each patient self-assessed their own
current function from 0 to 4.
Patients with lung cancer were identified by clinic staff
and asked to complete the questionnaire. The questionnaire
was sequentially offered to all patients with lung cancer and
was used within the clinical review to identify on-going
problems. No other exclusions were applied. Over the
course of 1 year, questionnaires including an adapted POS
and respiratory symptom (dyspnoea, cough and haemopt-
ysis) score were completed by 170 patients (new and
returning) attending a lung cancer clinic. This represented
the majority of patients attending the clinic in which around
170 new referrals are seen each year. Questionnaires were
collated and audited alongside further data points derived
from case notes.
The study was reviewed by the Local Research Ethics
Committee. Information was entered into a spreadsheet
and statistical analyses performed using SPSS™ Version
14.0. Descriptive statistics were generated on the sample
characteristics. POS responses were compared between
patients who felt lower anxiety and those who felt higher
anxiety and patients who perceived high anxiety within
their carers and those who perceived low anxiety (Mann–
Whitney U test). The strength and direction of correlation
between POS responses and ‘anxiety felt’ by the patient
and also ‘support network anxiety perceived’ by the
patient was further examined (Spearman’s rho correlation
coefficient).
Patients attending the out-patient lung cancer clinic at
the study centre completed questionnaires over 12 months.
This included new patients (66.5% patients within 28 days
of diagnosis) and patients under long term follow-up
(33.5% more than 28 days from diagnosis). Table one
summarises the patient characteristics (Table 1).
Results
Anxiety and associations
Three main questions regarding anxiety and sharing of
feelings are asked within POS:
Question 1: ‘Over the past 4 weeks have you been feeling
anxious or worried about your illness or
treatment?’
Question 2: ‘Over the past 4 weeks have any of your
family or friends been anxious or worried
about you?’
Question 3: ‘Over the past 4 weeks have you been able to
share how you are feeling with your family or
friends?’
Each of these questions can be answered from 0 to 4,
with 0 being no anxiety or feeling able to share, and 4 being
preoccupation with worry or not being able to share with
Males Females Total
All patients 78 (46%) 92 (54%) 170
Age (mean/range) 68 (45–85) 70 (53–90) 69 (45–90)
Performance status (median/range) 1.5 (0–4) 2 (0–4) 2 (0–4)
Diagnosis
NSCLC 58 (34.1%) 57 (33.5%) 115 (67.6%)
Stage 1 14 (8.2%) 20 (11.8%) 34 (20.0%)
Stage 2 13 (7.6%) 6 (3.5%) 19 (11.2%)
Stage 3 15 (8.8%) 17 (10.0%) 32 (18.8%)
Stage 4 16 (9.4%) 14 (8.2%) 30 (17.6%)
SCLC 21 (12.4%)
Limited 4 (2.4%) 5 (2.9%) 9 (5.3%)
Extensive 4 (2.4%) 8 (4.7%) 12 (7.1%)
CLC 11 (6.5%) 20 (11.8%) 31 (18.2%)
Other (e.g. mesothelioma) 1 (0.6%) 2 (1.2%) 3 (1.8%)
Table 1 Characteristics of
patients and gender differences
(n=170)
PS performance status, NSCLC
non-small cell lung cancer,
SCLC small cell lung cancer,
CLC clinicoradiological lung
cancer
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anyone. A small number of patients (less than 3%) did not
answer all questions. Table 2 summarises the responses to
these three questions.
Personal anxiety felt (mean 1.51, median 1, range 0–
4, standard deviation (SD) 1.25) was reported to be
‘low’ (0–1) in 54.1% (n=92/170); 43.3% (n=74/170)
described higher anxiety levels (2–4). Carer anxiety
perceived in the support network (mean 2.12, median 3,
range 0–4, SD 1.45) was reported to be ‘low’ (0–1) by
42.9% (n=73/170) of patients and described as ‘higher’ (2–
4) by 54.1% (n=92/170). Being able to share feelings
(mean 0.77, median 0, range 0–4, SD 1.22) was reported to
be felt possible ‘as much as I want’ (0) or ‘most of the
time’ (1) in 75% (n=129/170) of patients.
Associations of personal anxiety
Personal anxiety was categorised as ‘lower’ (0–1) and
‘higher’ (2–4). Differences between the lower and higher
anxiety patients were examined in relation to the factors
listed in Table 3. Statistical significance of any difference
was assessed (Mann–Whitney U test). In addition, Spear-
man’s rho correlation coefficient was utilised to define the
direction and strength of correlation between ‘anxiety felt’
and the same factors (Table 3).
Significant differences were found between anxiety
bands for physical symptoms [dyspnoea (p<0.001),
cough (p=0.001), haemoptysis (p=0.015) and performance
status (p<0.001)] and psychological symptoms [low
self-esteem (p<0.001), feeling life was not worthwhile
(p<0.001)]. These variables were significantly correlated to
anxiety. Pain did not show a significant difference when
examined across anxiety bands, but a positive and significant
correlation was found. Survival from both diagnosis (p=0.24)
and questionnaire date (p=0.050), were significantly differ-
ent in each group of patients. Survival from diagnosis date
and clinic date were both negatively correlated with
increased anxiety.
Increased symptoms, decreased physical function, and
shorter prognosis seem to be accompanied by increased
anxiety—both felt by the patients and perceived by the
patient to be present within the support network. There was
no significant difference or correlation found in gender,
age, histology, weight (diagnosis and current), diagnosis
albumin, pain, ‘other’ symptoms and information needs.
CRP was significantly higher in the higher band of anxiety
patients
Patients’ perception that they were able to share feelings
within the support network correlated with anxiety levels
but no significant difference between ‘lower’ and ‘higher’
anxiety was found (Mann–Whitney test). This is explained
as the vast majority of patients (75%) felt able to share
either ‘as much as I want’ or ‘most of the time’. Ta
b
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Associations of perceived anxiety within the support
network
Anxiety perceived by the patient in their support group was
categorised as ‘lower’ (never anxious to sometimes
anxious) and ‘higher’ (most of the time to preoccupied).
The analysis was repeated to assess differences between
these categories (Table 4).
There was a strong positive correlation between ‘anxiety
felt’ and ‘anxiety perceived’ (rho 0.570; p<0.001). In
keeping with this, patients perceived increased anxiety
within the support group when symptoms were increased
and physical function declined. Perceived increased anxiety
within the support network was associated with shorter
survival.
Again, low self-esteem and feeling that life was not
worthwhile correlated strongly with anxiety perceived in
the support group. There were no differences in gender,
tumour type, current or diagnosis weight.
There was a significant difference and correlation between
information needs and anxiety perceived. This may reflect
patients’ awareness of the need to have shared information
within the support network.
Discussion
Anxiety is a common and normal response to a diagnosis of
cancer [32]. It can become maladaptive for some patients,
impacting on quality of life, function and symptom burden.
Maladaptive anxiety is characterised as being persistent,
intrusive and disproportionate to the stimulus. Assessing
anxiety within the context of a real and persistent but
dynamic threat such as cancer is a challenge [3, 7, 14, 32,
39, 42].
Lung cancer is a serious diagnosis that often heralds high
symptom burden, decline in physical health and short
survival. Patients diagnosed with lung cancer may not have
their supportive care needs fully recognised or met [25–27,
31, 37]. It has been recognised that patients deal with
illness in the context of a social environment and that this
may positively or negatively influence their ability to cope
[18, 21].
The concept of symptom distress, encompassing symp-
tom occurrence, intensity and impact on patients is gaining
Table 4 Variables compared between low and high perceived anxiety
Factor Mann–
Whitney
U
p
value
Spearman rho
correlation
coefficient
p
value
Dyspnoea 2,345 <0.001 0.281 <0.001
Cough 2,436 0.001 0.27 <0.001
Haemoptysis 2,937 0.009 0.15 0.054
Current PS 2,139 <0.001 0.326 <0.001
Low self-esteem 2,458 0.004 0.295 <0.001
Life not worthwhile 2,715 <0.001 0.190 0.016
Anxiety and worry 1,483 <0.001 0.570 <0.001
Survival from
diagnosis
242 0.001 −0.444 <0.001
Survival from
questionnaire
229 0.001 −0.434 <0.001
CRP 2,540 0.204 0.610 0.455
Perception that they are
able to share feelings
3,162 0.362 0.099 0.205
Pain 2,601 0.013 0.175 0.025
Age 2,607 0.009 −2.227 0.003
Gender 3,174 0.386
Histology 3117 0.261
PS at diagnosis 2,508 0.141 0.113 0.168
Weight at diagnosis 2,524 0.182 0.120 0.142
Current weight 2,948 0.471 −0.260 0.746
Albumin 2,090 <0.001 −0.256 0.001
Information needs 2,256 0.007 0.160 0.049
Table 3 Variables compared between patients feeling low and high
anxiety
Factor Mann–
Whitney
U
p
value
Spearman’s rho
correlation
coefficient
p
value
Dyspnoea 2,440 0.001 0.299 <0.001
Cough 2,462 0.001 0.256 0.001
Haemoptysis 2,994 0.021 0.189 0.015
Current PS 2,142 <0.001 0.318 <0.001
Low self-esteem 1,625 <0.001 0.515 <0.001
Life not worthwhile 1,874 <0.001 0.427 <0.001
Perception of anxiety
within the support
network
1,307 <0.001 0.570 <0.001
Survival from
diagnosis
390 0.030 −0.274 0.024
Survival from
questionnaire
368 0.024 −0.240 0.050
CRP 2,386 0.044 0.119 0.142
Perception that they
are able to share
feelings
2,931 0.134 0.204 0.009
Pain 2,891 0.139 0.203 0.009
Age 3,111 0.342 −0.148 0.075
Gender 3,156 0.349
Histology 3,111 0.248
PS at diagnosis 2,463 0.088 0.108 0.186
Weight at diagnosis 2,726 0.570 0.028 0.532
Current weight 2,827 0.281 −0.05 0.532
Diagnosis albumin 2,640 0.088 −0.137 0.084
Information needs 2,414 0.072 0.152 0.062
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ground [9]. Congruence between patient perception of
symptom distress and that of their support network or
professional carers may also influence their ability to cope
with and discuss their illness [4, 33, 44].
This evaluation confirms that anxiety is a significant
issue within the lung cancer population. Fifty-four percent
of patients experienced moderate or severe anxiety. Over
20% of these patients felt anxious about their illness ‘most
of the time’ or were ‘completely pre-occupied’. This is
consistent with findings of moderate to severe anxiety
ranging between 10% and 45% in other lung cancer studies
[22, 28, 32]. Confirming previous studies, there was a
strong correlation between anxiety and depression (‘Have
you felt your life worthwhile?’ and ‘have you felt good
about yourself?’) [8, 28]. It is of note that patients in this
study perceived higher levels of anxiety in their support
network (mean 2.12, median 3, SD 1.45) than the level
of personal anxiety they described (mean 1.51, median 1,
SD 1.25).
Patient anxiety is increased in advanced cancer, when
symptom burden is high and physical function is poor [7].
We confirmed this and further observed that specific
clinical variables of dyspnoea, cough, haemoptysis and
decline in performance status were associated with in-
creased anxiety. It is interesting to note that as a patient’s
own anxiety increases, they also perceive increased anxiety
within their own support network. This congruence of
psycho-emotional response may influence the support felt
by the patient and their willingness to discuss their illness
or feelings. It could be hypothesised that patients may feel
that support network anxiety which mirrors their own shows
recognition and understanding. For other patients, they may
wish to withhold their own worries in an attempt to protect
their significant others.
The relationship between anxiety and cancer survival is
unclear and remains controversial [2]. This study described
higher anxiety levels in patients who had shorter overall
survival and shorter survival from when the questionnaire
was completed.
Within this group of lung cancer patients, the vast
majority felt able to share ‘as much as they wanted’ or
‘most of the time’ and there was no difference between the
group that perceived ‘lower’ anxiety and ‘higher’ anxiety in
their support network. There was also no difference in this
freedom to share between those who were personally
experiencing ‘lower’ levels of anxiety and those experienc-
ing ‘higher’ levels of anxiety. A minority of patients felt
able to share only ‘occasionally’ or ‘not at all with anyone’.
Early identification of patients with low levels of perceived
support may be important to allow targeted supportive care
measures to meet this deficit in a timely fashion. This may
help prevent psychosocial distress or aid the treatment of
anxiety or other psychological issues.
Limitations of this study
This evaluation was conducted in a single centre and thus
may portray a site-specific experience. However, other
studies have shown similar prevalence of anxiety and
correlations of anxiety to depression, advanced disease,
high physical symptoms and poor performance status.
There were more females within the study group than
males. This is unusual in lung cancer studies as lung cancer
is more prevalent in the male population. This is likely to
be explained by the mixed population of recent diagnosis
(66.5%) and follow-up patients (33.5%).
Conclusions
Anxiety is an important issue in cancer care. It may reflect
recognition of advancing disease or become disproportion-
ate to the current condition. Maladaptive anxiety can
‘choke’ or ‘strangle’ the patient’s quality of life.
This paper confirms the significant prevalence of anxiety
within the lung cancer out-patient population. Patients do
perceive recognition within their support network that their
condition merits increased concern when symptoms are
high, function poor and survival short. The majority of
patients felt able to share their worries and concerns with
significant others, irrespective of their own anxiety levels.
Lung cancer care operates within a dynamic and often
rapidly declining situation. Prompt assessment and re-
sponse to distress within this acute illness trajectory is
necessary. Early recognition of anxiety and facilitating
further support—through significant others or members of
the health care team—may help relieve the stranglehold of
psychological distress.
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